

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 12
December 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

CUMULATIVE SUPPLEMENT 12
December 2017

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
TG UNITED LABS LLC (TG UNITED LABS)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-

counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a

particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)	18711 2708 (14.5%)	19012 2721 (14.3%)	19294 2758 (14.3%)
MULTISOURCE	15484 (85.4%)	15703 (85.4%)	16003 (85.5%)	16291 (85.7%)	16536 (85.7%)
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)	15882 (84.9%)	16180 (85.1%)	16431 (85.2%)
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)	121 (0.6%)	111 (0.6%)	105 (0.5%)
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)
NEW MOLECULAR ENTITIES APPROVED	7	14	17	14	25
NUMBER OF APPLICANTS	1051	1053	1050	1054	1075

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET;ORAL
 ABACAVIR SULFATE
 AB CIPLA LTD EQ 300MG BASE A078119 001 Nov 21, 2017 Nov NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL
 ABACAVIR SULFATE AND LAMIVUDINE
 AB AUROBINDO PHARMA LTD EQ 600MG BASE;300MG A206151 001 Mar 28, 2017 Mar NEWA
 AB CIPLA LTD EQ 600MG BASE;300MG A091144 001 Mar 28, 2017 Mar NEWA
 AB LUPIN LTD EQ 600MG BASE;300MG A204990 001 Mar 28, 2017 Mar NEWA

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS
 TYMLOS
 +! RADIUS HEALTH INC 3.12MG/1.56ML (2MG/ML) N208743 001 Apr 28, 2017 Apr NEWA

ABEMACICLIB

TABLET;ORAL
 VERZENIO
 + ELI LILLY AND CO 50MG N208716 001 Sep 28, 2017 Sep NEWA
 + 100MG N208716 002 Sep 28, 2017 Sep NEWA
 + 150MG N208716 003 Sep 28, 2017 Sep NEWA
 +! 200MG N208716 004 Sep 28, 2017 Sep NEWA

ABIRATERONE ACETATE

TABLET;ORAL
 ZYTIGA
 + JANSSEN BIOTECH 500MG N202379 002 Apr 14, 2017 May NEWA

ACALABRUTINIB

CAPSULE;ORAL
 CALQUENCE
 +! ACERTA PHARMA BV 100MG N210259 001 Oct 31, 2017 Oct NEWA
 +! ASTRAZENECA 100MG N210259 001 Oct 31, 2017 Nov CAHN

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
 ACAMPROSATE CALCIUM
 AB ZYDUS PHARMS USA INC 333MG A205995 001 May 26, 2017 May NEWA

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
 ACETAMINOPHEN
 AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 Jan CAHN

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
 >A> BUTALBITAL AND ACETAMINOPHEN
 >A> MIKART INC 300MG;50MG A207313 001 Dec 27, 2017 Dec NEWA
 TABLET;ORAL
 BUTALBITAL AND ACETAMINOPHEN
 AA TEDOR PHARMA INC 300MG;50MG A207635 001 Jun 05, 2017 May NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 >D> AB ! NEXGEN PHARMA 300MG;50MG;40MG A040885 001 Nov 16, 2009 Dec CTEC
 >A> AA ! 300MG;50MG;40MG A040885 001 Nov 16, 2009 Dec CTEC
 AB TEDOR PHARMA INC 300MG;50MG;40MG A206615 001 Aug 04, 2017 Jul NEWA
 TABLET;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AA ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Apr CTNA
 >D> AA MALLINCKRODT INC 325MG;50MG;40MG A087804 001 Jan 24, 1985 Dec CAHN
 AA 325MG;50MG;40MG A087804 001 Jan 24, 1985 Mar CAHN
 @ NOVAST LABS LTD 325MG;50MG;40MG A040864 001 Dec 01, 2008 Sep CAHN
 >A> AA @ SPECGX LLC 325MG;50MG;40MG A087804 001 Jan 24, 1985 Dec CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@ HIKMA INTL PHARMS 325MG;50MG;40MG;30MG A075618 001 Mar 23, 2001 Nov DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA @ ALLIED PHARMA INC 120MG/5ML;12MG/5ML A086366 001 Jul CAHN
 >A> AA WOCKHARDT 120MG/5ML;12MG/5ML A087006 001 Dec CAHN
 >A> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A087006 001 Dec CAHN

SUSPENSION;ORAL

CAPITAL AND CODEINE

@ VALEANT PHARMS LLC 120MG/5ML;12MG/5ML A086024 001 Aug DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ ANDA REPOSITORY 300MG;15MG A089673 002 Feb 10, 1988 Nov CMS1
 @ 300MG;30MG A089673 003 Feb 10, 1988 Nov CMS1
 @ 300MG;60MG A089673 001 Feb 10, 1988 Sep CAHN
 >D> AA ! MALLINCKRODT INC 300MG;15MG A040419 001 May 31, 2001 Dec CAHN
 >D> AA 300MG;30MG A040419 002 May 31, 2001 Dec CAHN
 >D> AA 300MG;60MG A040419 003 May 31, 2001 Dec CAHN
 >A> AA ! SPECGX LLC 300MG;15MG A040419 001 May 31, 2001 Dec CAHN
 >A> AA 300MG;30MG A040419 002 May 31, 2001 Dec CAHN
 >A> AA 300MG;60MG A040419 003 May 31, 2001 Dec CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

ZYFREL

@ CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML A090468 001 Apr 14, 2016 Nov DISC

TABLET;ORAL

ANEXSIA 5/325

>D> AA MALLINCKRODT 325MG;5MG A040409 001 Oct 20, 2000 Dec CAHN
 >A> AA SPECGX LLC 325MG;5MG A040409 001 Oct 20, 2000 Dec CAHN

ANEXSIA 7.5/325

>D> AA MALLINCKRODT 325MG;7.5MG A040405 001 Sep 08, 2000 Dec CAHN
 >A> AA SPECGX LLC 325MG;7.5MG A040405 001 Sep 08, 2000 Dec CAHN

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ABHAI LLC 300MG;5MG A209036 001 Jun 21, 2017 Jun NEWA
 AA 300MG;7.5MG A209036 002 Jun 21, 2017 Jun NEWA
 AA 300MG;10MG A209036 003 Jun 21, 2017 Jun NEWA
 AA 325MG;5MG A209037 001 Jun 21, 2017 Jun NEWA
 AA 325MG;7.5MG A209037 002 Jun 21, 2017 Jun NEWA
 AA 325MG;10MG A209037 003 Jun 21, 2017 Jun NEWA
 AA AMNEAL PHARMS NY 300MG;5MG A206869 001 Jun 23, 2017 Jun NEWA
 AA LANNETT HOLDINGS INC 300MG;5MG A207171 001 Jun 20, 2017 Jun NEWA
 AA 300MG;7.5MG A207171 002 Jun 20, 2017 Jun NEWA
 AA 300MG;10MG A207171 003 Jun 20, 2017 Jun NEWA
 AA 325MG;5MG A207172 001 Jun 22, 2017 Jun NEWA
 AA 325MG;7.5MG A207172 002 Jun 22, 2017 Jun NEWA
 AA 325MG;10MG A207172 003 Jun 22, 2017 Jun NEWA
 >D> AA MALLINCKRODT 325MG;10MG A040400 001 Jul 26, 2000 Dec CAHN
 >D> AA MALLINCKRODT INC 300MG;5MG A206718 001 Mar 31, 2017 Dec CAHN
 AA 300MG;5MG A206718 001 Mar 31, 2017 Mar NEWA
 >D> AA 300MG;7.5MG A206718 002 Mar 31, 2017 Dec CAHN
 AA 300MG;7.5MG A206718 002 Mar 31, 2017 Mar NEWA
 >D> AA 300MG;10MG A206718 003 Mar 31, 2017 Dec CAHN
 AA 300MG;10MG A206718 003 Mar 31, 2017 Mar NEWA
 AA ! MIKART 300MG;7.5MG A040658 002 Mar 24, 2006 May CHRS
 AA 300MG;7.5MG A040658 002 Mar 24, 2006 Apr CMS1
 AA ! 300MG;10MG A040658 003 Jun 23, 2004 May CHRS
 AA 300MG;10MG A040658 003 Jun 23, 2004 Apr CMS1
 >A> AA SPECGX LLC 300MG;5MG A206718 001 Mar 31, 2017 Dec CAHN
 >A> AA 300MG;7.5MG A206718 002 Mar 31, 2017 Dec CAHN
 >A> AA 300MG;10MG A206718 003 Mar 31, 2017 Dec CAHN
 >A> AA 325MG;10MG A040400 001 Jul 26, 2000 Dec CAHN
 AA UPSHER-SMITH LABS 325MG;5MG A206484 001 Mar 24, 2017 Jun CAHN
 AA 325MG;5MG A206484 001 Mar 24, 2017 Mar NEWA
 AA 325MG;7.5MG A206484 002 Mar 24, 2017 Jun CAHN
 AA 325MG;7.5MG A206484 002 Mar 24, 2017 Mar NEWA
 AA 325MG;10MG A206484 003 Mar 24, 2017 Jun CAHN
 AA 325MG;10MG A206484 003 Mar 24, 2017 Mar NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		WES PHARMA INC	325MG;5MG	A210211	001	Oct 30, 2017	Oct	NEWA
AA			325MG;7.5MG	A210211	002	Oct 30, 2017	Oct	NEWA
AA			325MG;10MG	A210211	003	Oct 30, 2017	Oct	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	!	MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Dec	CAHN
>A>	AA	!	SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Dec	CAHN

TABLET;ORAL

OXYCET

>D>	AA		MALLINCKRODT	325MG;5MG	A087463	001	Dec 07, 1983	Dec	CAHN
>A>	AA		SPECGX LLC	325MG;5MG	A087463	001	Dec 07, 1983	Dec	CAHN

OXYCODONE AND ACETAMINOPHEN

	AA		AMNEAL PHARMS	325MG;5MG	A040777	001	Nov 27, 2007	May	CAHN
	AA		ASCENT PHARMS INC	325MG;2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
	AA			325MG;5MG	A207419	002	Mar 22, 2017	Mar	NEWA
	AA			325MG;7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
	AA			325MG;10MG	A207419	004	Mar 22, 2017	Mar	NEWA
	AA		CHEMO RESEARCH SL	325MG;5MG	A207574	001	Dec 13, 2016	Nov	CAHN
	AA		LANNETT HOLDINGS INC	325MG;5MG	A207333	001	Sep 25, 2017	Sep	NEWA
	AA			325MG;10MG	A207333	002	Sep 25, 2017	Sep	NEWA
>D>	AA		MALLINCKRODT	325MG;7.5MG	A040545	001	Jun 30, 2004	Dec	CAHN
>D>	AA			325MG;10MG	A040545	002	Jun 30, 2004	Dec	CAHN
>A>	AA		NESHER PHARMS	325MG;2.5MG	A210079	001	Dec 28, 2017	Dec	NEWA
>A>	AA			325MG;5MG	A210079	002	Dec 28, 2017	Dec	NEWA
>A>	AA			325MG;7.5MG	A210079	003	Dec 28, 2017	Dec	NEWA
>A>	AA			325MG;10MG	A210079	004	Dec 28, 2017	Dec	NEWA
	AA		NOVEL LABS INC	325MG;2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
	AA			325MG;5MG	A204407	002	Feb 24, 2017	Feb	NEWA
	AA			325MG;7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
	AA			325MG;10MG	A204407	004	Feb 24, 2017	Feb	NEWA
>A>	AA		SPECGX LLC	325MG;7.5MG	A040545	001	Jun 30, 2004	Dec	CAHN
>A>	AA			325MG;10MG	A040545	002	Jun 30, 2004	Dec	CAHN

PERCOCET

AA	!	VINTAGE PHARMS LLC	325MG;7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Jan	CMS1

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

	+	@	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014	Aug	DISC
--	---	---	------------------	-------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB			ALKEM LABS LTD	325MG;37.5MG	A202076	001	Mar 30, 2012	Nov	CAHN
AB			APOGEE PHARMA	325MG;37.5MG	A202076	001	Mar 30, 2012	Sep	CAHN
AB			AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
		@	CSPC OUYI PHARM CO	325MG;37.5MG	A076914	001	Jul 26, 2006	Oct	CAHN
AB			MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	Apr	NEWA

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB			STRIDES PHARMA	125MG	A209734	001	Nov 20, 2017	Nov	NEWA
AB				250MG	A209734	002	Nov 20, 2017	Nov	NEWA
AB			SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988	Jul	CMS1

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP			PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun	NEWA
----	--	--	----------------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT			ICU MEDICAL INC	250MG/100ML	N017656	001		Feb	CAHN
----	--	--	-----------------	-------------	---------	-----	--	-----	------

SOLUTION/DROPS;OTIC

ACETIC ACID

>D>	AT	!	WOCKHARDT	2%	A040166	001	Jul 26, 1996	Dec	CAHN
>A>	AT	!	WOCKHARDT BIO AG	2%	A040166	001	Jul 26, 1996	Dec	CAHN

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

@ BAUSCH AND LOMB 2%;0.79% A040063 001 Feb 25, 1994 Oct DISC

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

@ WATSON LABS TEVA 250MG A071893 001 Nov 25, 1987 May CAHN

@ 500MG A071894 001 Nov 25, 1987 May CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP SAGENT PHARMS 6GM/30ML (200MG/ML) A091684 001 Oct 31, 2017 Oct NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

@ MYLAN PHARMS INC 17.5MG A203707 001 Sep 10, 2015 Oct DISC

@ 22.5MG A203707 002 Sep 10, 2015 Oct DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB ! APOTEX INC 200MG A075677 001 Sep 28, 2005 Oct CHRS

AB BOSCOGEN 200MG A075090 001 Jan 26, 1999 May CAHN

AB CARLSBAD TECHNOLOGY 200MG A206261 001 Aug 16, 2017 Aug NEWA

@ CHARTWELL MOLECULES 200MG A074872 001 Apr 22, 1997 Jan CAHN

@ MYLAN 200MG A074727 001 Apr 22, 1997 Jun DISC

ZOVIRAX

AB + MYLAN PHARMS INC 200MG N018828 001 Jan 25, 1985 Oct CHRS

OINTMENT;TOPICAL

ACYCLOVIR

AB G AND W LABS INC 5% A205591 001 Nov 13, 2017 Oct NEWA

AB GLENMARK PHARMS LTD 5% A205510 001 Jul 31, 2017 Jul NEWA

AB TOLMAR 5% A206437 001 Jul 31, 2017 Jul NEWA

SUSPENSION;ORAL

ZOVIRAX

AB +! MYLAN PHARMS INC 200MG/5ML N019909 001 Dec 22, 1989 Jan CAHN

TABLET;BUCCAL

SITAVIG

+! EPI HLTH 50MG N203791 001 Apr 12, 2013 Jun CAHN

TABLET;ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES 400MG A074834 001 Apr 24, 1997 Jan CAHN

@ 800MG A074834 002 Apr 24, 1997 Jan CAHN

AB HERITAGE PHARMS INC 400MG A074891 001 Oct 31, 1997 Apr CMFD

AB 800MG A074891 002 Oct 31, 1997 Apr CMFD

AB MYLAN PHARMS INC 400MG A075211 001 Sep 28, 1998 Mar CAHN

AB 800MG A075211 002 Sep 28, 1998 Mar CAHN

ZOVIRAX

AB + MYLAN PHARMS INC 400MG N020089 001 Apr 30, 1991 Jan CAHN

AB +! 800MG N020089 002 Apr 30, 1991 Jan CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ ATHENEX INC EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997 Mar CAHN

@ EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Mar CAHN

AP ! HIKMA PHARMS EQ 1GM BASE/VIAL A205771 002 Feb 29, 2016 Mar CTEC

>D> AP MYLAN LABS LTD EQ 500MG BASE/VIAL A203927 001 Mar 29, 2017 Dec DISC

>A> @ EQ 500MG BASE/VIAL A203927 001 Mar 29, 2017 Dec DISC

AP EQ 500MG BASE/VIAL A203927 001 Mar 29, 2017 Mar NEWA

>D> AP EQ 1GM BASE/VIAL A203927 002 Mar 29, 2017 Dec DISC

>A> @ EQ 1GM BASE/VIAL A203927 002 Mar 29, 2017 Dec DISC

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar	NEWA
AP	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May	NEWA
AP		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May	NEWA

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

AP	WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan	CAHN
AP		3MG/ML	A076500	001	Jun 16, 2004	Jan	CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Jan	CAHN

SOLUTION; IV (INFUSION)
ADENOSINE

AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Oct	NEWA
AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Oct	NEWA
AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Nov	NEWA
AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Nov	NEWA

ALBENDAZOLE

TABLET; ORAL
ALBENZA

+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA

BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN
----	---	------------------	--------------------	---------	-----	--------------	-----	------

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE	A206224	001	Oct 17, 2017	Oct	NEWA
AN	SUN PHARMA GLOBAL	EQ 0.083% BASE	A207857	001	Jul 21, 2017	Jul	NEWA

TABLET; ORAL
ALBUTEROL SULFATE

>A>	@	FOSUN PHARMA	EQ 2MG BASE	A072151	001	Dec 05, 1989	Dec	CAHN
>A>	@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Dec	CAHN
>D>	@	SANDOZ	EQ 2MG BASE	A072151	001	Dec 05, 1989	Dec	CAHN
>D>	@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Dec	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	SUN PHARMA GLOBAL	EQ 0.083% BASE; 0.017%	A207875	001	Aug 07, 2017	Nov	CMS1
AN		EQ 0.083% BASE; 0.17%	A207875	001	Aug 07, 2017	Jul	NEWA
AN	WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb	CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL
FOSAMAX

+	@	MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Sep	CRLD
---	---	-------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL
ALENDRONATE SODIUM

@	UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Jun	CAHN
@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Jun	CAHN
@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Jun	CAHN
@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Jun	CAHN
@		EQ 70MG BASE	A075871	005	Apr 22, 2009	Jun	CAHN

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET; ORAL
TEKTURNA

+	NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017	Nov	NEWA
---	--------------	----------------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	SUN PHARM INDUSTRIES	100MG	A071450	002	Jan 09, 1987	Nov	CMS1
AB	ZYDUS PHARMS USA INC	100MG	A210117	001	Oct 12, 2017	Oct	NEWA
AB		300MG	A210117	002	Oct 12, 2017	Oct	NEWA

ZYLOPRIM

AB	+	CASPER PHARMA LLC	100MG	N016084	001		Jul	CAHN
AB	+		300MG	N016084	002		Jul	CAHN

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

	+	ARDEA BIOSCIENCES	200MG; 200MG	N209203	001	Aug 18, 2017	Aug	NEWA
	+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Aug	NEWA
	+	IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Sep	CAHN
	+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Sep	CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May	CAHN
AB			EQ 1MG BASE	A206647	002	Dec 22, 2016	May	CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

	+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May	CAHN
--	---	------------	---	---------	-----	--------------	-----	------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

	+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May	CAHN
--	---	------------	--	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr	CAHN
AB			0.5MG	A074342	002	Oct 31, 1993	Apr	CAHN
AB			1MG	A074342	003	Oct 31, 1993	Apr	CAHN
AB			2MG	A074342	004	Oct 31, 1993	Apr	CAHN
		@ MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993	Nov	DISC
		@	0.5MG	A074046	002	Oct 19, 1993	Nov	DISC
		@	1MG	A074046	003	Oct 19, 1993	Nov	DISC
		@	2MG	A074046	004	May 07, 1997	Nov	DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan	CAHN
AB			1MG	A090871	002	Jun 07, 2011	Jan	CAHN
AB			2MG	A090871	003	Jun 07, 2011	Jan	CAHN
AB			3MG	A090871	004	Jun 07, 2011	Jan	CAHN
		@ MYLAN	0.5MG	A077391	002	Jan 26, 2006	Nov	DISC
		@	1MG	A077391	003	Jan 26, 2006	Nov	DISC
		@	2MG	A077391	004	Jan 26, 2006	Nov	DISC
		@	3MG	A077391	001	Jan 26, 2006	Nov	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Sep	CAHN
AB			0.5MG	A078561	002	Mar 16, 2010	Sep	CAHN
AB			1MG	A078561	003	Mar 16, 2010	Sep	CAHN
AB			2MG	A078561	004	Mar 16, 2010	Sep	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

		@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May	CAHN
AP	+		0.01MG/VIAL	N020649	002	Jun 12, 1997	May	CAHN
	+	!	0.01MG/VIAL	N020649	005	Jul 30, 1998	May	CAHN
AP	+		0.02MG/VIAL	N020649	003	Jun 12, 1997	May	CAHN
	+	!	0.02MG/VIAL	N020649	006	Jul 30, 1998	May	CAHN
AP	+		0.04MG/VIAL	N020649	004	Jun 12, 1997	May	CAHN
	+	!	0.04MG/VIAL	N020649	007	Jul 30, 1998	May	CAHN

SUPPOSITORY; URETHRAL

MUSE

	+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar	CAHN
	+		0.25MG	N020700	002	Nov 19, 1996	Mar	CAHN

SUPPOSITORY; URETHRAL
MUSE

+	!		0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN
+	!		1MG	N020700	004	Nov 19, 1996	Mar	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun	NEWA
AB		HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May	NEWA
AB		LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May	NEWA
AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May	NEWA
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

GOCOVRI

+		ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NEWA
+	!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	NEWA

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May	CAHN
>D>	AA	!	WOCKHARDT	A075060	001	Dec 24, 1998	Dec	CAHN
>A>	AA	!	WOCKHARDT BIO AG	A075060	001	Dec 24, 1998	Dec	CAHN

SYMMETREL

+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD
---	---	-------------	----------	---------	-----	--	-----	------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May	NEWA
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun	CAHN

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.025%	N018116	001		Jun	CRLD
+	@		0.1%	N018116	002		Jun	CRLD

LOTION; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun	CRLD
---	---	----------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N018498	001		Jun	CRLD
---	---	----------	------	---------	-----	--	-----	------

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

AP		MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017	Jul	NEWA
AP		SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr	CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB		WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Jul	CAHN
----	--	------------------	-----	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>		@ FOSUN PHARMA	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Dec	CAHN
>D>		@ SANDOZ	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Dec	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb	CAHN
--	--	-----------------	------------------	---------	-----	--	-----	------

AMINOSYN 10% (PH6)

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb	CAHN
--	--	-----------------	------------------	---------	-----	--------------	-----	------

AMINOSYN 3.5%

		ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb	CAHN
--	--	-----------------	--------------------	---------	-----	--	-----	------

AMINOSYN 5%

		ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb	CAHN
--	--	-----------------	----------------	---------	-----	--	-----	------

INJECTABLE; INJECTION

AMINOSYN 7%						
ICU MEDICAL INC	7% (7GM/100ML)	N017673	002			Feb CAHN
AMINOSYN 7% (PH6)						
ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985		Feb CAHN
AMINOSYN 8.5%						
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004			Feb CAHN
AMINOSYN 8.5% (PH6)						
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985		Feb CAHN
AMINOSYN II 10%						
ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986		Feb CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER						
ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991		Feb CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER						
ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991		Feb CAHN
AMINOSYN II 3.5%						
@ ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986		Feb CAHN
AMINOSYN II 5%						
@ ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986		Feb CAHN
AMINOSYN II 7%						
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986		Feb CAHN
AMINOSYN II 8.5%						
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986		Feb CAHN
AMINOSYN-HBC 7%						
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985		Feb CAHN
AMINOSYN-HF 8%						
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996		Jun CAHN
AMINOSYN-PF 10%						
ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986		Feb CAHN
AMINOSYN-PF 7%						
ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985		Feb CAHN
AMINOSYN-RF 5.2%						
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001			Apr CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M						
ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N017789	003			Feb CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M						
@ ICU MEDICAL INC	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789	005			Feb CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES						
ICU MEDICAL INC	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	004	Apr 03, 1986		Apr CAHN
AMINOSYN II 7% W/ ELECTROLYTES						
@ ICU MEDICAL INC	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	006	Apr 03, 1986		Apr CAHN
AMINOSYN II 8.5% W/ ELECTROLYTES						
ICU MEDICAL INC	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	005	Apr 03, 1986		Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M						
@ ICU MEDICAL INC	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML	N019437	007	Apr 03, 1986		Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES						
ICU MEDICAL INC	7%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017789	002			Feb CAHN
AMINOSYN 8.5% W/ ELECTROLYTES						
ICU MEDICAL INC	8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017673	005			Feb CAHN

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL
GLEOLAN

+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017	Jun	NEWA
----	------	------------	---------	-----	--------------	-----	------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	50MG/ML	A204550	001	Oct 25, 2017	Oct	NEWA
----	----------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

>A>	AB	MAYNE PHARMA INC	100MG	A075389	002	Dec 28, 2017	Dec	NEWA
	AB		200MG	A075389	001	Jan 25, 2001	Jan	CAHN
>A>	AB		400MG	A075389	003	Dec 28, 2017	Dec	NEWA
	@	MYLAN	200MG	A075188	001	Feb 24, 1999	Mar	DISC
	!	SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar	CHRS
	AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar	CAHN
	AB		200MG	A075424	001	Mar 30, 2001	Mar	CAHN
			300MG	A076362	002	Dec 02, 2003	Mar	CAHN
	AB		400MG	A076362	001	Nov 29, 2002	Mar	CAHN
		PACERONE						
	AB	UPSHER-SMITH LABS	100MG	A075135	002	Apr 12, 2005	Jun	CAHN
	AB		200MG	A075135	001	Apr 30, 1998	Jun	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A210086	001	Oct 06, 2017	Sep	NEWA
AB		25MG	A210086	002	Oct 06, 2017	Sep	NEWA
AB		50MG	A210086	003	Oct 06, 2017	Sep	NEWA
AB		75MG	A210086	004	Oct 06, 2017	Sep	NEWA
AB		100MG	A210086	005	Oct 06, 2017	Sep	NEWA
AB		150MG	A210086	006	Oct 06, 2017	Sep	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep	CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Sep	CAHN
@	WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

>A>	@	FOSUN PHARMA	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Dec	CAHN
>A>	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Dec	CAHN
>A>	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Dec	CAHN
AB	@	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar	CAHN
	@		EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May	DISC
AB	@		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar	CAHN
	@		EQ 5MG BASE	A078224	002	Feb 27, 2008	May	DISC
AB	@		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar	CAHN
	@		EQ 10MG BASE	A078224	003	Feb 27, 2008	May	DISC
>D>	@	SANDOZ	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Dec	CAHN
>D>	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Dec	CAHN
>D>	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Dec	CAHN
	@	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Sep	DISC
	@		EQ 5MG BASE	A204900	002	Jul 23, 2015	Sep	DISC
	@		EQ 10MG BASE	A204900	003	Jul 23, 2015	Sep	DISC
AB		UPSHER-SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun	CAHN
AB			EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun	CAHN
AB			EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun	CAHN
AB		VIVIMED GLOBAL	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Aug	CAHN
AB			EQ 5MG BASE	A077516	002	Jul 11, 2007	Aug	CAHN
AB			EQ 10MG BASE	A077516	003	Jul 11, 2007	Aug	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	AUROBINDO PHARMA LTD	5MG;12.5MG;160MG	A206180	001	Dec 19, 2017	Dec	NEWA
>A>	AB		5MG;25MG;160MG	A206180	002	Dec 19, 2017	Dec	NEWA
>A>	AB		10MG;12.5MG;160MG	A206180	003	Dec 19, 2017	Dec	NEWA
>A>	AB		10MG;25MG;160MG	A206180	004	Dec 19, 2017	Dec	NEWA
>A>	AB		10MG;25MG;320MG	A206180	005	Dec 19, 2017	Dec	NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017	Jul	NEWA
AB			EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017	Jul	NEWA
AB			EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017	Jul	NEWA
AB			EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017	Jul	NEWA
AB		ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017	Jul	NEWA
AB			EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017	Jul	NEWA
AB			EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017	Jul	NEWA
AB			EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017	Jul	NEWA
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May	NEWA
AB			EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May	NEWA
AB			EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May	NEWA
AB			EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May	NEWA
AB		GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Jun	NEWA
AB			EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Jun	NEWA
AB			EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Jun	NEWA
AB			EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Jun	NEWA
AB		JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May	NEWA
AB			EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May	NEWA
AB			EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May	NEWA
AB			EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May	NEWA
AB		MICRO LABS	EQ 5MG BASE;20MG	A207435	001	Nov 02, 2017	Oct	NEWA
AB			EQ 5MG BASE;40MG	A207435	002	Nov 02, 2017	Oct	NEWA
AB			EQ 10MG BASE;20MG	A207435	003	Nov 02, 2017	Oct	NEWA
AB			EQ 10MG BASE;40MG	A207435	004	Nov 02, 2017	Oct	NEWA
AB		TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr	CAHN
AB			EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr	CAHN
AB			EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr	CAHN
AB			EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr	CAHN
AB		ZYDUS PHARMS USA INC	EQ 5MG BASE;20MG	A207771	001	Sep 22, 2017	Sep	NEWA
AB			EQ 5MG BASE;40MG	A207771	002	Sep 22, 2017	Sep	NEWA
AB			EQ 10MG BASE;20MG	A207771	003	Sep 22, 2017	Sep	NEWA
AB			EQ 10MG BASE;40MG	A207771	004	Sep 22, 2017	Sep	NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

>A>	+	MARINA BIOTECH	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Dec	CAHN
>A>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Dec	CAHN
>A>	+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Dec	CAHN
>D>	+	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Dec	CAHN
>D>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Dec	CAHN
>D>	+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Dec	CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May	CAHN
----	--	----------	------------------------------------	---------	-----	--------------	-----	------

AMMONIUM LACTATE

LOTION;TOPICAL

LAC-HYDRIN

+	@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan	CRLD
---	---	---------	-------------	---------	-----	--------------	-----	------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

@		UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Jun	CAHN
@			50MG	A072944	001	Jun 28, 1991	Jun	CAHN
@			100MG	A072878	001	Jun 28, 1991	Jun	CAHN
@			150MG	A072879	001	Jun 28, 1991	Jun	CAHN

TABLET;ORAL

AMOXAPINE

@	WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb	CAHN
@		50MG	A072419	001	May 11, 1989	Feb	CAHN
@		100MG	A072420	001	May 11, 1989	Feb	CAHN
@		150MG	A072421	001	May 11, 1989	Feb	CAHN

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

>D>	AB	WOCKHARDT	400MG/5ML	A065319	002	Jun 18, 2007	Dec	CAHN
>A>	AB	WOCKHARDT BIO AG	400MG/5ML	A065319	002	Jun 18, 2007	Dec	CAHN
		AMOXIL						
+	@	DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Sep	CRLD
	@		200MG/5ML	N050760	001	Apr 15, 1999	Feb	DISC
+	@		400MG/5ML	N050760	002	Apr 15, 1999	Sep	CRLD
	@		400MG/5ML	N050760	002	Apr 15, 1999	Feb	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995	Feb	CTEC
!			250MG	A064013	001	Dec 22, 1992	Feb	CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	WOCKHARDT	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Dec	CAHN
>A>	AB	WOCKHARDT BIO AG	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Dec	CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Dec	CAHN
>D>	AB	WOCKHARDT EU OPERATN	600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Dec	CAHN
		AUGMENTIN '125'						
+		DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Nov	CTEC
		AUGMENTIN '200'						
+	@	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb	DISC
	@		AUGMENTIN '400'					
+	@	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb	DISC
	@		AUGMENTIN ES-600					
+	@	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb	DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb	CHRS
AB	!		875MG;EQ 125MG BASE	A065063	001	Mar 14, 2002	Oct	CHRS
AB	!	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb	CHRS
		AUGMENTIN '875'						
AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Oct	CHRS

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb	CTEC
!			400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb	CTEC
		AUGMENTIN '200'						
+	@	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb	DISC
	@		AUGMENTIN '400'					
+	@	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb	DISC

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

+	!	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep	NEWA
---	---	------------------	-------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

+		SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jun	NEWA
+			6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jun	NEWA
+			9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jun	NEWA
+			12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jun	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ALVOGEN MALTA	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017	Jul	NEWA
AB			1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017	Jul	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017	Jul	NEWA
AB			3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017	Jul	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017	Jul	NEWA	
AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017	Jul	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017	Jul	NEWA	
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May	CAHN	
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	CAHN	
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May	CAHN	
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	CAHN	
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	CAHN	
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May	CAHN	
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May	CAHN	
>D>	AB	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Dec	CAHN
>D>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Dec	CAHN
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Dec	CAHN
>D>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Dec	CAHN
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Dec	CAHN
>D>	AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Dec	CAHN
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Dec	CAHN
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Oct	NEWA	
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Oct	NEWA	
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Oct	NEWA	
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Oct	NEWA	
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Oct	NEWA	
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Oct	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Oct	NEWA	
>A>	AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Dec	CAHN
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Dec	CAHN
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Dec	CAHN
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Dec	CAHN
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Dec	CAHN
>A>	AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Dec	CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Dec	CAHN
>A>	AB	SUNRISE PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017	Dec	NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017	Dec	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017	Dec	NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017	Dec	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017	Dec	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017	Dec	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017	Dec	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION
ABELCET

+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995	Nov	CAHN
----	---------------------	--------	---------	-----	--------------	-----	------

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

	@ HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Oct	CMS1
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Oct	CMS1
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Oct	CMS1
	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Oct	CMS1
	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Oct	CMS1
AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Oct	CMS1
	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Oct	CMS1
	@ WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan	CAHN
	@	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan	CAHN
	@	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan	CAHN
	@	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan	CAHN
	@	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan	CAHN
	PENBRITIN-S						
+	@ WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001		Jun	CRLD
+	@	EQ 250MG BASE/VIAL	N050072	002		Jun	CRLD
+	@	EQ 500MG BASE/VIAL	N050072	003		Jun	CRLD
+	@	EQ 1GM BASE/VIAL	N050072	004		Jun	CRLD
+	@	EQ 2GM BASE/VIAL	N050072	005		Jun	CRLD
+	@	EQ 4GM BASE/VIAL	N050072	006		Jun	CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015	Jul	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015	Jul	CAHN
AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
ANAGRELIDE HYDROCHLORIDE

AB	@ MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May	DISC
AB		EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar	CAHN
	@	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May	DISC
	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	May	DISC
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar	CAHN
	@	EQ 1MG BASE	A077613	002	Jun 27, 2006	May	DISC
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151	001	Jun 30, 2017	Jun	NEWA
AB		EQ 1MG BASE	A209151	002	Jun 30, 2017	Jun	NEWA
	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun	CAHN
	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun	CAHN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

	@ SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Sep	DISC
	@ WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May	CAHN
AB	+! ASTRAZENECA PHARMS	1MG	N020541	001	Dec 27, 1995	May	CAHN

>A> ANGIOTENSIN II

>A> SOLUTION; IV (INFUSION)
>A> GIAPREZA

>A>	+! LA JOLLA PHARM CO	2.5MG/ML (2.5MG/ML)	N209360	001	Dec 21, 2017	Dec	NEWA
>A>	+!	5MG/2ML (2.5MG/ML)	N209360	002	Dec 21, 2017	Dec	NEWA

APREPITANT

CAPSULE; ORAL
APREPITANT

AB	GLENMARK PHARMS LTD	40MG	A207777	001	Oct 12, 2017	Oct	NEWA
AB		80MG	A207777	002	Oct 12, 2017	Oct	NEWA
AB		125MG	A207777	003	Oct 12, 2017	Oct	NEWA

EMULSION; IV (INFUSION)
CINVANTI

	+! HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017	Nov	NEWA
--	----------------------	-----------------------	---------	-----	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

	+! HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb	NEWA
AP	+! NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jun	CAHN

INJECTABLE; IV (INFUSION)
ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	May	NEWA
AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	CFTG

ARIPIPIRAZOLE

TABLET; ORAL
ABILIFY MYCITE KIT

	+ OTSUKA PHARM CO LTD	2MG	N207202	001	Nov 13, 2017	Nov	NEWA
	+!	5MG	N207202	002	Nov 13, 2017	Nov	NEWA
	+	10MG	N207202	003	Nov 13, 2017	Nov	NEWA
	+	15MG	N207202	004	Nov 13, 2017	Nov	NEWA
	+	20MG	N207202	005	Nov 13, 2017	Nov	NEWA
	+	30MG	N207202	006	Nov 13, 2017	Nov	NEWA

ARIPIPIRAZOLE

AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May	NEWA
AB		5MG	A202683	002	May 23, 2017	May	NEWA

<u>TABLET;ORAL</u>							
<u>ARIPIPIRAZOLE</u>							
AB		10MG	A202683	003	May 23, 2017	May	NEWA
AB		15MG	A202683	004	May 23, 2017	May	NEWA
AB		20MG	A202683	005	May 23, 2017	May	NEWA
AB		30MG	A202683	006	May 23, 2017	May	NEWA
AB	PRINSTON INC	2MG	A205363	001	Dec 04, 2017	Nov	NEWA
AB		5MG	A205363	002	Dec 04, 2017	Nov	NEWA
AB		10MG	A205363	003	Dec 04, 2017	Nov	NEWA
AB		15MG	A205363	004	Dec 04, 2017	Nov	NEWA
AB		20MG	A205363	005	Dec 04, 2017	Nov	NEWA
AB		30MG	A205363	006	Dec 04, 2017	Nov	NEWA
AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May	CAHN
AB		5MG	A091279	002	Jan 09, 2017	May	CAHN
AB		10MG	A091279	003	Jan 09, 2017	May	CAHN
AB		15MG	A091279	004	Jan 09, 2017	May	CAHN
AB		20MG	A091279	005	Jan 09, 2017	May	CAHN
AB		30MG	A091279	006	Jan 09, 2017	May	CAHN
<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>							
<u>ARIPIPIRAZOLE</u>							
AB	! ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Nov	CTEC
AB		15MG	A202102	002	Apr 28, 2015	Nov	CTEC
AB	ORCHID HLTHCARE	10MG	A202547	001	Dec 11, 2017	Nov	NEWA
AB		15MG	A202547	002	Dec 11, 2017	Nov	NEWA
<u>ARIPIPIRAZOLE LAUROXIL</u>							
<u>SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR</u>							
<u>ARISTADA</u>							
+	ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun	NEWA
<u>ARMODAFINIL</u>							
<u>TABLET;ORAL</u>							
<u>ARMODAFINIL</u>							
AB	NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Sep	NEWA
		200MG	A202768	005	Sep 28, 2017	Sep	NEWA
<u>ARSENIC TRIOXIDE</u>							
<u>INJECTABLE;INJECTION</u>							
<u>TRISENOX</u>							
+	! CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Oct	NEWA
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE</u>							
<u>INJECTABLE;INJECTION</u>							
<u>SEPTOCAINE</u>							
AP	! DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun	CFTG
<u>ULTACAN</u>							
AP	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun	NEWA
<u>ULTACAN FORTE</u>							
AP	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun	NEWA
<u>ASCORBIC ACID</u>							
<u>SOLUTION;IV (INFUSION)</u>							
<u>ASCOR</u>							
+	! MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Oct	NEWA
<u>ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K</u>							
<u>INJECTABLE;IV (INFUSION)</u>							
<u>INFUVITE PEDIATRIC</u>							
+	! SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	May	CAHN
<u>INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)</u>							
+	! SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004	May	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

@	HOSPIRA	10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG /ML; 20 IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/ML; 0.3MG/ML; 330 UNITS/ML; 1	N008809	004	Aug 08, 1985	Nov	CTNA
+	@	20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG /ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML	N008809	006	Sep 09, 2004	Nov	CTNA
+	@	20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG /ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML	N008809	006	Sep 09, 2004	Aug	DISC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

@	HOSPIRA	20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG /ML; 20 IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/ML; 0.6MG/ML; 330 UNITS/ML; 1	N008809	005	Apr 22, 2004	Nov	CTNA
---	---------	---	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORINAL

+	@	ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Jan	CRLD
---	---	--------------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		NOVAST LABS LTD	325MG; 200MG	A040832	001	Jan 07, 2010	Sep	CAHN
----	--	-----------------	--------------	---------	-----	--------------	-----	------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	May	CAHN
AB		IMPAX LABS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Jan	NEWA
AB		PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Jan	NEWA
AB		SANDOZ INC	25MG; 200MG	A206739	001	Jan 18, 2017	Jan	NEWA
AB		ZYDUS PHARMS USA INC	25MG; 200MG	A206753	001	Aug 29, 2017	Aug	NEWA

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

@	SUN PHARM INDUSTRIES	325MG; 200MG	N011702	003	Dec 29, 1983	Oct	CAHN
---	----------------------	--------------	---------	-----	--------------	-----	------

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		UNIQUE PHARM LABS	25MG	A077443	001	Sep 13, 2006	Aug	CAHN
AB			50MG	A077443	002	Sep 13, 2006	Aug	CAHN
AB			100MG	A077443	003	Sep 13, 2006	Aug	CAHN
@	WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May	CAHN	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB		SUN PHARM INDUSTRIES	50MG; 25MG	A073582	002	Apr 29, 1993	Nov	CMS1
----	--	----------------------	------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX INC	10MG	A078983	001	May 30, 2017	May	NEWA
AB			18MG	A078983	002	May 30, 2017	May	NEWA
AB			25MG	A078983	003	May 30, 2017	May	NEWA
AB			40MG	A078983	004	May 30, 2017	May	NEWA
AB			60MG	A078983	005	May 30, 2017	May	NEWA
AB			80MG	A078983	006	May 30, 2017	May	NEWA
AB			100MG	A078983	007	May 30, 2017	May	NEWA

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A 079016	001	May 30, 2017	May	NEWA
AB		18MG	A 079016	002	May 30, 2017	May	NEWA
AB		25MG	A 079016	003	May 30, 2017	May	NEWA
AB		40MG	A 079016	004	May 30, 2017	May	NEWA
AB		60MG	A 079016	005	May 30, 2017	May	NEWA
AB		80MG	A 079016	006	May 30, 2017	May	NEWA
AB		100MG	A 079016	007	May 30, 2017	May	NEWA
AB	GLENMARK PHARMS LTD	10MG	A 079019	001	May 30, 2017	May	NEWA
AB		18MG	A 079019	002	May 30, 2017	May	NEWA
AB		25MG	A 079019	003	May 30, 2017	May	NEWA
AB		40MG	A 079019	004	May 30, 2017	May	NEWA
AB		60MG	A 079019	005	May 30, 2017	May	NEWA
AB		80MG	A 079019	006	May 30, 2017	May	NEWA
AB		100MG	A 079019	007	May 30, 2017	May	NEWA
AB	TEVA PHARMS USA	10MG	A 079022	001	May 30, 2017	May	NEWA
AB		18MG	A 079022	002	May 30, 2017	May	NEWA
AB		25MG	A 079022	003	May 30, 2017	May	NEWA
AB		40MG	A 079022	004	May 30, 2017	May	NEWA
AB		60MG	A 079022	005	May 30, 2017	May	NEWA
AB		80MG	A 079022	006	May 30, 2017	May	NEWA
AB		100MG	A 079022	007	May 30, 2017	May	NEWA
STRATTERA							
AB	+ LILLY	10MG	N 021411	002	Nov 26, 2002	May	CFTG
AB	+	18MG	N 021411	003	Nov 26, 2002	May	CFTG
AB	+	25MG	N 021411	004	Nov 26, 2002	May	CFTG
AB	+	40MG	N 021411	005	Nov 26, 2002	May	CFTG
AB	+!	60MG	N 021411	006	Nov 26, 2002	May	CFTG
AB	+	80MG	N 021411	007	Feb 14, 2005	May	CFTG
AB	+	100MG	N 021411	008	Feb 14, 2005	May	CFTG

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A 205300	001	Mar 27, 2017	Mar	NEWA
AB		EQ 20MG BASE	A 205300	002	Mar 27, 2017	Mar	NEWA
AB		EQ 40MG BASE	A 205300	003	Mar 27, 2017	Mar	NEWA
AB		EQ 80MG BASE	A 205300	004	Mar 27, 2017	Mar	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A 206084	001	Apr 26, 2017	Apr	NEWA
		EQ 20MG BASE;10MG	A 206084	002	Apr 26, 2017	Apr	NEWA
		EQ 40MG BASE;10MG	A 206084	003	Apr 26, 2017	Apr	NEWA
!		EQ 80MG BASE;10MG	A 206084	004	Apr 26, 2017	Apr	NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	APOTEX INC	750MG/5ML	A 209750	001	Oct 11, 2017	Oct	NEWA
AB	PADDOCK LLC	750MG/5ML	A 207833	001	Apr 28, 2017	Apr	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	MYLAN LABS LTD	10MG/ML	A 206096	001	Jun 22, 2017	Jun	NEWA
	@ WATSON PHARMS TEVA	10MG/ML	A 074945	001	Jul 28, 1998	Feb	CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	MYLAN LABS LTD	10MG/ML	A 206001	001	Apr 07, 2017	Mar	NEWA
TRACRIUM							
+	@ HOSPIRA	10MG/ML	N 018831	002	Jun 20, 1985	Apr	CMS1
TRACRIUM PRESERVATIVE FREE							
+	@ HOSPIRA	10MG/ML	N 018831	001	Nov 23, 1983	Apr	CMS1

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABOJECT SYRINGE

+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N 021146	004	Aug 17, 2017	Aug	NEWA
+	!		1MG/10ML (0.1MG/ML)	N 021146	005	Aug 17, 2017	Aug	NEWA

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug	CDFR
+!		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug	CDFR
+!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov	CTEC
---	----------------------	-----------------------	---------	-----	--------------	-----	------

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jun	CMFD
----	----------------	---------------	---------	-----	--	-----	------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+	@ MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Nov	DISC
---	-----------------------	-------------------	---------	-----	--------------	-----	------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

ATNAA

>D>	@ US ARMY	2.1MG/0.7ML;600MG/0.7ML	N021175	001	Jan 17, 2002	Dec	CPOT
>A>	@	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002	Dec	CPOT

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+!	CEREXA	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May	CAHN
----	--------	------------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun	NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR
AP	VIDAZA						
AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+	@ CASPER PHARMA LLC	EQ 100MG BASE/VIAL	N017391	001		Jul	CAHN
---	---------------------	--------------------	---------	-----	--	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>D>	AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Dec	CHRS
>A>	AT	!	0.05%	A202305	001	May 31, 2012	Dec	CHRS
	AT		0.05%	A202305	001	May 31, 2012	Feb	CAHN
>D>		OPTIVAR						
>D>	AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Dec	DISC
>A>	AT	+ @	0.05%	N021127	001	May 22, 2000	Dec	DISC
	AT	+!	0.05%	N021127	001	May 22, 2000	Mar	CAHN

SPRAY, METERED;NASAL

ASTELIN

AB	+!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar	CAHN
		ASTEPRO						
		@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar	CAHN
AB	+!		EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar	CAHN
		AZELASTINE HYDROCHLORIDE						
AB		ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017	Aug	NEWA
AB		AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017	Aug	NEWA
>A>	AB		EQ 0.1876MG BASE/SPRAY	A208199	001	Dec 15, 2017	Dec	NEWA
AB		BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb	CAHN
AB		UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun	CAHN
AB			EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar	NEWA
AB		WEST-WARD PHARMS INT	EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017	Sep	NEWA
AB		ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Jul	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
	DYMISTA					
AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
	+!	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Aug CTEC
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Aug CTEC

INJECTABLE;INJECTION

AZITHROMYCIN

	@ CSPC OUYI PHARM CO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Oct CAHN
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA

TABLET;ORAL

AZITHROMYCIN

	@ MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
	@	EQ 500MG BASE	A065366	001	May 30, 2007	May DISC
	ZITHROMAX					
AB	+ PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
AB	+	EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

AP	AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Oct NEWA
----	-------	-------------------	---------	-----	--------------	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

CORTISPORIN

	+! MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
--	-------------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Nov CPOT
	NEOSPORIN					
AT	+ CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar CAHN
	GABLOFEN					
	+! MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar CRLD
AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
	+!	1MG/ML	N022462	004	Jun 22, 2012	Apr CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN

TABLET;ORAL

BACLOFEN

	@ MYLAN	10MG	A077181	001	Jul 29, 2005	May DISC
AB	OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr CMS1
	RUBICON RES PVT LTD	5MG	A209102	001	Nov 28, 2017	Nov NEWA
AB		10MG	A209102	002	Nov 28, 2017	Nov NEWA
AB		20MG	A209102	003	Nov 28, 2017	Nov NEWA
AB	SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006	Nov CMS1
AB	USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN
>A>	AB VINTAGE PHARMS	10MG	A077068	002	Aug 30, 2005	Dec CMS1

BALSALAZIDE DISODIUM

	CAPSULE;ORAL						
	BALSALAZIDE DISODIUM						
AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul	CTEC
BX		750MG	A077806	001	Dec 28, 2007	Apr	CTEC

BARIUM SULFATE

	FOR SUSPENSION;ORAL						
	E-Z-CAT DRY						
+ @	BRACCO	40% (9GM/POUCH)	N208036	003	Jan 03, 2017	Nov	DISC
+!		40% (9GM/POUCH)	N208036	003	Jan 03, 2017	Aug	NEWA
	E-Z-HD						
+!	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr	CPOT
	E-Z-PAQUE						
+!	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr	NEWA
	SUSPENSION;ORAL						
	LIQUID E-Z-PAQUE						
+!	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar	NEWA
	READI-CAT 2 SMOOTHIES						
+!	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Nov	CHRS
	TAGITOL V						
+!	BRACCO	40% (8GM/20ML)	N208143	005	Aug 04, 2017	Aug	NEWA
	VARIBAR NECTAR						
+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017	Jul	NEWA

BECLOMETHASONE DIPROPIONATE

	AEROSOL, METERED;INHALATION						
	QVAR REDIHALER						
+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Aug	NEWA
+!		0.08MG/INH	N207921	002	Aug 03, 2017	Aug	NEWA

BENZAEPRIIL HYDROCHLORIDE

	TABLET;ORAL						
	BENZAEPRIIL HYDROCHLORIDE						
AB	AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
AB		10MG	A076820	002	Feb 03, 2006	Apr	CAHN
AB		20MG	A076820	003	Feb 03, 2006	Apr	CAHN
AB		40MG	A076820	004	Feb 03, 2006	Apr	CAHN

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	LOTENSIN HCT						
+ @	US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May	DISC

BENDROFLUMETHIAZIDE; NADOLOL

	TABLET;ORAL						
	CORZIDE						
AB	+ KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+!	5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN
	NADOLOL AND BENDROFLUMETHIAZIDE						
	@ MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Nov	DISC
	@	5MG;80MG	A078688	002	Feb 15, 2008	Nov	DISC

>A> BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

>A>	SOLUTION/DROPS;OPHTHALMIC						
>A>	ALTAFLUOR BENOX						
>A>	+!	ALTAIRE PHARMS INC	N208582	001	Dec 14, 2017	Dec	NEWA

BENZNIDAZOLE

	TABLET;ORAL						
	BENZNIDAZOLE						
+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017	Aug	NEWA
+!		100MG	N209570	002	Aug 29, 2017	Aug	NEWA

BENZONATATE

	CAPSULE;ORAL						
	TESSALON						
AA	+ PFIZER	100MG	N011210	001		Apr	CRLD

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB	TARO	5%;1.2%	A206218	001	Dec 15, 2017	Dec	NEWA
	AB	TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Jun	NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

	AA	ANDA REPOSITORY	50MG	A040578	001	Apr 17, 2006	Sep	CAHN
		@ EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May	CAHN
>D>	AA	MALLINCKRODT INC	50MG	A040773	001	Apr 25, 2007	Dec	CAHN
>A>	AA	SPECGX LLC	50MG	A040773	001	Apr 25, 2007	Dec	CAHN
	AA	TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

		@ ANDA REPOSITORY	1MG	A081264	001	Jan 23, 1992	Sep	CAHN
		@	2MG	A081265	001	Jan 23, 1992	Sep	CAHN
	AA	EPIC PHARMA LLC	0.5MG	A072264	001	Feb 27, 1989	May	CAHN
	AA		1MG	A072265	001	Feb 27, 1989	May	CAHN
	AA		2MG	A072266	001	Feb 27, 1989	May	CAHN
		OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	May	CMS1
			1MG	A040706	003	Feb 14, 2008	May	CMS1
	AA	! UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb	CAHN
	AA	!	1MG	A040103	002	Dec 12, 1996	Feb	CAHN
	AA	!	2MG	A040103	003	Dec 12, 1996	Feb	CAHN
	AA	! USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jun	CAHN
	AA	!	1MG	A040103	002	Dec 12, 1996	Jun	CAHN
	AA	!	2MG	A040103	003	Dec 12, 1996	Jun	CAHN

BETAINE HYDROCHLORIDE

FOR SOLUTION;ORAL

CYSTADANE

	+	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	Jul	CAHN
--	---	---------------	--------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	! FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan	CAHN
		@ TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr	CAHN
		DIPROSONE						
		+ @ SCHERING	EQ 0.05% BASE	N017781	001		Jan	CRLD

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	! FOUGERA PHARMS INC	EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug	CAHN
	AB	TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr	CAHN

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	TELLIGENT PHARMA INC	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Oct	NEWA
--	----	----------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

	AB	PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr	CAHN
	AB	RICONPHARMA LLC	0.12%	A207144	001	May 24, 2017	May	NEWA
	AB	TARO PHARM	0.12%	A208204	001	May 24, 2017	May	NEWA

LUXIQ

	AB	! MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN
--	----	--------------------	-------	---------	-----	--------------	-----	------

CREAM;TOPICAL

BETAMETHASONE VALERATE

	AB	! FOUGERA PHARMS INC	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Aug	CAHN
--	----	----------------------	--------------	---------	-----	--------------	-----	------

LOTION;TOPICAL

BETAMETHASONE VALERATE

	AB	! FOUGERA PHARMS INC	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Aug	CAHN
--	----	----------------------	--------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

BETAMETHASONE VALERATE

	AB	! FOUGERA PHARMS INC	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Aug	CAHN
--	----	----------------------	--------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT	MEDIMETRIKS PHARMS	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Sep	CAHN
AT	TELIGENT	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Apr	CAHN

BETHANECHOL CHLORIDETABLET;ORAL
BETHANECHOL CHLORIDE

AA	ECI PHARMS LLC	5MG	A 040725	001	Oct 26, 2007	Sep	CAHN
AA		10MG	A 040726	001	Oct 26, 2007	Sep	CAHN
AA		25MG	A 040727	001	Oct 26, 2007	Sep	CAHN
AA		50MG	A 040728	001	Oct 26, 2007	Sep	CAHN
	@ IMPAX LABS	5MG	A 040721	001	Nov 01, 2006	Jan	CMS1
	@	10MG	A 040721	002	Nov 01, 2006	Jan	CMS1
	@	25MG	A 040721	003	Nov 01, 2016	Jan	CMS1
AA	LANNETT HOLDINGS INC	5MG	A 040677	002	Mar 27, 2008	May	CMS1
AA		10MG	A 040677	003	Mar 27, 2008	May	CMS1
AA		25MG	A 040677	004	Mar 27, 2008	May	CMS1
AA	UPSHER-SMITH LABS	5MG	A 040633	001	Jun 01, 2005	Jun	CAHN
AA		10MG	A 040634	001	Jun 01, 2005	Jun	CAHN
AA		25MG	A 040635	001	Jun 01, 2005	Jun	CAHN
AA		50MG	A 040636	001	Jun 01, 2005	Jun	CAHN

BETRIXABANCAPSULE;ORAL
BEVYXXA

+	PORTOLA PHARMS INC	40MG	N 208383	001	Jun 23, 2017	Jun	NEWA
+	!	80MG	N 208383	002	Jun 23, 2017	Jun	NEWA

BICALUTAMIDETABLET;ORAL
BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A 091011	001	Jun 10, 2015	May	CAHN
AB	WATSON LABS TEVA	50MG	A 078634	001	Aug 28, 2009	May	CAHN
	CASODEX						
AB	+! ASTRAZENECA PHARMS	50MG	N 020498	001	Oct 04, 1995	May	CAHN

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT	SANDOZ INC	0.03%	A 202565	001	May 05, 2015	Mar	CAHN
----	------------	-------	----------	-----	--------------	-----	------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDETABLET, CHEWABLE, TABLET, CAPSULE;ORAL
HELIDAC

+	@ CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG	N 050719	001	Aug 15, 1996	Jul	CAHN
---	---------------------	---	----------	-----	--------------	-----	------

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

	@ ANDA REPOSITORY	5MG	A 075474	001	Oct 25, 2002	Sep	CAHN
	@	10MG	A 075474	002	Oct 25, 2002	Sep	CAHN
AB	ORIT LABS LLC	5MG	A 204891	001	Jan 11, 2017	Jan	NEWA
AB		10MG	A 204891	002	Jan 11, 2017	Jan	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS TEVA	2.5MG;6.25MG	A 075469	001	Sep 25, 2000	May	CAHN
	@	5MG;6.25MG	A 075469	002	Sep 25, 2000	May	CAHN
	@	10MG;6.25MG	A 075469	003	Sep 25, 2000	May	CAHN
	ZIAC						
AB	+ TEVA BRANDED PHARM	2.5MG;6.25MG	N 020186	003	Mar 26, 1993	Jan	CAHN
AB	+	5MG;6.25MG	N 020186	001	Mar 26, 1993	Jan	CAHN
AB	+	10MG;6.25MG	N 020186	002	Mar 26, 1993	Jan	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS
BIVALIRUDIN

AP	ACCORD HLTHCARE	250MG/VIAL	A206551	001	Nov 22, 2017	Nov	NEWA	
AP	APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun	NEWA	
AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May	NEWA	
>A>	SOLUTION; IV (INFUSION)							
>A>	BIVALIRUDIN IN 0.9% SODIUM CHLORIDE							
>A>	+!	CELERITY PHARMS	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Dec	NEWA
>A>	+!		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Dec	NEWA

BORTEZOMIB

POWDER; INTRAVENOUS
BORTEZOMIB

	FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	Nov	NEWA
--	--------------------	------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET, FOR SUSPENSION; ORAL
TRACLEER

+!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017	Sep	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

BOSUTINIB MONOHYDRATE

TABLET; ORAL
BOSULIF

+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Oct	NEWA
---	-------------	---------------	---------	-----	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
---	----------------------	---------	---------	-----	--------------	-----	------

BREXPIPIRAZOLE

TABLET; ORAL
REXULTI

+!	OTSUKA PHARM CO LTD	2MG	N205422	004	Jul 10, 2015	Aug	CHRS
+		4MG	N205422	006	Jul 10, 2015	Aug	CHRS

BRIGATINIB

TABLET; ORAL
ALUNBRIG

+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr	NEWA
+!		90MG	N208772	002	Apr 28, 2017	Apr	NEWA
+		180MG	N208772	003	Oct 02, 2017	Oct	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT	SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
AT		0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
	QOLIANA						
AT	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN	
AT1	!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
AT2	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

@	UPSHER-SMITH LABS	4MG	A083215	001		Jun	CAHN
---	-------------------	-----	---------	-----	--	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

AA	TARO PHARM	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
----	------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE; ORAL		BUDESONIDE					
AB	AMNEAL PHARMS	3MG		A206200	001	Jul 31, 2017	Jul NEWA
AB	APPCO PHARMA LLC	3MG		A207367	001	Apr 07, 2017	Mar NEWA
AB	SCIECURE PHARMA INC	3MG		A209041	001	Sep 28, 2017	Sep NEWA
AB	ZYDUS PHARMS USA INC	3MG		A206134	001	May 04, 2017	Apr NEWA
SUSPENSION; INHALATION		BUDESONIDE					
AN	CIPLA LTD	0.25MG/2ML		A205710	001	Nov 16, 2017	Oct NEWA
AN		0.5MG/2ML		A205710	002	Nov 16, 2017	Oct NEWA
AN		1MG/2ML		A205710	003	Nov 16, 2017	Oct NEWA

BUMETANIDE

INJECTABLE; INJECTION		BUMETANIDE					
AP	! ATHENEX INC	0.25MG/ML		A074441	001	Jan 27, 1995	Mar CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML		A079196	001	Apr 30, 2008	Jan CAHN
BUMEX							
	+ @ VALIDUS PHARMS	0.25MG/ML		N018226	001	Feb 28, 1983	Jun CAHN
TABLET; ORAL		BUMETANIDE					
AB	AMNEAL PHARMS CO	0.5MG		A209724	001	Oct 18, 2017	Oct NEWA
AB		1MG		A209724	002	Oct 18, 2017	Oct NEWA
AB		2MG		A209724	003	Oct 18, 2017	Oct NEWA
BUMEX							
AB	+ VALIDUS PHARMS	0.5MG		N018225	002	Feb 28, 1983	Jun CAHN
AB	+	1MG		N018225	001	Feb 28, 1983	Jun CAHN
AB	+	2MG		N018225	003	Jun 14, 1985	Jun CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL		BUPIVACAINE HYDROCHLORIDE					
AP	BAXTER HLTHCARE CORP	0.75%		A207266	001	Jul 25, 2016	Aug CAHN

BUPRENORPHINE

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS		SUBLOCADE					
	+ INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)		N209819	001	Nov 29, 2017	Nov NEWA
	+!	300MG/1.5ML (200MG/ML)		N209819	002	Nov 29, 2017	Nov NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL		BELBUCA					
	+ BDSI	EQ 0.075MG BASE		N207932	001	Oct 23, 2015	Jan CAHN
	+	EQ 0.15MG BASE		N207932	002	Oct 23, 2015	Jan CAHN
	+	EQ 0.3MG BASE		N207932	003	Oct 23, 2015	Jan CAHN
	+	EQ 0.45MG BASE		N207932	004	Oct 23, 2015	Jan CAHN
	+	EQ 0.6MG BASE		N207932	005	Oct 23, 2015	Jan CAHN
	+	EQ 0.75MG BASE		N207932	006	Oct 23, 2015	Jan CAHN
	+!	EQ 0.9MG BASE		N207932	007	Oct 23, 2015	Jan CAHN
TABLET; SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE					
AB	RHODES PHARMS	EQ 2MG BASE		A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE		A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
AB	AMNEAL PHARMS	EQ 8MG BASE; EQ 2MG BASE		A203136	002	Feb 22, 2013	May CAHN
>A>	AB MALLINCKRODT INC	EQ 2MG BASE; EQ 0.5MG BASE		A207000	001	Dec 13, 2017	Dec NEWA
>A>	AB	EQ 8MG BASE; EQ 2MG BASE		A207000	002	Dec 13, 2017	Dec NEWA
>A>	AB SPECGX LLC	EQ 2MG BASE; EQ 0.5MG BASE		A207000	001	Dec 13, 2017	Dec CAHN
>A>	AB	EQ 8MG BASE; EQ 2MG BASE		A207000	002	Dec 13, 2017	Dec CAHN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE		A203136	001	Feb 22, 2013	May CAHN
ZUBSOLV							
	+ OREXO US INC	EQ 5.7MG BASE; EQ 1.4MG BASE		N204242	002	Jul 03, 2013	Jan CHRS
	+!	EQ 11.4MG BASE; EQ 2.9MG BASE		N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE						
AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Sep NEWA
AB		100MG	A207389	002	Sep 18, 2017	Sep NEWA
WELLBUTRIN						
+ @	GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	Sep CRLD
+ @		75MG	N018644	002	Dec 30, 1985	Sep CRLD
+ @		100MG	N018644	003	Dec 30, 1985	Sep CRLD
TABLET, EXTENDED RELEASE; ORAL						
BUPROPION HYDROCHLORIDE						
AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207224	002	Jun 30, 2017	Jun NEWA
AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207459	002	Jun 30, 2017	Jun NEWA
AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA
AB3	SINOTHERAPEUTICS INC	150MG	A208652	001	Aug 21, 2017	Aug NEWA
AB3		300MG	A208652	002	Aug 21, 2017	Aug NEWA
AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016	Sep CAHN
AB3	TWI PHARMS INC	150MG	A210081	001	Nov 03, 2017	Oct NEWA
AB3		300MG	A210081	002	Nov 03, 2017	Oct NEWA
FORFIVO XL						
+!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE						
AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA
AB		7.5MG	A208829	002	May 24, 2017	May NEWA
AB		10MG	A208829	003	May 24, 2017	May NEWA
AB		15MG	A208829	004	May 24, 2017	May NEWA
AB		30MG	A208829	005	May 24, 2017	May NEWA
@	MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
@		10MG	A075467	003	Feb 28, 2002	Jun DISC
@		15MG	A075467	004	Feb 28, 2002	Jun DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN
AB		7.5MG	A202330	005	Feb 17, 2017	Sep NEWA
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	ACTAVIS LLC	6MG/ML	A205139	001	Dec 08, 2017	Nov NEWA
>A>	AMNEAL PHARMS CO	6MG/ML	A209580	001	Dec 18, 2017	Dec NEWA
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA
AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun NEWA
MYLERAN						
AP	ASPEN GLOBAL INC	6MG/ML	A208536	001	Nov 20, 2017	Nov NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

@	MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
+!		30MG	N000793	004		Mar CAHN
@		50MG	N000793	003		Mar CAHN
@		100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@	BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001	Aug CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
@	BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001	Aug CAHN
@		2MG/ML	A075695	002	Oct 23, 2001	Aug CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFFEINE CITRATE

>A>	AP	MICRO LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A207400	001	Dec 14, 2017	Dec	NEWA
-----	----	------------	------------------------------------	---------	-----	--------------	-----	------

CALCIPOTRIENEAEROSOL, FOAM;TOPICAL
SORILUX

+!	MAYNE PHARMA	0.005%		N022563	001	Oct 06, 2010	Jan	CAHN
----	--------------	--------	--	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
CALCIPOTRIENE

!	GLENMARK PHARMS INC	0.005%		A090633	001	Mar 24, 2010	May	CAHN
---	---------------------	--------	--	---------	-----	--------------	-----	------

SOLUTION;TOPICAL
CALCIPOTRIENE

>A>	AT	NOVEL LABS INC	0.005%	A207163	001	Dec 26, 2017	Dec	NEWA
-----	----	----------------	--------	---------	-----	--------------	-----	------

CALCITONIN SALMONSPRAY, METERED;NASAL
CALCITONIN-SALMON

AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr	CHRS
----	---	------------	--------------	---------	-----	--------------	-----	------

MIACALCIN

+	@	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr	DISC
---	---	-------------------	--------------	---------	-----	--------------	-----	------

CALCITONIN SALMON RECOMBINANTSPRAY, METERED;NASAL
FORTICAL

@	UPSHER-SMITH LABS	200 IU/SPRAY		N021406	001	Aug 12, 2005	Jun	CAHN
---	-------------------	--------------	--	---------	-----	--------------	-----	------

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB		AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May	NEWA
----	--	---------------	---------	---------	-----	--------------	-----	------

AB			0.5MCG	A203289	001	Jun 14, 2017	May	NEWA
----	--	--	--------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION
CALCIJEX

+	@	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May	CRLD
---	---	--------	------------	---------	-----	--------------	-----	------

+	@		0.002MG/ML	N018874	002	Sep 25, 1986	May	CRLD
---	---	--	------------	---------	-----	--------------	-----	------

CALCITRIOL

!	AKORN	0.001MG/ML		A078066	001	Jan 29, 2008	May	CHRS
---	-------	------------	--	---------	-----	--------------	-----	------

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

AB		CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar	CAHN
----	--	--------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL
CALCIUM ACETATE

AB	!	PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr	CHRS
----	---	-------------	-------	---------	-----	--------------	-----	------

ELIPHOS

AB		CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	CHRS
----	--	---------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDEINJECTABLE;INJECTION
CALCIUM CHLORIDE 10%

AP		LUITPOLD PHARMS INC	100MG/ML	A209088	001	Jul 27, 2017	Jul	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	+!	HOSPIRA	100MG/ML	N021117	001	Jan 28, 2000	Jul	CFTG
----	----	---------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

@	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;86	0MG/100ML	N018254	001		Aug	DISC
---	---------	------------------------------------	-----------	---------	-----	--	-----	------

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B	BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;86	0MG/100ML	N020000	001	Apr 17, 1992	Aug	CTEC
---	-------	------------------------------------	-----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 30MG/100ML; 60 0MG/100ML; 310MG/100ML	N017608	001			Dec	CRLD
>A>	AP	+	20MG/100ML; 5GM/100ML; 30MG/100ML; 60 0MG/100ML; 310MG/100ML	N017608	001			Dec	CRLD
	AP		20MG/100ML; 5GM/100ML; 30MG/100ML; 60 0MG/100ML; 310MG/100ML	N017608	001			Feb	CAHN
			POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		@ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988		Feb	CAHN
		@	20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988		Feb	CAHN
			POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		@ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988		Feb	CAHN
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	002	Oct 17, 1988		Feb	CAHN
	AP		20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	008	Oct 17, 1988		Feb	CAHN
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		@ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988		Feb	CAHN
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988		Feb	CAHN
			POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
		@ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988		Feb	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

	AP	ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251	001			Feb	CAHN
			SOLUTION; IRRIGATION						
			RINGER'S IN PLASTIC CONTAINER						
	AT	ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N017635	001			Feb	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

	AP	ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017641	001			Feb	CAHN
			SOLUTION; IRRIGATION						
			LACTATED RINGER'S IN PLASTIC CONTAINER						
	AT	+! ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019416	001	Jan 17, 1986		Feb	CAHN

CALCIUM GLUCONATE

SOLUTION; IV (INFUSION)

CALCIUM GLUCONATE

	+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Jun	NEWA
	+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Jun	NEWA
	+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Jun	NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

	AB	ALEMBIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017	Jun	NEWA
	AB	ZYDUS PHARMS USA INC	4MG	A091390	001	Aug 23, 2017	Aug	NEWA
	AB		8MG	A091390	002	Aug 23, 2017	Aug	NEWA
	AB		16MG	A091390	003	Aug 23, 2017	Aug	NEWA
	AB		32MG	A091390	004	Aug 23, 2017	Aug	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

	AB	MYLAN PHARMS INC	16MG; 12.5MG	A090704	001	Dec 04, 2012	May	CAHN
	AB		32MG; 12.5MG	A090704	002	Dec 04, 2012	May	CAHN
	AB		32MG; 25MG	A090704	003	Dec 04, 2012	May	CAHN
	AB	ZYDUS PHARMS USA INC	16MG; 12.5MG	A203466	001	Nov 27, 2017	Nov	NEWA

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		32MG;12.5MG	A203466	002	Nov 27, 2017	Nov	NEWA
AB		32MG;25MG	A203466	003	Nov 27, 2017	Nov	NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ALKEM LABS LTD	150MG	A207652	001	Nov 24, 2017	Nov	NEWA
AB		500MG	A207652	002	Nov 24, 2017	Nov	NEWA
AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb	NEWA
AB		500MG	A204741	002	Feb 28, 2017	Feb	NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

AP	+! AKORN	EQ 1GM BASE/VIAL	N050095	001		Nov	CFTG
AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Nov	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@ BOSCOGEN	12.5MG	A074677	004	May 30, 1997	May	CAHN
	@	25MG	A074677	002	May 30, 1997	May	CAHN
	@	50MG	A074677	001	May 30, 1997	May	CAHN
	@	100MG	A074677	003	May 30, 1997	May	CAHN
>A>	@ FOSUN PHARMA	12.5MG	A074363	001	Nov 09, 1995	Dec	CAHN
>A>	@	25MG	A074363	002	Nov 09, 1995	Dec	CAHN
>A>	@	50MG	A074363	003	Nov 09, 1995	Dec	CAHN
>A>	@	100MG	A074363	004	Nov 09, 1995	Dec	CAHN
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar	CAHN
AB		25MG	A074434	002	Feb 13, 1996	Mar	CAHN
AB		50MG	A074434	003	Feb 13, 1996	Mar	CAHN
AB	!	100MG	A074434	004	Feb 13, 1996	Mar	CAHN
>D>	@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Dec	CAHN
>D>	@	25MG	A074363	002	Nov 09, 1995	Dec	CAHN
>D>	@	50MG	A074363	003	Nov 09, 1995	Dec	CAHN
>D>	@	100MG	A074363	004	Nov 09, 1995	Dec	CAHN
>D>	AB WOCKHARDT	12.5MG	A074532	001	Mar 28, 1997	Dec	CAHN
>D>	AB	25MG	A074532	002	Mar 28, 1997	Dec	CAHN
>D>	AB	50MG	A074532	003	Mar 28, 1997	Dec	CAHN
>D>	AB	100MG	A074532	004	Mar 28, 1997	Dec	CAHN
>A>	AB WOCKHARDT LTD	12.5MG	A074532	001	Mar 28, 1997	Dec	CAHN
>A>	AB	25MG	A074532	002	Mar 28, 1997	Dec	CAHN
>A>	AB	50MG	A074532	003	Mar 28, 1997	Dec	CAHN
>A>	AB	100MG	A074532	004	Mar 28, 1997	Dec	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

EQUETRO

+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004	Jun	CAHN
+		200MG	N021710	002	Dec 10, 2004	Jun	CAHN
+	!	300MG	N021710	003	Dec 10, 2004	Jun	CAHN

SOLUTION;IV (INFUSION)

CARNEXIV

+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan	CAHN
---	---------------------	----------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

CARBAMAZEPINE

>D>	AB WOCKHARDT	100MG/5ML	A075714	001	Jun 05, 2002	Dec	CAHN
>A>	AB WOCKHARDT BIO AG	100MG/5ML	A075714	001	Jun 05, 2002	Dec	CAHN
	AB TERIL						
	AB TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	NOVEL LABS INC	25MG	A204763	001	Oct 20, 2017	Oct	NEWA
----	----------------	------	---------	-----	--------------	-----	------

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

@	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May	CAHN
@		150MG/VIAL	A076162	002	Oct 14, 2004	May	CAHN
@		450MG/VIAL	A076162	003	Oct 14, 2004	May	CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan	NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr	NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr	NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr	NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr	NEWA

CARISOPRODOLCAPSULE; ORAL
SOMA

@	MYLAN SPECIALITY LP	250MG	N011792	003		Mar	CAHN
---	---------------------	-------	---------	-----	--	-----	------

TABLET; ORAL

CARISOPRODOL

@	EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May	CAHN
AA	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr	CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr	NEWA
	SOMA						
AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar	CAHN
AA	+	350MG	N011792	001		Mar	CAHN

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May	CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar	CAHN
	OCUPRESS						
+	@ NOVARTIS	1%	N019972	001	May 23, 1990	May	DISC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007	Jul	DISC
@		6.25MG	A078240	002	Oct 30, 2007	Jul	DISC
@		12.5MG	A078240	003	Oct 30, 2007	Jul	DISC
@		25MG	A078240	004	Oct 30, 2007	Jul	DISC

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL
CARVEDILOL PHOSPHATE

AB	SUN PHARM INDUSTRIES	10MG	A090132	001	Oct 25, 2017	Oct	NEWA
AB		20MG	A090132	002	Oct 25, 2017	Oct	NEWA
AB		40MG	A090132	003	Oct 25, 2017	Oct	NEWA
AB		80MG	A090132	004	Oct 25, 2017	Oct	NEWA
	COREG CR						
AB	+ SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	Oct	CFTG
AB	+	20MG	N022012	002	Oct 20, 2006	Oct	CFTG
AB	+!	40MG	N022012	003	Oct 20, 2006	Oct	CFTG
AB	+	80MG	N022012	004	Oct 20, 2006	Oct	CFTG

CASPOFUNGIN ACETATEPOWDER; IV (INFUSION)
CANCIDAS

AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR
AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR
	CASPOFUNGIN ACETATE						
AP	GLAND PHARMA LTD	50MG/VIAL	A207092	001	Sep 29, 2017	Sep	NEWA
AP		70MG/VIAL	A207092	002	Sep 29, 2017	Sep	NEWA

INJECTABLE; INJECTION

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984	Sep CRLD
+ @	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984	Sep CRLD

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB		500MG	A065340	002	May 24, 2007	Jan CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE SODIUM

AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	A090701	001	Oct 04, 2017	Sep NEWA
AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
	+ @ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+ @	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+ @	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	ACS DOBFAR SPA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep CAHN	
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep CAHN	
	ZINACEF						
AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN
	ZINACEF IN PLASTIC CONTAINER						
	@ TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN	
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN	
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS						
	CEFUROXIME SODIUM						
AB	ACS DOBFAR SPA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep CAHN	
	ZINACEF						
AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXIN

	CAPSULE;ORAL							
	CEPHALEXIN							
AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A 065253	001	Nov 16, 2005	Jan	CAHN	
AB		EQ 500MG BASE	A 065253	002	Nov 16, 2005	Jan	CAHN	
	FOR SUSPENSION;ORAL							
	CEPHALEXIN							
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A 065336	001	Jul 25, 2007	Aug	CMFD	
AB		EQ 250MG BASE/5ML	A 065336	002	Jul 25, 2007	Aug	CMFD	

CEPHAPIRIN SODIUM

	INJECTABLE;INJECTION							
	CEPHAPIRIN SODIUM							
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A 062720	001	Jul 02, 1987	Jan	CAHN	
	@	EQ 1GM BASE/VIAL	A 062720	002	Jul 02, 1987	Jan	CAHN	
	@	EQ 2GM BASE/VIAL	A 062720	003	Jul 02, 1987	Jan	CAHN	
	@	EQ 20GM BASE/VIAL	A 062720	004	Jul 02, 1987	Jan	CAHN	

CETIRIZINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	ZERVIAE							
	+! EYEVANCE PHARMS	EQ 0.24% BASE	N 208694	001	May 30, 2017	Oct	CAHN	
	+! NICOX OPTHALMICS	EQ 0.24% BASE	N 208694	001	May 30, 2017	May	NEWA	
	SYRUP;ORAL							
	CETIRIZINE HYDROCHLORIDE							
AA	ALLIED PHARMA INC	5MG/5ML	A 090191	001	Nov 12, 2009	Apr	CAHN	

CEVIMELINE HYDROCHLORIDE

	CAPSULE;ORAL							
	CEVIMELINE HYDROCHLORIDE							
AB	RISING PHARMS INC	30MG	A 203775	001	Jun 04, 2014	May	CAHN	

CHENODIOL

	TABLET;ORAL							
	CHENIX							
	+ @ LEADIANT BIOSCI INC	250MG	N 018513	002	Jul 28, 1983	Feb	CAHN	

CHLORAMPHENICOL SODIUM SUCCINATE

	INJECTABLE;INJECTION							
	CHLOROMYCETIN							
	+ @ PARKEDALE	EQ 1GM BASE/VIAL	N 050155	001		Mar	CRLD	

CHLORDIAZEPOXIDE HYDROCHLORIDE

	CAPSULE;ORAL							
	CHLORDIAZEPOXIDE HYDROCHLORIDE							
	@ UPSHER-SMITH LABS	5MG	A 084678	001		Jun	CAHN	
	@	5MG	A 084919	001		Aug	CAHN	
	@	10MG	A 084041	001		Jun	CAHN	
	@	10MG	A 084920	001		Aug	CAHN	
	@	25MG	A 084679	002		Jun	CAHN	
	@	25MG	A 084823	001		Aug	CAHN	

CHLORHEXIDINE GLUCONATE

	SOLUTION;DENTAL							
	CHLORHEXIDINE GLUCONATE							
>D>	AT	WOCKHARDT	0.12%	A 075006	001	Mar 03, 2004	Dec	CAHN
>A>	AT	WOCKHARDT BIO AG	0.12%	A 075006	001	Mar 03, 2004	Dec	CAHN
	PERIOGARD							
AT	COLGATE PALMOLIVE CO	0.12%	A 073695	001	Jan 14, 1994	May	CAHN	

CHLOROPROCAINE HYDROCHLORIDE

	SOLUTION;INTRATHECAL							
	CLOROTEKAL							
>A>	+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N 208791	001	Sep 26, 2017	Dec	CAHN
>D>	+	SINETICA SA	50MG/5ML (10MG/ML)	N 208791	001	Sep 26, 2017	Dec	CAHN
	+		50MG/5ML (10MG/ML)	N 208791	001	Sep 26, 2017	Sep	NEWA

CHLOROQUINE PHOSPHATE

	TABLET;ORAL						
	ARALEN						
	+ @ SANOFI AVENTIS US	EQ 300MG BASE		N006002	001		Sep DISC
	CHLOROQUINE PHOSPHATE						
AA	! NATCO PHARMA LTD	EQ 300MG BASE		A090612	001	Jan 21, 2011	Sep CHRS

CHLOROTHIAZIDE

	TABLET;ORAL						
	CHLOROTHIAZIDE						
	! MYLAN	250MG		A084217	002		Sep CMS1

CHLORPHENESIN CARBAMATE

	TABLET;ORAL						
	MAOLATE						
	@ PAMLAB LLC	400MG		N014217	002		Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

	SOLUTION;ORAL						
	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE						
AA	ACELLA PHARMS LLC	4MG/5ML;5MG/5ML		A206891	001	Jun 09, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML;5MG/5ML		A206438	001	Jan 27, 2015	Sep DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION;ORAL						
	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
AA	BIO-PHARM INC	4MG/5ML;5MG/5ML;60MG/5ML		A206660	001	May 15, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML		A203838	001	Nov 26, 2014	Sep DISC

CHLORPROMAZINE HYDROCHLORIDE

	TABLET;ORAL						
	CHLORPROMAZINE HYDROCHLORIDE						
	USL PHARMA	10MG		A083386	001		Jun CAHN
		10MG		A083386	001		May CTEC
	!	25MG		A084112	001		Jun CAHN
	!	25MG		A084112	001		May CHRS
		50MG		A084113	001		Jun CAHN
		50MG		A084113	001		May CTEC
	!	100MG		A084114	001		Jun CAHN
	!	100MG		A084114	001		May CHRS
		200MG		A084115	001		Jun CAHN
		200MG		A084115	001		May CTEC
	THORAZINE						
	@ GLAXOSMITHKLINE	10MG		N009149	002		May CRLD
	@	25MG		N009149	007		May CRLD
	@	50MG		N009149	013		May CRLD
	@	100MG		N009149	018		May CRLD
	@	200MG		N009149	020		May CRLD

CHLORPROPAMIDE

	TABLET;ORAL						
	CHLORPROPAMIDE						
	@ ANI PHARMS INC	250MG		A087353	001		Jan CAHN
	@ WATSON LABS TEVA	250MG		A088826	001	Sep 26, 1984	May CAHN
	GLUCAMIDE						
AB	ANI PHARMS INC	250MG		A088641	001	Oct 11, 1984	Jul CMFD

CHLORTHALIDONE

	TABLET;ORAL						
	CHLORTHALIDONE						
AB	RICONPHARMA LLC	25MG		A206904	001	Mar 30, 2017	Mar NEWA
AB		50MG		A206904	002	Mar 30, 2017	Mar NEWA

CHOLESTYRAMINE

	POWDER;ORAL						
	CHOLESTYRAMINE LIGHT						
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL		A202902	001	Apr 25, 2017	Aug CTNA
AB		EQ 4GM RESIN/SCOOPFUL		A202902	001	Apr 25, 2017	Apr NEWA
	PREVALITE						
AB	UPSHER-SMITH LABS	EQ 4GM RESIN/PACKET		A073263	001	Feb 22, 1996	Jun CAHN
AB		EQ 4GM RESIN/SCOOPFUL		A073263	002	Oct 30, 1997	Jun CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS
CHOLINE C-11

AP	UCSF RODIOPHARM	4-33.1mCi/ML	A208444	001	Nov 20, 2017	Nov	NEWA
	UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015	Jul	CPOT

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL
FENOFIBRIC ACID

AB	ALEMBIC PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A208705	001	May 12, 2017	May	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A208705	002	May 12, 2017	May	NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION
ALVESCO

+	ASTRAZENECA PHARMS	0.08MG/INH	N021658	002	Jan 10, 2008	Jul	CAHN
+		0.16MG/INH	N021658	003	Jan 10, 2008	Jul	CAHN

AEROSOL, METERED; NASAL
ZETONNA

+	ASTRAZENECA PHARMS	0.037MG/INH	N202129	001	Jan 20, 2012	Jul	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
OMNARIS

+	ASTRAZENECA PHARMS	0.05MG/INH	N022004	001	Oct 20, 2006	Jul	CAHN
---	--------------------	------------	---------	-----	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

AB	PERRIGO NEW YORK	0.77%	A077364	001	Mar 03, 2006	Apr	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL
CICLOPIROX

AB	+	CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Sep	CTNA
----	---	------------------	-------	---------	-----	--------------	-----	------

SHAMPOO; TOPICAL
CICLOPIROX

AT	PERRIGO CO	1%	A078594	001	Feb 16, 2010	Apr	CAHN
----	------------	----	---------	-----	--------------	-----	------

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

AB	CHARTWELL RX	50MG	A077722	001	Sep 24, 2012	Sep	CAHN
AB		100MG	A077831	001	Sep 24, 2012	Sep	CAHN
	@ EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May	CAHN
	@	100MG	A077022	001	Nov 23, 2004	May	CAHN
	@ MYLAN	50MG	A077323	002	Apr 20, 2006	May	DISC
	@	100MG	A077323	001	Apr 20, 2006	May	DISC
	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar	DISC
	@	100MG	A077019	002	Nov 23, 2004	Mar	DISC
	@ PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar	DISC
	@	100MG	A077898	002	Oct 29, 2007	Mar	DISC
	PLETAL						
	+ @ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan	CRLD
	+ @	100MG	N020863	002	Jan 15, 1999	Jan	CRLD

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan	CAHN
	@	300MG	A074281	002	May 17, 1994	Jan	CAHN
	@	400MG	A074281	003	May 17, 1994	Jan	CAHN
	@	800MG	A074329	001	May 17, 1994	Jan	CAHN
>A>	@ FOSUN PHARMA	200MG	A074100	001	Jan 31, 1995	Dec	CAHN
>A>	@	300MG	A074100	002	Jan 31, 1995	Dec	CAHN
>A>	@	400MG	A074100	003	Jan 31, 1995	Dec	CAHN
>A>	@	800MG	A074100	004	Jan 31, 1995	Dec	CAHN
>D>	@ SANDOZ	200MG	A074100	001	Jan 31, 1995	Dec	CAHN
>D>	@	300MG	A074100	002	Jan 31, 1995	Dec	CAHN
>D>	@	400MG	A074100	003	Jan 31, 1995	Dec	CAHN
>D>	@	800MG	A074100	004	Jan 31, 1995	Dec	CAHN
	@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar	CAHN
	@	300MG	A074250	002	Jun 29, 1995	Mar	CAHN
	@	400MG	A074250	003	Jun 29, 1995	Mar	CAHN
	@	800MG	A074250	004	Jun 29, 1995	Mar	CAHN

TABLET;ORAL

CIMETIDINE

	@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun	CAHN
	@	300MG	A074506	002	Jan 24, 1996	Jun	CAHN
	@	400MG	A074506	003	Jan 24, 1996	Jun	CAHN
	@	800MG	A074506	004	Jan 24, 1996	Jun	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

	DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	Nov	CTEC
--	-----------------	-------------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May	CAHN
>D>	AA WOCKHARDT	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Dec	CAHN
>A>	AA WOCKHARDT BIO AG	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Dec	CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPRO

	+ @ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb	DISC
	+ @	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb	DISC
	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+ @ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb	DISC
	+ @	400MG/200ML	N019857	002	Dec 26, 1990	Feb	DISC

CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Aug	CAHN
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Aug	CAHN
AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb	CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb	CHRS
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE CORP	200MG/100ML	A078024	001	Mar 18, 2008	Aug	CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Aug	CAHN
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb	CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb	CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

	@ AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Oct	DISC
AT		EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar	CAHN
AT	TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr	CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@ MYLAN	EQ 250MG BASE	A075685	002	Jun 09, 2004	Aug	DISC
	@	EQ 500MG BASE	A075685	003	Jun 09, 2004	Aug	DISC
	@	EQ 750MG BASE	A075685	001	Jun 09, 2004	Aug	DISC
AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar	CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar	CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar	CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar	CAHN
AB	UNIQUE PHARM LABS	EQ 250MG BASE	A076639	001	Sep 10, 2004	Aug	CAHN
AB		EQ 500MG BASE	A076639	002	Sep 10, 2004	Aug	CAHN
AB		EQ 750MG BASE	A076639	003	Sep 10, 2004	Aug	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun	NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A209334	001	Aug 30, 2017	Aug	NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun	NEWA
AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun	NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan	NEWA
AP		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Nov	CAIN

CISATRACURIUM BESYLATE PRESERVATIVE FREE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	JIANGSU HENGRUI MED	EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Sep	NEWA
----	---------------------	-----------------	---------	-----	--------------	-----	------

CISPLATIN

INJECTABLE; INJECTION		CISPLATIN					
AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar	NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar	CRLD
PLATINOL							
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar	CRLD
	+ @	50MG/VIAL	N018057	002		Mar	CRLD
PLATINOL-AQ							
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar	CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL		CITALOPRAM HYDROBROMIDE					
	@ MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar	DISC
	@	EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar	DISC
	@	EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar	DISC
SOLUTION; ORAL		CITALOPRAM HYDROBROMIDE					
AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan	CAHN
TABLET; ORAL		CITALOPRAM HYDROBROMIDE					
	@ EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May	CAHN
	@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May	CAHN
	@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May	CAHN
	@ MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun	DISC
	@	EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun	DISC
	@	EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun	DISC
	@ MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May	DISC
	@	EQ 20MG BASE	A077037	002	Nov 05, 2004	May	DISC
	@	EQ 40MG BASE	A077037	003	Nov 05, 2004	May	DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL		PREPOPIK					
	+! FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET	N202535	001	Jul 16, 2012	Mar	CAHN
		ET					
SOLUTION; ORAL		CLENPIQ					
	+! FERRING PHARMS INC	12GM/160ML; 3.5GM/160ML; 10MG/160ML	N209589	001	Nov 28, 2017	Nov	NEWA

CLARITHROMYCIN

TABLET; ORAL		CLARITHROMYCIN					
	@ MYLAN	250MG	A065195	001	Mar 11, 2005	May	DISC
	@	500MG	A065195	002	Mar 11, 2005	May	DISC

CLEMASTINE FUMARATE

TABLET; ORAL		CLEMASTINE FUMARATE					
	@ SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb	DISC
	! TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb	CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL		CLINDAMYCIN HYDROCHLORIDE					
AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May	CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May	CAHN
AB	LANNETT	EQ 75MG BASE	A065243	002	Aug 12, 2005	Aug	CMS1
	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May	DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May	DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May	DISC
CLINDAMYCIN HYDROCHLORIDE							
AB	LANNETT	EQ 150MG BASE	A065243	003	Aug 12, 2005	Aug	CMS1

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL		CLINDAMYCIN PALMITATE HYDROCHLORIDE					
AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr	NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun	CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr	CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL							
EVOCLIN							
AT	+!	MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
INJECTABLE;INJECTION							
CLINDAMYCIN PHOSPHATE							
AP		MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Sep NEWA
AP			EQ 150MG BASE/ML	A204749	001	Oct 10, 2017	Sep NEWA
AP		SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
AP		WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jul CAHN
AP			EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jul CAHN
AP			EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jul CAHN
AP		CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
AP			EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
AP			EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA
SOLUTION;IV (INFUSION)							
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE							
+!		BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
+!			EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
+!			EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN
+!		CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
+!			EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
+!			EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
		@ NOVAST LABS LTD	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep CAHN
SWAB;TOPICAL							
CLINDETS							
AT		PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr CAHN
<u>CLOBAZAM</u>							
SUSPENSION;ORAL							
ONFI							
+!		LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
TABLET;ORAL							
ONFI							
		@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
			10MG	N202067	002	Oct 21, 2011	Jan CAHN
			20MG	N202067	003	Oct 21, 2011	Jan CAHN
<u>CLOBETASOL PROPIONATE</u>							
AEROSOL, FOAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1		INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	Jul NEWA
OLUX							
AB1	+!	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN
OLUX E							
AB2	+!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
AB1		MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
		@	0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN
CLOBETASOL PROPIONATE (EMOLLIENT)							
		@ NOVAST LABS LTD	0.05%	A075733	001	Aug 22, 2001	Sep CAHN
AB2		TELLIGENT PHARMA INC	0.05%	A209411	001	Aug 21, 2017	Aug NEWA
IMPOYZ							
+!		PROMIUS PHARMA LLC	0.025%	N209483	001	Nov 28, 2017	Nov NEWA
GEL;TOPICAL							
CLOBETASOL PROPIONATE							
AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN

	GEL;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA	
	LOTION;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	LUPIN LTD	0.05%	A209147	001	Sep 22, 2017	Sep	NEWA	
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA	
AB	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Nov	CTEC	
AB1		0.05%	A075057	001	Aug 12, 1998	May	CMFD	
	@	0.05%	A075057	001	Aug 12, 1998	Jan	CAHN	
AB	TARO	0.05%	A074248	001	Jul 12, 1996	Apr	CAHN	
AB	ZYDUS PHARMS USA INC	0.05%	A210199	001	Oct 27, 2017	Oct	NEWA	
	TEMOVATE							
	+ @ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD	
	SHAMPOO;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	HI-TECH PHARMACAL	0.05%	A209871	001	Oct 27, 2017	Oct	NEWA	
	SOLUTION;TOPICAL							
	CLOBETASOL PROPIONATE							
AT	MACLEODS PHARMS LTD	0.05%	A209361	001	Oct 25, 2017	Oct	NEWA	
AT	TARO	0.05%	A075224	001	Nov 16, 1998	Apr	CAHN	
>D>	AT	WOCKHARDT	A075205	001	Nov 13, 1998	Dec	CAHN	
>A>	AT	WOCKHARDT BIO AG	A075205	001	Nov 13, 1998	Dec	CAHN	
	SPRAY;TOPICAL							
	CLOBETASOL PROPIONATE							
AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	NEWA	
AT	ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA	
	<u>CLOFARABINE</u>							
	INJECTABLE;IV (INFUSION)							
	CLOFARABINE							
AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr	NEWA	
AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	Oct	NEWA	
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	Oct	NEWA	
AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	Nov	NEWA	
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	Oct	NEWA	
	CLOLAR							
AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr	CFTG	
	<u>CLOFAZIMINE</u>							
	CAPSULE;ORAL							
	LAMPRENE							
	+ @ NOVARTIS	50MG	N019500	002	Dec 15, 1986	Aug	DISC	
	<u>CLOFIBRATE</u>							
	CAPSULE;ORAL							
	CLOFIBRATE							
	@ USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun	CAHN	
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	ANAFRANIL							
>D>	AB	+! MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Dec	CAHN
>D>	AB	+	50MG	N019906	002	Dec 29, 1989	Dec	CAHN
>D>	AB	+	75MG	N019906	003	Dec 29, 1989	Dec	CAHN
>A>	AB	+! SPECGX LLC	25MG	N019906	001	Dec 29, 1989	Dec	CAHN
>A>	AB	+	50MG	N019906	002	Dec 29, 1989	Dec	CAHN
>A>	AB	+	75MG	N019906	003	Dec 29, 1989	Dec	CAHN
	CLOMIPRAMINE HYDROCHLORIDE							
AB	SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb	CMFD	
AB		50MG	A074953	002	Jun 25, 1997	Feb	CMFD	
AB		75MG	A074953	003	Jun 25, 1997	Feb	CMFD	
>A>	AB	ZYDUS PHARMS USA INC	25MG	A208961	001	Dec 27, 2017	Dec	NEWA
>A>	AB		50MG	A208961	002	Dec 27, 2017	Dec	NEWA
>A>	AB		75MG	A208961	003	Dec 27, 2017	Dec	NEWA

CLONAZEPAM

TABLET; ORAL		CLONAZEPAM							
	@ MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar	DISC		
	@	1MG	A074940	002	Oct 30, 1997	Mar	DISC		
	@	2MG	A074940	003	Oct 30, 1997	Mar	DISC		
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb	CAHN		
AB		1MG	A077856	002	Jun 28, 2006	Feb	CAHN		
AB		2MG	A077856	003	Jun 28, 2006	Feb	CAHN		

CLONIDINE HYDROCHLORIDE

TABLET; ORAL		CLONIDINE HYDROCHLORIDE							
	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Jul	CMS1		
		0.2MG	A071785	003	Apr 05, 1988	Jul	CMS1		
	@	0.3MG	A071785	001	Apr 05, 1988	Feb	CAHN		
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb	CAHN		
AB		0.2MG	A077901	002	Mar 09, 2007	Feb	CAHN		
AB		0.3MG	A077901	003	Mar 09, 2007	Feb	CAHN		
TABLET, EXTENDED RELEASE; ORAL		CLONIDINE HYDROCHLORIDE							
AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr	CAHN		
AB1		0.1MG	A203320	001	May 15, 2015	Apr	CAHN		
	@	0.2MG	A202792	002	May 15, 2015	Apr	CAHN		
	@	0.2MG	A203320	002	May 15, 2015	Apr	CAHN		
AB1	AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017	Nov	NEWA		
AB1	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017	Nov	NEWA		
AB1	LUPIN LTD	0.1MG	A209285	001	Oct 23, 2017	Oct	NEWA		
AB1	XIAMEN LP PHARM CO	0.1MG	A209757	001	Nov 20, 2017	Nov	NEWA		

CLOPIDOGREL BISULFATE

TABLET; ORAL		CLOPIDOGREL BISULFATE							
AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012	Jul	CAHN		
AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar	CAHN		
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan	NEWA		

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL		CLORAZEPATE DIPOTASSIUM							
	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017	Aug	CMS1		
		7.5MG	A072112	003	Aug 11, 2017	Aug	CMS1		
TABLET; ORAL		CLORAZEPATE DIPOTASSIUM							
	@ SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Oct	DISC		
	@	7.5MG	A076911	002	Sep 29, 2004	Oct	DISC		
	@	15MG	A076911	003	Sep 29, 2004	Oct	DISC		
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN		
AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN		
AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN		

CLOTTRIMAZOLE

SOLUTION; TOPICAL		CLOTTRIMAZOLE							
AT	! TARO	1%	A074580	001	Jul 29, 1996	Apr	CAHN		
	LOTTRIMIN								
	+ @ SCHERING PLOUGH	1%	N017613	001		Jul	CRLD		

CLOZAPINE

SUSPENSION; ORAL		VERSACLOZ							
	+! TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013	Sep	CAHN		
TABLET; ORAL		CLOZAPINE							
AB	MAYNE PHARMA	50MG	A203807	003	Aug 22, 2017	Aug	NEWA		
AB		200MG	A203807	004	Aug 22, 2017	Aug	NEWA		
AB	SUN PHARM INDS INC	200MG	A075713	004	Nov 07, 2017	Oct	NEWA		
AB	ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017	Nov	NEWA		
AB		50MG	A209480	002	Dec 06, 2017	Nov	NEWA		
AB		100MG	A209480	003	Dec 06, 2017	Nov	NEWA		
AB		200MG	A209480	004	Dec 06, 2017	Nov	NEWA		

>A>	<u>COCAINE HYDROCHLORIDE</u>							
>A>	SOLUTION;NASAL							
>A>	GOPRELTO							
>A>	+!	GENUS LIFESCIENCES 4%		N209963	001	Dec 14, 2017	Dec	NEWA
	<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>							
	SYRUP;ORAL							
	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
	@	PHARM ASSOC 10MG/5ML;6.25MG/5ML		A089647	001	Dec 22, 1988	May	CAHN
>D> AA		WOCKHARDT 10MG/5ML;6.25MG/5ML		A088875	001	Dec 17, 1984	Dec	CAHN
>A> AA		WOCKHARDT BIO AG 10MG/5ML;6.25MG/5ML		A088875	001	Dec 17, 1984	Dec	CAHN
	<u>CODEINE SULFATE</u>							
	SOLUTION;ORAL							
	CODEINE SULFATE							
	@	WEST-WARD PHARMS INT 30MG/5ML		N202245	001	Jun 30, 2011	Jan	CAHN
	TABLET;ORAL							
	CODEINE SULFATE							
AB	+	WEST-WARD PHARMS INT 15MG		N022402	001	Jul 16, 2009	Jan	CAHN
AB	+	30MG		N022402	002	Jul 16, 2009	Jan	CAHN
AB	+	60MG		N022402	003	Jul 16, 2009	Jan	CAHN
	<u>COLESTIPOL HYDROCHLORIDE</u>							
	GRANULE;ORAL							
	COLESTID							
AB	+	PHARMACIA UPJOHN 5GM/SCOOPFUL		N017563	003	Sep 22, 1995	Nov	CAHN
AB	+	5GM/PACKET		N017563	004	Sep 22, 1995	Nov	CAHN
	FLAVORED COLESTID							
	+	PHARMACIA UPJOHN 5GM/PACKET		N017563	001		Nov	CAHN
	+	5GM/SCOOPFUL		N017563	002		Nov	CAHN
	TABLET;ORAL							
	COLESTID							
AB	+	PHARMACIA UPJOHN 1GM		N020222	001	Jul 19, 1994	Nov	CAHN
	<u>COPANLISIB DIHYDROCHLORIDE</u>							
	POWDER;IV (INFUSION)							
	ALIQOPA							
	+	BAYER HEALTHCARE 60MG/VIAL		N209936	001	Sep 14, 2017	Sep	NEWA
	<u>COPPER</u>							
	INTRAUTERINE DEVICE;INTRAUTERINE							
	PARAGARD T 380A							
	+	COOPERSURGICAL 309MG/COPPER		N018680	001	Nov 15, 1984	Nov	CAHN
	<u>CORTICOTROPIN</u>							
	INJECTABLE;INJECTION							
	PURIFIED CORTROPHIN GEL							
	@	ANI PHARMS INC 40 UNITS/ML		N008975	001		May	CAHN
	@	80 UNITS/ML		N008975	002		May	CAHN
	<u>CORTICOTROPIN-ZINC HYDROXIDE</u>							
	INJECTABLE;INJECTION							
	CORTROPHIN-ZINC							
	@	ANI PHARMS INC 40 UNITS/ML		N009854	001		May	CAHN
	<u>COSYNTROPIN</u>							
	SOLUTION;INTRAVENOUS							
	COSYNTROPIN							
	@	SANDOZ INC 0.25MG/ML (0.25MG/ML)		N022028	001	Feb 21, 2008	May	CAHN
	<u>CROMOLYN SODIUM</u>							
	CONCENTRATE;ORAL							
	CROMOLYN SODIUM							
AA		AILEX PHARMS LLC 100MG/5ML		A209264	001	Oct 16, 2017	Oct	NEWA
AA		RISING PHARMS INC 100MG/5ML		A202583	001	Oct 27, 2011	Oct	CAHN
	GASTROCROM							
AA	+	MYLAN SPECIALITY LP 100MG/5ML		N020479	001	Feb 29, 1996	Mar	CAHN
	SOLUTION;INHALATION							
	CROMOLYN SODIUM							
AN		AILEX PHARMS LLC 10MG/ML		A209453	001	Oct 16, 2017	Oct	NEWA

	SOLUTION; INHALATION							
	CROMOLYN SODIUM							
	@ BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Jul	DISC	
AN		10MG/ML	A075585	001	Dec 21, 2000	Feb	CAHN	
>D>	AN	WOCKHARDT	10MG/ML	A075346	001	Oct 25, 1999	Dec	CAHN
>A>	AN	WOCKHARDT BIO AG	10MG/ML	A075346	001	Oct 25, 1999	Dec	CAHN
	INTAL							
	+ @ KING PHARMS LLC	10MG/ML	N018596	001	May 28, 1982	Sep	CRLD	
	@	10MG/ML	N018596	001	May 28, 1982	May	CAHN	
	SOLUTION/DROPS; OPHTHALMIC							
	CROLOM							
	@ BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995	Oct	DISC	
	<u>CYANOCOBALAMIN</u>							
	INJECTABLE; INJECTION							
	CYANOCOBALAMIN							
AP	MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May	NEWA	
	DODEX							
	@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jun	CAHN	
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	CYCLOBENZAPRINE HYDROCHLORIDE							
AB	JUBILANT CADISTA	7.5MG	A077563	003	Aug 25, 2017	Aug	NEWA	
AB	OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May	CMS1	
AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb	CAHN	
AB		10MG	A077797	002	Feb 28, 2007	Feb	CAHN	
AB	RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May	NEWA	
AB		7.5MG	A208170	002	May 31, 2017	May	NEWA	
AB		10MG	A208170	003	May 31, 2017	May	NEWA	
	@ UPSHER-SMITH LABS	5MG	A072854	002	Feb 03, 2006	Jun	CAHN	
	@	10MG	A072854	001	Nov 19, 1991	Jun	CAHN	
	<u>CYCLOPHOSPHAMIDE</u>							
	CAPSULE; ORAL							
	CYCLOPHOSPHAMIDE							
	+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan	CAHN	
	+!	50MG	N203856	002	Sep 16, 2013	Jan	CAHN	
	INJECTABLE; INJECTION							
	CYTOXAN (LYOPHILIZED)							
	+ @ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb	CRLD	
	+ @	1GM/VIAL	N012142	004	Aug 30, 1982	Feb	CRLD	
	+ @	2GM/VIAL	N012142	005	Aug 30, 1982	Feb	CRLD	
	<u>CYCLOSPORINE</u>							
	SOLUTION; ORAL							
	CYCLOSPORINE							
>D>	AB2	WOCKHARDT	100MG/ML	A065133	001	Sep 17, 2004	Dec	CAHN
>A>	AB2	WOCKHARDT BIO AG	100MG/ML	A065133	001	Sep 17, 2004	Dec	CAHN
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>							
	SYRUP; ORAL							
	CYPROHEPTADINE HYDROCHLORIDE							
AA	BIO-PHARM INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep	CAHN	
AA	SILARX PHARMS INC	2MG/5ML	A203191	001	Jul 13, 2017	Jul	NEWA	
	PERIACTIN							
	+ @ MERCK	2MG/5ML	N013220	002		Jan	CRLD	
	TABLET; ORAL							
	CYPROHEPTADINE HYDROCHLORIDE							
AA	AILEX PHARMS LLC	4MG	A207555	001	Jan 31, 2017	Sep	CAHN	
AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan	NEWA	
>A>	AA	COREPHARMA	4MG	A040537	001	Sep 30, 2003	Dec	CAHN
>D>	AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Dec	CAHN
AA		4MG	A040537	001	Sep 30, 2003	Feb	CAHN	
AA	SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May	CAHN	
AA	ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May	NEWA	

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL
PROCYSBI

	+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar	CAHN
	+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar	CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYSTARAN

	+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb	CAHN
--	---	---	---------------------	---------------	---------	-----	--------------	-----	------

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE

AP		HONG KONG	20MG/ML	A206190	001	Nov 09, 2017	Nov	CAHN
AP		MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
AP		SAGENT PHARMS	20MG/ML	A206190	001	Nov 09, 2017	Oct	NEWA
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar	CTEC
	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar	CHRS
	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar	CHRS
	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar	CHRS
		CYTOSAR-U						
	@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar	DISC
	@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar	DISC
	@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar	DISC
	@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar	DISC

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS
VYXEOS

	+	!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	Aug	NEWA
--	---	---	----------------	------------	---------	-----	--------------	-----	------

POWDER;IV (INFUSION)
VYXEOS

	+	!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	Nov	CDFR
--	---	---	----------------	------------	---------	-----	--------------	-----	------

DACARBAZINE

INJECTABLE;INJECTION
DACARBAZINE

	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Nov	CTEC	
AP	!		100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS	
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS	
		DTIC-DOME							
	+	@	BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr	DISC
	+	@		200MG/VIAL	N017575	002		Apr	DISC

DACTINOMYCIN

INJECTABLE;INJECTION
DACTINOMYCIN

AP		MYLAN LABS LTD	0.5MG/VIAL	A203385	001	Nov 09, 2017	Oct	NEWA
----	--	----------------	------------	---------	-----	--------------	-----	------

DALBAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)
DALVANCE

	+	!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Aug	CAHN
--	---	---	--------------------	--------------------	---------	-----	--------------	-----	------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
AMPYRA

AB	+	!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
			DALFAMPRIDINE						
AB			ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
AB			AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION
DANTROLENE SODIUM

AP			HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun	NEWA
----	--	--	--------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR

+ ASTRAZENECA AB EQ 2.5MG BASE;1GM N205649 005 Jul 28, 2017 Jul NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
QTERN

+! ASTRAZENECA AB EQ 10MG BASE;EQ 5MG BASE N209091 001 Feb 27, 2017 Feb NEWA

DAPSONE

GEL;TOPICAL
ACZONE

AB +! ALLERGAN 5% N021794 001 Jul 07, 2005 Oct CFTG

DAPSONE

AB TARO 5% A209506 001 Oct 16, 2017 Oct NEWA

TABLET;ORAL
DAPSONE

AB ACTAVIS LLC 25MG A204380 001 Mar 23, 2017 Mar NEWA

AB 100MG A204380 002 Mar 23, 2017 Mar NEWA

AB NOVITIUM PHARMA 25MG A206505 001 Dec 01, 2016 Oct CAHN

AB 100MG A206505 002 Dec 01, 2016 Oct CAHN

AB VIRTUS PHARMS 25MG A204074 001 May 10, 2016 Sep CAHN

AB 100MG A204074 002 May 10, 2016 Sep CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS
DAPTOMYCIN

+! SAGENT PHARMS 350MG/VIAL N208385 001 Sep 12, 2017 Sep NEWA

POWDER;IV (INFUSION)

DAPTOMYCIN

+! SAGENT PHARMS 350MG/VIAL N208385 001 Sep 12, 2017 Nov CDFR

+! XELLIA PHARMS APS 350MG/VIAL N209949 001 Oct 20, 2017 Oct NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN

AB MACLEODS PHARMS LTD EQ 7.5MG BASE A207302 001 Jul 28, 2017 Jul NEWA

AB EQ 15MG BASE A207302 002 Jul 28, 2017 Jul NEWA

DARIFENACIN HYDROBROMIDE

AB ALEMBIC PHARMS LTD EQ 7.5MG BASE A207681 001 Dec 08, 2017 Nov NEWA

AB EQ 15MG BASE A207681 002 Dec 08, 2017 Nov NEWA

DARUNAVIR ETHANOLATE

TABLET;ORAL

DARUNAVIR ETHANOLATE

AB TEVA PHARMS USA EQ 600MG BASE A202118 001 Nov 21, 2017 Nov NEWA

PREZISTA

AB + JANSSEN PRODS EQ 600MG BASE N021976 002 Feb 25, 2008 Nov CFTG

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP ACCORD HLTHCARE 50MG/VIAL A203475 001 Feb 27, 2017 Feb NEWA

AP CHEMI SPA 50MG/VIAL A206033 001 Sep 22, 2017 Sep NEWA

AP CIPLA LTD 50MG/VIAL A208601 001 Nov 16, 2017 Nov NEWA

AP PHARMASCIENCE INC 50MG/VIAL A204607 001 May 31, 2017 May NEWA

DEFERASIROX

GRANULE;ORAL

JADENU SPRINKLE

+ NOVARTIS PHARMS CORP 90MG N207968 001 May 18, 2017 May NEWA

+ 180MG N207968 002 May 18, 2017 May NEWA

+! 360MG N207968 003 May 18, 2017 May NEWA

DEFEROXAMINE MESYLATE

	INJECTABLE; INJECTION						
	DEFEROXAMINE MESYLATE						
AP	GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017	Sep	NEWA
AP		2GM/VIAL	A207384	002	Sep 29, 2017	Sep	NEWA

DEFLAZACORT

	SUSPENSION; ORAL						
	EMFLAZA						
+	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN
	TABLET; ORAL						
	EMFLAZA						
+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb	NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
+		36MG	N208684	004	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
+		36MG	N208684	004	Feb 09, 2017	Apr	CAHN

DELAFLOXACIN MEGLUMINE

	POWDER; IV (INFUSION)						
	BAXDELA						
+	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Nov	CAHN
+	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun	NEWA
	TABLET; ORAL						
	BAXDELA						
+	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017	Nov	CAHN
+	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun	NEWA

DESIPRAMINE HYDROCHLORIDE

	TABLET; ORAL							
	DESIPRAMINE HYDROCHLORIDE							
>A>	AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Dec	CAHN
>A>	AB		25MG	A205153	002	Oct 28, 2016	Dec	CAHN
>A>	AB		50MG	A205153	003	Oct 28, 2016	Dec	CAHN
>A>	AB		75MG	A205153	004	Oct 28, 2016	Dec	CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016	Dec	CAHN
>A>	AB		150MG	A205153	006	Oct 28, 2016	Dec	CAHN
>D>	AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Dec	CAHN
	AB		10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>D>	AB		25MG	A205153	002	Oct 28, 2016	Dec	CAHN
	AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>D>	AB		50MG	A205153	003	Oct 28, 2016	Dec	CAHN
	AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>D>	AB		75MG	A205153	004	Oct 28, 2016	Dec	CAHN
	AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>D>	AB		100MG	A205153	005	Oct 28, 2016	Dec	CAHN
	AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>D>	AB		150MG	A205153	006	Oct 28, 2016	Dec	CAHN
	AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN
>A>	AB	INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Dec	NEWA
>A>	AB		25MG	A204963	002	Dec 26, 2017	Dec	NEWA
>A>	AB		50MG	A204963	003	Dec 26, 2017	Dec	NEWA
>A>	AB		75MG	A204963	004	Dec 26, 2017	Dec	NEWA
>A>	AB		100MG	A204963	005	Dec 26, 2017	Dec	NEWA
>A>	AB		150MG	A204963	006	Dec 26, 2017	Dec	NEWA

DESMETHYL PIROXICAM

	CAPSULE; ORAL						
	PIROXICAM						
	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Mar	CMS1

DESMOPRESSIN ACETATE

	INJECTABLE; INJECTION						
	DESMOPRESSIN ACETATE						
	@ HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul	DISC
AP	SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017	Aug	NEWA
AP		0.004MG/ML	A204751	001	Aug 22, 2017	Aug	NEWA

INJECTABLE; INJECTION									
DESMOPRESSIN ACETATE									
	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul	DISC		
SPRAY, METERED; NASAL									
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)									
AB	ZYDUS PHARMS USA INC	0.01MG/SPRAY	A091345	001	Oct 03, 2017	Sep	NEWA		
NOCTIVA									
+	AVADEL SPECLT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Oct	CAHN		
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Oct	CAHN		
+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar	NEWA		
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar	NEWA		
STIMATE									
	@ FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994	Jun	CAHN		
STIMATE (NEEDS NO REFRIGERATION)									
+	!	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Jun	CAHN	
TABLET; ORAL									
DESMOPRESSIN ACETATE									
AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May	NEWA		
AB		0.1MG	A207880	001	May 26, 2017	May	CAHN		
AB		0.2MG	A207880	002	May 26, 2017	May	NEWA		
AB		0.2MG	A207880	002	May 26, 2017	May	CAHN		
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>									
TABLET; ORAL-28									
DESOGESTREL AND ETHINYL ESTRADIOL									
AB	ACCORD HLTHCARE	0.15MG, N/A; 0.02MG, 0.01MG	A209170	001	Jun 05, 2017	May	NEWA		
AB	AUROBINDO PHARMA LTD	0.15MG, N/A; 0.02MG, 0.01MG	A206853	001	Mar 22, 2017	Mar	NEWA		
ISIBLOOM									
AB	LABS LEON FARMA	0.15MG; 0.03MG	A202789	001	Aug 12, 2015	Nov	CAHN		
KALLIGA									
AB	AUROBINDO PHARMA LTD	0.15MG; 0.03MG	A207081	001	May 17, 2017	May	NEWA		
VOLNEA									
AB	LABS LEON FARMA	0.15MG, N/A; 0.02MG, 0.01MG	A202689	001	Sep 09, 2016	Nov	CAHN		
<u>DESONIDE</u>									
CREAM; TOPICAL									
DESONIDE									
AB	GLENMARK PHARMS	0.05%	A209729	001	Jul 24, 2017	Jul	NEWA		
LOTION; TOPICAL									
DESONIDE									
AB	GLENMARK PHARMS	0.05%	A209494	001	Sep 26, 2017	Sep	NEWA		
AB	TELIGENT PHARMA INC	0.05%	A207855	001	Sep 28, 2017	Sep	NEWA		
OINTMENT; TOPICAL									
DESONIDE									
AB	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Sep	NEWA		
AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar	NEWA		
<u>DESOXIMETASONE</u>									
CREAM; TOPICAL									
TOPICORT									
AB	!	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CAHN	
AB	!		0.25%	A073193	001	Nov 30, 1990	Apr	CAHN	
+	@		0.25%	N017856	001		May	CAHN	
TOPICORT LP									
+	@	TARO	0.05%	N018309	001		May	CAHN	
GEL; TOPICAL									
DESOXIMETASONE									
AB	RISING PHARMS INC	0.05%	A204675	001	Aug 12, 2016	May	CAHN		
TOPICORT									
AB	!	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CAHN	
+	@		0.05%	N018586	001	Mar 29, 1982	May	CAHN	
+	@	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD	
OINTMENT; TOPICAL									
DESOXIMETASONE									
AB	RISING PHARMS INC	0.25%	A204272	001	Nov 30, 2016	May	CAHN		
AB	ZYDUS PHARMS USA INC	0.25%	A205206	001	Sep 19, 2017	Sep	NEWA		
TOPICORT									
AB	+	!	TARO	0.05%	N018594	001	Jan 17, 1985	May	CAHN
AB	!		0.25%	A074286	001	Jun 07, 1996	Apr	CAHN	
+	@		0.25%	N018763	001	Sep 30, 1983	May	CAHN	

SPRAY; TOPICAL
DESOXIMETASONE

AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May	CAHN
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May	CAHN
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May	CAHN
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A204082	002	Aug 28, 2017	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A204020	001	Oct 11, 2017	Sep	NEWA
AB		EQ 100MG BASE	A204020	002	Oct 11, 2017	Sep	NEWA

DEUTETRABENAZINE

TABLET; ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr	NEWA
+		9MG	N208082	002	Apr 03, 2017	Apr	NEWA
+	!	12MG	N208082	003	Apr 03, 2017	Apr	NEWA

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

>A>	AA	WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983	Dec	CAHN
>D>	AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	Dec	CAHN

TABLET; ORAL
DEXAMETHASONE

AB	LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017	Jul	NEWA
BP	PAR PHARM	6MG	A088481	001	Nov 28, 1983	May	CHRS
	@ UPSHER SMITH	0.75MG	A087534	001		Jun	CAHN
	@	1.5MG	A087533	001		Jun	CAHN
BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983	Aug	CAHN
BP		1.5MG	A088237	001	Apr 28, 1983	Jul	CAHN
	HEXADROL						
	@ ASPEN GLOBAL INC	0.5MG	N012675	004		Oct	CAHN
	@	0.75MG	N012675	007		Oct	CAHN
	@	1.5MG	N012675	009		Oct	CAHN
	@	4MG	N012675	010		Oct	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A084282	001		Aug	CMFD
	SOLUTION/DROPS; OPHTHALMIC, OTIC						
AT	! SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	SANDOZ INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062341	001	May 22, 1984	Feb	CAHN
----	------------	---	---------	-----	--------------	-----	------

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL
DEXCHLORPHENIRAMINE MALEATE

>D>	!	WOCKHARDT	2MG/5ML	A088251	001	Mar 23, 1984	Dec	CAHN
>A>	!	WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Dec	CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
DEXILANT

AB	+!	TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr	CFTG
		DEXLANSOPRAZOLE						
AB		PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr	NEWA
		TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL						
		DEXILANT SOLUTAB						
	+ @	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Aug	DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar	CAHN
AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Sep	NEWA
AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	CAHN
AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	NEWA
AP	TEVA PHARMS USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205272	001	Nov 28, 2017	Nov	NEWA
AP	WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	25MG	A203614	001	Jul 05, 2017	Jun	NEWA
AB		35MG	A203614	002	Jul 05, 2017	Jun	NEWA
AB	TEVA PHARMS USA	25MG	A202731	001	Jul 05, 2017	Jun	NEWA
AB		35MG	A202731	004	Jul 05, 2017	Jun	NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017	Sep	NEWA
AB		5MG	A209468	002	Sep 25, 2017	Sep	NEWA
AB		10MG	A209468	003	Sep 25, 2017	Sep	NEWA
AB	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Nov	NEWA
AB		5MG	A208756	002	Nov 20, 2017	Nov	NEWA
AB		10MG	A208756	003	Nov 20, 2017	Nov	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	+ IMPAX LABS INC	5MG	N017078	001		Aug	CAHN
AB	+	10MG	N017078	002		Aug	CAHN
AB	+!	15MG	N017078	003		Aug	CAHN

DEXTROAMPHETAMINE SULFATE

>D>	AB	MALLINCKRODT	5MG	A076353	001	May 06, 2003	Dec	CAHN
>D>	AB		10MG	A076353	002	May 06, 2003	Dec	CAHN
>D>	AB		15MG	A076353	003	May 06, 2003	Dec	CAHN
	AB	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017	Jun	NEWA
	AB		10MG	A209111	002	Jun 27, 2017	Jun	NEWA
	AB		15MG	A209111	003	Jun 27, 2017	Jun	NEWA
>A>	AB	SPECGX LLC	5MG	A076353	001	May 06, 2003	Dec	CAHN
>A>	AB		10MG	A076353	002	May 06, 2003	Dec	CAHN
>A>	AB		15MG	A076353	003	May 06, 2003	Dec	CAHN
	AB	VINTAGE PHARMS	5MG	A205673	001	Oct 31, 2017	Oct	NEWA
	AB		10MG	A205673	002	Oct 31, 2017	Oct	NEWA
	AB		15MG	A205673	003	Oct 31, 2017	Oct	NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	@	EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014	May	CAHN
	@		10MG	A090652	002	Mar 07, 2014	May	CAHN
>D>	AA	MALLINCKRODT	5MG	A040436	001	Jan 29, 2002	Dec	CAHN
>D>	AA		10MG	A040436	002	Jan 29, 2002	Dec	CAHN
>A>	AA	SPECGX LLC	5MG	A040436	001	Jan 29, 2002	Dec	CAHN
>A>	AA		10MG	A040436	002	Jan 29, 2002	Dec	CAHN
	AA	SUNRISE PHARM INC	5MG	A210059	001	Oct 18, 2017	Oct	NEWA
	AA		10MG	A210059	002	Oct 18, 2017	Oct	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHAN

>D>	AA	WOCKHARDT	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Dec	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	20MG;10MG	A202934	001	Oct 10, 2017	Sep	NEWA
AB	+	AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010	Sep	CFTG

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	10GM/100ML	N018080	001		Feb	CAHN
AP	+	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN
AP	+	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN
AP	+	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	May	CAHN
AP	+	ICU MEDICAL INC	50MG/ML	N016367	002		Feb	CAHN
AP	+	ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN
		@	50GM/100ML	N019894	001	Dec 26, 1989	Jun	CAHN
			DEXTROSE 60% IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982	Nov	CTEC
AP	+	ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982	Apr	CAHN
AP	+		70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001		Feb	CAHN
--	--	-----------------	--	---------	-----	--	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986	Feb	CAHN
--	--	-----------------	--	---------	-----	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993	Aug	DISC
--	--	-----------	---	---------	-----	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;22MG/100ML;526MG/100ML;502MG/100ML	N017609	001		Feb	CAHN
--	--	-----------------	--	---------	-----	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004		Sep	CRLD
AP	+	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634	001		Sep	CRLD
AP	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Sep	CRLD
AP	+	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634	002		Sep	CRLD
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001		Apr	CAHN
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003		Apr	CAHN
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
		ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002		Apr	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
 INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ B BRAUN

5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML; N019870 001 Jun 10, 1993 Aug DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D>		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Dec	CRLD
>A>	+		5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Dec	CRLD
			5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN
>D>			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Dec	CRLD
>A>	+		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Dec	CRLD
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN
			5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
AP			5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN
AP			5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
>D>		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Dec	CRLD
>A>	+		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Dec	CRLD
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Feb	CAHN
>D>			5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Dec	CRLD
>A>	+		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Dec	CRLD
			5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
AP			5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN
AP			5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jun	CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jun	CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002		Feb	CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003		Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun	CAHN
			5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun	CAHN

<u>INJECTABLE; INJECTION</u>							
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN
AP		5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Apr	CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Apr	CAHN
<u>DEXTROSE; SODIUM CHLORIDE</u>							
<u>INJECTABLE; INJECTION</u>							
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	B BRAUN	10GM/100ML; 900MG/100ML	N019631	015	Feb 24, 1988	Aug	CTEC
	@ BAXTER HLTHCARE	10GM/100ML; 900MG/100ML	N016696	001		Nov	DISC
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
+!	ICU MEDICAL INC	5GM/100ML; 225MG/100ML	N017606	001		Feb	CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
+!	ICU MEDICAL INC	5GM/100ML; 300MG/100ML	N017799	001		Feb	CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	ICU MEDICAL INC	5GM/100ML; 450MG/100ML	N017607	001		Feb	CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	+! ICU MEDICAL INC	5GM/100ML; 900MG/100ML	N017585	001		Aug	CRLD
AP		5GM/100ML; 900MG/100ML	N017585	001		Feb	CAHN
<u>DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM</u>							
<u>INJECTABLE; INJECTION</u>							
MD-76R							
+ @	LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Aug	DISC
RENOGRAFIN-76							
+!	BRACCO	66%; 10%	N010040	001		Aug	CTEC
<u>DIAZEPAM</u>							
<u>TABLET; ORAL</u>							
DIAZEPAM							
	@ UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun	CAHN
	@	5MG	A070303	001	Dec 20, 1985	Jun	CAHN
	@	10MG	A070304	001	Dec 20, 1985	Jun	CAHN
	@ VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb	CAHN
	@	5MG	A070463	001	Feb 25, 1986	Feb	CAHN
	@	10MG	A070464	001	Feb 25, 1986	Feb	CAHN
<u>DICHLORPHENAMIDE</u>							
<u>TABLET; ORAL</u>							
KEVEYIS							
+!	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	Aug	CRLD
<u>DICLOFENAC POTASSIUM</u>							
<u>TABLET; ORAL</u>							
DICLOFENAC POTASSIUM							
	@ WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May	CAHN
<u>DICLOFENAC SODIUM</u>							
<u>SOLUTION; TOPICAL</u>							
DICLOFENAC SODIUM							
AT	ANDA REPOSITORY	1.5%	A202393	001	Nov 24, 2014	Sep	CAHN
AT	! APOTEX INC	1.5%	A202027	001	May 27, 2014	Jul	CHRS
AT	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Jul	NEWA
AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar	CAHN
PENNSAID							
+!	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	Oct	CTEC
AT	+!	2%	N204623	001	Jan 16, 2014	May	CFTG
<u>SOLUTION/DROPS; OPHTHALMIC</u>							
DICLOFENAC SODIUM							
AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb	CAHN
<u>TABLET, DELAYED RELEASE; ORAL</u>							
DICLOFENAC SODIUM							
	@ ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr	CAHN
	@	75MG	A074986	002	Feb 26, 1999	Apr	CAHN
AB	UNIQUE PHARM LABS	25MG	A090066	001	Dec 01, 2010	Aug	CAHN
AB		50MG	A090066	002	Dec 01, 2010	Aug	CAHN
AB		75MG	A077863	003	Jun 08, 2007	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL									
DICLOFENAC SODIUM									
	@	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr	DISC	
AB	!	DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr	CHRS	
VOLTAREN-XR									
	+	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Jul	CRLD	
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>									
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM AND MISOPROSTOL									
AB		EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN	
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN	
AB		EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN	
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN	
<u>DICYCLOMINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DICYCLOMINE HYDROCHLORIDE									
AP		LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb	NEWA	
<u>DIDANOSINE</u>									
CAPSULE, DELAYED REL PELLETS;ORAL									
DIDANOSINE									
	@	MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010	May	DISC	
	@		200MG	A090788	002	Apr 08, 2010	May	DISC	
	@		250MG	A090788	003	Apr 08, 2010	May	DISC	
	@		400MG	A090788	004	Apr 08, 2010	May	DISC	
FOR SOLUTION;ORAL									
DIDANOSINE									
	@	AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007	Jul	DISC	
VIDEX									
	+	!	BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991	Jul	CTEC
TABLET, FOR SUSPENSION;ORAL									
DIDANOSINE									
	@	AUROBINDO	100MG	A077275	001	Aug 14, 2012	Jul	DISC	
	@		150MG	A077275	002	Aug 14, 2012	Jul	DISC	
	@		200MG	A077275	003	Aug 14, 2012	Jul	DISC	
<u>DIENOGEST; ESTRADIOL VALERATE</u>									
TABLET;ORAL									
NATAZIA									
	+	!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252	001	May 06, 2010	Apr	CTEC
<u>DIETHYLPROPION HYDROCHLORIDE</u>									
TABLET;ORAL									
DIETHYLPROPION HYDROCHLORIDE									
	@	EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008	May	CAHN	
<u>DIFLORASONE DIACETATE</u>									
CREAM;TOPICAL									
PSORCON									
	+	@	TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992	Sep	CRLD
OINTMENT;TOPICAL									
DIFLORASONE DIACETATE									
AB			RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb	NEWA
AB	!		TARO	0.05%	A075331	001	May 14, 1999	Apr	CAHN
PSORCON									
	+	@	PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985	Mar	CRLD
<u>DIFLUNISAL</u>									
TABLET;ORAL									
DIFLUNISAL									
	@	ALLIED PHARMA INC	250MG	A073562	001	Nov 27, 1992	Jul	CAHN	
	@		500MG	A073563	001	Nov 27, 1992	Jul	CAHN	
AB			ZYDUS PHARMS USA INC	500MG	A203547	001	Jun 16, 2017	Jun	NEWA

DIGOXIN

	ELIXIR;ORAL								
	DIGOXIN								
	+! WEST-WARD PHARMS INT	0.05MG/ML			N021648	001	Aug 26, 2004	Jan	CAHN
	INJECTABLE;INJECTION								
	DIGOXIN								
AP	SANDOZ INC	0.25MG/ML			A040481	001	Aug 21, 2003	Mar	CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML			A083391	001		Jul	CAHN
	LANOXIN								
AP	+! COVIS PHARMA BV	0.25MG/ML			N009330	002		May	CAHN
	LANOXIN PEDIATRIC								
	+! COVIS PHARMA BV	0.1MG/ML			N009330	004		May	CAHN

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE;INJECTION								
	DIHYDROERGOTAMINE MESYLATE								
AP	HIKMA PHARMS	1MG/ML			A206621	001	Sep 15, 2017	Sep	NEWA
AP	WEST-WARD PHARMS INT	1MG/ML			A040453	001	Jun 09, 2003	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL								
	DILTIAZEM HYDROCHLORIDE								
AB3	SUN PHARM INDS LTD	120MG			A203023	001	Jun 08, 2017	May	NEWA
AB3		180MG			A203023	002	Jun 08, 2017	May	NEWA
AB3		240MG			A203023	003	Jun 08, 2017	May	NEWA
AB3		300MG			A203023	004	Jun 08, 2017	May	NEWA
AB3		360MG			A203023	005	Jun 08, 2017	May	NEWA
AB3	ZYDUS PHARMS USA INC	120MG			A206534	001	Aug 08, 2017	Jul	NEWA
AB4		120MG			A206641	001	Aug 11, 2017	Jul	NEWA
AB3		180MG			A206534	002	Aug 08, 2017	Jul	NEWA
AB4		180MG			A206641	002	Aug 11, 2017	Jul	NEWA
AB3		240MG			A206534	003	Aug 08, 2017	Jul	NEWA
AB4		240MG			A206641	003	Aug 11, 2017	Jul	NEWA
AB3		300MG			A206534	004	Aug 08, 2017	Jul	NEWA
AB4		300MG			A206641	004	Aug 11, 2017	Jul	NEWA
AB3		360MG			A206534	005	Aug 08, 2017	Jul	NEWA
AB4		360MG			A206641	005	Aug 11, 2017	Jul	NEWA
AB4		420MG			A206641	006	Aug 11, 2017	Jul	NEWA
	INJECTABLE;INJECTION								
	DILTIAZEM HYDROCHLORIDE								
AP	! ATHENEX INC	5MG/ML			A074617	001	Feb 28, 1996	Mar	CAHN
AP	WEST-WARD PHARMS INT	5MG/ML			A078538	001	Dec 17, 2008	Jan	CAHN
	TABLET;ORAL								
	DILTIAZEM HYDROCHLORIDE								
	@ CHARTWELL MOLECULES	30MG			A074093	001	Nov 05, 1992	Feb	CAHN
	@	60MG			A074093	002	Nov 05, 1992	Feb	CAHN
	@	90MG			A074093	003	Nov 05, 1992	Feb	CAHN
	@	120MG			A074093	004	Nov 05, 1992	Feb	CAHN

DIMENHYDRINATE

	INJECTABLE;INJECTION								
	DIMENHYDRINATE								
	@ WATSON LABS TEVA	50MG/ML			A080615	001		May	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

	ELIXIR;ORAL								
	DIPHENHYDRAMINE HYDROCHLORIDE								
	! PHARM ASSOC	12.5MG/5ML			A087513	001	Feb 10, 1982	May	CAHN
	INJECTABLE;INJECTION								
	DIPHENHYDRAMINE HYDROCHLORIDE								
	@ WATSON LABS TEVA	10MG/ML			A080873	001		May	CAHN
	@	50MG/ML			A080873	002		May	CAHN
	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE								
	@ WATSON LABS TEVA	50MG/ML			A080873	003		May	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
 DIPYRIDAMOLE
 AP ! ATHENEX INC 5MG/ML A074939 001 Apr 13, 1998 Mar CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
 DISOPYRAMIDE PHOSPHATE
 AB MAYNE PHARMA EQ 150MG BASE A070173 002 May 31, 1985 Sep CMS1
 CAPSULE, EXTENDED RELEASE; ORAL
 NORPACE CR
 +! GD SEARLE LLC EQ 150MG BASE N018655 002 Jul 20, 1982 Nov CTEC

DISULFIRAM

TABLET; ORAL
 DISULFIRAM
 AB CHARTWELL MOLECULES 250MG A091563 001 Dec 31, 2012 Jan CAHN
 AB 500MG A091563 002 Dec 31, 2012 Jan CAHN
 @ WATSON LABS TEVA 500MG A086890 001 May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
 DIVALPROEX SODIUM
 AB PRINSTON INC EQ 125MG VALPROIC ACID A090210 001 Nov 30, 2009 Feb CAHN
 AB EQ 250MG VALPROIC ACID A090210 002 Nov 30, 2009 Feb CAHN
 AB EQ 500MG VALPROIC ACID A090210 003 Nov 30, 2009 Feb CAHN
 AB UPSHER-SMITH LABS EQ 125MG VALPROIC ACID A078182 001 Jul 29, 2008 Jun CAHN
 AB EQ 250MG VALPROIC ACID A078182 002 Jul 29, 2008 Jun CAHN
 AB EQ 500MG VALPROIC ACID A078182 003 Jul 29, 2008 Jun CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DOBUTREX
 + @ LILLY EQ 12.5MG BASE/ML N017820 002 Aug CRLD

DOCETAXEL

INJECTABLE; INJECTION
 DOCEFREZ
 + @ SUN PHARMA GLOBAL 20MG/VIAL N022534 001 May 03, 2011 Aug DISC
 + @ 80MG/VIAL N022534 002 May 03, 2011 Aug DISC
 DOCETAXEL
 AP ACTAVIS LLC 20MG/ML (20MG/ML) N203551 001 Apr 12, 2013 Feb CAHN
 AP 80MG/4ML (20MG/ML) N203551 002 Apr 12, 2013 Feb CAHN
 140MG/7ML (20MG/ML) N203551 003 Apr 12, 2013 Feb CAHN
 AP DFB ONCOLOGY LTD 20MG/ML (20MG/ML) A206177 001 Jan 20, 2017 Jan NEWA
 AP 80MG/4ML (20MG/ML) A206177 002 Jan 20, 2017 Jan NEWA
 200MG/10ML (20MG/ML) A206177 003 Jan 20, 2017 Jan NEWA
 + @ HOSPIRA INC 120MG/6ML (20MG/ML) N022234 006 Jun 23, 2016 Aug DISC
 + 160MG/8ML (20MG/ML) N022234 007 Jan 24, 2017 Jan NEWA
 AP INGENUS PHARMS LLC 20MG/2ML (10MG/ML) A207563 001 Aug 31, 2017 Aug NEWA
 AP 80MG/8ML (10MG/ML) A207563 002 Aug 31, 2017 Aug NEWA
 AP 160MG/16ML (10MG/ML) A207563 003 Aug 31, 2017 Aug NEWA
 AP JIANGSU HENGRUI MED 20MG/ML (20MG/ML) A207252 001 Aug 09, 2017 Jul NEWA
 ! 40MG/ML A203170 001 Feb 15, 2017 Jan NEWA
 AP 80MG/4ML (20MG/ML) A207252 002 Aug 09, 2017 Jul NEWA
 AP 160MG/8ML (20MG/ML) A207252 003 Aug 09, 2017 Jul NEWA
 @ PFIZER LABS 20MG/2ML (10MG/ML) N202356 001 Mar 13, 2014 Jan DISC
 @ 80MG/8ML (10MG/ML) N202356 002 Mar 13, 2014 Jan DISC
 @ 130MG/13ML (10MG/ML) N202356 003 Mar 13, 2014 Jan DISC
 @ 200MG/20ML (10MG/ML) N202356 004 Mar 13, 2014 Jan DISC

DOFETILIDE

CAPSULE; ORAL
 DOFETILIDE
 AB MAYNE PHARMA INC 0.125MG A207058 001 Jun 06, 2016 Feb CAHN
 AB 0.25MG A207058 002 Jun 06, 2016 Feb CAHN
 AB 0.5MG A207058 003 Jun 06, 2016 Feb CAHN

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+ @ US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Oct	DISC
+ @	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Oct	DISC

TABLET; ORAL
ANZEMET

+ @ US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Oct	DISC
+ @	100MG	N020623	002	Sep 11, 1997	Oct	DISC

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDETABLET; ORAL
JULUCA

+! VIIV HLTHCARE	EQ 50MG BASE; EQ 25MG BASE	N210192	001	Nov 21, 2017	Nov	NEWA
------------------	----------------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662	001	May 31, 2011	Jun	CAHN
AB		10MG	A078662	002	May 31, 2011	Jun	CAHN
AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar	CAHN
AB		10MG	A078662	002	May 31, 2011	Mar	CAHN
AB	CADILA PHARMS LTD	5MG	A204609	001	Sep 19, 2017	Sep	NEWA
AB		10MG	A204609	002	Sep 19, 2017	Sep	NEWA
AB	VIVIMED GLOBAL	5MG	A090551	001	May 31, 2011	Aug	CAHN
AB		10MG	A090551	002	May 31, 2011	Aug	CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar	NEWA
AB	ZYDUS PHARMS USA INC	23MG	A203162	001	Aug 31, 2017	Aug	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG; 14MG	A208328	001	Jan 27, 2017	Jan	NEWA
AB		10MG; 28MG	A208328	002	Jan 27, 2017	Jan	NEWA
	NAMZARIC						
AB	+ FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Jan	CFTG
AB	+!	10MG; 28MG	N206439	002	Dec 23, 2014	Jan	CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

!	LUITPOLD	160MG/ML	A070826	001	Feb 11, 1987	Nov	CTEC
@	TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May	CAHN

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

+ @ SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Sep	DISC
+ @	500MG/VIAL	N022106	001	Oct 12, 2007	Sep	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar	CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb	CAHN
	@ ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013	Nov	DISC
AT		EQ 2% BASE	A091034	001	Dec 04, 2013	Sep	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar	CAHN
AT	ZAMBON SPA	EQ 2% BASE; EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A>	@ FOSUN PHARMA	EQ 1MG BASE	A 075646	001	Oct 18, 2000	Dec	CAHN
>A>	@	EQ 2MG BASE	A 075646	002	Oct 18, 2000	Dec	CAHN
>A>	@	EQ 4MG BASE	A 075646	003	Oct 18, 2000	Dec	CAHN
>A>	@	EQ 8MG BASE	A 075646	004	Oct 18, 2000	Dec	CAHN
>D>	@ SANDOZ	EQ 1MG BASE	A 075646	001	Oct 18, 2000	Dec	CAHN
>D>	@	EQ 2MG BASE	A 075646	002	Oct 18, 2000	Dec	CAHN
>D>	@	EQ 4MG BASE	A 075646	003	Oct 18, 2000	Dec	CAHN
>D>	@	EQ 8MG BASE	A 075646	004	Oct 18, 2000	Dec	CAHN
AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A 208719	001	Jul 07, 2017	Jun	NEWA
AB		EQ 2MG BASE	A 208719	002	Jul 07, 2017	Jun	NEWA
AB		EQ 4MG BASE	A 208719	003	Jul 07, 2017	Jun	NEWA
AB		EQ 8MG BASE	A 208719	004	Jul 07, 2017	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A 207482	001	Jun 28, 2017	Jun	NEWA
AB		EQ 25MG BASE	A 207482	002	Jun 28, 2017	Jun	NEWA
AB		EQ 50MG BASE	A 207482	003	Jun 28, 2017	Jun	NEWA
AB		EQ 75MG BASE	A 207482	004	Jun 28, 2017	Jun	NEWA
AB		EQ 100MG BASE	A 207482	005	Jun 28, 2017	Jun	NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A 072987	001	Mar 29, 1991	May	CAHN

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

>D> AA	WOCKHARDT	EQ 10MG BASE/ML	A 071918	001	Jul 20, 1988	Dec	CAHN
>A> AA	WOCKHARDT BIO AG	EQ 10MG BASE/ML	A 071918	001	Jul 20, 1988	Dec	CAHN

CREAM; TOPICAL

ZONALON

+!	MYLAN PHARMS INC	5%	N 020126	001	Apr 01, 1994	Jan	CAHN
----	------------------	----	----------	-----	--------------	-----	------

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 3MG BASE	A 202337	001	Jan 20, 2016	Nov	DISC
	@	EQ 6MG BASE	A 202337	002	Jan 20, 2016	Nov	DISC

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A 208974	001	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A 208974	002	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A 208975	001	May 24, 2017	May	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A 208888	001	Feb 17, 2017	Feb	NEWA
AP		50MG/VIAL	A 208888	002	Feb 17, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	2MG/ML	A 209825	001	Aug 11, 2017	Jul	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A 208657	001	May 15, 2017	May	NEWA
AB		50MG/25ML (2MG/ML)	A 208657	002	May 15, 2017	May	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	ALEMBIC PHARMS LTD	EQ 75MG BASE	A 209165	001	Jul 28, 2017	Jul	NEWA
AB		EQ 100MG BASE	A 209165	002	Jul 28, 2017	Jul	NEWA
AB	MAYNE PHARMA INC	EQ 50MG BASE	A 209396	001	Sep 29, 2017	Sep	NEWA
AB		EQ 75MG BASE	A 209396	002	Sep 29, 2017	Sep	NEWA
AB		EQ 100MG BASE	A 209396	003	Sep 29, 2017	Sep	NEWA

TABLET; ORAL

DOXYCYCLINE

AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A 209582	001	Sep 28, 2017	Sep	NEWA
AB		EQ 75MG BASE	A 209582	002	Sep 28, 2017	Sep	NEWA
AB		EQ 100MG BASE	A 209582	003	Sep 28, 2017	Sep	NEWA
AB		EQ 150MG BASE	A 209582	004	Sep 28, 2017	Sep	NEWA

DOXYCYCLINE HYCLATE

	CAPSULE;ORAL							
	PERIOSTAT							
	+ @	COLLAGENEX	EQ 20MG BASE	N050744	001	Sep 30, 1998	Nov	CDFR
	CAPSULE, DELAYED RELEASE;ORAL							
	DOXYCYCLINE HYCLATE							
	@	MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005	Jul	DISC
	@		EQ 100MG BASE	A065281	002	Dec 21, 2005	Jul	DISC
	INJECTABLE;INJECTION							
	DOXY 200							
AP	!	FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A062475	002	Dec 09, 1983	Nov	CTEC
	DOXYCYCLINE							
AP		ZYDUS PHARMS USA INC	EQ 100MG BASE/VIAL	A207757	001	Sep 28, 2017	Sep	NEWA
AP			EQ 200MG BASE/VIAL	A207757	002	Sep 28, 2017	Sep	NEWA
	VIBRAMYCIN							
	+ @	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD
	+ @		EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD
	TABLET;ORAL							
	ACTICLATE							
AB	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG
	DOXYCYCLINE HYCLATE							
AB		AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017	Sep	NEWA
AB			EQ 150MG BASE	A209372	002	Oct 06, 2017	Sep	NEWA
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD
	@		EQ 50MG BASE	A062269	003		Jan	CAHN
AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN
	@	EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	May	CAHN
AB		LUPIN LTD	EQ 75MG BASE	A208818	001	Sep 27, 2017	Sep	NEWA
AB			EQ 150MG BASE	A208818	002	Sep 27, 2017	Sep	NEWA
AB		MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May	NEWA
AB			EQ 150MG BASE	A208765	002	Jun 14, 2017	May	NEWA
AB		NOVEL LABS INC	EQ 100MG BASE	A207558	001	Sep 06, 2017	Aug	NEWA
AB		ZYDUS PHARMS USA INC	EQ 100MG BASE	A207773	001	Oct 30, 2017	Oct	NEWA
	TABLET, DELAYED RELEASE;ORAL							
	DORYX MPC							
>D>	+	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Dec	DISC
>A>	+ @		EQ 60MG BASE	N050795	007	May 20, 2016	Dec	DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

	TABLET, DELAYED RELEASE;ORAL							
	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB		PAR PHARM INC	10MG;10MG	A208518	001	Dec 06, 2017	Nov	NEWA

DRONABINOL

	SOLUTION;ORAL							
	SYNDROS							
	+	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA

DROPERIDOL

	INJECTABLE;INJECTION							
	DROPERIDOL							
>A>	AP	EUROHLTH INTL SARL	2.5MG/ML	A208197	001	Dec 14, 2017	Dec	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

	TABLET;ORAL							
	DROSPIRENONE AND ETHINYL ESTRADIOL							
>A>	AB	CYNDEA PHARMA	3MG;0.02MG	A209423	001	Dec 22, 2017	Dec	NEWA
	AB	PII	3MG;0.02MG	A203291	001	Jul 18, 2017	Jul	NEWA
	LORYNA							
AB		LABS LEON FARMA	3MG;0.02MG	A079221	001	Mar 28, 2011	Nov	CAHN
	TABLET;ORAL-28							
	SYEDA							
AB		LABS LEON FARMA	3MG;0.03MG	A090114	001	Mar 28, 2011	Nov	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL
TYDEMY

AB	LUPIN LTD	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A205948	001	Dec 12, 2017	Nov	NEWA
----	-----------	------------------------------------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar	NEWA
AB		EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar	NEWA
AB		EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar	NEWA
AB	PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May	NEWA
AB		EQ 30MG BASE	A206653	002	May 18, 2017	May	NEWA
AB		EQ 60MG BASE	A206653	003	May 18, 2017	May	NEWA
AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr	CAHN
AB		EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr	CAHN
AB		EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr	CAHN

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May	CAHN
AB	HAUPT PHARMA	0.5MG	A207935	001	Oct 13, 2017	Oct	NEWA
AB	HUMANWELL PURACAP	0.5MG	A209909	001	Nov 21, 2017	Nov	NEWA
AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017	Sep	NEWA

DYPHYLLINE

TABLET;ORAL
LUFYLLIN

	@ MYLAN SPECIALITY LP	200MG	A084566	001		Mar	CAHN
	@	400MG	A084566	002		Mar	CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL
ECOZA

+	!	CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	May	CAHN
---	---	-------------------	----	---------	-----	--------------	-----	------

CREAM;TOPICAL
SPECTAZOLE

AB	+	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Sep	CMFD
	+	@	1%	N018751	001	Dec 23, 1982	Mar	CMS1

EDARAVONE

SOLUTION;IV (INFUSION)
RADICAVA

+	!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	May	NEWA
---	---	-------------------	-----------------------	---------	-----	--------------	-----	------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION
TENSILON

+	@	TELIGENT	10MG/ML	N007959	001		Apr	CAHN
---	---	----------	---------	---------	-----	--	-----	------

TENSILON PRESERVATIVE FREE

+	@	TELIGENT	10MG/ML	N007959	002		Apr	CAHN
---	---	----------	---------	---------	-----	--	-----	------

EFAVIRENZ

CAPSULE;ORAL
EFAVIRENZ

>A>	AB	AUROBINDO PHARMA LTD	50MG	A078064	001	Dec 15, 2017	Dec	NEWA
>A>			100MG	A078064	002	Dec 15, 2017	Dec	NEWA
>A>	AB		200MG	A078064	003	Dec 15, 2017	Dec	NEWA

SUSTIVA

>D>	+	BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Dec	CFTG
>A>	AB	+	50MG	N020972	001	Sep 17, 1998	Dec	CFTG
>D>		+	200MG	N020972	003	Sep 17, 1998	Dec	CFTG
>A>	AB	+	200MG	N020972	003	Sep 17, 1998	Dec	CFTG

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A205186	001	Aug 29, 2017	Aug	NEWA
AB		EQ 40MG BASE	A205186	002	Aug 29, 2017	Aug	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A205152	001	Aug 11, 2017	Jul	NEWA
AB		EQ 40MG BASE	A205152	002	Aug 11, 2017	Jul	NEWA
AB	TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun	NEWA
AB		EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun	NEWA
AB		EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun	NEWA
RELPAK							
AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun	CFTG
AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun	CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May	NEWA
TRUVADA							
AB	+! GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May	CFTG

ENALAPRIL MALEATE

SOLUTION;ORAL

EPANED

+!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Jul	CRLD
----	-------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ENALAPRIL MALEATE

>A>	AB	WOCKHARDT LTD	2.5MG	A075483	001	Aug 22, 2000	Dec	CAHN
>A>	AB		5MG	A075483	002	Aug 22, 2000	Dec	CAHN
>A>	AB		10MG	A075483	003	Aug 22, 2000	Dec	CAHN
>A>	AB		20MG	A075483	004	Aug 22, 2000	Dec	CAHN
>D>	AB	WOCKHARDT USA	2.5MG	A075483	001	Aug 22, 2000	Dec	CAHN
>D>	AB		5MG	A075483	002	Aug 22, 2000	Dec	CAHN
>D>	AB		10MG	A075483	003	Aug 22, 2000	Dec	CAHN
>D>	AB		20MG	A075483	004	Aug 22, 2000	Dec	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Jun	CAHN
@		10MG;25MG	A076116	002	Sep 19, 2001	Jun	CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	!	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN
VASOTEC								
	+ @	BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar	CRLD

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017	Aug	NEWA
+!		EQ 100MG BASE	N209606	002	Aug 01, 2017	Aug	NEWA

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB	AJANTA PHARMA LTD	200MG	A205792	001	Aug 31, 2017	Aug	NEWA
AB	MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May	NEWA
	@ MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May	DISC

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Aug	NEWA
AB		1MG	A205824	002	Aug 25, 2017	Aug	NEWA
AB	PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017	Sep	NEWA
AB		1MG	A208782	002	Oct 10, 2017	Sep	NEWA
AB	SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May	NEWA

TABLET;ORAL
ENTECAVIR

AB		1MG	A206672	002	May 11, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun	NEWA
AB		1MG	A206745	002	Jun 23, 2017	Jun	NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
AKOVAZ

AP	+! FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar	CTEC
AP	AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar	NEWA
AP	SANDOZ INC	50MG/ML (50MG/ML)	A209784	001	Aug 23, 2017	Aug	NEWA

SOLUTION;IV (INFUSION)
CORPHEDRA

	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan	NEWA
--	----------------------	-------------------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr	NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENACLICK

BX	+! IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun	CAHN
BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun	CAHN
	TWINJECT 0.15						
	@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun	CAHN
	TWINJECT 0.3						
	@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun	CAHN

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug	CDFR
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Aug	CDFR
	AUVI-Q						
	+ KALEO INC	EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017	Nov	NEWA
BX	+!	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov	CDFR
BX	+	EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov	CDFR

SYMJEPI

>D>	+! ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Dec	CPOT
>A>	+!	0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017	Dec	CPOT
	+!	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	@ BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb	CAHN
	@	0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb	CAHN
	@ WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar	CAHN
	@	0.01MG/ML;2%	A080406	002		Mar	CAHN
	XYLOCAINE W/ EPINEPHRINE						
	+! FRESENIUS KABI USA	0.005MG/ML;1%	N006488	018	Nov 13, 1986	Nov	CTEC

EPLERENONE

TABLET;ORAL
EPLERENONE

AB	ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul	NEWA
AB		50MG	A206922	002	Jul 13, 2017	Jul	NEWA
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan	NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan	NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	Oct	NEWA
AP		75MG/100ML	A205557	002	Nov 06, 2017	Oct	NEWA
AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr	NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr	NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May	CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May	CAHN

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES

! SUN PHARM INDUSTRIES 1MG A081113 001 Oct 31, 1991 May CHRS
HYDERGINE
+ @ NOVARTIS 1MG N017993 001 May DISC

>A> ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

>A> + MERCK SHARP DOHME 5MG N209803 001 Dec 19, 2017 Dec NEWA
>A> +! 15MG N209803 002 Dec 19, 2017 Dec NEWA

>A> ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

>A> + MERCK SHARP DOHME 2.5MG;500MG N209806 001 Dec 19, 2017 Dec NEWA
>A> + 2.5MG;1GM N209806 002 Dec 19, 2017 Dec NEWA
>A> + 7.5MG;500MG N209806 003 Dec 19, 2017 Dec NEWA
>A> +! 7.5MG;1GM N209806 004 Dec 19, 2017 Dec NEWA

>A> ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STELUJAN

>A> + MERCK SHARP DOHME 5MG;EQ 100MG BASE N209805 001 Dec 19, 2017 Dec NEWA
>A> +! 15MG;EQ 100MG BASE N209805 002 Dec 19, 2017 Dec NEWA

ERYTHROMYCIN

GEL;TOPICAL

E-GLADES

@ MYLAN PHARMS INC 2%

A065009 001 Mar 18, 2002 Jan CAHN

ERYGEL

AT +! MYLAN PHARMS INC 2% N050617 001 Oct 21, 1987 Jan CAHN

ERYTHROMYCIN

AT PERRIGO CO 2% A063211 001 Jan 29, 1993 Apr CAHN

AT TELIGENT PHARMA INC 2% A208154 001 Jul 19, 2017 Jul NEWA

OINTMENT;TOPICAL

AKNE-MYCIN

+ @ DOW PHARM 2% N050584 001 Jan 10, 1985 Oct DISC

SOLUTION;TOPICAL

A/T/S

@ TARO 2%

A062405 001 Nov 18, 1982 Apr CAHN

ERYTHRA-DERM

@ SAPTALIS PHARMS 2%

A062687 001 Feb 05, 1988 Oct CAHN

ERYTHROMYCIN

@ FOUGERA PHARMS 2% A064187 001 Sep 30, 1997 Aug DISC

AT ! PERRIGO NEW YORK 2% A063038 001 Jan 11, 1991 Aug CHRS

AT TELIGENT PHARMA INC 2% A208100 001 Nov 20, 2017 Nov NEWA

>D> AT WOCKHARDT 2% A062825 001 Oct 23, 1987 Dec CAHN

>A> AT WOCKHARDT BIO AG 2% A062825 001 Oct 23, 1987 Dec CAHN

SWAB;TOPICAL

ERYCETTE

+ @ JOHNSON AND JOHNSON 2% N050594 001 Feb 15, 1985 Sep CRLD

ERYTHROMYCIN

@ MYLAN PHARMS INC 2% A064128 001 Jul 03, 1996 Jan CAHN

AT ! PERRIGO CO 2% A064126 001 Jul 03, 1996 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

+ ARBOR PHARMS LLC EQ 200MG BASE/5ML N050207 001 Oct CTEC

ERYPED

+ ARBOR PHARMS LLC EQ 200MG BASE/5ML N050207 003 Mar 30, 1987 Oct CTEC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

@ BARR EQ 200MG BASE/5ML;EQ 600MG A062759 001 May 20, 1988 Jul DISC
BASE/5ML

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May	NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017	May	NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017	May	NEWA
	@ MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Nov	DISC
	@	EQ 10MG BASE	A077550	002	May 14, 2015	Nov	DISC
	@	EQ 20MG BASE	A077550	003	May 14, 2015	Nov	DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	ALKEM LABS LTD	EQ 20MG BASE	A208333	001	Oct 20, 2017	Oct	NEWA
AB		EQ 40MG BASE	A208333	002	Oct 20, 2017	Oct	NEWA
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A205563	001	Sep 01, 2017	Aug	NEWA
AB		EQ 40MG BASE	A205563	002	Sep 01, 2017	Aug	NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May	CRLD
---	--------------------	---------------------	---------	-----	--------------	-----	------

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>D>	AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Dec	DISC
	AP	!		EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May	CHRS
>D>	AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Dec	CHRS
>A>	AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Dec	CHRS
	AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Aug	CHRS
	AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May	CHRS
	AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA
>D>	AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Dec	DISC
	AP			EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May	NEWA
	AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May	NEWA
>D>	AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Dec	DISC
			NEXIUM IV						
		+	@ ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May	DISC
AP		+	!	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	CMFD
		+	@	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May	DISC

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

>D>	+	R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013	Dec	DISC
>A>	+	@	24.65MG	N202342	001	Aug 06, 2013	Dec	DISC

ESTRADIOL

CREAM;VAGINAL

ESTRACE

>D>	!	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Dec	CFTG	
>A>	AB	!	0.01%	A086069	001	Jan 31, 1984	Dec	CFTG	
>A>			ESTRADIOL						
>A>	AB		MYLAN PHARMS INC	0.01%	A208788	001	Dec 29, 2017	Dec	NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADERM

+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May	DISC	
+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May	DISC	
			VIVELLE						
		@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May	DISC
		@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	DISC

GEL, METERED;TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar	CAHN
			SPRAY;TRANSDERMAL					
			EVAMIST					
+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN

TABLET;VAGINAL
ESTRADIOL

AB	TEVA PHARMS USA	10MCG	A206388	001	Jul 21, 2017	Jul NEWA
----	-----------------	-------	---------	-----	--------------	----------

ESTRADIOL ACETATE

TABLET;ORAL
FEMTRACE

+ @	APIL	0.45MG	N021633	001	Aug 20, 2004	Jun DISC
+ @		0.9MG	N021633	002	Aug 20, 2004	Jun DISC
+ @		1.8MG	N021633	003	Aug 20, 2004	Jun DISC

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Apr CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB		1MG;0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

+ @	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Aug CRLD
+ @		0.45MG	N020992	005	Feb 05, 2004	Aug CRLD
+ @		0.625MG	N020992	002	Mar 24, 1999	Aug CRLD
+ @		0.9MG	N020992	003	Mar 24, 1999	Aug CRLD
+ @		1.25MG	N020992	004	Mar 13, 2000	Aug CRLD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUUIA

@	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Aug DISC
		0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
@		0.45MG	N021443	002	Dec 20, 2004	Aug DISC
		0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
@		0.625MG	N021443	003	May 10, 2004	Apr CAHN
@		0.9MG	N021443	005	Apr 27, 2007	Aug DISC
		0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
@		1.25MG	N021443	004	May 10, 2004	Apr CAHN

ESTROGENS, ESTERIFIED

TABLET;ORAL
MENEST

	MONARCH PHARMS	0.3MG	A084951	001		Jun CAHN
		0.625MG	A084948	001		Jun CAHN
		1.25MG	A084950	001		Jun CAHN
!		2.5MG	A084949	001		Jun CAHN

ESTRONE

INJECTABLE;INJECTION
ESTRONE

@	WATSON LABS TEVA	5MG/ML	A085239	001		May CAHN
---	------------------	--------	---------	-----	--	----------

ESTROPIPATE

TABLET;ORAL
ESTROPIPATE

>D>	AB	MYLAN	0.75MG	A040359	001	Aug 26, 1999	Dec CTEC
>A>			0.75MG	A040359	001	Aug 26, 1999	Dec CTEC
>D>	AB		1.5MG	A040359	002	Aug 26, 1999	Dec CTEC
>A>			1.5MG	A040359	002	Aug 26, 1999	Dec CTEC
>D>	AB	WATSON LABS	0.75MG	A081213	001	Sep 23, 1993	Dec DISC
>A>		@	0.75MG	A081213	001	Sep 23, 1993	Dec DISC
>D>	AB		1.5MG	A081214	001	Sep 23, 1993	Dec DISC
>A>		@	1.5MG	A081214	001	Sep 23, 1993	Dec DISC
>D>		! WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	Dec DISC
>A>		@	3MG	A081215	001	Sep 23, 1993	Dec DISC
		!	3MG	A081215	001	Sep 23, 1993	May CHRS

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21		NORETHIN 1/35E-21					
	@ WATSON PHARMS TEVA	0.035MG;1MG	A 071480	001	Apr 12, 1988	Mar	CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL							
	@ WATSON PHARMS TEVA	0.035MG;1MG	A 070685	001	Jan 29, 1987	Mar	CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)							
	@ WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A 071041	001	Sep 24, 1991	May	CAHN
TABLET;ORAL-28		NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	ACCORD HLTHCARE	0.035MG;1MG	A 206864	001	Apr 28, 2017	Apr	NEWA
	@ MYLAN LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A 200486	001	Dec 28, 2015	Oct	DISC
	@	0.035MG;0.5MG	A 200488	001	Oct 21, 2015	Sep	DISC
	@	0.035MG;1MG	A 200489	001	Oct 21, 2015	Sep	DISC
AB	WATSON LABS TEVA	0.035MG;1MG	A 070687	001	Jan 29, 1987	May	CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)							
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A 071044	001	Apr 01, 1988	May	CAHN
TABLET, CHEWABLE;ORAL		NEXESTA FE					
AB	AUROBINDO PHARMA LTD	0.035MG;0.4MG	A 207535	001	Feb 02, 2017	Jan	NEWA
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	ACCORD HLTHCARE	0.035MG;0.4MG	A 207066	001	Mar 29, 2017	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL		AUROVELA 24 FE					
AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A 207504	001	Jun 15, 2017	Jun	NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	MYLAN LABS LTD	0.0025MG;0.5MG	A 207260	001	Feb 02, 2017	Jan	NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A 204847	001	Nov 17, 2017	Nov	NEWA
TABLET;ORAL-21		AUROVELA 1.5/30					
AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A 207581	001	Jun 26, 2017	Jun	NEWA
AUROVELA 1/20							
AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A 207506	001	Jun 16, 2017	Jun	NEWA
TABLET;ORAL-28		AUROVELA FE 1.5/30					
AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A 207580	001	Jun 15, 2017	May	NEWA
AUROVELA FE 1/20							
AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A 207505	001	Jun 16, 2017	Jun	NEWA
HAILEY FE 1/20							
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A 206597	001	Nov 21, 2017	Nov	NEWA
LOESTRIN FE 1/20							
AB	+ APIL	0.02MG;1MG	N 017354	001		Jul	CRLD
TABLET, CHEWABLE;ORAL		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	AMNEAL PHARMS	0.02MG;1MG	A 207514	001	Sep 11, 2017	Aug	NEWA
>A>	AB	GLENMARK PHARMS LTD	A 210369	001	Dec 26, 2017	Dec	NEWA
AB	MYLAN LABS LTD	0.02MG;1MG	A 206120	001	Sep 12, 2017	Sep	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28		ESTARYLLA					
AB	LABS LEON FARMA	0.035MG;0.25MG	A 090794	001	Jan 30, 2013	Nov	CAHN
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	AMNEAL PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A 203873	001	May 12, 2016	Sep	CAHN
TRI-ESTARYLLA							
AB	LABS LEON FARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A 090793	001	Jan 30, 2013	Nov	CAHN
TRI-LO-ESTARYLLA							
AB	LABS LEON FARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A 091232	001	Jun 29, 2015	Nov	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28		NORGESTREL AND ETHINYL ESTRADIOL						
	@ MYLAN LABS LTD	0.03MG; 0.3MG		A201828	001	Jun 21, 2016	Oct	DISC
	@	0.05MG; 0.5MG		A202875	001	May 08, 2017	Oct	DISC
AB		0.05MG; 0.5MG		A202875	001	May 08, 2017	Apr	NEWA
	OGESTREL 0.5/50-28							
	! WATSON LABS	0.05MG; 0.5MG		A075406	002	Dec 15, 1999	Oct	CTEC
AB	!	0.05MG; 0.5MG		A075406	002	Dec 15, 1999	May	CTEC

ETHOSUXIMIDE

SYRUP; ORAL		ETHOSUXIMIDE						
AA	PHARM ASSOC	250MG/5ML		A040253	001	Nov 22, 2000	May	CAHN
	ZARONTIN							
AA	! PARKE-DAVIS	250MG/5ML		A080258	001		Mar	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL		DIDRONEL						
	+ @ APIL	200MG		N017831	001		Jun	DISC
	+ @	400MG		N017831	002		Jun	DISC
	ETIDRONATE DISODIUM							
	MYLAN	200MG		A075800	001	Jan 24, 2003	Jun	CTEC
	!	400MG		A075800	002	Jan 24, 2003	Jun	CHRS

ETODOLAC

CAPSULE; ORAL		ETODOLAC						
	@ CHARTWELL MOLECULES	200MG		A074842	001	Jul 17, 1997	Mar	CAHN
	@	300MG		A074842	002	Jul 17, 1997	Mar	CAHN
	@ CHARTWELL PHARMS LLC	200MG		A074842	001	Jul 17, 1997	Jan	CAHN
	@	300MG		A074842	002	Jul 17, 1997	Jan	CAHN
	@ ECI PHARMS LLC	300MG		A074929	001	Jan 30, 1998	Apr	CAHN
	LODINE							
	+ @ WYETH PHARMS INC	300MG		N018922	003	Jan 31, 1991	Jul	CRLD
	TABLET; ORAL							
	ETODOLAC							
	@ CHARTWELL MOLECULES	400MG		A074841	001	Jun 27, 1997	Jan	CAHN
	@ MYLAN PHARMS INC	400MG		A075104	001	Feb 06, 1998	May	DISC
AB		400MG		A075104	001	Feb 06, 1998	Mar	CAHN
	@	500MG		A075104	002	Nov 20, 1998	May	DISC
AB		500MG		A075104	002	Nov 20, 1998	Mar	CAHN

ETOMIDATE

INJECTABLE; INJECTION		ETOMIDATE						
AP	AUROBINDO PHARMA LTD	2MG/ML		A206126	001	Feb 24, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	2MG/ML		A209058	001	Apr 18, 2017	Apr	NEWA
AP	MYLAN LABS LTD	2MG/ML		A201044	001	Feb 07, 2017	Jan	NEWA
AP	WEST-WARD PHARMS INT	2MG/ML		A074593	001	Nov 04, 1996	Jan	CAHN

ETOPOSIDE

CAPSULE; ORAL		VEPESID						
	+ @ DAVA PHARMS INC	50MG		N019557	001	Dec 30, 1986	Sep	CRLD
	+ @	100MG		N019557	002	Dec 30, 1986	Sep	CRLD
	INJECTABLE; INJECTION							
	ETOPOSIDE							
AP	MYLAN LABS LTD	20MG/ML		A203507	001	Nov 20, 2017	Nov	NEWA
AP		20MG/ML		A204927	001	Oct 31, 2017	Oct	NEWA

EXAMETAZIME

POWDER; INTRAVENOUS		DRAX EXAMETAZIME						
AP	JUBILANT DRAXIMAGE	0.5MG/VIAL		N208870	001	Aug 17, 2017	Aug	NEWA

EXEMESTANETABLET;ORAL
EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb	NEWA
AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Aug	CAHN
AB		25MG	A209208	001	Jul 26, 2017	Jul	NEWA

EXENATIDESUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE

+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Oct	NEWA
----	----------------	-------------------------	---------	-----	--------------	-----	------

EZETIMIBETABLET;ORAL
EZETIMIBE

>A>	AB	ALKEM LABS LTD	10MG	A209234	001	Dec 21, 2017	Dec	NEWA
	AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May	NEWA
	AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May	NEWA
	AB	AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017	Aug	NEWA
	AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May	NEWA
	AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May	NEWA
	AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May	NEWA
	AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May	NEWA
	AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May	NEWA

EZETIMIBE; SIMVASTATINTABLET;ORAL
EZETIMIBE AND SIMVASTATIN

>A>	AB	ALKEM LABS LTD	10MG;10MG	A209222	001	Dec 22, 2017	Dec	NEWA
>A>	AB		10MG;20MG	A209222	002	Dec 22, 2017	Dec	NEWA
>A>	AB		10MG;40MG	A209222	003	Dec 22, 2017	Dec	NEWA
>A>	AB		10MG;80MG	A209222	004	Dec 22, 2017	Dec	NEWA
	AB	AMNEAL PHARMS CO	10MG;10MG	A208831	001	Nov 21, 2017	Nov	NEWA
	AB		10MG;20MG	A208831	002	Nov 21, 2017	Nov	NEWA
	AB		10MG;40MG	A208831	003	Nov 21, 2017	Nov	NEWA
	AB		10MG;80MG	A208831	004	Nov 21, 2017	Nov	NEWA
	AB	DR REDDYS LABS INTL	10MG;10MG	A200909	001	Apr 26, 2017	Apr	NEWA
	AB		10MG;20MG	A200909	002	Apr 26, 2017	Apr	NEWA
	AB		10MG;40MG	A200909	003	Apr 26, 2017	Apr	NEWA
	AB		10MG;80MG	A200909	004	Apr 26, 2017	Apr	NEWA
	AB	DR REDDYS LABS SA	10MG;10MG	A200909	001	Apr 26, 2017	May	CAHN
	AB		10MG;20MG	A200909	002	Apr 26, 2017	May	CAHN
	AB		10MG;40MG	A200909	003	Apr 26, 2017	May	CAHN
	AB		10MG;80MG	A200909	004	Apr 26, 2017	May	CAHN
	AB	IMPAX LABS INC	10MG;10MG	A201890	001	Apr 26, 2017	Apr	NEWA
	AB		10MG;20MG	A201890	002	Apr 26, 2017	Apr	NEWA
	AB		10MG;40MG	A201890	003	Apr 26, 2017	Apr	NEWA
	AB		10MG;80MG	A201890	004	Apr 26, 2017	Apr	NEWA
	AB	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Apr	NEWA
	AB		10MG;20MG	A202968	002	Apr 26, 2017	Apr	NEWA
	AB		10MG;40MG	A202968	003	Apr 26, 2017	Apr	NEWA
	AB		10MG;80MG	A202968	004	Apr 26, 2017	Apr	NEWA
		VYTORIN						
	AB	+ MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Apr	CFTG
	AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Apr	CFTG
	AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Apr	CFTG
	AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Apr	CFTG

FAMCICLOVIRTABLET;ORAL
FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan	CHRS
		FAMVIR						
	+	@ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan	DISC
	+	@	250MG	N020363	001	Apr 26, 1996	Jan	DISC
	+	@	500MG	N020363	002	Jun 29, 1994	Jan	DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	NOVEL LABS INC	40MG/5ML	A201695	001	Dec 17, 2012	Nov	CDFR
----	----------------	----------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

FAMOTIDINE

AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

AP		10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN
----	--	---------	---------	-----	--------------	-----	------

@ WEST-WARD PHARMS INT 10MG/ML

FAMOTIDINE PRESERVATIVE FREE

AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN
----	--	---------	---------	-----	--------------	-----	------

@ WEST-WARD PHARMS INT 10MG/ML

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001	Nov	CTEC
---	-----------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

FAMOTIDINE

AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN
----	-----------------	------	---------	-----	--------------	-----	------

AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN
----	--	------	---------	-----	--------------	-----	------

>D>	AB	WOCKHARDT	20MG	A075786	001	Apr 16, 2001	Dec	CAHN
-----	----	-----------	------	---------	-----	--------------	-----	------

>D>	AB		40MG	A075786	002	Apr 16, 2001	Dec	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB	WOCKHARDT LTD	20MG	A075786	001	Apr 16, 2001	Dec	CAHN
-----	----	---------------	------	---------	-----	--------------	-----	------

>A>	AB		40MG	A075786	002	Apr 16, 2001	Dec	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun	NEWA
----	------------	-----------	---------	-----	--------------	-----	------

FELBATOL

AB	+!	MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN
----	----	---------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

FELBAMATE

AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AB		600MG	A202284	002	Nov 04, 2015	Feb	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA
----	------------	-------	---------	-----	--------------	-----	------

AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

AB		600MG	A208970	002	May 30, 2017	May	NEWA
----	--	-------	---------	-----	--------------	-----	------

FELBATOL

AB	+	MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
----	---	---------------------	-------	---------	-----	--------------	-----	------

AB	+!		600MG	N020189	002	Jul 29, 1993	Mar	CAHN
----	----	--	-------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB	CNTY LINE PHARMS	67MG	A207805	001	Nov 16, 2017	Nov	NEWA
----	------------------	------	---------	-----	--------------	-----	------

AB		134MG	A207805	002	Nov 16, 2017	Nov	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		200MG	A207805	003	Nov 16, 2017	Nov	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB	!	IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun	CHRS
----	---	------------	-------	---------	-----	--------------	-----	------

AB		INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		200MG	A075753	003	Apr 09, 2002	Jun	CHRS
----	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL

FENOFIBRATE

>A>	AB	CNTY LINE PHARMS	54MG	A207803	001	Dec 19, 2017	Dec	NEWA
-----	----	------------------	------	---------	-----	--------------	-----	------

>A>	AB		160MG	A207803	002	Dec 19, 2017	Dec	NEWA
-----	----	--	-------	---------	-----	--------------	-----	------

AB	!	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
----	---	------------	-------	---------	-----	--------------	-----	------

AB		RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS
----	--	---------------	-------	---------	-----	--------------	-----	------

AB		SUN PHARM INDS LTD	48MG	A200884	001	Sep 07, 2017	Aug	NEWA
----	--	--------------------	------	---------	-----	--------------	-----	------

AB			145MG	A200884	002	Sep 07, 2017	Aug	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TRICOR

+ @ ABBVIE INC 54MG

N021203	001	Sep 04, 2001	Aug	CAHN
---------	-----	--------------	-----	------

+ @ 160MG

N021203	003	Sep 04, 2001	Aug	CAHN
---------	-----	--------------	-----	------

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
 FENOLDOPAM MESYLATE
 AP SANDOZ INC EQ 10MG BASE/ML A077155 001 Feb 15, 2005 Mar CAHN

FENOPROFEN CALCIUM

CAPSULE; ORAL
 NALFON
 +! XSPIRE PHARMA EQ 200MG BASE N017604 003 Aug CAHN
 @ EQ 300MG BASE N017604 002 Aug CAHN
 + EQ 400MG BASE N017604 004 Jul 21, 2009 Aug CAHN
 TABLET; ORAL
 FENOPROFEN CALCIUM
 ! XSPIRE PHARMA EQ 600MG BASE A072267 001 Aug 17, 1988 Aug CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
 FENTANYL-100
 AB 3M DRUG DELIVERY 100MCG/HR A202097 005 Nov 04, 2016 Mar CAHN
 AB ACTAVIS LABS UT INC 100MCG/HR A076709 004 Aug 20, 2007 Mar CAHN
 >D> AB MALLINCKRODT INC 100MCG/HR A077154 004 Feb 09, 2011 Dec CAHN
 AB MAYNE PHARMA 100MCG/HR A077062 004 Aug 20, 2007 Mar CAHN
 >A> AB SPECGX LLC 100MCG/HR A077154 004 Feb 09, 2011 Dec CAHN
 FENTANYL-12
 AB 3M DRUG DELIVERY 12.5MCG/HR A202097 001 Nov 04, 2016 Mar CAHN
 >D> AB MALLINCKRODT INC 12.5MCG/HR A077154 005 Jun 11, 2015 Dec CAHN
 >A> AB SPECGX LLC 12.5MCG/HR A077154 005 Jun 11, 2015 Dec CAHN
 FENTANYL-25
 AB 3M DRUG DELIVERY 25MCG/HR A202097 002 Nov 04, 2016 Mar CAHN
 AB ACTAVIS LABS UT INC 25MCG/HR A076709 001 Aug 20, 2007 Mar CAHN
 >D> AB MALLINCKRODT INC 25MCG/HR A077154 001 Feb 09, 2011 Dec CAHN
 AB MAYNE PHARMA 25MCG/HR A077062 001 Aug 20, 2007 Mar CAHN
 >A> AB SPECGX LLC 25MCG/HR A077154 001 Feb 09, 2011 Dec CAHN
 FENTANYL-37
 AB AVEVA 37.5MCG/HR A077449 006 Dec 06, 2017 Nov NEWA
 FENTANYL-50
 AB 3M DRUG DELIVERY 50MCG/HR A202097 003 Nov 04, 2016 Mar CAHN
 AB ACTAVIS LABS UT INC 50MCG/HR A076709 002 Aug 20, 2007 Mar CAHN
 >D> AB MALLINCKRODT INC 50MCG/HR A077154 002 Feb 09, 2011 Dec CAHN
 AB MAYNE PHARMA 50MCG/HR A077062 002 Aug 20, 2007 Mar CAHN
 >A> AB SPECGX LLC 50MCG/HR A077154 002 Feb 09, 2011 Dec CAHN
 FENTANYL-62
 AB AVEVA 62.5MCG/HR A077449 007 Dec 06, 2017 Nov NEWA
 FENTANYL-75
 AB 3M DRUG DELIVERY 75MCG/HR A202097 004 Nov 04, 2016 Mar CAHN
 AB ACTAVIS LABS UT INC 75MCG/HR A076709 003 Aug 20, 2007 Mar CAHN
 >D> AB MALLINCKRODT INC 75MCG/HR A077154 003 Feb 09, 2011 Dec CAHN
 AB MAYNE PHARMA 75MCG/HR A077062 003 Aug 20, 2007 Mar CAHN
 >A> AB SPECGX LLC 75MCG/HR A077154 003 Feb 09, 2011 Dec CAHN
 FENTANYL-87
 AB AVEVA 87.5MCG/HR A077449 008 Dec 06, 2017 Nov NEWA
 SPRAY; SUBLINGUAL
 SUBSYS
 + INSYS DEV CO INC 0.1MG N202788 001 Jan 04, 2012 May CAHN
 + 0.2MG N202788 002 Jan 04, 2012 May CAHN
 +! 0.4MG N202788 003 Jan 04, 2012 May CAHN
 + 0.6MG N202788 004 Jan 04, 2012 May CAHN
 + 0.8MG N202788 005 Jan 04, 2012 May CAHN
 + 1.2MG N202788 006 Aug 30, 2012 May CAHN
 + 1.6MG N202788 007 Aug 30, 2012 May CAHN

FENTANYL CITRATE

SPRAY, METERED; NASAL
 LAZANDA
 + ELEFSEE PHARMS INTL EQ 0.1MG BASE N022569 001 Jun 30, 2011 Nov CAHN
 + EQ 0.3MG BASE N022569 003 Dec 21, 2015 Nov CAHN
 +! EQ 0.4MG BASE N022569 002 Jun 30, 2011 Nov CAHN
 TABLET; SUBLINGUAL
 ABSTRAL
 AB + SENTYNL THERAPS INC EQ 0.1MG BASE N022510 001 Jan 07, 2011 Nov CFTG
 AB + EQ 0.2MG BASE N022510 002 Jan 07, 2011 Nov CFTG

TABLET;SUBLINGUAL

ABSTRAL

AB	+	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Nov	CFTG
AB	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Nov	CFTG
AB	+	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Nov	CFTG
AB	+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Nov	CFTG

FENTANYL CITRATE

AB	ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Nov	NEWA
AB		EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Nov	NEWA
AB		EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Nov	NEWA
AB		EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Nov	NEWA
AB		EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Nov	NEWA
AB		EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Nov	NEWA

TROCHE/LOZENGE;TRANSMUCOSAL

FENTANYL CITRATE

>D>	AB	MALLINCKRODT	EQ 0.2MG BASE	A078907	001	Oct 30, 2009	Dec	CAHN
>D>	AB		EQ 0.4MG BASE	A078907	002	Oct 30, 2009	Dec	CAHN
>D>	AB		EQ 0.6MG BASE	A078907	003	Oct 30, 2009	Dec	CAHN
>D>	AB		EQ 0.8MG BASE	A078907	004	Oct 30, 2009	Dec	CAHN
>D>	AB		EQ 1.2MG BASE	A078907	005	Oct 30, 2009	Dec	CAHN
>D>	AB		EQ 1.6MG BASE	A078907	006	Oct 30, 2009	Dec	CAHN
>A>	AB	SPECGX LLC	EQ 0.2MG BASE	A078907	001	Oct 30, 2009	Dec	CAHN
>A>	AB		EQ 0.4MG BASE	A078907	002	Oct 30, 2009	Dec	CAHN
>A>	AB		EQ 0.6MG BASE	A078907	003	Oct 30, 2009	Dec	CAHN
>A>	AB		EQ 0.8MG BASE	A078907	004	Oct 30, 2009	Dec	CAHN
>A>	AB		EQ 1.2MG BASE	A078907	005	Oct 30, 2009	Dec	CAHN
>A>	AB		EQ 1.6MG BASE	A078907	006	Oct 30, 2009	Dec	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb	NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	4MG	A204946	001	Oct 03, 2017	Sep	NEWA
AB		8MG	A204946	002	Oct 03, 2017	Sep	NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar	CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May	CAHN

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Nov 03, 2017	Oct	NEWA
AB		100MG	A202821	002	Nov 03, 2017	Oct	NEWA
AB		150MG	A202821	003	Nov 03, 2017	Oct	NEWA

FLOXURIDINE

INJECTABLE;INJECTION

FLOXURIDINE

AP	PHARMAFORCE	500MG/VIAL	A203008	001	Nov 22, 2017	Nov	NEWA
----	-------------	------------	---------	-----	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan	CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan	CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar	DISC	
+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar	DISC	
		DIFLUCAN IN SODIUM CHLORIDE 0.9%						
+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar	DISC	
+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar	DISC	
		DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar	DISC	
+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar	DISC	
		FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	CHRS

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	RENAISSANCE SSA LLC	200MG/100ML (2MG/ML)	A 077988	001	May 26, 2010	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A 077988	002	May 26, 2010	Aug	CAHN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
AP	BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A 077947	001	May 26, 2010	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A 077947	002	May 26, 2010	Aug	CAHN
	WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A 076087	002	Sep 26, 2008	Jan	CAHN
AP		200MG/100ML (2MG/ML)	A 076087	001	Jul 29, 2004	Jan	CAHN
AP		400MG/200ML (2MG/ML)	A 076087	003	Jul 29, 2004	Jan	CAHN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	! ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A 079104	001	Jul 30, 2009	Mar	CHRS
AP	!	400MG/200ML (2MG/ML)	A 079104	002	Jul 30, 2009	Mar	CHRS
	RENAISSANCE SSA LLC	100MG/50ML (2MG/ML)	A 077909	003	Apr 20, 2015	Aug	CAHN
AP		200MG/100ML (2MG/ML)	A 077909	001	May 26, 2010	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A 077909	002	May 26, 2010	Aug	CAHN
AP	WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A 078107	001	Jul 30, 2008	Jan	CAHN
AP		400MG/200ML (2MG/ML)	A 078107	002	Jul 30, 2008	Jan	CAHN

TABLET; ORAL

FLUCONAZOLE							
AB	UNIQUE PHARM LABS	50MG	A 076957	001	Sep 28, 2005	Aug	CAHN
AB		100MG	A 076957	002	Sep 28, 2005	Aug	CAHN
AB		150MG	A 076957	004	Feb 27, 2017	Aug	CAHN
AB		150MG	A 076957	004	Feb 27, 2017	Feb	NEWA
AB		200MG	A 076957	003	Sep 28, 2005	Aug	CAHN
AB	ZYDUS PHARMS USA INC	50MG	A 208963	001	Feb 16, 2017	Feb	NEWA
AB		100MG	A 208963	002	Feb 16, 2017	Feb	NEWA
AB		150MG	A 208963	003	Feb 16, 2017	Feb	NEWA
AB		200MG	A 208963	004	Feb 16, 2017	Feb	NEWA

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE							
AB	NOVEL LABS INC	250MG	A 204652	001	Jul 07, 2017	Jun	NEWA
AB		500MG	A 204652	002	Jul 07, 2017	Jun	NEWA
AB	ROXANE	250MG	A 206550	001	Oct 17, 2017	Oct	NEWA
AB		500MG	A 206550	002	Oct 17, 2017	Oct	NEWA
AB	WEST-WARD PHARMS INT	250MG	A 206550	001	Oct 17, 2017	Oct	CAHN
AB		500MG	A 206550	002	Oct 17, 2017	Oct	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE							
AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A 203738	001	Feb 28, 2017	Feb	NEWA
AP	CUSTOPHARM INC	50MG/VIAL	A 076349	001	Aug 28, 2003	Oct	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18							
AP	JUBILANT DRAXIMAGE	20-300mCi/ML	A 203920	001	Jun 23, 2015	Sep	CAHN
AP	SOFIE	20-300mCi/ML	A 203591	001	Aug 31, 2015	Nov	CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL							
	@ BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A 076755	002	Oct 12, 2004	Aug	CAHN
	@	1MG/10ML (0.1MG/ML)	A 076755	001	Oct 12, 2004	Aug	CAHN
AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A 077071	001	May 03, 2005	Apr	CAHN
AP		1MG/10ML (0.1MG/ML)	A 077071	002	May 03, 2005	Apr	CAHN
AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A 076256	002	Oct 12, 2004	Jan	CAHN
AP		0.5MG/5ML (0.1MG/ML)	A 076787	002	Oct 12, 2004	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	A 076256	001	Oct 12, 2004	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	A 076787	001	Oct 12, 2004	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA							
+!	MYLAN SPECIALITY LP	0.078MG/INH	N 021247	001	Jan 27, 2006	Mar	CAHN

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL		FLUOCINOLONE ACETONIDE					
AT	FOUGERA PHARMS INC	0.01%	A 088170	001	Dec 16, 1982	Jan	CAHN
AT		0.025%	A 088169	001	Dec 16, 1982	Jan	CAHN
	@ TARO	0.01%	A 040035	001	Oct 31, 1994	Apr	CAHN
	@	0.025%	A 040042	001	Oct 31, 1994	Apr	CAHN
OIL/DROPS;OTIC		FLUOCINOLONE ACETONIDE					
AT	PERRIGO ISRAEL	0.01%	A 202849	001	Jul 17, 2017	Jul	NEWA
OINTMENT;TOPICAL		FLUOCINOLONE ACETONIDE					
AT	FOUGERA PHARMS INC	0.025%	A 088168	001	Dec 16, 1982	Jan	CAHN
AT	TARO	0.025%	A 040041	001	Sep 15, 1994	Apr	CAHN
SOLUTION;TOPICAL		FLUOCINOLONE ACETONIDE					
AT	FOUGERA PHARMS INC	0.01%	A 088167	001	Dec 16, 1982	Jan	CAHN
>A>	GLASSHOUSE PHARMS	0.01%	A 209596	001	Dec 26, 2017	Dec	NEWA

FLUOCINONIDE

CREAM;TOPICAL		FLUOCINONIDE					
AB1	FOUGERA PHARMS INC	0.05%	A 073030	001	Oct 17, 1994	Jan	CAHN
AB	PERRIGO ISRAEL	0.1%	A 090256	001	Jan 14, 2014	Apr	CAHN
AB1	TARO	0.05%	A 071500	001	Jun 10, 1987	Mar	CMFD
FLUOCINONIDE EMULSIFIED BASE							
AB2	G AND W LABS INC	0.05%	A 074204	001	Jun 13, 1995	May	CMFD
GEL;TOPICAL		FLUOCINONIDE					
AB	+ CNTY LINE PHARMS	0.05%	N 017373	001		Oct	CMFD
AB	FOUGERA PHARMS INC	0.05%	A 072933	001	Dec 30, 1994	Jan	CAHN
AB	! TARO	0.05%	A 074935	001	Jul 29, 1997	Apr	CAHN
OINTMENT;TOPICAL		FLUOCINONIDE					
AB	NOVEL LABS INC	0.05%	A 207538	001	Jul 31, 2017	Jul	NEWA
AB	! TARO	0.05%	A 075008	001	Jun 30, 1999	Apr	CAHN
SOLUTION;TOPICAL		FLUOCINONIDE					
AT	FOUGERA PHARMS INC	0.05%	A 072934	001	Feb 27, 1995	Nov	CAHN
AT	NOVEL LABS INC	0.05%	A 206003	001	Jul 21, 2017	Jul	NEWA
AT	! TARO	0.05%	A 074799	001	Dec 31, 1996	Apr	CAHN
LIDEX							
AT	+ CNTY LINE PHARMS	0.05%	N 018849	001	Apr 06, 1984	Mar	CRLD

FLUOROURACIL

CREAM;TOPICAL		FLUOROURACIL					
AB	MYLAN PHARMS INC	0.5%	A 203122	001	Apr 20, 2015	Jun	CAHN
INJECTABLE;INJECTION		FLUOROURACIL					
AP	GLAND PHARMA LTD	500MG/10ML (50MG/ML)	A 210123	001	Oct 27, 2017	Oct	NEWA
AP		1GM/20ML (50MG/ML)	A 210123	002	Oct 27, 2017	Oct	NEWA
>A>	AP	2.5GM/50ML (50MG/ML)	A 210124	001	Dec 26, 2017	Dec	NEWA
>A>	AP	5GM/100ML (50MG/ML)	A 210124	002	Dec 26, 2017	Dec	NEWA
AP	SAGENT PHARMS	500MG/10ML (50MG/ML)	A 203608	001	May 11, 2017	May	NEWA
AP		1GM/20ML (50MG/ML)	A 203608	002	May 11, 2017	May	NEWA
	@ SANDOZ	2.5GM/50ML (50MG/ML)	A 091299	001	May 02, 2011	Jul	DISC
	@	5GM/100ML (50MG/ML)	A 091299	002	May 02, 2011	Jul	DISC
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N 012209	001		Jan	CRLD
	+ @	2.5GM/50ML (50MG/ML)	N 012209	002	Jul 29, 2016	Aug	DISC
SOLUTION;TOPICAL		FLUOROURACIL					
AT	TARO PHARM	2%	A 076526	001	Nov 05, 2003	Mar	CAHN
AT		5%	A 076526	002	Nov 05, 2003	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	MALLINCKRODT	EQ 10MG BASE	A 075658	001	Jan 29, 2002	Dec	CAHN
>D>	AB1		EQ 20MG BASE	A 075658	002	Jan 29, 2002	Dec	CAHN
		@ MYLAN	EQ 10MG BASE	A 075207	001	Jan 30, 2002	Jun	DISC
		@	EQ 20MG BASE	A 075207	002	Jan 30, 2002	Jun	DISC
		@	EQ 40MG BASE	A 075207	003	May 25, 2007	Jun	DISC
		@ MYLAN PHARMS INC	EQ 10MG BASE	A 075577	001	Jan 29, 2002	Nov	DISC
		@	EQ 20MG BASE	A 075577	002	Jan 29, 2002	Nov	DISC
>A>	AB1	SPECGX LLC	EQ 10MG BASE	A 075658	001	Jan 29, 2002	Dec	CAHN
>A>	AB1		EQ 20MG BASE	A 075658	002	Jan 29, 2002	Dec	CAHN

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

	AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A 079209	001	Mar 20, 2009	Jan	CAHN
>D>	AA	MALLINCKRODT	EQ 20MG BASE/5ML	A 075920	001	Jan 29, 2002	Dec	CAHN
	AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A 076015	001	Jan 30, 2002	May	CAHN
>A>	AA	SPECGX LLC	EQ 20MG BASE/5ML	A 075920	001	Jan 29, 2002	Dec	CAHN
>D>	AA	WOCKHARDT	EQ 20MG BASE/5ML	A 075514	001	Aug 29, 2002	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	EQ 20MG BASE/5ML	A 075514	001	Aug 29, 2002	Dec	CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A 208698	001	Apr 05, 2017	Mar	NEWA
	AB		EQ 20MG BASE	A 208698	002	Apr 05, 2017	Mar	NEWA
	AB	+! ALVOGEN	EQ 60MG BASE	N 202133	001	Oct 06, 2011	Oct	CTEC
		+!	EQ 60MG BASE	N 202133	001	Oct 06, 2011	Jan	CAHN
	AB	INVENTIA HLTHCARE	EQ 60MG BASE	A 209695	001	Nov 20, 2017	Nov	NEWA
	AB	PAR PHARM INC	EQ 60MG BASE	A 209419	001	Nov 16, 2017	Oct	NEWA

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

	!	USL PHARMA	10MG	A 088342	001	Oct 21, 1983	Jun	CAHN
--	---	------------	------	----------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

	AO	AUROBINDO PHARMA LTD	25MG/ML	A 207739	001	Oct 17, 2017	Oct	NEWA
--	----	----------------------	---------	----------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	ANI PHARMS INC	5MG/ML	A 073058	001	Aug 30, 1991	Jan	CAHN
	!	PHARM ASSOC	5MG/ML	A 074725	001	Sep 16, 1996	May	CAHN

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	2.5MG/5ML	A 040146	001	Aug 21, 1996	May	CAHN
--	---	-------------	-----------	----------	-----	--------------	-----	------

PROLIXIN

	+	@ APOTHECON	2.5MG/5ML	N 012145	003		Sep	DISC
--	---	-------------	-----------	----------	-----	--	-----	------

TABLET;ORAL

PROLIXIN

>D>		@ APOTHECON	1MG	N 011751	004		Dec	CRLD
>A>		+ @	1MG	N 011751	004		Dec	CRLD
>D>		@	2.5MG	N 011751	001		Dec	CRLD
>A>		+ @	2.5MG	N 011751	001		Dec	CRLD
>D>		@	5MG	N 011751	003		Dec	CRLD
>A>		+ @	5MG	N 011751	003		Dec	CRLD
>D>		@	10MG	N 011751	002		Dec	CRLD
>A>		+ @	10MG	N 011751	002		Dec	CRLD

FLURANDRENOLIDE

CREAM;TOPICAL

FLURANDRENOLIDE

	AT	CINTEX SVCS	0.05%	A 205342	001	Apr 13, 2016	Jun	CAHN
--	----	-------------	-------	----------	-----	--------------	-----	------

LOTION;TOPICAL

FLURANDRENOLIDE

	AT	CINTEX SVCS	0.05%	A 205343	001	Dec 22, 2016	Jun	CAHN
--	----	-------------	-------	----------	-----	--------------	-----	------

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 15MG A071717 002 Jul 31, 1991 Jan CMS1

FLUTAMIDE

CAPSULE;ORAL

EULEXIN

+ @ SCHERING 125MG N018554 001 Jan 27, 1989 Sep CRLD

FLUTAMIDE

>A> @ FOSUN PHARMA 125MG A075818 001 Sep 18, 2001 Dec CAHN

@ MYLAN 125MG A076224 001 May 09, 2003 Jun DISC

>D> @ SANDOZ 125MG A075818 001 Sep 18, 2001 Dec CAHN

FLUTICASON E FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

TRELEGY ELLIPTA

+! GLAXOSMITHKLINE 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ N209482 001 Sep 18, 2017 Sep NEWA
0.025MG BASE/INH

FLUTICASON E PROPIONATE

POWDER;INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM 0.055MG/INH N208798 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH N208798 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH N208798 003 Jan 27, 2017 Jan NEWA

SPRAY, METERED;NASAL

FLONASE

+ @ GLAXOSMITHKLINE 0.05MG/SPRAY N020121 001 Oct 19, 1994 Jul CRLD

FLUTICASON E PROPIONATE

AB ! WEST-WARD PHARMS INT 0.05MG/SPRAY A076504 001 Feb 22, 2006 Jul CHRS

>D> AB WOCKHARDT 0.05MG/SPRAY A078492 001 Jan 09, 2012 Dec CAHN

>A> AB WOCKHARDT BIO AG 0.05MG/SPRAY A078492 001 Jan 09, 2012 Dec CAHN

FLUTICASON E PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH N208799 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH;EQ 0.014MG BASE/INH N208799 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH;EQ 0.014MG BASE/INH N208799 003 Jan 27, 2017 Jan NEWA

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB ! MYLAN PHARMS INC EQ 40MG BASE A090595 002 Apr 11, 2012 May CHRS

LESCOL

+ @ NOVARTIS EQ 20MG BASE N020261 001 Dec 31, 1993 May DISC

+ @ EQ 40MG BASE N020261 002 Dec 31, 1993 May DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB ! ACTAVIS ELIZABETH 150MG A091482 002 Nov 18, 2013 Apr CHRS

LUVOX CR

+ @ JAZZ PHARMS 100MG N022033 001 Feb 28, 2008 Apr DISC

+ @ 150MG N022033 002 Feb 28, 2008 Apr DISC

TABLET;ORAL

FLUVOXAMINE MALEATE

@ ECI PHARMS LLC 25MG A075900 001 Feb 23, 2006 May CAHN

@ 50MG A075900 002 Feb 23, 2006 May CAHN

@ 100MG A075900 003 Feb 23, 2006 May CAHN

@ UPSHER-SMITH LABS 25MG A075887 001 Jan 05, 2001 Jun CAHN

AB 25MG A075888 001 Nov 29, 2000 Jun CAHN

@ 50MG A075887 002 Jan 05, 2001 Jun CAHN

AB 50MG A075888 002 Nov 29, 2000 Jun CAHN

@ 100MG A075887 003 Jan 05, 2001 Jun CAHN

AB ! 100MG A075888 003 Nov 29, 2000 Jun CAHN

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS
FONDAPARINUX SODIUM

>A>	AP	AUROBINDO PHARMA LTD	2.5MG/0.5ML	A206918	001	Dec 26, 2017	Dec	NEWA
>A>	AP		5MG/0.4ML	A206918	002	Dec 26, 2017	Dec	NEWA
>A>	AP		7.5MG/0.6ML	A206918	003	Dec 26, 2017	Dec	NEWA
>A>	AP		10MG/0.8ML	A206918	004	Dec 26, 2017	Dec	NEWA

FORMOTEROL FUMARATE

POWDER;INHALATION
FORADIL

+	@	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb	DISC
---	---	----------	-------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE

+	!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar	CAHN
---	---	--------------------	---------------------------	---------	-----	--------------	-----	------

FOSCARNET SODIUM

INJECTABLE;INJECTION
FOSCARNET SODIUM

@		HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep	DISC
+	!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep	CTEC

FOSINOPRIL SODIUM

TABLET;ORAL
FOSINOPRIL SODIUM

@		UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Jun	CAHN
AB			10MG	A076483	001	Apr 23, 2004	Jun	CAHN
	@		20MG	A076188	002	Oct 08, 2004	Jun	CAHN
AB			20MG	A076483	002	Apr 23, 2004	Jun	CAHN
	@		40MG	A076188	003	Oct 08, 2004	Jun	CAHN
AB			40MG	A076483	003	Apr 23, 2004	Jun	CAHN
		MONOPRIL						
+	@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan	CRLD
+	@		20MG	N019915	003	May 16, 1991	Jan	CRLD
+	@		40MG	N019915	004	Mar 28, 1995	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun	CMFD
AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan	CAHN
AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan	CAHN

FUROSEMIDE

INJECTABLE;INJECTION
FUROSEMIDE

@		ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Jun	CAHN
AP		BAXTER HLTHCARE CORP	10MG/ML	A202747	001	Jan 27, 2014	Aug	CAHN

SOLUTION;ORAL

FUROSEMIDE

>D>	AA	WOCKHARDT	10MG/ML	A070655	001	Oct 02, 1987	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	Dec	CAHN

TABLET;ORAL

FUROSEMIDE

AB		IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Aug	CTEC
BX			20MG	A078010	001	Sep 18, 2006	Apr	CTEC
AB			40MG	A078010	002	Sep 18, 2006	Aug	CTEC
BX			40MG	A078010	002	Sep 18, 2006	Apr	CTEC
AB			80MG	A078010	003	Sep 18, 2006	Aug	CTEC
BX			80MG	A078010	003	Sep 18, 2006	Apr	CTEC
AB		PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb	CAHN
AB			40MG	A076796	002	Mar 26, 2004	Feb	CAHN
AB			80MG	A076796	003	Mar 26, 2004	Feb	CAHN
	@	SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May	DISC
	@		40MG	A091258	002	Apr 01, 2014	May	DISC
	@		40MG	N018790	001	Nov 29, 1983	Oct	CAHN
	@		80MG	A091258	003	Apr 01, 2014	May	DISC
AB		WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan	CAHN

TABLET;ORAL							
FUROSEMIDE							
AB		40MG		N018823	002	Nov 10, 1983	Jan CAHN
<u>GABAPENTIN</u>							
CAPSULE;ORAL							
GABAPENTIN							
AB	AUROBINDO PHARMA LTD	100MG		A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG		A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG		A078787	003	Jan 31, 2008	Jan CAHN
	@ CSPC OUYI PHARM CO	100MG		A075477	001	Mar 23, 2005	Oct CAHN
	@	300MG		A075477	002	Mar 23, 2005	Oct CAHN
	@	400MG		A075477	003	Mar 23, 2005	Oct CAHN
AB	EPIC PHARMA LLC	100MG		A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG		A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG		A207099	003	Mar 24, 2017	Mar NEWA
AB	JIANGSU HENGRUI MED	100MG		A091008	001	Oct 26, 2017	Oct NEWA
AB		300MG		A091008	002	Oct 26, 2017	Oct NEWA
AB		400MG		A091008	003	Oct 26, 2017	Oct NEWA
TABLET;ORAL							
GABAPENTIN							
AB	CSPC OUYI PHARM CO	600MG		A207057	001	Oct 26, 2017	Oct NEWA
AB		800MG		A207057	002	Oct 26, 2017	Oct NEWA
AB	GLENMARK PHARMS LTD	600MG		A077662	001	Aug 18, 2006	May CAHN
AB		800MG		A077662	002	Aug 18, 2006	May CAHN
AB	TEVA PHARMS USA	600MG		A205807	001	Mar 10, 2017	Feb NEWA
AB		800MG		A205807	002	Mar 10, 2017	Feb NEWA
<u>GADOTERATE MEGLUMINE</u>							
SOLUTION;INTRAVENOUS							
DOTAREM							
+	!	GUERBET	1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep CMS1
+	!		1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Aug NEWA
<u>GALANTAMINE HYDROBROMIDE</u>							
TABLET;ORAL							
GALANTAMINE HYDROBROMIDE							
	@ MYLAN	EQ 4MG BASE		A077603	001	Aug 28, 2008	Oct DISC
	@	EQ 8MG BASE		A077603	002	Aug 28, 2008	Oct DISC
	@	EQ 12MG BASE		A077603	003	Aug 28, 2008	Oct DISC
AB	YABAO PHARM	EQ 4MG BASE		A077604	001	Feb 06, 2009	Jul CMFD
AB		EQ 8MG BASE		A077604	002	Feb 06, 2009	Jul CMFD
AB		EQ 12MG BASE		A077604	003	Feb 06, 2009	Jul CMFD
<u>GANCICLOVIR</u>							
SOLUTION;IV (INFUSION)							
GANCICLOVIR							
+	!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
<u>GANCICLOVIR SODIUM</u>							
INJECTABLE;INJECTION							
GANCICLOVIR							
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL		A204560	001	Nov 17, 2017	Nov NEWA
AP	PHARMASCIENCE INC	EQ 500MG BASE/VIAL		A207645	001	Dec 08, 2017	Nov NEWA
<u>GATIFLOXACIN</u>							
SOLUTION/DROPS;OPHTHALMIC							
GATIFLOXACIN							
AT	SANDOZ INC	0.5%		A204227	001	Jul 11, 2016	Feb CAHN
<u>GEMCITABINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
GEMCITABINE HYDROCHLORIDE							
AP	ACTAVIS TOTOWA	EQ 2GM BASE/VIAL		A079160	003	Jul 28, 2016	Oct NEWA
AP	APOTEX INC	200MG/5.26ML (38MG/ML)		A206776	001	May 23, 2017	May NEWA
AP		1GM/26.3ML (38MG/ML)		A206776	002	May 23, 2017	May NEWA
AP		2GM/52.6ML (38MG/ML)		A206776	003	May 23, 2017	May NEWA
AP	MYLAN LABS LTD	200MG/5.26ML (38MG/ML)		A205242	001	Dec 06, 2017	Nov NEWA
AP		1GM/26.3ML (38MG/ML)		A205242	002	Dec 06, 2017	Nov NEWA
AP		2GM/52.6ML (38MG/ML)		A205242	003	Dec 06, 2017	Nov NEWA
	@ SAGENT PHARMS	EQ 200MG BASE/VIAL		A091597	001	May 07, 2013	Nov DISC

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

	@	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Nov	DISC
SOLUTION; IV (INFUSION)							
GEMCITABINE HYDROCHLORIDE							
	+	ACCORD HLTHCARE 1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Aug	NEWA
	+	1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Aug	NEWA
	+	2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Aug	NEWA
	+	200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Aug	NEWA

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB		CARIBE HOLDINGS 600MG	A078012	001	Mar 26, 2007	Jan	CAHN
>A>	@	FOSUN PHARMA 600MG	A074615	001	Sep 29, 1995	Dec	CAHN
>D>	@	SANDOZ 600MG	A074615	001	Sep 29, 1995	Dec	CAHN

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

AB	+	LG CHEM LTD EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar	CAHN
----	---	---------------------------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

	@	FOUGERA PHARMS INC EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan	DISC
AT	!	PERRIGO NEW YORK EQ 0.1% BASE	A062307	001		Jan	CHRS
	@	TARO EQ 0.1% BASE	A062427	001	May 26, 1983	Jan	DISC

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan	CAHN
----	--	---------------------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC
GENOPTIC

AT	!	ALLERGAN EQ 0.3% BASE	A062452	001	Oct 10, 1984	Oct	CHRS
>D>	@	BAUSCH AND LOMB EQ 0.3% BASE	A064048	001	May 11, 1994	Dec	CMFD
>A>	AT	EQ 0.3% BASE	A064048	001	May 11, 1994	Dec	CMFD
	@	EQ 0.3% BASE	A064048	001	May 11, 1994	Oct	DISC
AT		SANDOZ INC EQ 0.3% BASE	A062196	001		Mar	CAHN

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA 40MG/ML	N020622	003	Jan 28, 2014	Sep	CFTG
AP		MYLAN PHARMS INC 20MG/ML	A091646	001	Oct 03, 2017	Sep	NEWA
AP		40MG/ML	A206936	001	Oct 03, 2017	Sep	NEWA

GLECAPREVIR; PIBRENTASVIR

TABLET; ORAL
MAVYRET

	+	ABBVIE INC 100MG; 40MG	N209394	001	Aug 03, 2017	Aug	NEWA
--	---	------------------------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

	@	EPIC PHARMA LLC 1MG	A077274	001	Oct 06, 2005	May	CAHN
	@	2MG	A077274	002	Oct 06, 2005	May	CAHN
	@	4MG	A077274	003	Oct 06, 2005	May	CAHN
AB		PRINSTON INC 1MG	A077370	001	Dec 23, 2005	Feb	CAHN
AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN
AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN
AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN
AB		VIVA HLTHCARE 1MG	A091220	001	Jun 29, 2012	Nov	CAHN
AB		2MG	A091220	002	Jun 29, 2012	Nov	CAHN
		3MG	A091220	003	Jun 29, 2012	Nov	CAHN
AB		4MG	A091220	004	Jun 29, 2012	Nov	CAHN
		6MG	A091220	005	Jun 29, 2012	Nov	CAHN
AB		8MG	A091220	006	Jun 29, 2012	Nov	CAHN

GLIPIZIDE

TABLET;ORAL		GLIPIZIDE					
	@ MYLAN	5MG	A 074438	001	Jun 20, 1995	Nov	DISC
	@	10MG	A 074438	002	Jun 20, 1995	Nov	DISC
AB	WATSON LABS TEVA	5MG	A 074223	001	Feb 27, 1995	May	CAHN
AB		10MG	A 074223	002	Feb 27, 1995	May	CAHN
TABLET, EXTENDED RELEASE;ORAL		GLIPIZIDE					
AB	AUROBINDO PHARMA LTD	2.5MG	A 206928	001	May 12, 2017	May	NEWA
AB		5MG	A 206928	002	May 12, 2017	May	NEWA
AB		10MG	A 206928	003	May 12, 2017	May	NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL		GLIPIZIDE AND METFORMIN HYDROCHLORIDE					
AB	EPIC PHARMA LLC	2.5MG;250MG	A 077507	001	Oct 27, 2005	May	CAHN
AB		2.5MG;500MG	A 077507	002	Oct 27, 2005	May	CAHN
AB		5MG;500MG	A 077507	003	Oct 27, 2005	May	CAHN
METAGLIP							
+ @	BRISTOL MYERS SQUIBB	2.5MG;250MG	N 021460	001	Oct 21, 2002	Jan	CRLD
+ @		2.5MG;500MG	N 021460	002	Oct 21, 2002	Jan	CRLD
+ @		5MG;500MG	N 021460	003	Oct 21, 2002	Jan	CRLD

GLUTETHIMIDE

TABLET;ORAL		GLUTETHIMIDE					
	@ UPSHER-SMITH LABS	500MG	A 083234	002		Jun	CAHN

GLYBURIDE

TABLET;ORAL		GLYBURIDE					
AB1	EPIC PHARMA LLC	1.25MG	A 076257	001	Jun 27, 2002	May	CAHN
AB1		2.5MG	A 076257	002	Jun 27, 2002	May	CAHN
AB1		5MG	A 076257	003	Jun 27, 2002	May	CAHN
AB2	IMPAX LABS INC	1.25MG	A 206079	001	Sep 30, 2015	Feb	CAHN
AB2		2.5MG	A 206079	002	Sep 30, 2015	Feb	CAHN
AB2		5MG	A 206079	003	Sep 30, 2015	Feb	CAHN
GLYBURIDE (MICRONIZED)							
>A>	@ FOSUN PHARMA	1.5MG	A 075174	001	Jun 22, 1998	Dec	CAHN
>A>	@	3MG	A 075174	002	Jun 22, 1998	Dec	CAHN
>D>	@ SANDOZ	1.5MG	A 075174	001	Jun 22, 1998	Dec	CAHN
>D>	@	3MG	A 075174	002	Jun 22, 1998	Dec	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL		GLUCOVANCE					
+ @	BRISTOL MYERS SQUIBB	2.5MG;500MG	N 021178	002	Jul 31, 2000	Aug	DISC
+ @		5MG;500MG	N 021178	003	Jul 31, 2000	Aug	DISC
GLYBURIDE AND METFORMIN HYDROCHLORIDE							
AB	! AUROBINDO PHARMA	2.5MG;500MG	A 077870	002	Nov 14, 2007	Aug	CHRS
	@ IMPAX LABS INC	1.25MG;250MG	A 076731	001	Nov 19, 2004	Feb	CAHN
	@	2.5MG;500MG	A 076731	002	Nov 19, 2004	Feb	CAHN
	@	5MG;500MG	A 076731	003	Nov 19, 2004	Feb	CAHN

GLYCINE

SOLUTION;IRRIGATION		GLYCINE 1.5% IN PLASTIC CONTAINER					
AT	ICU MEDICAL INC	1.5GM/100ML	N 018315	001		Feb	CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION		GLYCOPYRROLATE					
AP	AMNEAL PHARMS CO	0.2MG/ML	A 208973	001	Jun 15, 2017	Jun	NEWA
>D>	AA FRESENIUS KABI USA	0.2MG/ML	A 209328	001	Oct 27, 2017	Dec	CTEC
>A>	AP	0.2MG/ML	A 209328	001	Oct 27, 2017	Dec	CTEC
AA		0.2MG/ML	A 209328	001	Oct 27, 2017	Oct	NEWA
AP	SOMERSET THERAPS LLC	0.2MG/ML	A 207639	001	Jun 23, 2017	Jun	NEWA
POWDER;INHALATION		SEEBRI					
+!	SUNOVION PHARMS INC	15.6MCG/INH	N 207923	001	Oct 29, 2015	Jan	CAHN

	SOLUTION; INHALATION						
>A>	LONHALA MAGNAIR KIT						
>A>	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017	Dec NEWA
	TABLET; ORAL						
	GLYCOPYRROLATE						
	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May CAHN
	@		2MG	A040568	002	Dec 22, 2004	May CAHN
		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Nov CTEC
AA		SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May CAHN
AA			2MG	A091182	002	Feb 03, 2014	May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION
UTIBRON

	+!	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Jan CAHN
--	----	---------------------	--------------------------	---------	-----	--------------	----------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL

	@	WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar CAHN
	@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar CAHN
	@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

	+!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan CMFD
--	----	---------	------------------	---------	-----	--	----------

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX

	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May CAHN
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN						
AT		AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar CAHN
	NEOSPORIN						
AT	!	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Aug CAHN
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Aug CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Aug CAHN
>A>	AP	MYLAN ASI	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137	002	Apr 09, 2010	Dec CAHN
	AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Mar NEWA
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Mar NEWA
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan NEWA
>D>	AP	SAGENT AGILA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137	002	Apr 09, 2010	Dec CAHN
	AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078534	001	Apr 30, 2009	Mar CAHN
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar CAHN
	AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

	@	EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May CAHN
AB		TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar CAHN

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

@ CHARTWELL RX	250MG	A 060569	002		Sep CAHN
@	500MG	A 060569	001		Sep CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	CHARTWELL RX	125MG/5ML	A 065200	001	Mar 02, 2005	Jun CAHN
----	--------------	-----------	----------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

@ CHARTWELL RX	125MG	A 061996	001		Sep CAHN
@	250MG	A 061996	002		Sep CAHN

FULVICIN P/G 165

@ CHARTWELL RX	165MG	A 061996	003	Apr 06, 1982	Sep CAHN
----------------	-------	----------	-----	--------------	----------

FULVICIN P/G 330

@ CHARTWELL RX	330MG	A 061996	004	Apr 06, 1982	Sep CAHN
----------------	-------	----------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROSIZED

TABLET;ORAL

GRISEOFULVIN, ULTRAMICROSIZED

>A>	AB	COREPHARMA	125MG	A 204371	001	Jan 09, 2014	Dec CAHN
>A>	AB		250MG	A 204371	002	Jan 09, 2014	Dec CAHN
>D>	AB	IMPAX LABS INC	125MG	A 204371	001	Jan 09, 2014	Dec CAHN
	AB		125MG	A 204371	001	Jan 09, 2014	Sep CAHN
>D>	AB		250MG	A 204371	002	Jan 09, 2014	Dec CAHN
	AB		250MG	A 204371	002	Jan 09, 2014	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

+ @ SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N 205474	001	Nov 14, 2014	Aug DISC
----------------------	---------------------	----------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 1MG BASE	A 205689	001	Nov 16, 2017	Nov NEWA
AB		EQ 2MG BASE	A 205689	002	Nov 16, 2017	Nov NEWA
AB		EQ 3MG BASE	A 205689	003	Nov 16, 2017	Nov NEWA
AB		EQ 4MG BASE	A 205689	004	Nov 16, 2017	Nov NEWA

HALCINONIDE

CREAM;TOPICAL

HALOG-E

@ SUN PHARM INDS INC	0.1%	N 018234	001		Aug CAHN
----------------------	------	----------	-----	--	----------

OINTMENT;TOPICAL

HALOG

+! SUN PHARM INDS INC	0.1%	N 017824	001		Aug CAHN
-----------------------	------	----------	-----	--	----------

SOLUTION;TOPICAL

HALOG

@ SUN PHARM INDS INC	0.1%	N 017823	001		Aug CAHN
----------------------	------	----------	-----	--	----------

HALOBETASOL PROPIONATE

CREAM;TOPICAL

HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A 078162	001	Apr 24, 2007	Apr CHRS
----	----------------	-------	----------	-----	--------------	----------

ULTRAVATE

AB	+ SUN PHARM INDS LTD	0.05%	N 019967	001	Dec 27, 1990	Apr CHRS
----	----------------------	-------	----------	-----	--------------	----------

AB	+!	0.05%	N 019967	001	Dec 27, 1990	Mar CAHN
----	----	-------	----------	-----	--------------	----------

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A 077721	001	Sep 07, 2006	Jun CHRS
----	----------------	-------	----------	-----	--------------	----------

AB	G AND W LABS INC	0.05%	A 077109	001	Jun 14, 2005	Nov CMFD
----	------------------	-------	----------	-----	--------------	----------

AB	PERRIGO ISRAEL	0.05%	A 076872	001	Dec 16, 2004	Apr CAHN
----	----------------	-------	----------	-----	--------------	----------

ULTRAVATE

AB	+ RANBAXY	0.05%	N 019968	001	Dec 17, 1990	Jun CHRS
----	-----------	-------	----------	-----	--------------	----------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Sep	CAHN
@		1MG	A071157	001	Jan 02, 1987	Sep	CAHN
@		2MG	A071172	001	Jan 02, 1987	Sep	CAHN
@		5MG	A071212	001	Jan 07, 1988	Sep	CAHN
@		10MG	A071173	001	Jan 07, 1988	Sep	CAHN
@		20MG	A071177	001	Jan 07, 1988	Sep	CAHN
@	FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May	NEWA
AO		EQ 100MG BASE/ML	A205241	002	May 12, 2017	May	NEWA
@	SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar	CAHN
@		EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May	CAHN
AP	AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug	NEWA
@	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Aug	CAHN
@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Aug	CAHN
@	SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA
AP	MYLAN LABS LTD	1,000 UNITS/ML	A203851	001	Nov 30, 2017	Nov	NEWA
AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	Nov	NEWA
AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	Nov	NEWA
AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	Nov	NEWA
@	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul	CAHN
@		2,500 UNITS/ML	N017007	007		Jul	CAHN
@		5,000 UNITS/ML	N017007	002		Jul	CAHN
@		5,000 UNITS/0.5ML	N017007	010		Jul	CAHN
@		7,500 UNITS/ML	N017007	003		Jul	CAHN
@		10,000 UNITS/ML	N017007	004		Jul	CAHN
@		15,000 UNITS/ML	N017007	005		Jul	CAHN
@		20,000 UNITS/ML	N017007	006		Jul	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA
AA	BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA
AA	NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA
AA	PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA
>D>	AA	WOCKHARDT	A088008	001	Mar 03, 1983	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	A088008	001	Mar 03, 1983	Dec	CAHN

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AVANTHI INC	1.5MG; 5MG	A207176	001	Aug 07, 2017	Jul	NEWA
AA	! KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986	Sep	CAHN
@		25MG	A089258	001	May 05, 1986	Sep	CAHN
@		50MG	A089259	001	May 05, 1986	Sep	CAHN
@		100MG	A088729	001	Apr 11, 1985	Sep	CAHN
@	MYLAN	10MG	A090413	001	Dec 08, 2010	Nov	DISC
@		25MG	A090413	002	Dec 08, 2010	Nov	DISC

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

	@	50MG	A090413	003	Dec 08, 2010	Nov	DISC
	@	100MG	A090413	004	Dec 08, 2010	Nov	DISC
AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May	NEWA
AA		25MG	A205236	002	May 26, 2017	May	NEWA
AA		50MG	A205236	003	May 26, 2017	May	NEWA
AA		100MG	A205236	004	May 26, 2017	May	NEWA
AA	TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Sep	CAHN
AA		25MG	A205236	002	May 26, 2017	Sep	CAHN
AA		50MG	A205236	003	May 26, 2017	Sep	CAHN
AA		100MG	A205236	004	May 26, 2017	Sep	CAHN
	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun	CAHN
	@	25MG	A083560	001		Jun	CAHN
	@	50MG	A083561	001		Jun	CAHN
	@	50MG	A085088	001		Sep	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	25MG	A087565	001	Mar 09, 1982	Dec	CAHN
>A>	@	50MG	A084912	001		Dec	CAHN
	@ JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Sep	DISC
	@	50MG	A040809	002	Sep 04, 2007	Sep	DISC
>A>	AB LEADING PHARMA LLC	12.5MG	A040702	003	May 10, 2017	Dec	NEWA
	@ MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007	Nov	DISC
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN
>D>	@ SANDOZ	25MG	A087565	001	Mar 09, 1982	Dec	CAHN
>D>	@	50MG	A084912	001		Dec	CAHN
AB	TECH ORGANIZED	25MG	A203018	001	Jul 23, 2014	Sep	CAHN
AB		50MG	A203018	002	Jul 23, 2014	Sep	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar	CAHN
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar	CAHN
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CAHN
AB	UNICHEM LABS LTD	12.5MG;150MG	A207018	001	Sep 19, 2017	Sep	NEWA
AB		12.5MG;300MG	A207018	002	Sep 19, 2017	Sep	NEWA
AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May	NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May	NEWA
AB		12.5MG;20MG	A204058	002	May 23, 2017	May	NEWA
AB		25MG;20MG	A204058	003	May 23, 2017	May	NEWA
	PRINZIDE						
+ @	MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan	CRLD
+ @		12.5MG;20MG	N019778	001	Feb 16, 1989	Jan	CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;50MG	A204901	001	Nov 06, 2017	Oct	NEWA
AB		12.5MG;100MG	A204901	002	Nov 06, 2017	Oct	NEWA
AB		25MG;100MG	A204901	003	Nov 06, 2017	Oct	NEWA
AB	UNICHEM LABS LTD	12.5MG;50MG	A204832	001	Jul 21, 2017	Jul	NEWA
AB		12.5MG;100MG	A204832	002	Jul 21, 2017	Jul	NEWA
AB		25MG;100MG	A204832	003	Jul 21, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	15MG;250MG	A070182	001	Jan 15, 1986	Dec	CAHN
>A>	@	25MG;250MG	A070183	001	Jan 15, 1986	Dec	CAHN
>A>	@	30MG;500MG	A070543	001	Jan 15, 1986	Dec	CAHN
>D>	@ SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986	Dec	CAHN

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	@	25MG;250MG	A070183	001	Jan 15, 1986	Dec CAHN
>D>	@	30MG;500MG	A070543	001	Jan 15, 1986	Dec CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@		12.5MG;15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@		25MG;15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB		HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB			25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A204233	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A204233	003	Apr 24, 2017	Apr NEWA
AB		AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A205391	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A205391	003	Apr 24, 2017	Apr NEWA
AB		PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A207804	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A207804	003	Apr 24, 2017	Apr NEWA
AB		TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A200532	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A200532	003	Apr 24, 2017	Apr NEWA
AB		TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr NEWA
AB			12.5MG;40MG	A206515	002	May 03, 2017	Apr NEWA
AB			25MG;40MG	A206515	003	May 03, 2017	Apr NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@	FOSUN PHARMA	25MG;40MG	A071060	001	Aug 26, 1987	Dec CAHN
>A>	@		25MG;80MG	A071061	001	Aug 26, 1987	Dec CAHN
>D>	@	SANDOZ	25MG;40MG	A071060	001	Aug 26, 1987	Dec CAHN
>D>	@		25MG;80MG	A071061	001	Aug 26, 1987	Dec CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun CMS1
AB			12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun CMS1
AB			25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

>A>	@	FOSUN PHARMA	25MG;25MG	A086881	001		Dec CAHN
>D>	@	SANDOZ	25MG;25MG	A086881	001		Dec CAHN
		SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE					
	@	UPSHER SMITH	25MG;25MG	A087553	001		Jun CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG;40MG	A209028	001	Nov 06, 2017	Oct NEWA
AB			12.5MG;80MG	A209028	002	Nov 06, 2017	Oct NEWA
AB			25MG;80MG	A209028	003	Nov 06, 2017	Oct NEWA
AB		ZYDUS PHARMS USA INC	12.5MG;40MG	A204221	001	Aug 15, 2017	Jul NEWA
AB			12.5MG;80MG	A204221	002	Aug 15, 2017	Jul NEWA
AB			25MG;80MG	A204221	003	Aug 15, 2017	Jul NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A201662	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A201662	005	Mar 21, 2013	May	CAHN
AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A091519	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

>D>	+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Dec	CAHN
>A>	+		10MG	N202880	001	Oct 25, 2013	Dec	CAHN
>D>	+		15MG	N202880	002	Oct 25, 2013	Dec	CAHN
>A>	+		15MG	N202880	002	Oct 25, 2013	Dec	CAHN
>D>	+		20MG	N202880	003	Oct 25, 2013	Dec	CAHN
>A>	+		20MG	N202880	003	Oct 25, 2013	Dec	CAHN
>D>	+		30MG	N202880	004	Oct 25, 2013	Dec	CAHN
>A>	+		30MG	N202880	004	Oct 25, 2013	Dec	CAHN
>D>	+		40MG	N202880	005	Oct 25, 2013	Dec	CAHN
>A>	+		40MG	N202880	005	Oct 25, 2013	Dec	CAHN
>D>	+		50MG	N202880	006	Oct 25, 2013	Dec	CAHN
>A>	+		50MG	N202880	006	Oct 25, 2013	Dec	CAHN

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan	NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan	NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan	NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	!	AMNEAL PHARMS NY	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep	CHRS
		VICOPROFEN						
	+	@ ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Sep	DISC
--	---	-----------------	------------------	---------	-----	--------------	-----	------

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan	CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan	CAHN
		SYNACORT						
	@	MEDICIS	1%	A087458	001		Jul	DISC
	@		2.5%	A087457	001		Jul	DISC

LOTION; TOPICAL

STIE-CORT

	@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr	CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan	CAHN
		HYDROCORTISONE IN ABSORBASE						
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr	CAHN

TABLET; ORAL

HYDROCORTISONE

AB		PII	5MG	A207029	001	Apr 27, 2017	Apr	NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr	NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr	NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL
CORTIFOAM

	+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar	CAHN
		CREAM;TOPICAL						
		HYDROCORTISONE ACETATE						
		@ FERNDALE LABS	2.5%	A040259	001	Jul 29, 1999	Sep	DISC
		MICORT-HC						
		@ SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002	Nov	DISC

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL
CORTISPORIN

	+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN
--	----	----------------	---------------------------------------	---------	-----	--------------	-----	------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL
EPIFOAM

BX		MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar	CAHN
		PROCTOFOAM HC						
BX		MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar	CAHN

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL
HYDROCORTISONE BUTYRATE

AB2		ACTAVIS MID ATLANTIC	0.1%	A205134	001	Dec 08, 2017	Nov	NEWA
		LOTION;TOPICAL						
		HYDROCORTISONE BUTYRATE						
AB		TELIGENT PHARMA INC	0.1%	A209556	001	Nov 21, 2017	Nov	NEWA
		LOCOID						
AB	+!	PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	Nov	CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION
A-HYDROCORT

		@ HOSPIRA	EQ 100MG BASE/VIAL	A040666	001	Apr 06, 2006	Sep	DISC
		SOLU-CORTEF						
	+!	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001		Sep	CTEC
	+!		EQ 250MG BASE/VIAL	N009866	002		Nov	CTEC
	+!		EQ 500MG BASE/VIAL	N009866	003		Nov	CTEC
	+!		EQ 1GM BASE/VIAL	N009866	004		Nov	CTEC

HYDROCORTISONE VALERATE

CREAM;TOPICAL
HYDROCORTISONE VALERATE

AB	!	TARO	0.2%	A075042	001	Aug 25, 1998	Apr	CAHN
		OINTMENT;TOPICAL						
		HYDROCORTISONE VALERATE						
	!	TARO	0.2%	A075043	001	Aug 25, 1998	Apr	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC
CORTISPORIN

AT	+!	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr	CAHN
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar	CAHN
AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN
		SUSPENSION/DROPS;OPHTHALMIC						
		CORTISPORIN						
		@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr	CAHN
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb	CAHN
		SUSPENSION/DROPS;OTIC						
		CASPORYN HC						
>A>	AT	+!	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000	N060613	001	Dec	CTNA

		SUSPENSION/DROPS;OTIC									
>A>	CASPORYN HC		UNITS/ML								
>D>	CORTISPORIN										
>D>	AT	+!	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001			Dec	CTNA	
	AT		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE		A065219	001	May 01, 2006		Mar	CAHN	
	AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985		Feb	CAHN	
	AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML							
		<u>HYDROFLUMETHIAZIDE</u>									
		TABLET;ORAL									
		SALURON									
			+ @ SHIRE LLC	50MG	N011949	001			Nov	DISC	
			+!	50MG	N011949	001			Sep	CTEC	
>A>	<u>HYDROGEN PEROXIDE</u>										
>A>	SOLUTION;TOPICAL										
>A>	ESKATA										
>A>		+!	ACLARIS THERAPS INC	40%	N209305	001	Dec 14, 2017		Dec	NEWA	
		<u>HYDROMORPHONE HYDROCHLORIDE</u>									
		INJECTABLE;INJECTION									
		DILAUDID									
AP		+!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009		Jan	CAHN	
AP		+!		2MG/ML	N019034	004	Apr 30, 2009		Jan	CAHN	
AP		+!		4MG/ML	N019034	005	Apr 30, 2009		Jan	CAHN	
		DILAUDID-HP									
AP		+!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984		Jan	CAHN	
			@	250MG/VIAL	N019034	002	Aug 04, 1994		Jan	CAHN	
		HYDROMORPHONE HYDROCHLORIDE									
			@ HOSPIRA	10MG/ML	A074598	001	Jun 19, 1997		Sep	DISC	
		SOLUTION;ORAL									
		DILAUDID									
AA		+!	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992		Jun	CAHN	
		HYDROMORPHONE HYDROCHLORIDE									
AA			ASCENT PHARMS INC	5MG/5ML	A210176	001	Oct 27, 2017		Oct	NEWA	
		TABLET;ORAL									
		DILAUDID									
AB		+	RHODES PHARMS	2MG	N019892	003	Nov 09, 2007		Jun	CAHN	
AB		+		4MG	N019892	002	Nov 09, 2007		Jun	CAHN	
AB		+!		8MG	N019892	001	Dec 07, 1992		Jun	CAHN	
		HYDROMORPHONE HYDROCHLORIDE									
>D>	AB		MALLINCKRODT	2MG	A076855	002	Sep 19, 2007		Dec	CAHN	
>D>	AB			4MG	A076855	003	Sep 19, 2007		Dec	CAHN	
>D>	AB			8MG	A076855	001	Dec 23, 2004		Dec	CAHN	
>A>	AB		SPECGX LLC	2MG	A076855	002	Sep 19, 2007		Dec	CAHN	
>A>	AB			4MG	A076855	003	Sep 19, 2007		Dec	CAHN	
>A>	AB			8MG	A076855	001	Dec 23, 2004		Dec	CAHN	
		TABLET, EXTENDED RELEASE;ORAL									
		EXALGO									
>D>	AB	+	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010		Dec	CAHN	
>D>	AB	+		12MG	N021217	002	Mar 01, 2010		Dec	CAHN	
>D>	AB	+		16MG	N021217	003	Mar 01, 2010		Dec	CAHN	
>D>	AB	+!		32MG	N021217	004	Aug 24, 2012		Dec	CAHN	
>A>	AB	+	SPECGX LLC	8MG	N021217	001	Mar 01, 2010		Dec	CAHN	
>A>	AB	+		12MG	N021217	002	Mar 01, 2010		Dec	CAHN	
>A>	AB	+		16MG	N021217	003	Mar 01, 2010		Dec	CAHN	
>A>	AB	+!		32MG	N021217	004	Aug 24, 2012		Dec	CAHN	
		HYDROMORPHONE HYDROCHLORIDE									
AB			PADDOCK LLC	32MG	A204278	004	Sep 20, 2017		Sep	NEWA	
		<u>HYDROXOCOBALAMIN</u>									
		INJECTABLE;INJECTION									
		HYDROXOCOBALAMIN									
		!	ACTAVIS LLC	1MG/ML	A085998	001			Feb	CAHN	

HYDROXYUREA

>A>	TABLET;ORAL							
>A>	SIKLOS							
>A>	+ ADDMEDICA SAS	100MG	N208843	001	Dec 21, 2017	Dec	NEWA	
>A>	+	1GM	N208843	002	Dec 21, 2017	Dec	NEWA	

HYDROXYZINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	VISTARIL							
	+ @ PFIZER	25MG/ML	N011111	001		Jan	CRLD	
	+ @	50MG/ML	N011111	002		Jan	CRLD	
	SYRUP;ORAL							
	HYDROXYZINE HYDROCHLORIDE							
>D> AA	! WOCKHARDT	10MG/5ML	A087294	001	Apr 12, 1982	Dec	CAHN	
>A> AA	! WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Dec	CAHN	
	TABLET;ORAL							
	HYDROXYZINE HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan	CMS1	
	@	25MG	A087871	003	Dec 20, 1982	Jan	CMS1	
AB	BAYSHORE PHARMS LLC	10MG	A207120	001	Mar 29, 2017	Sep	CAHN	
AB		50MG	A207122	001	Mar 29, 2017	Sep	CAHN	
AB	NUVO PHARM	10MG	A207120	001	Mar 29, 2017	Nov	CAHN	
AB		50MG	A207122	001	Mar 29, 2017	Nov	CAHN	
AB	NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar	NEWA	
AB		25MG	A207121	001	Mar 29, 2017	Mar	NEWA	
AB		50MG	A207122	001	Mar 29, 2017	Mar	NEWA	
AB	PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb	CAHN	
AB		25MG	A040574	001	May 27, 2005	Feb	CAHN	
AB		50MG	A040580	001	May 27, 2005	Feb	CAHN	

IBANDRONATE SODIUM

	TABLET;ORAL							
	IBANDRONATE SODIUM							
AB	MACLEODS PHARMS LTD	EQ 150MG BASE	A206887	001	Oct 31, 2017	Oct	NEWA	
	@ MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	May	DISC	
AB	WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May	CAHN	

IBRUTINIB

	CAPSULE;ORAL							
	IMBRUVICA							
>A>	+ PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Dec	NEWA	

IBUPROFEN

	SUSPENSION;ORAL							
	IBUPROFEN							
AB	! ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May	CAHN	
AB	TARO	100MG/5ML	A209204	001	Jun 23, 2017	Jun	NEWA	
	MOTRIN							
	+ @ MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan	CRLD	
	TABLET;ORAL							
	IBUPROFEN							
	@ MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar	CAHN	
	@ PLIVA	400MG	A071666	001	Jun 18, 1987	Aug	CAHN	

IBUPROFEN; OXYCODONE HYDROCHLORIDE

	TABLET;ORAL							
	OXYCODONE HYDROCHLORIDE AND IBUPROFEN							
	@ WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007	Jun	DISC	
BX		400MG;5MG	A078394	001	Nov 26, 2007	Apr	CTEC	

ICOSAPENT ETHYL

	CAPSULE;ORAL							
	VASCEPA							
	+ AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	NEWA	

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC
DENDRID

+ @ ALCON 0.1% N014169 001 Jul DISC

IFOSFAMIDE

INJECTABLE; INJECTION
IFOSFAMIDE

AP WEST-WARD PHARMS INT 1GM/20ML (50MG/ML) A 076619 001 Jun 29, 2011 Nov CMS1
AP 3GM/60ML (50MG/ML) A 076619 002 Jun 29, 2011 Nov CMS1

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT

@ TEVA PHARMS USA 1GM/20ML;1GM/10ML (50MG/ML;100MG/ML) A 075874 001 Feb 26, 2002 Mar DISC
@ 3GM/60ML;1GM/10ML (50MG/ML;100MG/ML) A 075874 002 Feb 26, 2002 Mar DISC

IMATINIB MESYLATE

TABLET; ORAL
IMATINIB MESYLATE

AB MYLAN PHARMS INC EQ 100MG BASE A 204644 001 Jun 21, 2017 Jun NEWA
AB EQ 400MG BASE A 204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

>D> AB MALLINCKRODT INC 10MG A 087846 002 May 22, 1984 Dec CAHN
AB 10MG A 087846 002 May 22, 1984 Aug CMS1
>D> AB 25MG A 087846 003 May 22, 1984 Dec CAHN
AB 25MG A 087846 003 May 22, 1984 Aug CMS1
OXFORD PHARMS 10MG A 040751 003 Feb 28, 2008 May CMS1
25MG A 040751 002 Feb 28, 2008 May CMS1
@ PAR PHARM 10MG A 089422 001 Jul 14, 1987 Jul DISC
>A> AB SPECGX LLC 10MG A 087846 002 May 22, 1984 Dec CAHN
>A> AB 25MG A 087846 003 May 22, 1984 Dec CAHN
TOFRANIL
>D> AB ! MALLINCKRODT INC 50MG A 087846 001 May 22, 1984 Dec CAHN
>A> AB ! SPECGX LLC 50MG A 087846 001 May 22, 1984 Dec CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL
IMIPRAMINE PAMOATE

@ MYLAN PHARMS INC EQ 75MG HCL A 202338 001 Jun 28, 2013 Jun DISC
@ EQ 100MG HCL A 202338 002 Jun 28, 2013 Jun DISC
@ EQ 125MG HCL A 202338 003 Jun 28, 2013 Jun DISC
@ EQ 150MG HCL A 202338 004 Jun 28, 2013 Jun DISC
TOFRANIL-PM
>D> + @ MALLINCKRODT INC EQ 75MG HCL N 017090 001 Dec CAHN
>D> + @ EQ 100MG HCL N 017090 004 Dec CAHN
>D> + @ EQ 125MG HCL N 017090 003 Dec CAHN
>D> + @ EQ 150MG HCL N 017090 002 Dec CAHN
>A> + @ SPECGX LLC EQ 75MG HCL N 017090 001 Dec CAHN
>A> + @ EQ 100MG HCL N 017090 004 Dec CAHN
>A> + @ EQ 125MG HCL N 017090 003 Dec CAHN
>A> + @ EQ 150MG HCL N 017090 002 Dec CAHN

INDACATEROL MALEATE

POWDER; INHALATION
ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE N 022383 001 Jul 01, 2011 Jan CAHN

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

>A> @ FOSUN PHARMA 1.25MG A 074594 001 May 23, 1996 Dec CAHN
>A> @ 2.5MG A 074594 002 May 23, 1996 Dec CAHN
@ MYLAN PHARMS INC 1.25MG A 075105 001 Jul 23, 1998 Nov DISC
@ 2.5MG A 075105 002 Jul 23, 1998 Nov DISC
>D> @ SANDOZ 1.25MG A 074594 001 May 23, 1996 Dec CAHN
>D> @ 2.5MG A 074594 002 May 23, 1996 Dec CAHN

INDOMETHACIN

CAPSULE;ORAL		INDOMETHACIN							
	@	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CAHN	
	@		50MG	A070651	001	Mar 05, 1986	Apr	CAHN	
	@		50MG	N018829	001	Aug 06, 1984	Feb	CAHN	
AB		JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Aug	NEWA	
AB			50MG	A205215	002	Aug 25, 2017	Aug	NEWA	
CAPSULE, EXTENDED RELEASE;ORAL		INDOMETHACIN							
AB		CHARTWELL RX	75MG	A200529	001	Nov 30, 2010	Jun	CAHN	
AB		GLENMARK PHARMS LTD	75MG	A203501	001	Jun 22, 2017	Jun	NEWA	
AB		NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr	NEWA	
	@	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb	DISC	
AB		ZYDUS PHARMS USA INC	75MG	A202711	001	Sep 25, 2017	Sep	NEWA	

INDOMETHACIN SODIUM

INJECTABLE;INJECTION		INDOMETHACIN SODIUM							
AP		NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017	Jul	NEWA	

>A> INSULIN ASPART

SOLUTION;IV (INFUSION), SUBCUTANEOUS		FIASP							
>A>	+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Dec	CAIN	
>A>									
>A>	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Dec	CAIN	

>D> INSULIN ASPART RECOMBINANT

SOLUTION;IV (INFUSION), SUBCUTANEOUS		FIASP							
>D>	+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Dec	CAIN	
>D>	+		1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Sep	NEWA	
>D>									
>D>	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Dec	CAIN	
>D>	+		300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Sep	NEWA	

INSULIN LISPRO

SOLUTION;IV (INFUSION), SUBCUTANEOUS		ADMELOG							
>A>	+	SANOFI-AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N209196	001	Dec 11, 2017	Dec	NEWA	
>A>									
>A>	+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	002	Dec 11, 2017	Dec	NEWA	

IODIPAMIDE MEGLUMINE

INJECTABLE;INJECTION		CHOLOGRAFIN MEGLUMINE							
	+	@ BRACCO	52%	N009321	003		Aug	DISC	

IODIXANOL

INJECTABLE;INJECTION		VISIPAQUE 270							
	@	GE HEALTHCARE	55%	N020808	001	Aug 29, 1997	Aug	DISC	

IOPAMIDOL

INJECTABLE;INJECTION		SCANLUX-300							
AP		MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010	Jan	CAHN	
AP		SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Feb	CAHN	
AP		MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010	Jan	CAHN	
AP		SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb	CAHN	

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST 150

+ @	BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995	Aug	DISC
	ULTRAVIST 300 IN PLASTIC CONTAINER						
+ @	BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008	Aug	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

@	BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001	Jul	DISC
---	---------------------	-------	---------	-----	--------------	-----	------

IRBESARTAN

TABLET; ORAL
IRBESARTAN

	@	AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Oct	DISC
	@		150MG	A203685	002	Dec 10, 2015	Oct	DISC
	@		300MG	A203685	003	Dec 10, 2015	Oct	DISC
>D>	AB	MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012	Dec	DISC
>A>		@	75MG	A200461	001	Sep 27, 2012	Dec	DISC
>D>	AB		150MG	A200461	002	Sep 27, 2012	Dec	DISC
>A>		@	150MG	A200461	002	Sep 27, 2012	Dec	DISC
>D>	AB		300MG	A200461	003	Sep 27, 2012	Dec	DISC
>A>		@	300MG	A200461	003	Sep 27, 2012	Dec	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May	NEWA	
AP			100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May	NEWA	
AP		INTAS PHARMS USA	40MG/2ML (20MG/ML)	A203054	001	Aug 31, 2017	Aug	NEWA	
AP			100MG/5ML (20MG/ML)	A203054	002	Aug 31, 2017	Aug	NEWA	
		@	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul	DISC
		@		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul	DISC
AP		WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan	CAHN	
AP			100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan	CAHN	

INJECTABLE, LIPOSOMAL; IV (INFUSION)
ONIVYDE

+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Apr	CAHN
----	-----------	--------------------------------------	---------	-----	--------------	-----	------

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID

!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar	CAHN
	SYRUP; ORAL						
	ISONIAZID						
!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Apr	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP		NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jul	NEWA
	ISUPREL							
AP	+!	HOSPIRA	0.2MG/ML	N010515	001		Jul	CTEC

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

@	WATSON LABS TEVA	5MG	A086031	001	Sep 29, 1987	May	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	ISOSORBIDE DINITRATE						
@	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb	CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET

AB	+	LANNETT CO INC	10MG	N020215	002	Jun 30, 1993	Nov	CAHN
AB	+!		20MG	N020215	001	Jun 30, 1993	Nov	CAHN

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE MONONITRATE

AB		ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Oct	NEWA
AB			60MG	A209684	002	Oct 24, 2017	Oct	NEWA
AB			120MG	A209684	003	Oct 24, 2017	Oct	NEWA

ISOTRETINOIN

CAPSULE;ORAL
ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Aug	CAHN
BX	+		20MG	N021951	002	May 25, 2012	Aug	CAHN
	+		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
BX	+		30MG	N021951	003	May 25, 2012	Aug	CAHN
	+		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug	CAHN

ISOTRETINOIN

AB		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Sep	NEWA
AB			20MG	A207792	002	Sep 29, 2017	Sep	NEWA
AB			30MG	A207792	003	Sep 29, 2017	Sep	NEWA
AB			40MG	A207792	004	Sep 29, 2017	Sep	NEWA

ISRADIPINE

CAPSULE;ORAL
DYNACIRC

	+	@ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990	Sep	CRLD
	+	@	5MG	N019546	002	Dec 20, 1990	Sep	CRLD
AB		WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May	CAHN
AB	!		5MG	A077317	002	Jan 05, 2006	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

ISRADIPINE

		@ MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015	Nov	DISC
		@	10MG	A201067	002	Nov 27, 2015	Nov	DISC

ITRACONAZOLE

CAPSULE;ORAL
ITRACONAZOLE

AB		ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May	NEWA
AB		JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb	NEWA
AB		ZYDUS PHARMS USA INC	100MG	A204672	001	Sep 19, 2017	Sep	NEWA

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

		@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan	CAHN
		@	EQ 500MG BASE/2ML	A062324	002		Jan	CAHN
		@	EQ 1GM BASE/3ML	A062324	003		Jan	CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL
EXTINA

AT	+	MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan	CAHN
----	---	------------------	----	---------	-----	--------------	-----	------

CREAM;TOPICAL

NIZORAL

	+	@ JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May	CRLD
--	---	------------------	----	---------	-----	--------------	-----	------

TABLET;ORAL

NIZORAL

	+	@ JANSSEN PHARMS	200MG	N018533	001		Oct	CRLD
--	---	------------------	-------	---------	-----	--	-----	------

KETOPROFEN

CAPSULE;ORAL
KETOPROFEN

		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb	CAHN
AB			50MG	A074014	002	Jan 29, 1993	Feb	CAHN
AB			75MG	A074014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

		INJECTABLE; INJECTION							
		KETOROLAC TROMETHAMINE							
	@	BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001	Aug	CAHN	
	@		30MG/ML	A075631	001	Jun 29, 2001	Aug	CAHN	
AP		CYCLE PHARMS LTD	30MG/ML	A209900	001	Sep 15, 2017	Sep	NEWA	
	@	MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007	Oct	DISC	
	@		15MG/ML	A201155	001	Aug 04, 2014	Oct	DISC	
	@		30MG/ML	A078299	002	Jul 16, 2007	Oct	DISC	
	@		30MG/ML	A201155	002	Aug 04, 2014	Oct	DISC	
	@	SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN	
AP			30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN	
		SOLUTION/DROPS; OPHTHALMIC							
		ACUVAIL							
	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Sep	CTEC	
		KETOROLAC TROMETHAMINE							
AT		SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN	

L-GLUTAMINE

		FOR SOLUTION; ORAL							
		ENDARI							
	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul	NEWA	
		NUTRESTORE							
	+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAIN	

LABETALOL HYDROCHLORIDE

		INJECTABLE; INJECTION							
		LABETALOL HYDROCHLORIDE							
	@	BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Aug	CAHN	
AP		SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN	
		TABLET; ORAL							
		LABETALOL HYDROCHLORIDE							
AB		INNOGENIX	100MG	A075215	001	Jul 29, 1999	Sep	CAHN	
AB			200MG	A075215	002	Jul 29, 1999	Sep	CAHN	
AB			300MG	A075215	003	Jul 29, 1999	Sep	CAHN	
AB		ZYDUS PHARMS USA INC	100MG	A207743	001	Sep 19, 2017	Sep	NEWA	
AB			200MG	A207743	002	Sep 19, 2017	Sep	NEWA	
AB			300MG	A207743	003	Sep 19, 2017	Sep	NEWA	

LACOSAMIDE

		SOLUTION; ORAL							
		VIMPAT							
	+	UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Oct	CTEC	
		TABLET; ORAL							
		VIMPAT							
	+	UCB INC	50MG	N022253	001	Oct 28, 2008	Oct	CTEC	
	+		100MG	N022253	002	Oct 28, 2008	Oct	CTEC	
	+		150MG	N022253	003	Oct 28, 2008	Oct	CTEC	
	+		200MG	N022253	004	Oct 28, 2008	Oct	CTEC	

LACTULOSE

		SOLUTION; ORAL							
		LACTULOSE							
>D>	AA	MORTON GROVE	10GM/15ML	A074602	001	Nov 14, 1996	Dec	CAHN	
	AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May	CAHN	
>A>	AA	WOCKHARDT BIO AG	10GM/15ML	A074602	001	Nov 14, 1996	Dec	CAHN	
		SOLUTION; ORAL, RECTAL							
		GENERLAC							
>D>	AA	MORTON GROVE PHARMS	10GM/15ML	A074603	001	Oct 31, 1996	Dec	CAHN	
>A>	AA	WOCKHARDT BIO AG	10GM/15ML	A074603	001	Oct 31, 1996	Dec	CAHN	

LAMIVUDINE

		TABLET; ORAL							
		LAMIVUDINE							
AB		CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA	
AB			300MG	A077221	002	Mar 03, 2017	Feb	NEWA	
AB		ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016	Aug	CAHN	

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr	NEWA
BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar	NEWA

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
	@	100MG	A078443	002	Feb 11, 2009	Mar	CAHN
	@	150MG	A078443	003	Feb 11, 2009	Mar	CAHN
	@	200MG	A078443	004	Feb 11, 2009	Mar	CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May	CAHN
AB		25MG	A079099	002	Feb 19, 2009	May	CAHN
	@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jun	DISC
	@	25MG	A076630	002	Jan 22, 2009	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr	CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan	CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan	CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB	INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug	NEWA
AB		30MG	A205868	002	Aug 30, 2017	Aug	NEWA
AB	KREMERS URBAN PHARMS	15MG	A207156	001	Sep 28, 2017	Sep	NEWA
AB		30MG	A207156	002	Sep 28, 2017	Sep	NEWA

>D> TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

LANSOPRAZOLE

>D>	@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Dec	CDFR
>D>	@	30MG	A078730	002	Oct 15, 2010	Dec	CDFR

>D> PREVACID

>D> AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Dec	CDFR
AB	+	15MG	N021428	001	Aug 30, 2002	Sep	CTEC
>D> AB	+!	30MG	N021428	002	Aug 30, 2002	Dec	CDFR
AB	+!	30MG	N021428	002	Aug 30, 2002	Sep	CTEC

>A> TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

>A>	@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Dec	CDFR
>A>	@	30MG	A078730	002	Oct 15, 2010	Dec	CDFR
AB	TEVA PHARMS USA	15MG	A208784	001	Sep 21, 2017	Sep	NEWA
AB		30MG	A208784	002	Sep 21, 2017	Sep	NEWA

>A> PREVACID

>A> AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Dec	CDFR
>A> AB	+!	30MG	N021428	002	Aug 30, 2002	Dec	CDFR

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

AB	+ SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul	CFTG
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul	CFTG
AB	+!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul	CFTG

LANTHANUM CARBONATE

AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul	NEWA
AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul	NEWA
AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul	NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar	CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb	CAHN

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC
VYZULTA

+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Nov	NEWA
----	-----------------	--------	---------	-----	--------------	-----	------

LETTERMOVIR

SOLUTION;IV (INFUSION)
PREVYMIS

+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017	Nov	NEWA
+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017	Nov	NEWA

TABLET;ORAL
PREVYMIS

+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017	Nov	NEWA
+!		480MG	N209939	002	Nov 08, 2017	Nov	NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE

@	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jun	DISC
@	LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Jun	DISC
@	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	Oct	DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May	NEWA
----	----------------------	-----------------------------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	!	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999	Oct	CTEC
AP		MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May	NEWA
AP			EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May	NEWA
AP			EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May	NEWA
AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A209110	001	Oct 26, 2017	Oct	NEWA

TABLET;ORAL

LEUCOVORIN CALCIUM

@	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May	CAHN	
@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May	CAHN	
+	@	GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun	CRLD
+	@		EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun	CRLD

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN		AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan	NEWA
----	--	----------------------	---------------	---------	-----	--------------	-----	------

LEVETIRACETAM

INJECTABLE;IV (INFUSION)
LEVETIRACETAM

AP		JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jul	CAHN
AP		GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Oct	NEWA
AP			1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Oct	NEWA
AP			1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Oct	NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA		ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar	CAHN
AA		AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan	CAHN
>D>	AA	WOCKHARDT	100MG/ML	A090028	001	Mar 03, 2010	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Dec	CAHN

TABLET;ORAL

LEVETIRACETAM

AB		ACI HEALTHCARE LTD	250MG	A078042	001	Jan 15, 2009	Jun	CAHN
AB			500MG	A078042	002	Jan 15, 2009	Jun	CAHN
AB			750MG	A078042	003	Jan 15, 2009	Jun	CAHN
AB			1GM	A078042	004	Jan 15, 2009	Jun	CAHN
AB		ACIC PHARMS	250MG	A090767	001	Jul 28, 2010	Sep	CAHN
AB			500MG	A090767	002	Jul 28, 2010	Sep	CAHN
AB			750MG	A090767	003	Jul 28, 2010	Sep	CAHN

TABLET;ORAL						
LEVETIRACETAM						
AB		1GM	A090767	004	Jul 28, 2010	Sep CAHN
AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar CAHN
AB		500MG	A078042	002	Jan 15, 2009	Mar CAHN
AB		750MG	A078042	003	Jan 15, 2009	Mar CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar CAHN
ROWEEPRA						
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr NEWA
TABLET, EXTENDED RELEASE;ORAL						
LEVETIRACETAM						
AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr DISC
AB	PHARMTAK INC	500MG	A207175	001	Sep 28, 2017	Sep NEWA
AB		750MG	A207175	002	Sep 28, 2017	Sep NEWA
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb CAHN
TABLET, FOR SUSPENSION;ORAL						
SPRITAM						
+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015	Nov CAHN
+		500MG	N207958	002	Jul 31, 2015	Nov CAHN
+		750MG	N207958	003	Jul 31, 2015	Nov CAHN
+	!	1GM	N207958	004	Jul 31, 2015	Nov CAHN
<u>LEVOBUNOLOL HYDROCHLORIDE</u>						
SOLUTION/DROPS;OPHTHALMIC						
LEVOBUNOLOL HYDROCHLORIDE						
	@ BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN
<u>LEVOCARNITINE</u>						
INJECTABLE;INJECTION						
CARNITOR						
AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
SOLUTION;ORAL						
CARNITOR						
	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN
CARNITOR SF						
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN
TABLET;ORAL						
CARNITOR						
AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
LEVOCARNITINE						
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb CAHN
AB	RISING PHARMS INC	330MG	A076858	001	Sep 20, 2004	Oct CAHN
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>						
SOLUTION;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
AA	SILARX PHARMS INC	2.5MG/5ML	A204599	001	May 15, 2017	Nov CPOT
AA		2.5MG/ML	A204599	001	May 15, 2017	May NEWA
XYZAL						
AA	+! SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul CAHN
TABLET;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
AB	ALLIED PHARMA INC	5MG	A202046	001	Sep 17, 2013	Sep CAHN
AB		5MG	A204323	001	Dec 20, 2016	Apr CAHN
AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Nov CAHN
XYZAL						
AB	+! SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ @ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD
	+ @	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD
	+ @	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD

LEVOFLOXACIN

AP	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Aug	CAHN
AP	SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Aug	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Aug	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Aug	CAHN
AP	HIKMA FARMACEUTICA	EQ 500MG/100ML (EQ 5MG/ML)	A091375	002	Sep 16, 2011	Nov	CMS1

SOLUTION; ORAL

LEVAQUIN

	+ @ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004	Aug	DISC
--	--------------------	------------	---------	-----	--------------	-----	------

LEVOFLOXACIN

	! HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug	CHRS
--	------------------	------------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	MYLAN LABS LTD	0.5%	A204899	001	Dec 08, 2017	Nov	NEWA
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN

TABLET; ORAL

LEVOFLOXACIN

	@ MYLAN	250MG	A076276	001	Jun 20, 2011	Jul	DISC
	@	500MG	A076276	002	Jun 20, 2011	Jul	DISC
	@	750MG	A077097	001	Jun 20, 2011	Jun	DISC

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan	NEWA
	+!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May	CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan	NEWA

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Aug	NEWA
----	------------------	--	---------	-----	--------------	-----	------

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

	@ SEPTODONT INC	0.05MG/ML; 2%	A084697	001		May	CAHN
--	-----------------	---------------	---------	-----	--	-----	------

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

	@ BELMORA LLC	0.05MG/ML; 2%	A084850	002	Oct 21, 1983	Feb	CAHN
--	---------------	---------------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

	@ FDN CONSUMER	0.75MG	A078665	001	Aug 28, 2009	Nov	CAHN
	PLAN B						
	+ @ FDN CONSUMER	0.75MG	N021045	001	Jul 28, 1999	Nov	CAHN
	+ @	0.75MG	N021045	002	Aug 24, 2006	Nov	CAHN

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

>A>	+ INSTITUT BIOCHIMIQUE	0.013MG	N021924	013	Aug 01, 2007	Dec	CMS1
	+	0.175MG	N021924	011	Apr 25, 2017	Sep	NEWA
	+	0.200MG	N021924	012	Apr 25, 2017	Sep	NEWA

SOLUTION; ORAL

TIROSINT-SOL

	+ @ INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun	DISC
	+ @	25MCG/ML	N206977	002	Dec 15, 2016	Jun	DISC
	+ @	50MCG/ML	N206977	003	Dec 15, 2016	Jun	DISC
	+ @	75MCG/ML	N206977	004	Dec 15, 2016	Jun	DISC
	+ @	88MCG/ML	N206977	005	Dec 15, 2016	Jun	DISC

SOLUTION;ORAL
TIROSINT-SOL

+ @	100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
+ @	112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
+ @	125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
+ @	137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
+ @	150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
+ @	175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
+ @	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

>D>	AB1, + ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.05MG	N021342	002	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.075MG	N021342	003	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.088MG	N021342	004	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.1MG	N021342	005	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.112MG	N021342	006	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.125MG	N021342	007	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.137MG	N021342	012	Dec 08, 2003	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.15MG	N021342	008	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.175MG	N021342	009	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +	0.2MG	N021342	010	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>D>	AB1, +!	0.3MG	N021342	011	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, + CEDIPROF INC	0.025MG	N021342	001	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.05MG	N021342	002	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.075MG	N021342	003	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.088MG	N021342	004	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.1MG	N021342	005	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.112MG	N021342	006	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.125MG	N021342	007	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.137MG	N021342	012	Dec 08, 2003	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.15MG	N021342	008	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					
>A>	AB1, +	0.175MG	N021342	009	Mar 01, 2002	Dec CAHN
	AB2,					
	AB3					

TABLET;ORAL

LEVO-T

>A>	AB1, +	0.2MG	N021342	010	Mar 01, 2002	Dec	CAHN
	AB2,						
	AB3						
>A>	AB1, +!	0.3MG	N021342	011	Mar 01, 2002	Dec	CAHN
	AB2,						
	AB3						

LEVOLET

@	GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Sep	CAHN
@		0.05MG	N021137	002	Jun 06, 2003	Sep	CAHN
@		0.075MG	N021137	003	Jun 06, 2003	Sep	CAHN
@		0.088MG	N021137	004	Jun 06, 2003	Sep	CAHN
@		0.1MG	N021137	005	Jun 06, 2003	Sep	CAHN
@		0.112MG	N021137	006	Jun 06, 2003	Sep	CAHN
@		0.125MG	N021137	007	Jun 06, 2003	Sep	CAHN
@		0.137MG	N021137	008	Jun 06, 2003	Sep	CAHN
@		0.15MG	N021137	009	Jun 06, 2003	Sep	CAHN
@		0.175MG	N021137	010	Jun 06, 2003	Sep	CAHN
@		0.2MG	N021137	011	Jun 06, 2003	Sep	CAHN
@		0.3MG	N021137	012	Jun 06, 2003	Sep	CAHN

LEVOXYL

AB1, +	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May	CAHN
AB3							
AB1, +		0.05MG	N021301	002	May 25, 2001	May	CAHN
AB3							
AB1, +		0.075MG	N021301	003	May 25, 2001	May	CAHN
AB3							
AB1, +		0.088MG	N021301	004	May 25, 2001	May	CAHN
AB3							
AB1, +		0.1MG	N021301	005	May 25, 2001	May	CAHN
AB3							
AB1, +		0.112MG	N021301	006	May 25, 2001	May	CAHN
AB3							
AB1, +		0.125MG	N021301	007	May 25, 2001	May	CAHN
AB3							
AB1, +		0.137MG	N021301	008	May 25, 2001	May	CAHN
AB3							
AB1, +		0.15MG	N021301	009	May 25, 2001	May	CAHN
AB3							
AB1, +		0.175MG	N021301	010	May 25, 2001	May	CAHN
AB3							
AB1, +!		0.2MG	N021301	011	May 25, 2001	May	CAHN
AB3							
+ @		0.3MG	N021301	012	May 25, 2001	May	CAHN
	THYRO-TABS						
+ @	LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep	CTNA
+ @		0.05MG	N021116	002	Oct 24, 2002	Sep	CTNA
+ @		0.075MG	N021116	003	Oct 24, 2002	Sep	CTNA
+ @		0.088MG	N021116	010	Oct 24, 2002	Sep	CTNA
+ @		0.1MG	N021116	004	Oct 24, 2002	Sep	CTNA
+ @		0.112MG	N021116	011	Oct 24, 2002	Sep	CTNA
+ @		0.125MG	N021116	005	Oct 24, 2002	Sep	CTNA
+ @		0.137MG	N021116	012	Dec 07, 2004	Sep	CTNA
+ @		0.15MG	N021116	006	Oct 24, 2002	Sep	CTNA
+ @		0.175MG	N021116	007	Oct 24, 2002	Sep	CTNA
+ @		0.2MG	N021116	008	Oct 24, 2002	Sep	CTNA
+ @		0.3MG	N021116	009	Oct 24, 2002	Sep	CTNA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
AT	RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep	NEWA
AT	VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Sep	NEWA
	XYLOCAINE						
+ @	ASTRAZENECA	5%	N008048	001		Jan	CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	1%	A207182	001	Oct 30, 2017	Oct	NEWA
AP		2%	A207182	002	Oct 30, 2017	Oct	NEWA
	@ BELMORA LLC	2%	A080504	001		Feb	CAHN
	@ MYLAN LABS LTD	0.5%	A091056	001	Dec 08, 2010	Nov	DISC

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@	0.5%	A091058	001	Sep 30, 2010	Nov	DISC
@	1%	A091056	002	Dec 08, 2010	Nov	DISC
@	1%	A091058	002	Sep 30, 2010	Nov	DISC
@	2%	A202242	001	Apr 11, 2014	Nov	DISC

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010	Nov	DISC
------------------	----	---------	-----	--------------	-----	------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

>D> AT	WOCKHARDT	2%	A087872	001	Nov 18, 1982	Dec	CAHN
>A> AT	WOCKHARDT BIO AG	2%	A087872	001	Nov 18, 1982	Dec	CAHN

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

>D> AT	WOCKHARDT	4%	A087881	001	Nov 18, 1982	Dec	CAHN
>A> AT	WOCKHARDT BIO AG	4%	A087881	001	Nov 18, 1982	Dec	CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+! TARO PHARMS	7%; 7%	N021717	001	Jun 29, 2006	May	CAHN
----------------	--------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+ FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan	NEWA
-------------------	-------	---------	-----	--------------	-----	------

LINDANE

SHAMPOO; TOPICAL

LINDANE

>D> AT	! WOCKHARDT	1%	A088191	001	Sep 18, 1984	Dec	CAHN
>A> AT	! WOCKHARDT BIO AG	1%	A088191	001	Sep 18, 1984	Dec	CAHN

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	Jun	NEWA
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	Jun	NEWA
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Nov	NEWA
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Nov	NEWA
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb	NEWA
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb	NEWA

TABLET; ORAL

LINEZOLID

AB	ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	+ KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB	+	EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+!	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE; ORAL

VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan	NEWA
+		20MG	N208510	002	Jan 28, 2017	Jan	NEWA
+		30MG	N208510	003	Jan 28, 2017	Jan	NEWA
+		40MG	N208510	004	Jan 28, 2017	Jan	NEWA
+		50MG	N208510	005	Jan 28, 2017	Jan	NEWA
+	!	60MG	N208510	006	Jan 28, 2017	Apr	CHRS
+		60MG	N208510	006	Jan 28, 2017	Jan	NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb	CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb	CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb	CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb	CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb	CAHN

TABLET;ORAL
LISINOPRIL

AB 40MG A075743 006 Jul 01, 2002 Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB MYLAN PHARMS INC 150MG A076243 002 Feb 24, 2003 Jan CAHN
 AB 300MG A076243 001 Jun 27, 2002 Jan CAHN
 AB 600MG A078763 001 Apr 15, 2008 Jan CAHN
 AB + WEST-WARD PHARMS INT 150MG N017812 002 Jan 28, 1987 Jan CAHN
 AB + 300MG N017812 001 Jan CAHN
 AB +! 600MG N017812 003 Jan 28, 1987 Jan CAHN

TABLET;ORAL

LITHIUM CARBONATE

AB +! WEST-WARD PHARMS INT 300MG N018558 001 Jan 29, 1982 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB UNIQUE PHARM LABS 450MG A205663 001 Jun 05, 2017 May NEWA

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA +! WEST-WARD PHARMS INT EQ 300MG CARBONATE/5ML N018421 001 Jan CAHN
 >D> AA WOCKHARDT EQ 300MG CARBONATE/5ML A070755 001 May 21, 1986 Dec CAHN
 >A> AA WOCKHARDT BIO AG EQ 300MG CARBONATE/5ML A070755 001 May 21, 1986 Dec CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

>A> @ FOSUN PHARMA 2MG A072993 001 Aug 28, 1992 Dec CAHN
 >D> @ SANDOZ 2MG A072993 001 Aug 28, 1992 Dec CAHN

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

AA SAPTALIS PHARMS 2MG/ML A079244 001 Apr 28, 2009 Oct CAHN

INJECTABLE; INJECTION

LORAZEPAM

>D> AP SAGENT AGILA LLC 2MG/ML A200217 001 Apr 04, 2017 Dec DISC
 >A> @ 2MG/ML A200217 001 Apr 04, 2017 Dec DISC
 AP 2MG/ML A200217 001 Apr 04, 2017 Mar NEWA
 >D> AP 2MG/ML A200542 001 Apr 28, 2017 Dec DISC
 >A> @ 2MG/ML A200542 001 Apr 28, 2017 Dec DISC
 AP 2MG/ML A200542 001 Apr 28, 2017 Apr NEWA
 >D> AP 4MG/ML A200217 002 Apr 04, 2017 Dec DISC
 >A> @ 4MG/ML A200217 002 Apr 04, 2017 Dec DISC
 AP 4MG/ML A200217 002 Apr 04, 2017 Mar NEWA
 >D> AP 4MG/ML A200542 002 Apr 28, 2017 Dec DISC
 >A> @ 4MG/ML A200542 002 Apr 28, 2017 Dec DISC
 AP 4MG/ML A200542 002 Apr 28, 2017 Apr NEWA
 @ WEST-WARD PHARMS INT 2MG/ML A074496 001 Sep 28, 1998 Mar CAHN
 @ 4MG/ML A074496 002 Sep 28, 1998 Mar CAHN

TABLET;ORAL

LORAZEPAM

@ ANDA REPOSITORY 0.5MG A072553 001 Mar 29, 1991 Sep CAHN
 @ 1MG A072554 001 Mar 29, 1991 Sep CAHN
 @ 2MG A072555 001 Mar 29, 1991 Sep CAHN
 >A> AB AUROLIFE PHARMA LLC 0.5MG A203572 001 Dec 22, 2017 Dec NEWA
 >A> AB 1MG A203572 002 Dec 22, 2017 Dec NEWA
 >A> AB 2MG A203572 003 Dec 22, 2017 Dec NEWA
 @ MYLAN 2MG A071591 001 Oct 13, 1987 Nov DISC
 AB SANDOZ 0.5MG A071141 002 Apr 21, 1987 Nov CMS1
 AB 0.5 A071141 002 Apr 21, 1987 Apr CMS1
 AB 1MG A071141 003 Apr 21, 1987 Apr CMS1

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB HETERO LABS LTD V 25MG A203835 001 Aug 12, 2015 Jul CTEC
 AB 50MG A203835 002 Aug 12, 2015 Jul CTEC
 AB 100MG A203835 003 Aug 12, 2015 Jul CTEC

TABLET;ORAL

LOSARTAN POTASSIUM							
AB	UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun	CAHN
AB		50MG	A090544	002	Oct 06, 2010	Jun	CAHN
AB		100MG	A090544	003	Oct 06, 2010	Jun	CAHN
AB	VIVA HLTHCARE	25MG	A091541	001	Sep 24, 2012	Sep	CAHN
AB		50MG	A091541	002	Sep 24, 2012	Sep	CAHN
AB		100MG	A091541	003	Sep 24, 2012	Sep	CAHN
AB	VIVIMED GLOBAL	25MG	A090382	001	Oct 06, 2010	Aug	CAHN
AB		50MG	A090382	002	Oct 06, 2010	Aug	CAHN
AB		100MG	A090382	003	Oct 06, 2010	Aug	CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN							
	@ MYLAN	10MG	A075935	001	Dec 17, 2001	Mar	DISC
	@	20MG	A075935	002	Dec 17, 2001	Mar	DISC
	@	40MG	A075935	003	Dec 17, 2001	Mar	DISC
TABLET, EXTENDED RELEASE;ORAL							
ALTOPREV							
	@ COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002	Apr	CAHN
	+	20MG	N021316	002	Jun 26, 2002	Apr	CAHN
	+	40MG	N021316	003	Jun 26, 2002	Apr	CAHN
	+	60MG	N021316	004	Jun 26, 2002	Apr	CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE							
	+! GALEN UK	10MG	N022549	001	Dec 21, 2012	Sep	CAHN

>A> MACIMORELIN

SOLUTION;ORAL							
MACRILEN							
	+! AETERNA ZENTARIS	0.5MG/ML	N205598	001	Dec 21, 2017	Dec	NEWA

>A> MACIMORELIN ACETATE

FOR SOLUTION;ORAL							
MACRILEN							
	+! AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Dec	NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE							
AT	NOVAST LABS LTD	5%	A206716	001	Jul 31, 2017	Sep	CAHN
AT	RICONPHARMA LLC	5%	A206716	001	Jul 31, 2017	Jul	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER							
	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001		Feb	CAHN
SOLUTION;IRRIGATION							
PHYSIOSOL IN PLASTIC CONTAINER							
	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982	Feb	CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP	+ HOSPIRA	40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Nov	CMS1
AP	HQ SPCLT PHARMA	2GM/50ML (40MG/ML)	A207350	001	Dec 06, 2017	Nov	NEWA
AP		4GM/100ML (40MG/ML)	A207350	002	Dec 06, 2017	Nov	NEWA
AP		4GM/50ML (80MG/ML)	A207350	003	Dec 06, 2017	Nov	NEWA
AP		20GM/500ML (40MG/ML)	A207350	004	Dec 06, 2017	Nov	NEWA
AP		40GM/1000ML (40MG/ML)	A207350	005	Dec 06, 2017	Nov	NEWA

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE							
AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb	NEWA
AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb	CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

AA	SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE								
	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May	CAIN		
	SUPREP BOWEL PREP KIT								
AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May	CAIN		

MALATHIONLOTION;TOPICAL
OVIDE

AT	+! TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May	CAHN		
----	---------------	------	---------	-----	--------------	-----	------	--	--

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

	@ IC TARGETS	37.9MG/ML	N020652	001	Nov 26, 1997	Nov	CAHN		
--	--------------	-----------	---------	-----	--------------	-----	------	--	--

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb	CAHN		
	MANNITOL 15% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb	CAHN		
	MANNITOL 20% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb	CAHN		
	MANNITOL 5% IN PLASTIC CONTAINER								
AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb	CAHN		

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001		Feb	CAHN		
--	-----------------	-------------------------	---------	-----	--	-----	------	--	--

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

	@ WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988	May	CAHN		
	@	50MG	A072163	001	Jun 01, 1988	May	CAHN		

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995	Jun	CAHN		
---	----------------	-------	---------	-----	--------------	-----	------	--	--

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	May	CHRS		
---	---------------	-------	---------	-----	--------------	-----	------	--	--

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May	CAHN		
AA		25MG	A201451	002	Feb 23, 2011	May	CAHN		
	@	50MG	A201451	003	Feb 23, 2011	May	CAHN		
	@ PLIVA	25MG	A088734	001	Dec 11, 1985	Aug	CAHN		

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

	@ WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987	May	CAHN		
--	--------------------	---------------	---------	-----	--------------	-----	------	--	--

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMPHASTAR PHARMS INC	150MG/ML	A077235	001	Nov 28, 2017	Nov	NEWA		
AB		150MG/ML	A077334	001	Nov 28, 2017	Nov	NEWA		
	@ SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Jun	DISC		
AB		150MG/ML	A078711	001	May 20, 2009	Mar	CAHN		
AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN		

	TABLET;ORAL							
	MEDROXYPROGESTERONE ACETATE							
	@ USL PHARMA	10MG	A088484	001	Jul 26, 1984	Jun	CAHN	
	<u>MEFENAMIC ACID</u>							
	CAPSULE;ORAL							
	MEFENAMIC ACID							
AB	VIVA HLTHCARE	250MG	A090562	001	Nov 19, 2010	Sep	CAHN	
	<u>MEFLOQUINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	LARIAM							
	+ @ ROCHE	250MG	N019591	001	May 02, 1989	Sep	CRLD	
	MEFLOQUINE HYDROCHLORIDE							
AB	! BARR	250MG	A076392	001	Dec 29, 2003	Apr	CHRS	
	@ SANDOZ	250MG	A076175	001	Feb 20, 2002	Apr	DISC	
	<u>MEGESTROL ACETATE</u>							
	SUSPENSION;ORAL							
	MEGACE							
	+ @ BRISTOL MYERS SQUIBB	40MG/ML	N020264	001	Sep 10, 1993	Feb	DISC	
	MEGESTROL ACETATE							
AB	BRECKENRIDGE PHARM	125MG/ML	A204688	001	Dec 01, 2017	Nov	NEWA	
AB	HI-TECH PHARMACAL	40MG/ML	A203960	001	Jun 09, 2017	May	NEWA	
AB	! WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb	CHRS	
>D>	AB	WOCKHARDT	A076721	001	Nov 01, 2004	Dec	CAHN	
>A>	AB	WOCKHARDT BIO AG	A076721	001	Nov 01, 2004	Dec	CAHN	
	<u>MELOXICAM</u>							
	SUSPENSION;ORAL							
	MOBIC							
	+ @ BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004	Sep	DISC	
	TABLET;ORAL							
	MELOXICAM							
	@ ANDA REPOSITORY	7.5MG	A077935	001	Jul 19, 2006	Sep	CAHN	
	@	15MG	A077935	002	Jul 19, 2006	Sep	CAHN	
	@ IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006	Nov	CAHN	
	@	15MG	A077930	002	Jul 19, 2006	Nov	CAHN	
	<u>MELPHALAN</u>							
	TABLET;ORAL							
	ALKERAN							
AB	+! APOTEX INC	2MG	N014691	002		Mar	CFTG	
	MELPHALAN							
AB	ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar	NEWA	
	<u>MELPHALAN HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	ALKERAN							
	+ @ APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	May	DISC	
	MELPHALAN HYDROCHLORIDE							
>D>	AP	+ DR REDDYS LABS LTD	A203655	001	Dec 08, 2017	Dec	CRLD	
>A>	AP		A203655	001	Dec 08, 2017	Dec	CRLD	
AP	+		A203655	001	Dec 08, 2017	Nov	NEWA	
>A>	AP	FRESENIUS KABI USA	A203393	001	Dec 22, 2017	Dec	NEWA	
AP	!	MYLAN INSTITUTIONAL	A090270	001	Jun 09, 2009	May	CHRS	
AP		SAGENT PHARMS	A201379	001	Feb 28, 2017	Feb	NEWA	
	POWDER;IV (INFUSION)							
	EVOMELA							
	+! SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Aug	CRLD	
	<u>MEMANTINE HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	MEMANTINE HYDROCHLORIDE							
AB	AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	May	CAHN	
AB		14MG	A205825	002	Oct 12, 2016	May	CAHN	
AB		21MG	A205825	003	Oct 12, 2016	May	CAHN	
AB		28MG	A205825	004	Oct 12, 2016	May	CAHN	
AB	ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	May	NEWA	
AB		14MG	A205784	002	Jun 09, 2017	May	NEWA	
AB		21MG	A205784	003	Jun 09, 2017	May	NEWA	
AB		28MG	A205784	004	Jun 09, 2017	May	NEWA	

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	7MG	A203293	001	Aug 03, 2017	Jul	NEWA
AB		14MG	A203293	002	Aug 03, 2017	Jul	NEWA
AB		21MG	A203293	003	Aug 03, 2017	Jul	NEWA
AB		28MG	A203293	004	Aug 03, 2017	Jul	NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	May	CAHN
AB		10MG	A090041	002	Apr 10, 2015	May	CAHN
AB	STRIDES PHARMA	5MG	A202350	001	May 23, 2017	May	NEWA
AB		10MG	A202350	002	May 23, 2017	May	NEWA
AB	UPSHER-SMITH LABS	5MG	A090043	001	Jul 31, 2015	Jun	CAHN
AB		10MG	A090043	002	Jul 31, 2015	Jun	CAHN
AB	ZYDUS PHARMS USA INC	5MG	A090961	001	Jul 10, 2017	Jun	NEWA
AB		10MG	A090961	002	Jul 10, 2017	Jun	NEWA

MEPENZOLATE BROMIDE

TABLET;ORAL

CANTIL

	+ @ SANOFI AVENTIS US	25MG	N010679	003		Aug	DISC
--	-----------------------	------	---------	-----	--	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan	CAHN
AP		25MG/ML	A080455	007		Jan	CAHN
AP		50MG/ML	A080445	002		Jan	CAHN
AP		50MG/ML	A080455	008		Jan	CAHN
AP		75MG/ML	A080445	003		Jan	CAHN
AP		75MG/ML	A080455	009		Jan	CAHN
AP		100MG/ML	A080445	004		Jan	CAHN
AP		100MG/ML	A080455	010		Jan	CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	! ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr	CAHN
>D>	@ MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Dec	CAHN
	@	10MG/ML	A040163	001	May 12, 1997	Mar	CAHN
>A>	@ SPECGX LLC	10MG/ML	A040163	001	May 12, 1997	Dec	CAHN
AP	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr	CAHN

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>D>	AA	MALLINCKRODT	50MG	A040352	001	Jun 13, 2000	Dec	CAHN
>D>	AA		100MG	A040352	002	Jun 13, 2000	Dec	CAHN
>A>	AA	SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Dec	CAHN
>A>	AA		100MG	A040352	002	Jun 13, 2000	Dec	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE

AP	! SEPTODONT INC	3%	A080925	001		May	CAHN
	MEPIVACAINE HYDROCHLORIDE						
	@ BELMORA LLC	3%	A083559	001		Feb	CAHN

MERCAPTOPURINE

TABLET;ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun	CAHN
----	-------------------	------	---------	-----	--------------	-----	------

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP	AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar	NEWA
AP		1GM/VIAL	A205835	002	Mar 27, 2017	Mar	NEWA
	MERREM						
AP	+! PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun	CAHN
AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Jun	CAHN

MEROPENEM; VABORBACTAM

POWDER; IV (INFUSION)
VABOMERE

+! REMPEX PHARMS MEDCNS 1GM/VIAL;1GM/VIAL N209776 001 Aug 29, 2017 Aug NEWA

MESALAMINE

ENEMA; RECTAL
ROWASA

AB +! MYLAN SPECIALITY LP 4GM/60ML N019618 001 Dec 24, 1987 Mar CAHN

SFROWASA

AB + MYLAN SPECIALITY LP 4GM/60ML N019618 002 Jun 20, 2008 Mar CAHN

TABLET, DELAYED RELEASE; ORAL
ASACOL HD

AB +! APIL 800MG N021830 001 May 29, 2008 Jul CFTG

LIALDA

AB +! SHIRE 1.2GM N022000 001 Jan 16, 2007 May CFTG

MESALAMINE

AB ZYDUS PHARMS USA INC 800MG A203286 001 Jul 21, 2017 Jul NEWA

AB 1.2GM A091640 001 Jun 05, 2017 May NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

>A> AP GLAND PHARMA LTD 100MG/ML A206992 001 Dec 18, 2017 Dec NEWA

@ MYLAN LABS LTD 100MG/ML A203364 001 Jul 18, 2014 Oct DISC

METAXALONE

TABLET; ORAL

METAXALONE

AB ACTAVIS LABS FL INC 800MG A203695 001 Jun 15, 2017 Jun NEWA

>A> COREPHARMA 400MG A040486 001 Feb 27, 2015 Dec CAHN

@ EPIC PHARMA LLC 640MG N022503 001 Jun 01, 2015 May CAHN

>D> IMPAX LABS INC 400MG A040486 001 Feb 27, 2015 Dec CAHN

400MG A040486 001 Feb 27, 2015 Feb CAHN

AB SCIEGEN PHARMS INC 800MG A207466 001 Aug 31, 2017 Aug NEWA

SKELAXIN

+ @ KING PHARMS 400MG N013217 001 May CAHN

AB +! 800MG N013217 003 Aug 30, 2002 May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB MACLEODS PHARMS LTD 500MG A205330 001 Oct 31, 2017 Oct NEWA

AB 850MG A205330 002 Oct 31, 2017 Oct NEWA

AB 1GM A205330 003 Oct 31, 2017 Oct NEWA

@ MYLAN PHARMS INC 500MG A075969 001 Jan 29, 2002 May DISC

@ 850MG A075969 002 Jan 29, 2002 May DISC

@ 1GM A075969 003 Jan 29, 2002 May DISC

@ WATSON LABS FLORIDA 500MG A075961 001 Jan 25, 2002 Mar DISC

@ 850MG A075961 002 Jan 25, 2002 Mar DISC

@ 1GM A075961 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 INTELLIPHARMACEUTICS 500MG A202306 001 Feb 23, 2017 Feb NEWA

AB 750MG A202306 002 Feb 23, 2017 Feb NEWA

@ MYLAN 500MG A076650 001 Sep 13, 2005 Nov DISC

@ 750MG A077113 001 Sep 08, 2005 Oct DISC

>A> AB2 NOSTRUM LABS INC 500MG A203832 001 Dec 26, 2017 Dec NEWA

>A> AB2 1GM A203832 002 Dec 26, 2017 Dec NEWA

AB1 TORRENT PHARMS LTD 500MG A090014 001 Dec 30, 2009 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

+ @ NOVO NORDISK INC 500MG;1MG N022386 001 Jun 23, 2008 Oct DISC

+ @ 500MG;2MG N022386 002 Jun 23, 2008 Oct DISC

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

LUPIN LTD 500MG;1MG A200624 001 Jul 15, 2015 Oct CTEC

! 500MG;2MG A200624 002 Jul 15, 2015 Oct CHRS

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 1MG BASE

A 077337 005 May 19, 2017 May NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+ @ METHAPHARM

1600MG/VIAL

N 019193 002 Aug 29, 2016 Sep DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADOSE

>D> AA +! MALLINCKRODT INC 10MG/ML N 017116 002 Dec CAHN
 AA +! 10MG/ML N 017116 002 Apr CAHN
 >A> AA +! SPECGX LLC 10MG/ML N 017116 002 Dec CAHN

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP AKORN 10MG/ML A 208306 001 Oct 27, 2017 Oct NEWA
 AP +! MYLAN INSTITUTIONAL 10MG/ML N 021624 001 Oct CFTG

POWDER;FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

@ MALLINCKRODT INC 50GM/BOT
 50GM/BOT
 @ 100GM/BOT
 100GM/BOT
 @ 500GM/BOT
 500GM/BOT

N 006383 002 Oct DISC
 N 006383 002 Apr CAHN
 N 006383 003 Oct DISC
 N 006383 003 Apr CAHN
 N 006383 004 Oct DISC
 N 006383 004 Apr CAHN

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 10MG/30ML

N 006134 004 Jan CAHN

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT 5MG N 006134 002 Jan CAHN
 AA +! 10MG N 006134 010 Jan CAHN

METHADONE HYDROCHLORIDE

AA EPIC PHARMA LLC 5MG A 090065 001 Aug 18, 2015 May CAHN
 AA 10MG A 090065 002 Aug 18, 2015 May CAHN
 >D> AA MALLINCKRODT 5MG A 040517 001 Apr 27, 2004 Dec CAHN
 >D> AA 10MG A 040517 002 Apr 27, 2004 Dec CAHN
 >A> AA SPECGX LLC 5MG A 040517 001 Apr 27, 2004 Dec CAHN
 >A> AA 10MG A 040517 002 Apr 27, 2004 Dec CAHN

METHADOSE

>D> AA MALLINCKRODT 5MG A 040050 001 Apr 15, 1993 Dec CAHN
 >D> AA 10MG A 040050 002 Apr 15, 1993 Dec CAHN
 >A> AA SPECGX LLC 5MG A 040050 001 Apr 15, 1993 Dec CAHN
 >A> AA 10MG A 040050 002 Apr 15, 1993 Dec CAHN

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

>D> AA MALLINCKRODT INC 40MG A 077142 001 Jul 12, 2005 Dec CAHN
 >A> AA SPECGX LLC 40MG A 077142 001 Jul 12, 2005 Dec CAHN
 AA +! WEST-WARD PHARMS INT 40MG N 017058 001 Jan CAHN

METHADOSE

>D> AA MALLINCKRODT INC 40MG A 074184 001 Apr 29, 1993 Dec CAHN
 >A> AA SPECGX LLC 40MG A 074184 001 Apr 29, 1993 Dec CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB IMPAX LABS INC 1GM A 076411 001 Jun 20, 2003 Feb CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

@ ECI PHARMS LLC 15MG

A 040619 003 Jul 12, 2005 May CAHN

TAPAZOLE

AB KING PHARMS LLC 5MG A 040320 001 Mar 31, 2000 Feb CAHN
 AB 10MG A 040320 002 Mar 31, 2000 Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	LUITPOLD PHARMS INC	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017	Jun	NEWA
AP	NAVINTA LLC	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017	Nov	NEWA
AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan	NEWA
AP	RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar	CAHN
AP	SAGENT PHARMS	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017	Jul	NEWA
AP	SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017	Jul	NEWA

TABLET; ORAL

METHOCARBAMOL

AA	ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan	NEWA
AA		750MG	A203550	002	Feb 08, 2017	Jan	NEWA
AA	BEXIMCO PHARMS USA	500MG	A208507	001	Jul 21, 2017	Jul	NEWA
AA		750MG	A208507	002	Jul 21, 2017	Jul	NEWA
	@ UPSHER SMITH	500MG	A087453	001		Jun	CAHN
	@	750MG	A087454	001		Jun	CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

>D>	@ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Dec	CRLD
>A>	+ @	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Dec	CRLD
>D>	+	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Dec	CHRS
>A>	+!	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Dec	CHRS
>D>	+	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Dec	CHRS
>A>	+!	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Dec	CHRS
>D>	+	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Dec	CHRS
>A>	+!	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Dec	CHRS
>D>	+	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Dec	CHRS
>A>	+!	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Dec	CHRS
>D>	+	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Dec	CHRS
>A>	+!	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Dec	CHRS
>D>	+	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Dec	CHRS
>A>	+!	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Dec	CHRS

OTREXUP PFS

+	@ ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Nov	DISC
+		10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jul	NEWA
+	@	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Nov	DISC
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jul	NEWA
+	@	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Nov	DISC
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jul	NEWA
+	@	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Nov	DISC
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jul	NEWA
+	@	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Nov	DISC
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jul	NEWA
+	@	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Nov	DISC
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jul	NEWA

RASUVO

>D>	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Dec	CRLD
>A>	+	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Dec	CRLD
>D>		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Dec	CRLD
>A>	+	10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Dec	CRLD
>D>		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Dec	CRLD
>A>	+	12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Dec	CRLD
>D>		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Dec	CRLD
>A>	+	15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Dec	CRLD
>D>		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Dec	CRLD
>A>	+	17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Dec	CRLD
>D>		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Dec	CRLD
>A>	+	20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Dec	CRLD
>D>		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Dec	CRLD
>A>	+	22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Dec	CRLD
>D>		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Dec	CRLD
>A>	+	25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Dec	CRLD
>D>	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Dec	CRLD
>A>	+ @	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Dec	CRLD
	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun	DISC
>D>		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Dec	CRLD
>A>	+	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Dec	CRLD

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A 040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A 040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A 040843	004	Jan 11, 2010	Apr CMS1

SOLUTION; ORAL
XATMEP

+!	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N 208400	001	Apr 25, 2017	Apr NEWA
----	-------------------	------------------	----------	-----	--------------	----------

TABLET; ORAL
METHOTREXATE SODIUM

>A>	AB	AMNEAL PHARMS	EQ 2.5MG BASE	A 210040	001	Dec 22, 2017	Dec NEWA
	AB	ORION CORP ORION	EQ 2.5MG BASE	A 201749	001	May 21, 2015	Jul CAHN
	AB	SUN PHARMA GLOBAL	EQ 2.5MG BASE	A 201749	001	May 21, 2015	Oct CAHN
	AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A 207812	001	Jan 13, 2017	Jan NEWA

METHOXSALEN

CAPSULE; ORAL
8-MOP

+	@	VALEANT PHARM INTL	10MG	N 009048	001		Oct DISC
---	---	--------------------	------	----------	-----	--	----------

LOTION; TOPICAL
OXSORALEN

+	@	VALEANT PHARM INTL	1%	N 009048	002		Oct DISC
---	---	--------------------	----	----------	-----	--	----------

METHYLCLOTHIAZIDE

TABLET; ORAL
METHYLCLOTHIAZIDE

>A>	@	FOSUN PHARMA	2.5MG	A 089835	001	Aug 18, 1988	Dec CAHN
>A>	@		5MG	A 089837	001	Aug 18, 1988	Dec CAHN
>D>	@	SANDOZ	2.5MG	A 089835	001	Aug 18, 1988	Dec CAHN
>D>	@		5MG	A 089837	001	Aug 18, 1988	Dec CAHN

METHYLDOPA

TABLET; ORAL
METHYLDOPA

>A>	@	FOSUN PHARMA	250MG	N 018934	001	Jun 29, 1984	Dec CAHN
>A>	@		500MG	N 018934	002	Jun 29, 1984	Dec CAHN
>D>	@	SANDOZ	250MG	N 018934	001	Jun 29, 1984	Dec CAHN
>D>	@		500MG	N 018934	002	Jun 29, 1984	Dec CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HYDROCHLORIDE

!		LUITPOLD	50MG/ML	A 071279	001	Oct 02, 1987	Jan CTEC
---	--	----------	---------	----------	-----	--------------	----------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION
METHYLERGONOVINE MALEATE

AP		BRECKENRIDGE PHARM	0.2MG/ML	A 040889	001	Sep 13, 2010	Sep CAHN
----	--	--------------------	----------	----------	-----	--------------	----------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL
COTEMPLA XR-ODT

+		NEOS THERAPS INC	8.6MG	N 205489	001	Jun 19, 2017	Jun NEWA
+			17.3MG	N 205489	002	Jun 19, 2017	Jun NEWA
+			25.9MG	N 205489	003	Jun 19, 2017	Jun NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2		IMPAX LABS INC	10MG	A 205105	001	Jul 28, 2016	Feb CAHN
AB2			20MG	A 205105	002	Jul 28, 2016	Feb CAHN
AB2			30MG	A 205105	003	Jul 28, 2016	Feb CAHN
AB2			40MG	A 205105	004	Jul 28, 2016	Feb CAHN
AB2			50MG	A 205105	005	Jul 28, 2016	Feb CAHN
AB2			60MG	A 205105	006	Jul 28, 2016	Feb CAHN
>D>	AB2	MALLINCKRODT INC	10MG	A 203583	001	Sep 29, 2015	Dec CAHN
>D>	AB2		20MG	A 203583	002	Sep 29, 2015	Dec CAHN
>D>	AB2		30MG	A 203583	003	Sep 29, 2015	Dec CAHN

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB2		40MG	A203583	004	Sep 29, 2015	Dec	CAHN
>D>	AB2		50MG	A203583	005	Sep 29, 2015	Dec	CAHN
>D>	AB2		60MG	A203583	006	Sep 29, 2015	Dec	CAHN
	!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb	CHRS
>A>	AB2	SPECGX LLC	10MG	A203583	001	Sep 29, 2015	Dec	CAHN
>A>	AB2		20MG	A203583	002	Sep 29, 2015	Dec	CAHN
>A>	AB2		30MG	A203583	003	Sep 29, 2015	Dec	CAHN
>A>	AB2		40MG	A203583	004	Sep 29, 2015	Dec	CAHN
>A>	AB2		50MG	A203583	005	Sep 29, 2015	Dec	CAHN
>A>	AB2		60MG	A203583	006	Sep 29, 2015	Dec	CAHN

SOLUTION;ORAL

METHYLIN

>D>	AA	+	MALLINCKRODT	5MG/5ML	N021419	001	Dec 19, 2002	Dec	CAHN
>D>	AA	+	!	10MG/5ML	N021419	002	Dec 19, 2002	Dec	CAHN
>A>	AA	+	SPECGX LLC	5MG/5ML	N021419	001	Dec 19, 2002	Dec	CAHN
>A>	AA	+	!	10MG/5ML	N021419	002	Dec 19, 2002	Dec	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AA		BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013	Sep	CAHN
AA			10MG/5ML	A201466	002	Nov 12, 2013	Sep	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	5MG	A206932	001	May 11, 2017	Apr	NEWA
AB			10MG	A206932	002	May 11, 2017	Apr	NEWA
AB			20MG	A206932	003	May 11, 2017	Apr	NEWA
AB		BRECKENRIDGE PHARM	5MG	A207587	001	Mar 03, 2017	Sep	CAHN
AB			10MG	A207587	002	Mar 03, 2017	Sep	CAHN
AB			20MG	A207587	003	Mar 03, 2017	Sep	CAHN
>A>	AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Dec	CAHN
>A>	AB		10MG	A091159	002	Mar 12, 2014	Dec	CAHN
>A>	AB		20MG	A091159	003	Mar 12, 2014	Dec	CAHN
>D>	AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Dec	CAHN
AB			5MG	A091159	001	Mar 12, 2014	Feb	CAHN
>D>	AB		10MG	A091159	002	Mar 12, 2014	Dec	CAHN
AB			10MG	A091159	002	Mar 12, 2014	Feb	CAHN
>D>	AB		20MG	A091159	003	Mar 12, 2014	Dec	CAHN
AB			20MG	A091159	003	Mar 12, 2014	Feb	CAHN
>D>	AB	MALLINCKRODT	5MG	A040300	001	Nov 27, 1998	Dec	CAHN
>D>	AB		10MG	A040300	002	Nov 27, 1998	Dec	CAHN
>D>	AB		20MG	A040300	003	Nov 27, 1998	Dec	CAHN
AB		NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb	NEWA
AB			10MG	A207587	002	Mar 03, 2017	Feb	NEWA
AB			20MG	A207587	003	Mar 03, 2017	Feb	NEWA
>A>	AB	SPECGX LLC	5MG	A040300	001	Nov 27, 1998	Dec	CAHN
>A>	AB		10MG	A040300	002	Nov 27, 1998	Dec	CAHN
>A>	AB		20MG	A040300	003	Nov 27, 1998	Dec	CAHN

TABLET, CHEWABLE;ORAL

METHYLIN

>D>		+ @	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Dec	CAHN
>D>		+ @		5MG	N021475	002	Apr 15, 2003	Dec	CAHN
>D>		+ @		10MG	N021475	003	Apr 15, 2003	Dec	CAHN
>A>		+ @	SPECGX LLC	2.5MG	N021475	001	Apr 15, 2003	Dec	CAHN
>A>		+ @		5MG	N021475	002	Apr 15, 2003	Dec	CAHN
>A>		+ @		10MG	N021475	003	Apr 15, 2003	Dec	CAHN

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		ASCENT PHARMS INC	2.5MG	A210354	001	Dec 29, 2017	Dec	NEWA
>A>	AB			5MG	A210354	002	Dec 29, 2017	Dec	NEWA
>A>	AB			10MG	A210354	003	Dec 29, 2017	Dec	NEWA
AB		BRECKENRIDGE PHARM	2.5MG	A204954	001	Jan 26, 2017	Sep	CAHN	
AB			5MG	A204954	002	Jan 26, 2017	Sep	CAHN	
AB			10MG	A204954	003	Jan 26, 2017	Sep	CAHN	
AB		NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan	NEWA	
AB			5MG	A204954	002	Jan 26, 2017	Jan	NEWA	
AB			10MG	A204954	003	Jan 26, 2017	Jan	NEWA	

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

>D>	AB		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Dec	CAHN
>D>	AB			20MG	A075629	002	May 09, 2000	Dec	CAHN
>A>	AB		SPECGX LLC	10MG	A075629	001	May 09, 2000	Dec	CAHN
>A>	AB			20MG	A075629	002	May 09, 2000	Dec	CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	COREPHARMA	18MG	A208607	001	Jul 14, 2017	Dec CAHN
>A>	AB		27MG	A208607	002	Jul 14, 2017	Dec CAHN
>A>	AB		36MG	A208607	003	Jul 14, 2017	Dec CAHN
>A>	AB		54MG	A208607	004	Jul 14, 2017	Dec CAHN
>D>	AB	IMPAX LABS INC	18MG	A208607	001	Jul 14, 2017	Dec CAHN
	AB		18MG	A208607	001	Jul 14, 2017	Jul NEWA
>D>	AB		27MG	A208607	002	Jul 14, 2017	Dec CAHN
	AB		27MG	A208607	002	Jul 14, 2017	Jul NEWA
>D>	AB		36MG	A208607	003	Jul 14, 2017	Dec CAHN
	AB		36MG	A208607	003	Jul 14, 2017	Jul NEWA
>D>	AB		54MG	A208607	004	Jul 14, 2017	Dec CAHN
	AB		54MG	A208607	004	Jul 14, 2017	Jul NEWA
>D>	BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012	Dec CAHN
>D>	BX		36MG	A202608	002	Dec 28, 2012	Dec CAHN
>D>	BX		54MG	A202608	003	Dec 28, 2012	Dec CAHN
	AB	OSMOTICA	18MG	A205327	001	Jul 28, 2017	Jul NEWA
	AB		27MG	A205327	002	Jul 28, 2017	Jul NEWA
	AB		36MG	A205327	003	Jul 28, 2017	Jul NEWA
	AB		54MG	A205327	004	Jul 28, 2017	Jul NEWA
			72MG	A205327	005	Jul 28, 2017	Jul NEWA
>A>	BX	SPECGX LLC	27MG	A202608	001	Dec 28, 2012	Dec CAHN
>A>	BX		36MG	A202608	002	Dec 28, 2012	Dec CAHN
>A>	BX		54MG	A202608	003	Dec 28, 2012	Dec CAHN
	AB	RITALIN-SR					
	AB	+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

		+ PHARMACIA AND UPJOHN	2MG	N011153	002		Nov CTEC
--	--	------------------------	-----	---------	-----	--	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB		SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
AB			40MG/ML	A040794	001	Mar 05, 2009	Jul CAHN
AB			80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
AB			80MG/ML	A040794	002	Mar 05, 2009	Jul CAHN

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 10

		@ VALEANT PHARMS NORTH	10MG	A086450	001		May CAHN
--	--	------------------------	------	---------	-----	--	----------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

AT		SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN
>D>	AA	! WOCHKHARDT	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Dec CAHN
>A>	AA	! WOCHKHARDT BIO AG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Dec CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>		@ FOSUN PHARMA	EQ 5MG BASE	A074478	001	Oct 05, 1995	Dec CAHN
>A>		@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Dec CAHN
>A>		@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Dec CAHN
>D>		@ SANDOZ	EQ 5MG BASE	A074478	001	Oct 05, 1995	Dec CAHN
>D>		@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Dec CAHN
>D>		@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Dec CAHN
		@ SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997	May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	1MG/ML	A078950	001	Apr 29, 2013	Aug CAHN
AP		SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN

TABLET;ORAL
LOPRESSOR

AB	+	US PHARMS HOLDINGS I	50MG	N017963	001		Sep CRLD
AB	+		100MG	N017963	002		Sep CRLD

METOPROLOL TARTRATE

>A>		@ FOSUN PHARMA	50MG	A073288	001	Mar 25, 1994	Dec CAHN
>A>		@	100MG	A073289	001	Mar 25, 1994	Dec CAHN
>D>		@ SANDOZ	50MG	A073288	001	Mar 25, 1994	Dec CAHN
>D>		@	100MG	A073289	001	Mar 25, 1994	Dec CAHN
AB		SUN PHARM INDUSTRIES	50MG	A073654	003	Dec 21, 1993	Jul CMS1

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	375MG	A079065	001	Jun 23, 2009	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL

METRONIDAZOLE

AB		TARO PHARM	1%	A204651	001	Mar 14, 2017	Feb NEWA
----	--	------------	----	---------	-----	--------------	----------

GEL;VAGINAL

NUVESSA

+! CHEMO RESEARCH SL 1.3%

N205223	001	Mar 24, 2014	Aug CAHN
---------	-----	--------------	----------

INJECTABLE;INJECTION

METRONIDAZOLE

	@	WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984	May CAHN
METRONIDAZOLE IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE CORP	500MG/100ML	A078084	001	Mar 31, 2008	Aug CAHN
AP		MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Apr NEWA

TABLET;ORAL

METRONIDAZOLE

AB		CADILA PHARMS LTD	250MG	A209794	001	Dec 12, 2017	Nov NEWA
AB			500MG	A209794	002	Dec 12, 2017	Nov NEWA
	@	CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983	Jun CAHN
	@		500MG	N018930	001	Aug 18, 1983	Jun CAHN
AB		INNOGENIX	250MG	A070772	001	Jul 16, 1986	Sep CAHN
>A>	AB		500MG	A070772	002	Jul 16, 1986	Dec CMS1
AB		LUPIN LTD	250MG	A209096	001	Sep 12, 2017	Sep NEWA
AB			500MG	A209096	002	Sep 12, 2017	Sep NEWA
AB		ORIT LABS LLC	250MG	A208681	001	Jun 20, 2017	Jun NEWA
AB			500MG	A208681	002	Jun 20, 2017	Jun NEWA
AB		VIVIMED GLOBAL	250MG	A070040	001	Jan 29, 1985	Aug CAHN
AB			500MG	A070039	001	Jan 29, 1985	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	200MG	A073508	001	Nov 19, 1993	May CAHN
----	--	----------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
----	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A 075637	001	Oct 31, 2000	Aug CAHN
	@	EQ 5MG BASE/ML	A 075637	002	Oct 31, 2000	Aug CAHN
	FRESENIUS KABI USA	EQ 5MG BASE/ML	A 208878	001	Mar 28, 2017	Mar NEWA
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A 075243	001	Jun 20, 2000	Jan CAHN
AP		EQ 1MG BASE/ML	A 075247	002	Jun 23, 2000	Jan CAHN
AP		EQ 1MG BASE/ML	A 075324	001	Jun 20, 2000	Mar CAHN
AP		EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A 075243	002	Jun 20, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A 075247	001	Jun 23, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A 075324	002	Jun 20, 2000	Mar CAHN
AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Jan CAHN
	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML	A 090315	001	Nov 29, 2010	May CAHN
AP		EQ 5MG BASE/ML	A 090315	002	Nov 29, 2010	May CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 2MG BASE/ML

A 076058 001 Mar 15, 2002 May DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

BX	APOTEX INC	2.5MG	A 077746	001	Sep 12, 2006	Sep CTEC
BX		5MG	A 077746	002	Sep 12, 2006	Sep CTEC
BX		10MG	A 077746	003	Sep 12, 2006	Sep CTEC
	ORVATEN					
AB	UPSHER-SMITH LABS	2.5MG	A 076725	001	Nov 03, 2004	Jun CAHN
AB		5MG	A 076725	002	Nov 03, 2004	Jun CAHN
AB		10MG	A 076725	003	Nov 03, 2004	Jun CAHN
	PROAMATINE					
	+ @ SHIRE LLC	2.5MG	N 019815	001	Sep 06, 1996	Feb CRLD
	+ @	5MG	N 019815	002	Sep 06, 1996	Feb CRLD
	+ @	10MG	N 019815	003	Mar 20, 2002	Feb CRLD

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+! NOVARTIS PHARMS CORP 25MG N 207997 001 Apr 28, 2017 Apr NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

	@ WINDLAS HLTHCARE	12.5MG	A 205071	001	Jan 27, 2016	Sep CAHN
	@	25MG	A 205071	002	Jan 27, 2016	Sep CAHN
	@	50MG	A 205071	003	Jan 27, 2016	Sep CAHN
	@	100MG	A 205071	004	Jan 27, 2016	Sep CAHN
	SAVELLA					
AB	+ ALLERGAN SALES LLC	12.5MG	N 022256	001	Jan 14, 2009	Feb CAHN
AB	+	25MG	N 022256	002	Jan 14, 2009	Feb CAHN
AB	+!	50MG	N 022256	003	Jan 14, 2009	Feb CAHN
AB	+	100MG	N 022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A 076427	001	Sep 21, 2004	Aug CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A 075530	001	May 28, 2002	Jan CAHN
AP		EQ 1MG BASE/ML	A 075660	001	May 28, 2002	Jan CAHN
	@	EQ 1MG BASE/ML	A 075852	001	May 28, 2002	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 077151	002	Jul 20, 2005	Aug CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 077151	001	Jul 20, 2005	Aug CAHN
	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 075510	001	May 28, 2002	Mar CAHN
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 078113	001	May 21, 2008	Jan CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG	A 078113	002	May 21, 2008	Jan CAHN

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
 BASE/ML)
 PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	SANOVI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan	CRLD
+ @		EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan	CRLD
+ @		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan	CRLD
+ @		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
 DYNACIN

AB	CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep	CMFD
----	------------------	--------------	---------	-----	--------------	-----	------

MINOCIN

AB	+ PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	Nov	CRLD
AB	+	EQ 100MG BASE	N050649	002	May 31, 1990	Nov	CRLD

MINOCYCLINE HYDROCHLORIDE

AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL
 XIMINO

	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CMFD

TABLET, EXTENDED RELEASE; ORAL
 MINOCYCLINE HYDROCHLORIDE

@	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	NEWA
@		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	NEWA
@	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May	DISC
@		EQ 80MG BASE	A203443	002	Aug 22, 2014	May	DISC
@		EQ 90MG BASE	A090911	002	Jul 20, 2010	May	DISC
@		EQ 105MG BASE	A203443	003	Aug 22, 2014	May	DISC
@		EQ 135MG BASE	A090911	003	Jul 20, 2010	May	DISC
AB	ZYDUS PHARMS USA INC	EQ 45MG BASE	A203553	001	Nov 16, 2017	Oct	NEWA
AB		EQ 80MG BASE	A203553	004	Nov 16, 2017	Oct	NEWA
AB		EQ 90MG BASE	A203553	005	Nov 16, 2017	Oct	NEWA
AB		EQ 105MG BASE	A203553	006	Nov 16, 2017	Oct	NEWA
AB		EQ 135MG BASE	A203553	008	Nov 16, 2017	Oct	NEWA

MINOLIRA

	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May	NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May	NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
 MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
----	-------	------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL
 MIRTAZAPINE

@	MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003	Nov	DISC
@		30MG	A076176	002	Jun 19, 2003	Nov	DISC
@		45MG	A076176	003	Jun 19, 2003	Nov	DISC
@	UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
AB		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
@		30MG	A076189	002	Jun 19, 2003	Jun	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
@		45MG	A076189	003	Jun 19, 2003	Jun	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
 MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May	NEWA
AB		30MG	A205798	002	Jun 01, 2017	May	NEWA
AB		45MG	A205798	003	Jun 01, 2017	May	NEWA

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	MYLAN LABS LTD	5MG/VIAL	A202670	001	Oct 13, 2017	Oct	NEWA
AP		20MG/VIAL	A202670	002	Oct 13, 2017	Oct	NEWA
AP		40MG/VIAL	A203386	001	Oct 13, 2017	Oct	NEWA
AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN
	MUTAMYCIN						
	+ @ BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
	+ @	20MG/VIAL	N050450	002		Jan	CRLD

MODAFINIL

TABLET; ORAL

MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
AB		200MG	A202700	002	Oct 18, 2012	May	CAHN
AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Aug	NEWA
AB		200MG	A207196	002	Aug 16, 2017	Aug	NEWA
AB	ZYDUS PHARMS USA INC	100MG	A209966	001	Sep 14, 2017	Sep	NEWA
AB		200MG	A209966	002	Sep 14, 2017	Sep	NEWA

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr	CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr	CAHN

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May	CAHN
		10MG	A090453	002	Mar 20, 2015	May	CAHN
	!	25MG	A090453	003	Mar 20, 2015	May	CAHN

MOMETASONE FUROATE

IMPLANT; IMPLANTATION

SINUVA

>A>							
>A>	+ INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017	Dec	NEWA

LOTION; TOPICAL

MOMETASONE FUROATE

AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr	CAHN
----	----------------	------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	NEWA
----	---------------	----------------------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr	NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr	NEWA
	SINGULAIR						
AB	+! MSD MERCK CO	EQ 10MG BASE	N020829	002	Feb 20, 1998	Oct	CAHN

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr	NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr	NEWA

SINGULAIR

AB	+ MSD MERCK CO	EQ 4MG BASE	N020830	002	Mar 03, 2000	Oct	CAHN
AB	+!	EQ 5MG BASE	N020830	001	Feb 20, 1998	Oct	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr	CAHN
		45MG	A079040	002	Jan 16, 2013	Apr	CAHN
		60MG	A079040	003	Jan 16, 2013	Apr	CAHN
		75MG	A079040	004	Jan 16, 2013	Apr	CAHN
		90MG	A079040	005	Jan 16, 2013	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

	!	120MG	A079040	006	Jan 16, 2013	Apr	CAHN
AB	UPSHER-SMITH LABS	10MG	A202104	001	Jun 03, 2013	Jun	CAHN
AB		20MG	A202104	002	Jun 03, 2013	Jun	CAHN
AB		30MG	A202104	003	Jun 03, 2013	Jun	CAHN
AB		50MG	A202104	004	Jun 03, 2013	Jun	CAHN
AB		60MG	A202104	005	Jun 03, 2013	Jun	CAHN
AB		80MG	A202104	006	Jun 03, 2013	Jun	CAHN
AB		100MG	A202104	007	Jun 03, 2013	Jun	CAHN

INJECTABLE;INJECTION
MORPHINE SULFATE

	+ @	HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011	Aug	DISC
	@	ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992	Jun	CAHN
AP	+!		1MG/ML	N019916	001	Oct 30, 1992	Apr	CAHN
	+!		5MG/ML	N019916	002	Oct 27, 2006	Apr	CAHN
>D>	@	MALLINCKRODT INC	1MG/ML	N020631	001	Jul 03, 1996	Dec	CAHN
	@		1MG/ML	N020631	001	Jul 03, 1996	Apr	CAHN
>D>	@		2MG/ML	N020631	002	Jul 03, 1996	Dec	CAHN
	@		2MG/ML	N020631	002	Jul 03, 1996	Apr	CAHN
>A>	@	SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996	Dec	CAHN
>A>	@		2MG/ML	N020631	002	Jul 03, 1996	Dec	CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA		HI-TECH PHARMACAL	100MG/5ML	A208809	001	Jul 06, 2017	Jun	NEWA
>D>	AA	MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Dec	CAHN
	AA	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jun	NEWA
	AA		100MG/5ML	A206308	002	Jun 22, 2017	Jun	NEWA
>A>	AA	SPECGX LLC	100MG/5ML	A202348	001	Jul 15, 2011	Dec	CAHN
	AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan	CAHN
	AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan	CAHN
	AA	+!	100MG/5ML	N022195	003	Jan 25, 2010	Jan	CAHN

TABLET;ORAL

MORPHINE SULFATE

	+	WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan	CAHN
	+!		30MG	N022207	002	Mar 17, 2008	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

	+	EGALET	15MG	N208603	001	Jan 09, 2017	Jan	NEWA
	+		30MG	N208603	002	Jan 09, 2017	Jan	NEWA
	+		60MG	N208603	003	Jan 09, 2017	Jan	NEWA

MORPHABOND ER

	+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan	CTNA
	+		30MG	N206544	002	Oct 02, 2015	Jan	CTNA
	+		60MG	N206544	003	Oct 02, 2015	Jan	CTNA
	+!		100MG	N206544	004	Oct 02, 2015	Jan	CTNA

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr	CAHN
AB			30MG	A203849	002	Apr 06, 2015	Apr	CAHN
AB			60MG	A203849	003	Apr 06, 2015	Apr	CAHN
AB			100MG	A203849	004	Apr 06, 2015	Apr	CAHN
AB			200MG	A203849	005	Apr 06, 2015	Apr	CAHN
AB		EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	May	CAHN
AB			30MG	A091357	002	Jun 23, 2016	May	CAHN
AB			60MG	A091357	003	Jun 23, 2016	May	CAHN
AB			100MG	A091357	004	Jun 23, 2016	May	CAHN
AB			200MG	A091357	005	Jun 23, 2016	May	CAHN
>D>	AB	MALLINCKRODT	15MG	A076412	001	Jul 31, 2003	Dec	CAHN
>D>	AB		30MG	A076412	002	Jul 31, 2003	Dec	CAHN
>D>	AB		60MG	A076412	003	Jul 31, 2003	Dec	CAHN
>D>	AB		100MG	A076438	001	Jul 03, 2003	Dec	CAHN
>D>	AB		200MG	A076438	002	Jul 03, 2003	Dec	CAHN
>A>	AB	SPECGX LLC	15MG	A076412	001	Jul 31, 2003	Dec	CAHN
>A>	AB		30MG	A076412	002	Jul 31, 2003	Dec	CAHN
>A>	AB		60MG	A076412	003	Jul 31, 2003	Dec	CAHN
>A>	AB		100MG	A076438	001	Jul 03, 2003	Dec	CAHN
>A>	AB		200MG	A076438	002	Jul 03, 2003	Dec	CAHN
AB		SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016	Mar	CAHN
AB			30MG	A205634	002	Aug 25, 2016	Mar	CAHN
AB			60MG	A205634	003	Aug 25, 2016	Mar	CAHN
AB			100MG	A205634	004	Aug 25, 2016	Mar	CAHN
AB			200MG	A205634	005	Aug 25, 2016	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

>D>		AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER							
>D>	AP	+!	BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Dec	DISC
>A>		+ @		400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Dec	DISC
	AP	+!		400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr	CFTG
				MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
>D>	AP		MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Dec	CHRS
>A>		!		400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Dec	CHRS
	AP			400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr	NEWA

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1			AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Oct	NEWA
AT1			APOTEX INC	EQ 0.5% BASE	A090080	001	Jun 30, 2017	Jun	NEWA
AT1			AUROBINDO PHARMA LTD	EQ 0.5% BASE	A206242	001	Oct 04, 2017	Sep	NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB			MSN LABS PVT LTD	EQ 400MG BASE	A208682	001	Sep 22, 2017	Sep	NEWA
AB			NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan	NEWA

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB		!	PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003	May	CHRS
----	--	---	------------------	----	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB			GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	May	CAHN
----	--	--	---------------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

		@	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Sep	DISC
AB			ZHEJIANG HISUN PHARM	250MG	A204077	001	Nov 13, 2017	Oct	NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

		@	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Sep	DISC
AB			ZHEJIANG HISUN PHARM	500MG	A204076	001	Nov 16, 2017	Nov	NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP			AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb	NEWA
AP			MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar	NEWA
AP			ZYDUS PHARMS USA INC	500MG/VIAL	A204473	001	Aug 31, 2017	Aug	NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB			ACCORD HLTHCARE	180MG	A202555	001	Aug 23, 2017	Aug	NEWA
AB				360MG	A202555	002	Aug 23, 2017	Aug	NEWA

NABILONE

CAPSULE;ORAL

CESAMET

		+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar	CAHN
--	--	----	---------------------	-----	---------	-----	--------------	-----	------

NABUMETONE

TABLET;ORAL

NABUMETONE

>D>		@	DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Dec	CAHN
>D>		@		750MG	A078420	002	Sep 24, 2008	Dec	CAHN
>A>		@	SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Dec	CAHN
>A>		@		750MG	A078420	002	Sep 24, 2008	Dec	CAHN

NADOLOL

TABLET; ORAL		NADOLOL					
AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May	NEWA
AB		40MG	A208832	002	Jun 02, 2017	May	NEWA
AB		80MG	A208832	003	Jun 02, 2017	May	NEWA
AB	AUROBINDO PHARMA LTD	40MG	A201893	001	Sep 16, 2015	Nov	CAHN
AB		80MG	A201893	002	Sep 16, 2015	Nov	CAHN
AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Sep	NEWA
AB		40MG	A209309	002	Oct 05, 2017	Sep	NEWA
AB		80MG	A209309	003	Oct 05, 2017	Sep	NEWA
AB	ZYDUS PHARMS USA INC	20MG	A207761	001	Jul 28, 2017	Jul	NEWA
AB		40MG	A207761	002	Jul 28, 2017	Jul	NEWA
AB		80MG	A207761	003	Jul 28, 2017	Jul	NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL		NAFTIFINE HYDROCHLORIDE					
AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar	NEWA

NALDEMEDINE TOSYLATE

TABLET; ORAL		SYMPROIC					
+!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar	NEWA

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION		REVEX					
+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Nov	CRLD
+ @		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Nov	CRLD

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION		NALOXONE					
@	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986	Jan	CAHN
@		0.4MG/ML	A070496	001	Sep 24, 1986	Jan	CAHN
INJECTABLE; INJECTION		NALOXONE HYDROCHLORIDE					
AP	AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb	NEWA
AP		0.4MG/ML	A208872	001	Mar 14, 2017	Feb	NEWA
!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Nov	CTEC
AP	SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul	NEWA
AP		0.4MG/ML	A207634	001	Jul 26, 2017	Jul	NEWA
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS		EVZIO					
+ @	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Aug	DISC
SPRAY, METERED; NASAL		NARCAN					
+ @	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan	NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		TARGINIQ					
+ @	PURDUE PHARMA LP	5MG; 10MG	N205777	001	Jul 23, 2014	Oct	CRLD
+ @		10MG; 20MG	N205777	002	Jul 23, 2014	Oct	CRLD
+ @		20MG; 40MG	N205777	003	Jul 23, 2014	Oct	CRLD

NALTREXONE HYDROCHLORIDE

TABLET; ORAL		NALTREXONE HYDROCHLORIDE					
AB	APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul	NEWA
>D>	MALLINCKRODT	25MG	A076264	001	Mar 22, 2002	Dec	CAHN
>D>	!	50MG	A076264	002	Mar 22, 2002	Dec	CAHN
>D>		100MG	A076264	003	Mar 22, 2002	Dec	CAHN
>A>	SPECGX LLC	25MG	A076264	001	Mar 22, 2002	Dec	CAHN
>A>	!	50MG	A076264	002	Mar 22, 2002	Dec	CAHN
>A>		100MG	A076264	003	Mar 22, 2002	Dec	CAHN

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROXYCA ER

@	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016	Oct	DISC
@		2.4MG;20MG	N207621	002	Aug 19, 2016	Oct	DISC
@		3.6MG;30MG	N207621	003	Aug 19, 2016	Oct	DISC
@		4.8MG;40MG	N207621	004	Aug 19, 2016	Oct	DISC
@		7.2MG;60MG	N207621	005	Aug 19, 2016	Oct	DISC
@		9.6MG;80MG	N207621	006	Aug 19, 2016	Oct	DISC

NANDROLONE DECANOATE

INJECTABLE;INJECTION

NANDROLONE DECANOATE

!	LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

NAPROXEN

TABLET;ORAL

NAPROXEN

AB	AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB		375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB		500MG	A200429	003	Nov 08, 2011	Jan	CAHN
@	CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May	CAHN
@		375MG	A074410	002	Apr 28, 1995	May	CAHN
@		500MG	A074410	003	Apr 28, 1995	May	CAHN
@	HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May	DISC
@		375MG	A076494	002	Jan 14, 2004	May	DISC
@		500MG	A076494	003	Jan 14, 2004	May	DISC

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

@	MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001	Oct	DISC
@		500MG	A075390	002	Apr 19, 2001	Oct	DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

AB	GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May	CAHN
AB		EQ 500MG BASE	A078314	002	Apr 27, 2007	May	CAHN

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
---	----------------------	----	---------	-----	--	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

@	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May	DISC
AB		EQ 2.5MG BASE	A203821	001	May 25, 2017	May	NEWA
@		EQ 5MG BASE	A203821	002	May 25, 2017	May	DISC
AB		EQ 5MG BASE	A203821	002	May 25, 2017	May	NEWA
@		EQ 10MG BASE	A203821	003	May 25, 2017	May	DISC
AB		EQ 10MG BASE	A203821	003	May 25, 2017	May	NEWA
@		EQ 20MG BASE	A203821	004	May 25, 2017	May	DISC
AB		EQ 20MG BASE	A203821	004	May 25, 2017	May	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	May	CRLD
---	-----------------	------------------	---------	-----	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003	Nov	DISC
@		100MG	A076309	002	Sep 16, 2003	Nov	DISC
@		150MG	A076309	003	Sep 16, 2003	Nov	DISC
@		200MG	A076309	004	Sep 16, 2003	Nov	DISC
@		250MG	A076309	005	Sep 16, 2003	Nov	DISC
@	TEVA	50MG	A076037	001	Sep 16, 2003	Nov	CTEC
		100MG	A076037	002	Sep 16, 2003	Nov	CTEC
		150MG	A076037	003	Sep 16, 2003	Nov	CTEC

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	200MG		A076037	004	Sep 16, 2003	Nov	CTEC
!	250MG		A076037	005	Sep 16, 2003	Nov	CTEC

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

@ AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL		N020778	001	Mar 14, 1997	Jan	CAHN
------------------	-----------------------	--	---------	-----	--------------	-----	------

TABLET;ORAL

VIRACEPT

+! AGOURON PHARMS	EQ 250MG BASE		N020779	001	Mar 14, 1997	Jan	CAHN
+!	EQ 625MG BASE		N021503	001	Apr 30, 2003	Jan	CAHN

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	BRECKENRIDGE PHARM	500MG	A065468	001	Mar 29, 2010	Sep	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001		Apr	CAHN
----	---	----------------	----------------------------------	---------	-----	--	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933	001	Sep 25, 2017	Sep	NEWA
AP			10MG/10ML (1MG/ML)	A209933	002	Sep 25, 2017	Sep	NEWA
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	NEWA
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	NEWA

NERATINIB MALEATE

TABLET;ORAL

NERLYNX

+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017	Jul	NEWA
----	--------------	--------------	---------	-----	--------------	-----	------

>A> NETARSUDIL DIMESYLATE

>A> SOLUTION/DROPS;OPHTHALMIC

>A> RHOPRESSA

>A>	+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Dec	NEWA
-----	----	------------------	---------------	---------	-----	--------------	-----	------

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE

AA		CIPLA LTD	50MG/5ML	A207684	001	Aug 03, 2017	Jul	NEWA
----	--	-----------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

NEVIRAPINE

AB		TECH ORGANIZED	200MG	A203176	001	May 22, 2012	Sep	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB		AUROBINDO PHARMA LTD	400MG	A207698	001	Feb 28, 2017	Mar	CAHN
AB		AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Feb	NEWA
AB		MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Sep	NEWA
AB		SCIEGEN PHARMS INC	100MG	A207467	001	Jul 31, 2017	Jul	NEWA
AB			400MG	A207467	002	Jul 31, 2017	Jul	NEWA
AB		TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017	Sep	CAHN
AB			400MG	A207467	002	Jul 31, 2017	Sep	CAHN

NIACIN

TABLET;ORAL

NIACOR

AA	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000	Oct	CAHN
AA	!	UPSHER-SMITH LABS	500MG	A040378	001	May 03, 2000	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		LANNETT CO INC	500MG	A203899	001	Jun 16, 2017	Jun	NEWA
AB			1GM	A203899	002	Jun 16, 2017	Jun	NEWA

NICARDIPINE HYDROCHLORIDEINJECTABLE; INJECTION
NICARDIPINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan	CAHN
	INJECTABLE; INTRAVENOUS						
	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE						
	EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Feb	NEWA
		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Feb	NEWA

NIFEDIPINETABLET, EXTENDED RELEASE; ORAL
AFEDITAB CR

AB1	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May	CAHN
	NIFEDIPINE						
	@ MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May	DISC
AB2		30MG	A090602	001	Sep 13, 2010	Mar	CAHN
	@	60MG	A090602	002	Sep 13, 2010	May	DISC
AB2		60MG	A090602	002	Sep 13, 2010	Mar	CAHN
	@	90MG	A090602	003	Sep 13, 2010	May	DISC
AB2		90MG	A090602	003	Sep 13, 2010	Mar	CAHN
AB2	OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun	CAHN
>A>	AB2	ZYDUS PHARMS USA INC	A210012	001	Dec 19, 2017	Dec	NEWA
>A>	AB2		A210012	002	Dec 19, 2017	Dec	NEWA
>A>	AB2		A210012	003	Dec 19, 2017	Dec	NEWA

NIRAPARIB TOSYLATECAPSULE; ORAL
ZEJULA

+	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar	NEWA
---	------------	---------------	---------	-----	--------------	-----	------

NISOLDIPINETABLET, EXTENDED RELEASE; ORAL
SULAR

AB	+	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May	CAHN
	+ @		10MG	N020356	001	Feb 02, 1995	May	CAHN
AB	+		17MG	N020356	007	Jan 02, 2008	May	CAHN
	+ @		20MG	N020356	002	Feb 02, 1995	May	CAHN
	+ @		25.5MG	N020356	006	Jan 02, 2008	May	CAHN
	+ @		30MG	N020356	003	Feb 02, 1995	May	CAHN
AB	+		34MG	N020356	005	Jan 02, 2008	May	CAHN
	+ @		40MG	N020356	004	Feb 02, 1995	May	CAHN

NITISINONECAPSULE; ORAL
ORFADIN

+	SWEDISH ORPHAN	10MG	N021232	003	Jan 18, 2002	Oct	CHRS
---	----------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
NITYR

+	CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017	Jul	NEWA
+		5MG	N209449	002	Jul 26, 2017	Jul	NEWA
+		10MG	N209449	003	Jul 26, 2017	Jul	NEWA

NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORAL
NITROFURANTOIN

AB	ZYDUS PHARMS USA INC	50MG	A205005	001	Dec 12, 2017	Nov	NEWA
AB		100MG	A205005	002	Dec 12, 2017	Nov	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	AMNEAL PHARMS	75MG; 25MG	A207372	001	May 15, 2017	May	NEWA
----	---------------	------------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

AB1	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun	CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Jun	CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Jun	CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Jun	CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Jun	CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

+!		0.8MG/HR		N020145	006	Apr 04, 1995	Jun	CAHN
OINTMENT;TRANSDERMAL								
NITROGLYCERIN								
!	FOUGERA PHARMS INC	2%		A087355	001	Jul 08, 1988	Jan	CAHN
TABLET;SUBLINGUAL								
NITROGLYCERIN								
AB	ACTAVIS LABS FL INC	0.3MG		A203693	001	Oct 16, 2017	Oct	NEWA
AB		0.4MG		A203693	002	Oct 16, 2017	Oct	NEWA
AB		0.6MG		A203693	003	Oct 16, 2017	Oct	NEWA
AB	GLENMARK PHARMS LTD	0.3MG		A206391	001	Sep 19, 2017	Sep	NEWA
AB		0.4MG		A206391	002	Sep 19, 2017	Sep	NEWA
AB		0.6MG		A206391	003	Sep 19, 2017	Sep	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML		A040859	001	Mar 27, 2012	Aug	CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML		A040462	001	Oct 31, 2003	Jan	CAHN

NORFLOXACIN

TABLET;ORAL
NOROXIN

>D>	@ MERCK	400MG		N019384	002	Oct 31, 1986	Dec	CRLD
>A>	+ @	400MG		N019384	002	Oct 31, 1986	Dec	CRLD

NORGESTREL

TABLET;ORAL
OPILL

+ @	LABORATOIRE HRA	0.075MG		N017031	001		Oct	CTNA
+ @		0.075MG		N017031	001		Oct	CRLD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

	@ MYLAN	EQ 10MG BASE		A074234	001	Jul 26, 1993	Jun	DISC
	@	EQ 25MG BASE		A074234	002	Jul 26, 1993	Jun	DISC
	@	EQ 50MG BASE		A074234	003	Jul 26, 1993	Jun	DISC
	@	EQ 75MG BASE		A074234	004	Jul 26, 1993	Jun	DISC
AB	TARO PHARM	EQ 10MG BASE		A075520	004	May 08, 2000	Mar	CAHN
AB		EQ 25MG BASE		A075520	003	May 08, 2000	Mar	CAHN
AB		EQ 50MG BASE		A075520	001	May 08, 2000	Mar	CAHN
AB		EQ 75MG BASE		A075520	002	May 08, 2000	Mar	CAHN
PAMELOR								
>D>	AB + MALLINCKRODT LLC	EQ 10MG BASE		N018013	001		Dec	CAHN
>D>	AB +	EQ 25MG BASE		N018013	002		Dec	CAHN
>D>	AB +	EQ 50MG BASE		N018013	004		Dec	CAHN
>D>	AB +!	EQ 75MG BASE		N018013	003		Dec	CAHN
>A>	AB + SPECGX LLC	EQ 10MG BASE		N018013	001		Dec	CAHN
>A>	AB +	EQ 25MG BASE		N018013	002		Dec	CAHN
>A>	AB +	EQ 50MG BASE		N018013	004		Dec	CAHN
>A>	AB +!	EQ 75MG BASE		N018013	003		Dec	CAHN

SOLUTION;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AA	! PHARM ASSOC	EQ 10MG BASE/5ML		A075606	001	Aug 28, 2000	May	CAHN
PAMELOR								
>D>	@ MALLINCKRODT INC	EQ 10MG BASE/5ML		N018012	001		Dec	CAHN
>A>	@ SPECGX LLC	EQ 10MG BASE/5ML		N018012	001		Dec	CAHN

NYSTATIN

CREAM;TOPICAL
NYSTATIN

AT	CROWN LABS INC	100,000 UNITS/GM		A207733	001	Sep 26, 2017	Sep	NEWA
----	----------------	------------------	--	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
NYSTATIN

AT	G AND W LABS INC	100,000 UNITS/GM		A209114	001	Oct 06, 2017	Sep	NEWA
----	------------------	------------------	--	---------	-----	--------------	-----	------

PASTILLE;ORAL
MYCOSTATIN

	@ DELCOR ASSET CORP	200,000 UNITS		N050619	001	Apr 09, 1987	Jun	CAHN
--	---------------------	---------------	--	---------	-----	--------------	-----	------

	POWDER; TOPICAL							
	NYSTATIN							
AT	LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May	NEWA	
AT	NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May	NEWA	
AT	UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun	CAHN	
	SUSPENSION; ORAL							
	NILSTAT							
>D>	@ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Dec	CRLD	
>A>	+ @	100,000 UNITS/ML	N050299	001		Dec	CRLD	
	NYSTATIN							
	@ ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN	
AA	FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN	
AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN	
AA	TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN	
>D> AA	! WOCKHARDT	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Dec	CAHN	
>A> AA	! WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Dec	CAHN	
	TABLET; ORAL							
	NYSTATIN							
	@ USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun	CAHN	
	<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
	CREAM; TOPICAL							
	MYCOLOG-II							
	@ MYLAN PHARMS INC	100,000 UNITS/GM; 0.1%	A062606	001	May 15, 1985	Jan	CAHN	
	NYSTATIN AND TRIAMCINOLONE ACETONIDE							
>A> AT	CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207730	001	Dec 26, 2017	Dec	NEWA	
AT	FOUGERA PHARMS INC	100,000 UNITS/GM; 0.1%	A062599	001	Oct 08, 1985	Jan	CAHN	
AT	PERRIGO UK FINCO	100,000 UNITS/GM; 0.1%	A208479	001	Aug 14, 2017	Jul	NEWA	
	OINTMENT; TOPICAL							
	MYCOLOG-II							
	@ MYLAN PHARMS INC	100,000 UNITS/GM; 0.1%	A060572	001	Jun 28, 1985	Jan	CAHN	
	NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT	AKORN	100,000 UNITS/GM; 0.1%	A207217	001	Aug 04, 2017	Jul	NEWA	
>A> AT	CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207731	001	Dec 26, 2017	Dec	NEWA	
AT	DR REDDYS LABS LTD	100,000 UNITS/GM; 0.1%	A207741	001	Jan 31, 2017	Jan	NEWA	
AT	FOUGERA PHARMS INC	100,000 UNITS/GM; 0.1%	A062602	001	Oct 09, 1985	Jan	CAHN	
	<u>OCTREOTIDE ACETATE</u>							
	INJECTABLE; INJECTION							
	OCTREOTIDE ACETATE							
	@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008	Sep	DISC	
	@	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008	Sep	DISC	
	@	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008	Oct	DISC	
	@	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008	Sep	DISC	
	@	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008	Oct	DISC	
	<u>OFLOXACIN</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	OFLOXACIN							
AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN	
	SOLUTION/DROPS; OTIC							
	OFLOXACIN							
AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN	
	<u>OLANZAPINE</u>							
	TABLET; ORAL							
	OLANZAPINE							
	@ AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Oct	DISC	
	@	5MG	A206711	002	Aug 30, 2016	Oct	DISC	
	@	7.5MG	A206711	003	Aug 30, 2016	Oct	DISC	
	@	10MG	A206711	004	Aug 30, 2016	Oct	DISC	
	@	15MG	A206711	005	Aug 30, 2016	Oct	DISC	
	@	20MG	A206711	006	Aug 30, 2016	Oct	DISC	
AB	HIKMA PHARMS	2.5MG	A204866	001	Jun 16, 2017	Jun	NEWA	
AB		5MG	A204866	002	Jun 16, 2017	Jun	NEWA	
AB		7.5MG	A204866	003	Jun 16, 2017	Jun	NEWA	
AB		10MG	A204866	004	Jun 16, 2017	Jun	NEWA	
AB		15MG	A204866	005	Jun 16, 2017	Jun	NEWA	
AB		20MG	A204866	006	Jun 16, 2017	Jun	NEWA	
	@ MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun	DISC	
AB		2.5MG	A076866	001	Apr 23, 2012	Mar	CAHN	
	@	5MG	A076866	002	Apr 23, 2012	Jun	DISC	

TABLET;ORAL							
OLANZAPINE							
AB		5MG	A076866	002	Apr 23, 2012	Mar	CAHN
	@	7.5MG	A076866	003	Apr 23, 2012	Jun	DISC
AB		7.5MG	A076866	003	Apr 23, 2012	Mar	CAHN
	@	10MG	A076866	004	Apr 23, 2012	Jun	DISC
AB		10MG	A076866	004	Apr 23, 2012	Mar	CAHN
	@	15MG	A076866	005	Apr 23, 2012	Jun	DISC
AB		15MG	A076866	005	Apr 23, 2012	Mar	CAHN
	@	20MG	A076866	006	Apr 23, 2012	Jun	DISC
AB		20MG	A076866	006	Apr 23, 2012	Mar	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
OLANZAPINE							
AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May	NEWA
AB		10MG	A204320	002	May 30, 2017	May	NEWA
AB		15MG	A204320	003	May 30, 2017	May	NEWA
AB		20MG	A204320	004	May 30, 2017	May	NEWA
<u>OLAPARIB</u>							
CAPSULE;ORAL							
LYNPARZA							
+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar	CRLD
TABLET;ORAL							
LYNPARZA							
+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017	Aug	NEWA
+!		150MG	N208558	002	Aug 17, 2017	Aug	NEWA
<u>OLIVE OIL; SOYBEAN OIL</u>							
INJECTABLE;INJECTION							
CLINOLIPID 20%							
+	@ BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul	DISC
<u>OLMESARTAN MEDOXOMIL</u>							
TABLET;ORAL							
OLMESARTAN MEDOXOMIL							
AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr	NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr	NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May	NEWA
AB		20MG	A203281	002	May 25, 2017	May	NEWA
AB		40MG	A203281	003	May 25, 2017	May	NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr	NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr	NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr	NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr	NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Nov	NEWA
AT	APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017	Nov	NEWA
AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul	NEWA
AT		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Nov	NEWA
AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun	NEWA
AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep	CAHN

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

OLSALAZINE SODIUMCAPSULE;ORAL
DIPENTUM

+	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar	CAHN
---	---------------------	-------	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATEPOWDER;SUBCUTANEOUS
SYNRIBO

+	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr	CAHN
---	------------------	------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May	CAHN
AB	STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Sep	NEWA

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL
OMTRYG

+	@ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep	DISC
+		1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep	CAHN

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan	CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan	CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan	CAHN
AB	BRECKENRIDGE PHARM	10MG	A203481	001	Jul 03, 2017	Jun	NEWA
AB		20MG	A203481	002	Jul 03, 2017	Jun	NEWA
AB		40MG	A203481	003	Jul 03, 2017	Jun	NEWA
AB	TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May	NEWA
AB		40MG	A204661	002	Jun 13, 2017	May	NEWA

OMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May	CAHN
+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May	CAHN

OMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan	CTEC	
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan	CTEC	
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan	CMFD	
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan	CMFD	
AB	ZEGERID							
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan	CTEC
AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan	CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@	CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar	CAHN
@		8MG	A076506	002	Dec 26, 2006	Mar	CAHN
@		16MG	A077406	001	Dec 26, 2006	Mar	CAHN
@		24MG	A077406	002	Dec 26, 2006	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug	CAHN
	@	MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov	DISC
AP			EQ 2MG BASE/ML	A204906	001	Jul 31, 2017	Jul	NEWA
AP		SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar	CAHN
AP	@	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006	Oct	DISC
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug	CAHN
	@	MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov	DISC
AP		SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar	CAHN
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN

ORLISTAT

CAPSULE;ORAL

XENICAL

>A>	+	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999	Dec	CAHN
>D>	+	HOFFMANN LA ROCHE	120MG	N020766	001	Apr 23, 1999	Dec	CAHN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

@ TELIGENT 30MG/ML

N013055 001 Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

NORFLEX

+ @ MEDICIS 100MG N012157 001 Aug CRLD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May	NEWA
AB			EQ 45MG BASE	A209093	002	May 17, 2017	May	NEWA
AB			EQ 75MG BASE	A209093	003	May 17, 2017	May	NEWA
>A>	AB	LUPIN ATLANTIS	EQ 30MG BASE	A208348	001	Jan 09, 2018	Dec	NEWA
>A>	AB		EQ 45MG BASE	A208348	002	Jan 09, 2018	Dec	NEWA
>A>	AB		EQ 75MG BASE	A208348	003	Jan 09, 2018	Dec	NEWA
AB		MACLEODS PHARMS LTD	EQ 30MG BASE	A207211	001	Sep 14, 2017	Sep	NEWA
AB			EQ 45MG BASE	A207211	002	Sep 14, 2017	Sep	NEWA
AB			EQ 75MG BASE	A207211	003	Sep 14, 2017	Sep	NEWA
AB		NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA
AB			EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA
AB			EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	Oct	NEWA
AB		NESHER PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Sep	NEWA
		TAMIFLU						
AB	+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep	CFTG

OSPEMIFENE

TABLET;ORAL

OSPHENA

+! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Mar CAHN

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

	@	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Oct	DISC
	@		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Oct	DISC
AP		RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug	NEWA

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Oct	NEWA
AP	WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A207148	001	Nov 24, 2017	Nov	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
ELOXATIN

	+ @ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD
		OXALIPLATIN					
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar	NEWA
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar	NEWA
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar	NEWA
AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan	NEWA
AP		50MG/VIAL	A207385	001	May 23, 2017	May	NEWA
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan	NEWA
AP		100MG/VIAL	A207385	002	May 23, 2017	May	NEWA
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Oct	NEWA
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May	NEWA
AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May	NEWA
AP	MYLAN LABS LTD	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Oct	NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan	CTEC
AP	SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Aug	NEWA
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Aug	NEWA

OXANDROLONE

TABLET; ORAL
OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Jun	CAHN
AB		10MG	A078033	001	Mar 22, 2007	Jun	CAHN

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May	CMS1
AB		15MG	A072253	003	Apr 14, 1988	May	CMS1
	@ ANDA REPOSITORY	10MG	A071026	002	Aug 10, 1987	Sep	CAHN
	@	15MG	A071026	003	Aug 10, 1987	Sep	CAHN
	@	30MG	A071026	001	Aug 10, 1987	Sep	CAHN
	@ WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990	May	CAHN

TABLET; ORAL
OXAZEPAM

	@ SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987	Jan	CAHN
--	------------------------	------	---------	-----	--------------	-----	------

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May	CAHN
AB		300MG	A077802	002	Oct 09, 2007	May	CAHN
AB		600MG	A077802	003	Oct 09, 2007	May	CAHN
	@ JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Sep	DISC
AB		150MG	A090239	001	Jan 25, 2010	Apr	CAHN
	@	300MG	A090239	002	Jan 25, 2010	Sep	DISC
AB		300MG	A090239	002	Jan 25, 2010	Apr	CAHN
	@	600MG	A090239	003	Jan 25, 2010	Sep	DISC
AB		600MG	A090239	003	Jan 25, 2010	Apr	CAHN

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
 CHOLEDYL SA

@ WARNER CHILCOTT LLC 600MG A086742 001 Sep DISC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL
 DITROPAN

+ @ ORTHO MCNEIL JANSSEN 5MG/5ML N018211 001 Jan CRLD
 OXYBUTYNIN CHLORIDE

AA PHARM ASSOC 5MG/5ML A075137 001 Dec 18, 1998 May CAHN
 >D> AA ! WOCKHARDT 5MG/5ML A074868 001 Feb 12, 1997 Dec CAHN
 >A> AA ! WOCKHARDT BIO AG 5MG/5ML A074868 001 Feb 12, 1997 Dec CAHN

TABLET;ORAL

OXYBUTYNIN CHLORIDE

>A> AB ABHAI LLC 5MG A209335 001 Dec 22, 2017 Dec NEWA
 >A> AB APPCO PHARMA LLC 5MG A209025 001 Dec 21, 2017 Dec NEWA
 AB NOVITIUM PHARMA 5MG A209823 001 Oct 23, 2017 Oct NEWA
 AB UPSHER-SMITH LABS 5MG A074625 001 Jul 31, 1996 Sep CAHN
 AB USL PHARMA 5MG A074625 001 Jul 31, 1996 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB UNIQUE PHARM LABS 5MG A206121 001 May 27, 2016 Aug CAHN
 AB 10MG A206121 002 May 27, 2016 Aug CAHN
 AB 15MG A206121 003 May 27, 2016 Aug CAHN
 AB ZYDUS PHARMS USA INC 5MG A202332 001 Jun 26, 2017 Jun NEWA
 AB 10MG A202332 002 Jun 26, 2017 Jun NEWA
 AB 15MG A202332 003 Jun 26, 2017 Jun NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA ABHAI LLC 5MG/5ML A208593 001 Jul 21, 2017 Jul NEWA
 AA 100MG/5ML A208593 002 Jul 21, 2017 Jul NEWA
 AA ANI PHARMS INC 100MG/5ML A203447 001 Aug 30, 2017 Aug NEWA
 AA ASCENT PHARMS INC 5MG/5ML A209021 001 Nov 09, 2017 Oct NEWA
 AA 100MG/5ML A209021 002 Nov 09, 2017 Oct NEWA
 AA HI-TECH PHARMACAL 5MG/5ML A208817 001 Aug 10, 2017 Jul NEWA
 AA 100MG/5ML A208795 001 Aug 07, 2017 Jul NEWA
 AA PHARM ASSOC 100MG/5ML A206822 001 Aug 15, 2017 Jul NEWA
 AA WES PHARMA INC 100MG/5ML A209897 001 Sep 06, 2017 Aug NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB ASCENT PHARMS INC 15MG A207418 001 Aug 07, 2017 Jul NEWA
 AB 30MG A207418 002 Aug 07, 2017 Jul NEWA
 AB EPIC PHARMA LLC 5MG A090895 001 Aug 24, 2009 May CAHN
 AB 15MG A090895 002 Aug 24, 2009 May CAHN
 AB 30MG A090895 003 Aug 24, 2009 May CAHN
 >D> AB MALLINCKRODT INC 5MG A076758 003 Mar 19, 2007 Dec CAHN
 >D> AB 15MG A076758 001 Jun 30, 2004 Dec CAHN
 >D> AB 30MG A076758 002 Jun 30, 2004 Dec CAHN
 AB NOVEL LABS INC 5MG A204021 001 Jun 12, 2017 May NEWA
 AB 10MG A204021 002 Jun 12, 2017 May NEWA
 AB 15MG A204021 003 Jun 12, 2017 May NEWA
 AB 20MG A204021 004 Jun 12, 2017 May NEWA
 AB 30MG A204021 005 Jun 12, 2017 May NEWA
 >A> AB SPECGX LLC 5MG A076758 003 Mar 19, 2007 Dec CAHN
 >A> AB 15MG A076758 001 Jun 30, 2004 Dec CAHN
 >A> AB 30MG A076758 002 Jun 30, 2004 Dec CAHN

ROXICODONE

>D> AB + MALLINCKRODT INC 5MG N021011 003 May 15, 2009 Dec CAHN
 >D> AB +! 15MG N021011 001 Aug 31, 2000 Dec CAHN
 >D> AB + 30MG N021011 002 Aug 31, 2000 Dec CAHN
 >A> AB + SPECGX LLC 5MG N021011 003 May 15, 2009 Dec CAHN
 >A> AB +! 15MG N021011 001 Aug 31, 2000 Dec CAHN
 >A> AB + 30MG N021011 002 Aug 31, 2000 Dec CAHN

ROXYBOND

DAIICHI SANKYO INC 5MG N209777 001 Apr 20, 2017 Aug CAHN
 15MG N209777 002 Apr 20, 2017 Aug CAHN
 30MG N209777 003 Apr 20, 2017 Aug CAHN
 INSPIRION DELIVERY 5MG N209777 001 Apr 20, 2017 Apr NEWA
 15MG N209777 002 Apr 20, 2017 Apr NEWA

TABLET;ORAL
ROXYBOND

30MG

N209777 003 Apr 20, 2017 Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL
RHOFADE

+! ALLERGAN INC 1%

N208552 001 Jan 18, 2017 Jan NEWA

OXYMETHOLONE

TABLET;ORAL
ANADROL-50

+! MYLAN SPECIALITY LP 50MG

N016848 001 Mar CAHN

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION
OPANA

+ @ ENDO PHARMS 1MG/ML

N011707 002 Aug DISC

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB EPIC PHARMA LLC 5MG
 AB 10MG
 >D> AB MALLINCKRODT INC 5MG
 >D> AB 10MG
 >A> AB SPECGX LLC 5MG
 >A> AB 10MG

A201187 001 Dec 15, 2014 May CAHN
 A201187 002 Dec 15, 2014 May CAHN
 A202321 001 Apr 25, 2013 Dec CAHN
 A202321 002 Apr 25, 2013 Dec CAHN
 A202321 001 Apr 25, 2013 Dec CAHN
 A202321 002 Apr 25, 2013 Dec CAHN

TABLET, EXTENDED RELEASE;ORAL
OPANA ER

+ @ ENDO PHARMS 5MG
 + @ 7.5MG
 + @ 10MG
 + @ 15MG
 + @ 20MG
 + @ 30MG
 + @ 40MG

N201655 001 Dec 09, 2011 Aug DISC
 N201655 002 Dec 09, 2011 Aug DISC
 N201655 003 Dec 09, 2011 Aug DISC
 N201655 004 Dec 09, 2011 Aug DISC
 N201655 005 Dec 09, 2011 Aug DISC
 N201655 006 Dec 09, 2011 Aug DISC
 N201655 007 Dec 09, 2011 Aug DISC

OXYMORPHONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 5MG
 AB 7.5MG
 AB 10MG
 AB 15MG
 AB 20MG
 AB 30MG
 AB 40MG
 >D> AB MALLINCKRODT INC 5MG
 >D> AB 7.5MG
 >D> AB 10MG
 >D> AB 15MG
 >D> AB 20MG
 >D> AB 30MG
 >D> AB 40MG
 @ PAR PHARM 5MG
 @ 7.5MG
 @ 10MG
 @ 15MG
 @ 20MG
 @ 30MG
 @ 40MG
 >A> AB SPECGX LLC 5MG
 >A> AB 7.5MG
 >A> AB 10MG
 >A> AB 15MG
 >A> AB 20MG
 >A> AB 30MG
 >A> AB 40MG

A079046 003 Jul 11, 2013 Apr CAHN
 A079046 001 Dec 13, 2010 Apr CAHN
 A079046 004 Jul 11, 2013 Apr CAHN
 A079046 002 Dec 13, 2010 Apr CAHN
 A079046 005 Jul 11, 2013 Apr CAHN
 A079046 006 Jul 11, 2013 Apr CAHN
 A079046 007 Jul 11, 2013 Apr CAHN
 A202946 001 Jun 27, 2014 Dec CAHN
 A202946 002 Jun 27, 2014 Dec CAHN
 A202946 003 Jun 27, 2014 Dec CAHN
 A202946 004 Jun 27, 2014 Dec CAHN
 A202946 005 Jun 27, 2014 Dec CAHN
 A202946 006 Jun 27, 2014 Dec CAHN
 A202946 007 Jun 27, 2014 Dec CAHN
 A200792 001 Oct 24, 2014 May DISC
 A200792 002 Oct 24, 2014 May DISC
 A200792 003 Oct 24, 2014 May DISC
 A200792 004 Oct 24, 2014 May DISC
 A200792 005 Oct 24, 2014 May DISC
 A200792 006 Oct 24, 2014 May DISC
 A200792 007 Oct 24, 2014 May DISC
 A202946 001 Jun 27, 2014 Dec CAHN
 A202946 002 Jun 27, 2014 Dec CAHN
 A202946 003 Jun 27, 2014 Dec CAHN
 A202946 004 Jun 27, 2014 Dec CAHN
 A202946 005 Jun 27, 2014 Dec CAHN
 A202946 006 Jun 27, 2014 Dec CAHN
 A202946 007 Jun 27, 2014 Dec CAHN

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE

! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM

A061015 001 Jul CAHN

>A>	<u>OZENOXACIN</u>								
>A>	CREAM;TOPICAL								
>A>	XEPTI								
>A>	+!	FERRER INTERNACIONAL	1%		N208945	001	Dec 11, 2017	Dec	NEWA
	<u>PALONOSETRON HYDROCHLORIDE</u>								
	SOLUTION;INTRAVENOUS								
	PALONOSETRON HYDROCHLORIDE								
	@	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)		N203050	001	Mar 01, 2016	Sep	DISC
	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		N203050	002	Mar 01, 2016	Sep	DISC
	+	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		N208109	001	Nov 21, 2017	Nov	NEWA
	<u>PAMIDRONATE DISODIUM</u>								
	INJECTABLE;INJECTION								
	PAMIDRONATE DISODIUM								
	AREVA PHARMS		60MG/VIAL		A077433	002	Nov 26, 2008	Nov	CTEC
	<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	PERTZYE								
	+	DIGESTIVE CARE INC	90,750USP UNITS;24,000USP UNITS;86,250USP UNITS		N022175	004	Jul 13, 2017	Sep	NEWA
	ZENPEP								
>D>	+	FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS		N022210	007	Mar 25, 2014	Dec	CPOT
>A>	+		168,000USP UNITS;40,000USP UNITS;126,000USP UNITS		N022210	007	Mar 25, 2014	Dec	CPOT
>D>	+		10,000USP UNITS;16,000USP UNITS;3,000USP UNITS		N022210	005	Jun 15, 2011	Dec	CPOT
>D>	+		10,000USP UNITS;34,000USP UNITS;55,000USP UNITS		N022210	002	Aug 27, 2009	Dec	CPOT
>A>	+		14,000USP UNITS;3,000USP UNITS;10,000USP UNITS		N022210	005	Jun 15, 2011	Dec	CPOT
>D>	+		15,000USP UNITS;51,000USP UNITS;82,000USP UNITS		N022210	003	Aug 27, 2009	Dec	CPOT
>D>	+		17,000USP UNITS;27,000USP UNITS;5,000USP UNITS		N022210	001	Aug 27, 2009	Dec	CPOT
>A>	+		24,000USP UNITS;5,000USP UNITS;17,000USP UNITS		N022210	001	Aug 27, 2009	Dec	CPOT
>A>	+		42,000USP UNITS;10,000USP UNITS;32,000USP UNITS		N022210	002	Aug 27, 2009	Dec	CPOT
>A>	+		63,000USP UNITS;15,000USP UNITS;47,000USP UNITS		N022210	003	Aug 27, 2009	Dec	CPOT
>A>	+		84,000USP UNITS;20,000USP UNITS;63,000USP UNITS		N022210	004	Aug 27, 2009	Dec	CPOT
>A>	+!		105,000USP UNITS;25,000USP UNITS;79,000USP UNITS		N022210	006	Jul 13, 2011	Dec	CPOT
>D>	+		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS		N022210	004	Aug 27, 2009	Dec	CPOT
>D>	+!		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS		N022210	006	Jul 13, 2011	Dec	CPOT
	<u>PANCURONIUM BROMIDE</u>								
	INJECTABLE;INJECTION								
	PANCURONIUM BROMIDE								
	!	TEVA PHARMS USA	2MG/ML		A072760	001	Jul 31, 1990	Nov	CTEC
	PAVULON								
>D>	@	ORGANON USA INC	1MG/ML		N017015	002		Dec	CRLD
>A>	+	@	1MG/ML		N017015	002		Dec	CRLD
>D>	@		2MG/ML		N017015	001		Dec	CRLD
>A>	+	@	2MG/ML		N017015	001		Dec	CRLD
	<u>PANTOPRAZOLE SODIUM</u>								
	POWDER;IV (INFUSION)								
	PANTOPRAZOLE SODIUM								
	EXELA PHARMA SCS LLC		EQ 40MG BASE/VIAL		N209463	001	Jun 30, 2017	Jun	NEWA
	TABLET, DELAYED RELEASE;ORAL								
	PANTOPRAZOLE SODIUM								
	@	SUN PHARM INDS LTD	EQ 20MG BASE		A077058	001	Sep 10, 2007	Sep	DISC
AB			EQ 20MG BASE		A077058	001	Sep 10, 2007	Mar	CAHN
	@		EQ 40MG BASE		A077058	002	Sep 10, 2007	Sep	DISC
AB			EQ 40MG BASE		A077058	002	Sep 10, 2007	Mar	CAHN

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May	CAHN
AB		2MCG	A204327	002	Jan 13, 2016	May	CAHN
AB		4MCG	A204327	003	Jan 13, 2016	May	CAHN

ZEMPLAR

AB	+ ABBVIE	1MCG	N021606	001	May 26, 2005	Oct	CRLD
AB	+	2MCG	N021606	002	May 26, 2005	Oct	CRLD
	+ @	4MCG	N021606	003	May 26, 2005	Oct	CRLD

SOLUTION; INTRAVENOUS

PARICALCITOL

AP	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Oct	NEWA
AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb	NEWA
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb	NEWA
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb	NEWA
AP	MYLAN LABS LTD	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Oct	NEWA
AP		0.005MG/ML (0.005MG/ML)	A203897	002	Nov 02, 2017	Oct	NEWA
AP		0.01MG/2ML (0.005MG/ML)	A203897	003	Nov 02, 2017	Oct	NEWA
AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr	CAHN
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr	CAHN
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr	CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Sep	CTEC
----	---------------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

@ MYLAN PHARMS INC

@

@

@

@ UPSHER-SMITH LABS

@

@

@

@

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan	NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan	NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan	NEWA

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

AB	+! SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun	CFTG
----	-----------------------	---------------	---------	-----	--------------	-----	------

PAROXETINE MESYLATE

AB	ACTAVIS LABS FL INC	EQ 7.5MG BASE	A207139	001	Jun 20, 2017	Jun	NEWA
AB	PRINSTON INC	EQ 7.5MG BASE	A207188	001	Aug 18, 2017	Aug	NEWA

PENCICLOVIR

CREAM; TOPICAL

DENA VIR

+!	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan	CAHN
----	------------------	----	---------	-----	--------------	-----	------

PENICILLAMINE

TABLET; ORAL

DEPEN

+!	MYLAN SPECIALITY LP	250MG	N019854	001		Mar	CAHN
----	---------------------	-------	---------	-----	--	-----	------

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

+!	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		May	CAHN
BC	+!	600,000 UNITS/ML	N050141	001		May	CAHN

PERMAPEN

BC	CASPER PHARMA LLC	600,000 UNITS/ML	A060014	001		Jul	CAHN
----	-------------------	------------------	---------	-----	--	-----	------

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+!	KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML	N050138	002			Apr	CAHN
+!		300,000 UNITS/ML; 300,000 UNITS/ML	N050138	001			Apr	CAHN
		BICILLIN C-R 900/300						
+!	KING PHARMS LLC	900,000 UNITS/2ML; 300,000 UNITS/2ML	N050138	003			Apr	CAHN

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002			Jun	CAHN
!		600,000 UNITS/ML	A060101	001			Jun	CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAM

AP	+!	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	Sep	CTEC
		PENTAMIDINE ISETHIONATE						
AP		SETON PHARMS	300MG/VIAL	A206666	001	Sep 28, 2017	Sep	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

AP		CUSTOPHARM INC	50MG/ML	A203619	001	Nov 13, 2017	Oct	NEWA
AP		RENAISSANCE SSA LLC	50MG/ML	A206677	001	Nov 27, 2017	Nov	NEWA
AP		SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

	@	PLIVA	400MG	A074874	001	May 25, 1999	Aug	CAHN
		PENTOXIL						
AB		UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999	Jun	CAHN
		TRENTAL						
	+	@ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CRLD

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

AB	!	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	May	CHRS
AB	!		4MG	A079070	002	Nov 10, 2009	May	CHRS
AB	!		8MG	A079070	003	Nov 10, 2009	May	CHRS

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+!	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan	CAHN
		PERMETHRIN						
AB		ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	May	CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB		MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017	Apr	NEWA
AB			4MG	A206691	002	Apr 14, 2017	Apr	NEWA
AB			8MG	A206691	003	Apr 14, 2017	Apr	NEWA
AB			16MG	A206691	004	Apr 14, 2017	Apr	NEWA

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

>A>	AA	ELITE LABS INC	35MG	A203600	001	Dec 27, 2017	Dec	NEWA
		@ USL PHARMA	35MG	A084399	001		Jun	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
 PHENOXYBENZAMINE HYDROCHLORIDE
 AB PAR PHARM INC 10MG A204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
 PHENTERMINE HYDROCHLORIDE
 @ ELITE LABS INC 30MG A040227 001 Jun 18, 1997 May CAHN
 @ 30MG A040448 001 Jan 22, 2003 May CAHN
 AA 37.5MG A040228 001 Jun 19, 1997 May CAHN
 @ UPSHER-SMITH LABS 30MG A084487 001 Apr 09, 1982 Jun CAHN
 @ 30MG A088430 001 Mar 27, 1984 Jun CAHN
 TABLET;ORAL
 LOMAIRA
 AA ! AVANTHI INC 8MG A203495 001 Sep 12, 2016 Nov CTEC
 PHENTERMINE HYDROCHLORIDE
 AA ELITE LABS INC 37.5MG A040190 001 May 30, 1997 May CAHN
 AA KVK TECH INC 8MG A203436 001 Mar 17, 2017 Mar NEWA
 AA PRINSTON INC 37.5MG A040377 001 Jan 04, 2002 Feb CAHN
 TABLET, ORALLY DISINTEGRATING;ORAL
 PHENTERMINE HYDROCHLORIDE
 ZYDUS PHARMS USA INC 15MG A204663 001 Jun 28, 2017 Jun NEWA
 30MG A204663 002 Jun 28, 2017 Jun NEWA
 37.5MG A204663 003 Jun 28, 2017 Jun NEWA

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION
 PHENTOLAMINE MESYLATE
 AP PRECISION DOSE INC 5MG/VIAL A207686 001 Jul 14, 2017 Jul NEWA
 AP ! WEST-WARD PHARMS INT 5MG/VIAL A040235 001 Mar 11, 1998 Jul CTEC
 ! 5MG/VIAL A040235 001 Mar 11, 1998 May CHRS
 REGITINE
 + @ NOVARTIS 5MG/VIAL N008278 003 May DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)
 VAZCULEP
 + AVADEL LEGACY 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Jan CAHN
 + 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Jan CAHN
 +! 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Jan CAHN

PHENYTOIN

SUSPENSION;ORAL
 PHENYTOIN
 >D> AB WOCKHARDT 125MG/5ML A040420 001 Apr 19, 2002 Dec CAHN
 >A> AB WOCKHARDT EU OPERATN 125MG/5ML A040420 001 Apr 19, 2002 Dec CAHN
 TABLET, CHEWABLE;ORAL
 DILANTIN
 AB ! PFIZER 50MG A084427 001 Feb CAHN
 PHENYTOIN
 AB EPIC PHARMA LLC 50MG A040884 001 Nov 28, 2014 May CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL
 DILANTIN
 ! PARKE-DAVIS 30MG EXTENDED A084349 001 Nov CTEC
 AB ! 30MG EXTENDED A084349 001 Feb CAHN
 AB ! 100MG EXTENDED A084349 002 Feb CAHN
 INJECTABLE;INJECTION
 PHENYTOIN SODIUM
 AP ACELLA PHARMS LLC 50MG/ML A040573 001 Sep 13, 2006 May CAHN

PHYTONADIONE

INJECTABLE;INJECTION
 AQUAMEPHYTON
 + @ TELIGENT 1MG/0.5ML N012223 002 Apr CAHN
 + @ 10MG/ML N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
ISOPTO CARPINE

AT	+	NOVARTIS PHARMS CORP	1%	N200890	001	Jun 22, 2010	Sep CFTG
AT	+		2%	N200890	002	Jun 22, 2010	Sep CFTG
AT	+		4%	N200890	003	Jun 22, 2010	Sep CFTG

PILOCARPINE HYDROCHLORIDE

AT		AKORN INC	1%	A204398	001	Sep 27, 2017	Sep NEWA
AT			2%	A204398	002	Sep 27, 2017	Sep NEWA
AT			4%	A204398	003	Sep 27, 2017	Sep NEWA

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Mar CAHN
AB		INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Sep CAHN
AB		PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CMFD
AB			10MG	A073609	001	Mar 29, 1993	May CMFD
AB		ZYDUS PHARMS USA INC	5MG	A209866	001	Aug 18, 2017	Aug NEWA
AB			10MG	A209866	002	Aug 18, 2017	Aug NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun CAHN
AB		PURACAP PHARM LLC	EQ 15MG BASE	A206738	001	Oct 06, 2017	Sep NEWA
AB			EQ 30MG BASE	A206738	002	Oct 06, 2017	Sep NEWA
AB			EQ 45MG BASE	A206738	003	Oct 06, 2017	Sep NEWA
AB		WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	May CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	May CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA
AP		WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar NEWA

PIRFENIDONE

TABLET;ORAL

ESBRIET

	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
	+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
	+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		HIKMA PHARMS	10MG	A209256	001	Aug 11, 2017	Jul NEWA
AB			20MG	A209256	002	Aug 11, 2017	Jul NEWA
>A>	AB	+	MICRO LABS	A206152	001	Dec 29, 2017	Dec NEWA
>A>	AB	+		A206152	002	Dec 29, 2017	Dec NEWA

CAPSULE;ORAL

PIROXICAM

	@ MYLAN	10MG	A074102	001	Jul 31, 1992	Jul	DISC
	@	20MG	A074102	002	Jul 31, 1992	Jul	DISC
AB	PII	10MG	A206136	001	Jun 20, 2017	Jun	NEWA
AB		20MG	A206136	002	Jun 20, 2017	Jun	NEWA
AB	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct	CMS1
AB		20MG	A073536	001	Mar 12, 1993	Oct	CMFD
AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr	NEWA
AB		20MG	A208340	002	Apr 13, 2017	Apr	NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul	NEWA
+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul	NEWA
+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul	NEWA

PITAVASTATIN SODIUM

TABLET;ORAL

NIKITA

+	@ LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep	DISC
+		EQ 1MG BASE	N209875	001	Aug 04, 2017	Aug	NEWA
+	@	EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep	DISC
+		EQ 2MG BASE	N209875	002	Aug 04, 2017	Aug	NEWA
+	@	EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep	DISC
+	!	EQ 4MG BASE	N209875	003	Aug 04, 2017	Aug	NEWA

PLECANATIDE

TABLET;ORAL

TRULANCE

+	!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan	NEWA
---	---	----------------	-----	---------	-----	--------------	-----	------

PODOFILOX

SOLUTION;TOPICAL

PODOFILOX

	@ BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	Aug	DISC
--	-----------------------	------	---------	-----	--------------	-----	------

POLIDOCANOL

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

VARITHENA

>A>	+	!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Dec	NEWA
-----	---	---	-----------	-------------------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Apr	DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015	Apr	CAHN
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE					
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Mar	CAHN
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Feb	NEWA
		TRILYTE					
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Mar	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar	CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar	CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar	CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar	CAHN
	COLYTE WITH FLAVOR PACKS						
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar	CAHN
	COLYTE-FLAVORED						
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar	CAHN
	PEG 3350 AND ELECTROLYTES						
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr	DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CAHN
----	------------	--------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun	CAHN
AB		10MEQ	A203106	002	Jul 10, 2015	Jun	CAHN
	MICRO-K						
AB	+ NESHER PHARMS	8MEQ	N018238	001		Nov	CRLD
	MICRO-K 10						
AB	+ NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Nov	CRLD
	POTASSIUM CHLORIDE						
AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar	NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar	NEWA

FOR SOLUTION;ORAL

KLOR-CON

AA	UPSHER-SMITH LABS	20MEQ	A209662	001	Oct 23, 2017	Oct	CAHN
AA		20MEQ	A209662	001	Oct 23, 2017	Oct	NEWA
	POTASSIUM CHLORIDE						
AA	+! PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Oct	CFTG
	INJECTABLE;INJECTION						
	POTASSIUM CHLORIDE						
	@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr	DISC
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER						
AP	+ ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
AP	+	745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
AP	+	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON

AB2	+ UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun	CAHN
AB2	+!	10MEQ	N019123	002	Apr 17, 1986	Jun	CAHN
	KLOR-CON M10						
AB1	UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

		KLOR-CON M15							
		UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun	CAHN	
		KLOR-CON M20							
AB1	!	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun	CAHN	

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb	CAHN	
		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb	CAHN	
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb	CAHN	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

>A>	AB	COREPHARMA	5MEQ	A077440	001	Jun 09, 2006	Dec	CAHN	
>A>	AB		10MEQ	A077440	002	Jun 09, 2006	Dec	CAHN	
>D>	AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Dec	CAHN	
	AB		5MEQ	A077440	001	Jun 09, 2006	Feb	CAHN	
>D>	AB		10MEQ	A077440	002	Jun 09, 2006	Dec	CAHN	
	AB		10MEQ	A077440	002	Jun 09, 2006	Feb	CAHN	
	AB	STRIDES PHARMA	5MEQ	A206813	001	Sep 11, 2017	Aug	NEWA	
	AB		10MEQ	A206813	002	Sep 11, 2017	Aug	NEWA	
	AB		15MEQ	A206813	003	Sep 11, 2017	Aug	NEWA	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

		@ ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan	DISC	
		@	0.25MG	A091254	002	Nov 30, 2010	Jan	DISC	
		@	0.5MG	A091254	003	Nov 30, 2010	Jan	DISC	
		@	0.75MG	A091254	004	Nov 30, 2010	Jan	DISC	
		@	1MG	A091254	005	Nov 30, 2010	Jan	DISC	
		@	1.5MG	A091254	006	Nov 30, 2010	Jan	DISC	
AB		ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May	CAHN	
AB			0.25MG	A078894	002	Oct 08, 2010	May	CAHN	
AB			0.5MG	A078894	003	Oct 08, 2010	May	CAHN	
AB			1MG	A078894	004	Oct 08, 2010	May	CAHN	
AB			1.5MG	A078894	005	Oct 08, 2010	May	CAHN	

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr	CAHN	
AB			3.75MG	A203615	002	Jan 03, 2017	Apr	CAHN	
AB		MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan	NEWA	
AB		ZYDUS PHARMS USA INC	0.375MG	A202891	001	Dec 12, 2017	Nov	NEWA	
AB			0.75MG	A202891	002	Dec 12, 2017	Nov	NEWA	
AB			1.5MG	A202891	003	Dec 12, 2017	Nov	NEWA	
AB			2.25MG	A202891	004	Dec 12, 2017	Nov	NEWA	
AB			3MG	A202891	005	Dec 12, 2017	Nov	NEWA	
AB			3.75MG	A202891	006	Dec 12, 2017	Nov	NEWA	
AB			4.5MG	A202891	007	Dec 12, 2017	Nov	NEWA	

PRASTERONE

INSERT;VAGINAL

INTRAROSA

	+	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May	CAHN	
--	---	-----------------	-------	---------	-----	--------------	-----	------	--

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

AB	+	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun	CFTG	
AB	+		EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun	CFTG	

PRASUGREL

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A205888	001	Oct 16, 2017	Oct	NEWA	
AB			EQ 10MG BASE	A205888	002	Oct 16, 2017	Oct	NEWA	
AB		LIBERTY PHARMA INC	EQ 5MG BASE	A205790	001	Oct 16, 2017	Oct	NEWA	
AB			EQ 10MG BASE	A205790	002	Oct 16, 2017	Oct	NEWA	
AB		MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun	NEWA	
AB			EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun	NEWA	

TABLET;ORAL

AB	PRASUGREL	PANACEA BIOTEC LTD	EQ 5MG BASE	A205897	001	Oct 16, 2017	Oct	NEWA
AB			EQ 10MG BASE	A205897	002	Oct 16, 2017	Oct	NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

AB	PRAVASTATIN SODIUM	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan	NEWA
AB			20MG	A203367	002	Feb 02, 2017	Jan	NEWA
AB			40MG	A203367	003	Feb 02, 2017	Jan	NEWA
AB			80MG	A203367	004	Feb 02, 2017	Jan	NEWA

PRAZIQUANTEL

TABLET;ORAL

AB	BILTRICIDE	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Nov	CFTG
AB		PAR PHARM INC	600MG	A208820	001	Nov 27, 2017	Nov	NEWA

PREDNISOLONE

SYRUP;ORAL

AA	PREDNISOLONE	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	May	CAHN
AA		VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar	CAHN
>D> AA		WOCKHARDT	15MG/5ML	A040313	001	Sep 10, 2003	Dec	CAHN
>A> AA		WOCKHARDT BIO AG	15MG/5ML	A040313	001	Sep 10, 2003	Dec	CAHN

TABLET;ORAL

	PREDNISOLONE	@ CHARTWELL RX	5MG	A084542	001		Apr	CAHN
--	--------------	----------------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

AA	PREDNISOLONE SODIUM PHOSPHATE	@ AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009	May	DISC
AA		CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004	Jun	CAHN
>D> AA		@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	May	CAHN
>A> AA		WOCKHARDT	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Dec	CAHN
		WOCKHARDT BIO AG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Dec	CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

AT	SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE	! BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CAHN
AT		SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb	CAHN

PREDNISONE

TABLET;ORAL

AB	PREDNISONE	@ CHARTWELL RX	5MG	A083059	001		Apr	CAHN
AB		MYLAN PHARMS INC	5MG	A080292	001		Jan	CAHN
AB			10MG	A088832	001	Dec 04, 1985	Jan	CAHN
AB			20MG	A083677	001		Jan	CAHN
AB		SUN PHARM INDUSTRIES	10MG	A089246	001	Dec 04, 1985	May	CAHN
		@ UPSHER SMITH	5MG	A087471	001		Jun	CAHN
		@	20MG	A087470	001		Jun	CAHN

TABLET, DELAYED RELEASE;ORAL

AB	PREDNISONE	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr	NEWA
AB			2MG	A204867	002	Apr 25, 2017	Apr	NEWA
AB			5MG	A204867	003	Apr 25, 2017	Apr	NEWA
AB		RAYOS						
AB		+ HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr	CFTG
AB		+	2MG	N202020	002	Jul 26, 2012	Apr	CFTG
AB		+!	5MG	N202020	003	Jul 26, 2012	Apr	CFTG

PREGABALIN

TABLET, EXTENDED RELEASE;ORAL

	LYRICA CR							
+		PFIZER INC	82.5MG	N209501	001	Oct 11, 2017	Oct	NEWA
+			165MG	N209501	002	Oct 11, 2017	Oct	NEWA
+			330MG	N209501	003	Oct 11, 2017	Oct	NEWA

PRIMIDONE

	TABLET;ORAL						
	PRIMIDONE						
AB	ANDA REPOSITORY	50MG	A 040626	001	Sep 29, 2005	Sep	CAHN
AB		250MG	A 040626	002	Sep 29, 2005	Sep	CAHN

PROBENECID

	TABLET;ORAL						
	BENEMID						
	+ @ MERCK	500MG	N 007898	004		Jan	CRLD
	PROBENECID						
AB	WATSON LABS TEVA	500MG	A 084442	004	Mar 29, 1983	May	CAHN

PROCAINAMIDE HYDROCHLORIDE

	CAPSULE;ORAL						
	PROCAINAMIDE HYDROCHLORIDE						
	@ IDT AUSTRALIA LTD	375MG	A 089219	002	Jul 01, 1986	Aug	CMS1
	@	500MG	A 089219	003	Jul 01, 1986	Aug	CMS1
	INJECTABLE;INJECTION						
	PROCAINAMIDE HYDROCHLORIDE						
AP	NEXUS PHARMS	100MG/ML	A 206332	001	Oct 13, 2017	Oct	NEWA
AP		500MG/ML	A 206332	002	Oct 13, 2017	Oct	NEWA
	@ WEST-WARD PHARMS INT	100MG/ML	A 089029	001	Apr 17, 1986	Jan	CAHN
	@	500MG/ML	A 089030	001	Apr 17, 1986	Mar	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	PROCAINAMIDE HYDROCHLORIDE						
	@ IDT AUSTRALIA LTD	500MG	A 089369	002	Jan 09, 1987	Oct	DISC
		500MG	A 089369	002	Jan 09, 1987	Aug	CMS1
	@	750MG	A 089369	003	Aug 14, 1987	Oct	DISC
		750MG	A 089369	003	Aug 14, 1987	Aug	CMS1

PROCARBAZINE HYDROCHLORIDE

	CAPSULE;ORAL						
	MATULANE						
	+! LEADIANT BIOSCI INC	EQ 50MG BASE	N 016785	001		Feb	CAHN

PROCHLORPERAZINE EDISYLATE

	INJECTABLE;INJECTION						
	PROCHLORPERAZINE EDISYLATE						
	@ ATHENEX INC	EQ 5MG BASE/ML	A 040540	001	May 28, 2004	Mar	CAHN
	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A 089523	001	May 03, 1988	Jan	CAHN
AP		EQ 5MG BASE/ML	A 089903	001	Aug 29, 1989	Jan	CAHN

PROCYCLIDINE HYDROCHLORIDE

	TABLET;ORAL						
	KEMADRIN						
	@ MONARCH PHARMS	2MG	N 009818	005		Apr	CAHN
	@	5MG	N 009818	003		Apr	CAHN

PROGESTERONE

	CAPSULE;ORAL						
	PROGESTERONE						
AB	AMNEAL PHARMS NY	100MG	A 207724	001	Sep 07, 2017	Aug	NEWA
AB		200MG	A 207724	002	Sep 07, 2017	Aug	NEWA
AB	DR REDDYS LABS INC	100MG	A 208801	001	Feb 28, 2017	Feb	NEWA
AB		200MG	A 208801	002	Feb 28, 2017	Feb	NEWA
AB	SANDOZ INC	100MG	A 205229	001	Oct 20, 2017	Oct	NEWA
AB		200MG	A 205229	002	Oct 20, 2017	Oct	NEWA
	INJECTABLE;INJECTION						
	PROGESTERONE						
AO	+! ACTAVIS LABS UT INC	50MG/ML	N 017362	002		Feb	CAHN

PROMETHAZINE HYDROCHLORIDE

	SUPPOSITORY;RECTAL							
	PHENERGAN							
	+ @ MYLAN PHARMS INC	50MG	N 011689	001		Jan	CAHN	
	SYRUP;ORAL							
	PROMETHAZINE PLAIN							
>D>	AA !	WOCKHARDT	6.25MG/5ML	A 087953	001	Nov 15, 1982	Dec	CAHN
>A>	AA !	WOCKHARDT BIO AG	6.25MG/5ML	A 087953	001	Nov 15, 1982	Dec	CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE							
	IMPAX LABS	12.5MG	A 040791	002	Feb 12, 2008	Aug	CMS1
		25MG	A 040791	003	Feb 12, 2008	Aug	CMS1
	@ MYLAN	12.5MG	A 091054	001	Aug 30, 2011	Nov	DISC
	@	25MG	A 091054	002	Aug 30, 2011	Nov	DISC
	@	50MG	A 091054	003	Aug 30, 2011	Nov	DISC
AB	PRINSTON INC	12.5MG	A 040622	001	Jul 18, 2006	Feb	CAHN
AB		25MG	A 040622	002	Jul 18, 2006	Feb	CAHN
AB		50MG	A 040622	003	Jul 18, 2006	Feb	CAHN
AB	STRIDES PHARMA	12.5MG	A 209177	001	Jun 30, 2017	Jun	NEWA
AB		25MG	A 209177	002	Jun 30, 2017	Jun	NEWA
AB		50MG	A 209177	003	Jun 30, 2017	Jun	NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
PROPAFENONE HYDROCHLORIDE							
AB	GLENMARK PHARMS LTD	225MG	A 205268	001	Sep 08, 2017	Aug	NEWA
AB		325MG	A 205268	002	Sep 08, 2017	Aug	NEWA
AB		425MG	A 205268	003	Sep 08, 2017	Aug	NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	150MG	A 202445	001	May 11, 2016	Nov	CAHN
AB		225MG	A 202445	002	May 11, 2016	Nov	CAHN
AB		300MG	A 202445	003	May 11, 2016	Nov	CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION							
LARGON							
	@ WEST-WARD PHARMS INT	20MG/ML	N 012382	002		Jan	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
INNOPRAN XL							
BX	ANI PHARMS INC	80MG	N 021438	001	Mar 12, 2003	Mar	CAHN
BX		120MG	N 021438	002	Mar 12, 2003	Mar	CAHN
PROPRANOLOL HYDROCHLORIDE							
BX	UPSHER SMITH	60MG	A 078311	001	Mar 06, 2009	Apr	CMFD
	@	60MG	A 078311	001	Mar 06, 2009	Feb	DISC
BX		80MG	A 078311	002	Mar 06, 2009	Apr	CMFD
	@	80MG	A 078311	002	Mar 06, 2009	Feb	DISC
BX		120MG	A 078311	003	Mar 06, 2009	Apr	CMFD
	@	120MG	A 078311	003	Mar 06, 2009	Feb	DISC
BX		160MG	A 078311	004	Mar 06, 2009	Apr	CMFD
	@	160MG	A 078311	004	Mar 06, 2009	Feb	DISC
	@ UPSHER-SMITH LABS	60MG	A 078311	001	Mar 06, 2009	Sep	DISC
BX		60MG	A 078311	001	Mar 06, 2009	Jun	CAHN
	@	80MG	A 078311	002	Mar 06, 2009	Sep	DISC
BX		80MG	A 078311	002	Mar 06, 2009	Jun	CAHN
	@	120MG	A 078311	003	Mar 06, 2009	Sep	DISC
BX		120MG	A 078311	003	Mar 06, 2009	Jun	CAHN
	@	160MG	A 078311	004	Mar 06, 2009	Sep	DISC
BX		160MG	A 078311	004	Mar 06, 2009	Jun	CAHN

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE							
AP	ATHENEX INC	1MG/ML	A 075792	001	Aug 29, 2000	Mar	CAHN
	@ SANDOZ INC	1MG/ML	A 076400	001	Feb 26, 2003	Mar	CAHN

TABLET;ORAL

INDERAL							
+ @	WYETH PHARMS INC	40MG	N 016418	002		Jan	CRLD
PROPRANOLOL HYDROCHLORIDE							
	@ ANDA REPOSITORY	10MG	A 070319	001	Oct 22, 1985	Sep	CAHN
	@	20MG	A 070320	001	Oct 22, 1985	Sep	CAHN
	@	40MG	A 070103	001	Oct 22, 1985	Sep	CAHN
	@	60MG	A 070321	001	Sep 24, 1986	Sep	CAHN
	@	80MG	A 070322	001	Aug 04, 1986	Sep	CAHN
>A>	AB VINTAGE PHARMS	10MG	A 070221	002	Aug 01, 1986	Dec	CMS1
>A>	AB	20MG	A 070221	003	Aug 01, 1986	Dec	CMS1
>A>	AB	40MG	A 070221	004	Aug 01, 1986	Dec	CMS1
>A>	AB	60MG	A 070221	005	Sep 24, 1986	Dec	CMS1
	@ WATSON LABS TEVA	10MG	A 070548	001	Jul 10, 1986	May	CAHN
	@	20MG	A 070549	001	Apr 11, 1986	May	CAHN

	TABLET;ORAL								
	PROPRANOLOL HYDROCHLORIDE								
	@	40MG			A 070550	001	Apr 11, 1986	May	CAHN
	<u>PROPYLTHIOURACIL</u>								
	TABLET;ORAL								
	PROPYLTHIOURACIL								
	@ CHARTWELL RX	50MG			A 084543	001		Apr	CAHN
	<u>PROTAMINE SULFATE</u>								
	INJECTABLE;INJECTION								
	PROTAMINE SULFATE								
	@ WEST-WARD PHARMS INT	10MG/ML			A 089474	001	Nov 05, 1986	Mar	CAHN
	@	10MG/ML			A 089475	001	Nov 05, 1986	Jan	CAHN
	<u>PYRIDOSTIGMINE BROMIDE</u>								
	INJECTABLE;INJECTION								
	REGONOL								
AP	SANDOZ INC	5MG/ML			N 017398	001		May	CAHN
	TABLET;ORAL								
	PYRIDOSTIGMINE BROMIDE								
	@ IMPAX LABS INC	60MG			A 040457	001	Dec 26, 2002	Feb	CAHN
	TABLET, EXTENDED RELEASE;ORAL								
	PYRIDOSTIGMINE BROMIDE								
AB	KINEDEXE UK	180MG			A 205464	001	Aug 15, 2017	Jul	NEWA
	<u>PYRIMETHAMINE</u>								
	TABLET;ORAL								
	DARAPRIM								
	+! TURING PHARMS LLC	25MG			N 008578	001		May	CAHN
	<u>QUETIAPINE FUMARATE</u>								
	TABLET;ORAL								
	QUETIAPINE FUMARATE								
	@ MYLAN PHARMS INC	EQ 25MG BASE			A 090323	001	Mar 27, 2012	May	DISC
	SEROQUEL								
AB	+! ASTRAZENECA PHARMS	EQ 25MG BASE			N 020639	001	Sep 26, 1997	Sep	CAHN
AB	+	EQ 50MG BASE			N 020639	007	Oct 04, 2005	Sep	CAHN
AB	+	EQ 100MG BASE			N 020639	002	Sep 26, 1997	Sep	CAHN
	+ @	EQ 150MG BASE			N 020639	004	Dec 20, 1998	Sep	CAHN
AB	+	EQ 200MG BASE			N 020639	003	Sep 26, 1997	Sep	CAHN
AB	+!	EQ 300MG BASE			N 020639	005	Jul 26, 2000	Sep	CAHN
AB	+	EQ 400MG BASE			N 020639	006	Oct 04, 2005	Sep	CAHN
	TABLET, EXTENDED RELEASE;ORAL								
	QUETIAPINE FUMARATE								
AB	ACCORD HLTHCARE	EQ 50MG BASE			A 206252	001	Nov 29, 2017	Nov	NEWA
AB		EQ 150MG BASE			A 090681	001	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE			A 090681	002	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE			A 090681	003	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE			A 090681	004	Nov 01, 2016	Mar	CAHN
AB	ANCHEN PHARMS	EQ 150MG BASE			A 090757	001	Dec 01, 2017	Nov	NEWA
AB		EQ 200MG BASE			A 090757	002	Dec 01, 2017	Nov	NEWA
AB		EQ 300MG BASE			A 090757	003	Dec 01, 2017	Nov	NEWA
AB		EQ 400MG BASE			A 090757	004	Dec 01, 2017	Nov	NEWA
AB	AUROBINDO PHARMA LTD	EQ 50MG BASE			A 207655	001	Nov 29, 2017	Nov	NEWA
AB		EQ 150MG BASE			A 207655	002	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE			A 207655	003	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE			A 207655	004	Nov 29, 2017	Nov	NEWA
AB		EQ 400MG BASE			A 207655	005	Nov 29, 2017	Nov	NEWA
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE			A 202939	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE			A 202939	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE			A 202939	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE			A 202939	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE			A 202939	005	May 09, 2017	Apr	NEWA
AB	LUPIN LTD	EQ 50MG BASE			A 204203	001	May 17, 2017	May	NEWA
AB		EQ 150MG BASE			A 204203	002	May 17, 2017	May	NEWA
AB		EQ 200MG BASE			A 204203	003	May 17, 2017	May	NEWA
AB		EQ 300MG BASE			A 204203	004	May 17, 2017	May	NEWA
AB		EQ 400MG BASE			A 204203	005	May 17, 2017	May	NEWA
AB	MACLEODS PHARMS LTD	EQ 150MG BASE			A 204253	001	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE			A 204253	002	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE			A 204253	003	Nov 29, 2017	Nov	NEWA

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB		EQ 400MG BASE	A204253	004	Nov 29, 2017	Nov	NEWA
AB	NOVAST LABS LTD	EQ 50MG BASE	A208947	001	Nov 29, 2017	Nov	NEWA
AB		EQ 150MG BASE	A208947	002	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE	A208947	003	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE	A208947	004	Nov 29, 2017	Nov	NEWA
AB		EQ 400MG BASE	A208947	005	Nov 29, 2017	Nov	NEWA
AB	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
AB	SCIEGEN PHARMS INC	EQ 150MG BASE	A209635	001	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE	A209635	002	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE	A209635	003	Nov 29, 2017	Nov	NEWA
AB		EQ 400MG BASE	A209635	004	Nov 29, 2017	Nov	NEWA
SEROQUEL XR							
AB	+ ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Sep	CAHN
AB	+	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Sep	CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Sep	CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Sep	CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Sep	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>A>	@ FOSUN PHARMA	EQ 5MG BASE	A076803	001	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Dec	CAHN
>D>	@ SANDOZ	EQ 5MG BASE	A076803	001	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Dec	CAHN
	@ SUN PHARM INDS LTD	EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep	DISC
	@	EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep	DISC
	@	EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep	DISC
	@	EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep	DISC

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+	@ LILLY	80MG/ML	N007529	002	Feb 10, 1989	Nov	DISC
---	---------	---------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+	AVADEL PHARMS	5MG	N204736	001	Mar 26, 2013	Aug	CAHN
+	!	10MG	N204736	002	Mar 26, 2013	Aug	CAHN

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May	NEWA
---	-------------------	---------------	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE;ORAL
ALTACE

AB	+	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul	CAHN
AB	+		2.5MG	N019901	002	Jan 28, 1991	Jul	CAHN
AB	+		5MG	N019901	003	Jan 28, 1991	Jul	CAHN
AB	+		10MG	N019901	004	Jan 28, 1991	Jul	CAHN
<u>RAMIPRIL</u>								
AB		ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN
AB			2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN
AB			5MG	A202392	003	Apr 15, 2014	Mar	CAHN
AB			10MG	A202392	004	Apr 15, 2014	Mar	CAHN
>A>	@	FOSUN PHARMA	1.25MG	A077514	001	Jun 18, 2008	Dec	CAHN
>A>	@		2.5MG	A077514	002	Jun 18, 2008	Dec	CAHN
>A>	@		5MG	A077514	003	Jun 18, 2008	Dec	CAHN
>A>	@		10MG	A077514	004	Jun 18, 2008	Dec	CAHN
>D>	@	SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Dec	CAHN
>D>	@		2.5MG	A077514	002	Jun 18, 2008	Dec	CAHN
>D>	@		5MG	A077514	003	Jun 18, 2008	Dec	CAHN
>D>	@		10MG	A077514	004	Jun 18, 2008	Dec	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
ZANTAC

AP	+	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN
AP	+	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
<u>ZANTAC IN PLASTIC CONTAINER</u>								
		@ TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May	CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May	CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan	CAHN
AA		PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May	CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		ACIC PHARMS	EQ 150MG BASE	A203694	001	Nov 30, 2017	Nov	NEWA
AB			EQ 300MG BASE	A203694	002	Nov 30, 2017	Nov	NEWA
AB		GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May	CAHN
AB			EQ 300MG BASE	A078542	002	Nov 19, 2008	May	CAHN
>D>	AB	WOCKHARDT	EQ 150MG BASE	A075208	001	Dec 17, 1998	Dec	CAHN
>D>	AB		EQ 300MG BASE	A075208	002	Dec 17, 1998	Dec	CAHN
>A>	AB	WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998	Dec	CAHN
>A>	AB		EQ 300MG BASE	A075208	002	Dec 17, 1998	Dec	CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC	
+		1GM	N021526	001	Feb 12, 2007	Feb	CTEC	
<u>RANOLAZINE</u>								
	@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	DISC
	@		1GM	A201046	002	Jul 29, 2013	Feb	DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	EQ 0.5MG BASE	A201889	001	Oct 30, 2017	Oct	NEWA
AB			EQ 1MG BASE	A201889	002	Oct 30, 2017	Oct	NEWA
AB		MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jul	CMFD
	@		EQ 0.5MG BASE	A201971	001	May 15, 2017	Jun	DISC
AB			EQ 0.5MG BASE	A201971	001	May 15, 2017	May	NEWA
AB			EQ 1MG BASE	A201971	002	May 15, 2017	Jul	CMFD
	@		EQ 1MG BASE	A201971	002	May 15, 2017	Jun	DISC
AB			EQ 1MG BASE	A201971	002	May 15, 2017	May	NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb	CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb	CAHN
AB	+		2MG	N020741	003	Dec 22, 1997	Feb	CAHN

TABLET;ORAL
REPAGLINIDE

AB	BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Jun	CAHN
AB		1MG	A091517	002	Apr 24, 2015	Jun	CAHN
AB		2MG	A091517	003	Apr 24, 2015	Jun	CAHN

RESERPINE

TABLET;ORAL
RESERPINE

	+ @ SANDOZ	0.1MG	N009838	001		Apr	DISC
	+ @	0.25MG	N009838	002		Apr	DISC

RIBAVIRIN

CAPSULE;ORAL
RIBASPHERE

AB	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL
RIBAVIRIN

AB	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan	CAHN
AB		400MG	A077456	002	Dec 05, 2005	Jan	CAHN
AB	!	600MG	A077456	003	Dec 05, 2005	Jan	CAHN

RIBOCICLIB SUCCINATE

TABLET;ORAL
KISQALI

	+! NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar	NEWA
--	-------------------------	---------------	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

AP	WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	CAHN
AP	WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan	CAHN

RILUZOLE

TABLET;ORAL
RILUTEK

AB	+! COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995	Aug	CAHN
----	--------------------	------	---------	-----	--------------	-----	------

RILUZOLE

AB	GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May	CAHN
----	---------------------	------	---------	-----	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL
FLUMADINE

AB	+! SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993	Oct	CAHN
	RIMANTADINE HYDROCHLORIDE						
	@ IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb	CAHN

RISPERIDONE

TABLET;ORAL
RISPERIDONE

	@ JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr	CAHN
	@	0.5MG	A078828	002	Mar 23, 2009	Apr	CAHN
	@	1MG	A078828	003	Mar 23, 2009	Apr	CAHN
	@	2MG	A078828	004	Mar 23, 2009	Apr	CAHN
	@	3MG	A078828	005	Mar 23, 2009	Apr	CAHN
	@	4MG	A078828	006	Mar 23, 2009	Apr	CAHN
AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

>D>	AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Dec	DISC
>A>		@	0.25MG	A091537	006	Feb 12, 2013	Dec	DISC
>D>	AB		0.5MG	A091537	001	Mar 30, 2011	Dec	DISC
>A>		@	0.5MG	A091537	001	Mar 30, 2011	Dec	DISC
>D>	AB		1MG	A091537	002	Mar 30, 2011	Dec	DISC
>A>		@	1MG	A091537	002	Mar 30, 2011	Dec	DISC
>D>	AB		2MG	A091537	003	Mar 30, 2011	Dec	DISC
>A>		@	2MG	A091537	003	Mar 30, 2011	Dec	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

>D>	AB		3MG	A091537	004	Mar 30, 2011	Dec	DISC
>A>	@		3MG	A091537	004	Mar 30, 2011	Dec	DISC
>D>	AB		4MG	A091537	005	Mar 30, 2011	Dec	DISC
>A>	@		4MG	A091537	005	Mar 30, 2011	Dec	DISC
>D>	AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Dec	CTEC
>A>			0.25MG	A077494	001	Apr 30, 2009	Dec	CTEC

RITONAVIR

POWDER;ORAL
NORVIR

+!	ABBVIE INC		100MG/PACKET	N209512	001	Jun 07, 2017	Jun	NEWA
----	------------	--	--------------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	AJANTA PHARMA LTD	EQ	1.5MG BASE	A207797	001	Sep 28, 2017	Sep	NEWA
AB		EQ	3MG BASE	A207797	002	Sep 28, 2017	Sep	NEWA
AB		EQ	4.5MG BASE	A207797	003	Sep 28, 2017	Sep	NEWA
AB		EQ	6MG BASE	A207797	004	Sep 28, 2017	Sep	NEWA
AB	CADILA PHARMS LTD	EQ	1.5MG BASE	A203844	001	Feb 13, 2017	Jan	NEWA
AB		EQ	3MG BASE	A203844	002	Feb 13, 2017	Jan	NEWA
AB		EQ	4.5MG BASE	A203844	003	Feb 13, 2017	Jan	NEWA
AB		EQ	6MG BASE	A203844	004	Feb 13, 2017	Jan	NEWA
AB	SUN PHARM INDS LTD	EQ	1.5MG BASE	A077131	001	Oct 22, 2007	Mar	CAHN
AB		EQ	3MG BASE	A077131	002	Oct 22, 2007	Mar	CAHN
AB		EQ	4.5MG BASE	A077131	003	Oct 22, 2007	Mar	CAHN
AB		EQ	6MG BASE	A077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	ECI PHARMS LLC	EQ	5MG BASE	A202047	001	Dec 31, 2012	Mar	CAHN
AB		EQ	10MG BASE	A202047	002	Dec 31, 2012	Mar	CAHN
AB	UNICHEM LABS LTD	EQ	5MG BASE	A207836	001	Mar 07, 2017	Feb	NEWA
AB		EQ	10MG BASE	A207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	GLENMARK PHARMS LTD	EQ	5MG BASE	A201914	001	Jul 01, 2013	May	CAHN
AB		EQ	10MG BASE	A201914	002	Jul 01, 2013	May	CAHN
AB	PANACEA BIOTEC LTD	EQ	5MG BASE	A204722	001	Jan 11, 2017	Jan	NEWA
AB		EQ	10MG BASE	A204722	002	Jan 11, 2017	Jan	NEWA
AB	UNICHEM LABS LTD	EQ	5MG BASE	A207835	001	Mar 07, 2017	Feb	NEWA
AB		EQ	10MG BASE	A207835	002	Mar 07, 2017	Feb	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar	NEWA
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
AP	!	100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb	NEWA
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb	NEWA

ROLAPITANT HYDROCHLORIDE

EMULSION;IV (INFUSION)
VARUBI

+!	TESARO INC	EQ	166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Oct	NEWA
----	------------	----	--	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ	0.25MG BASE	A204022	001	Feb 28, 2017	Apr	CAHN
AB		EQ	0.5MG BASE	A204022	002	Feb 28, 2017	Apr	CAHN
AB		EQ	1MG BASE	A204022	003	Feb 28, 2017	Apr	CAHN
AB		EQ	2MG BASE	A204022	004	Feb 28, 2017	Apr	CAHN
AB		EQ	3MG BASE	A204022	005	Feb 28, 2017	Apr	CAHN
AB		EQ	4MG BASE	A204022	006	Feb 28, 2017	Apr	CAHN
AB		EQ	5MG BASE	A204022	007	Feb 28, 2017	Apr	CAHN
AB	ACCORD HLTHCARE INC	EQ	0.25MG BASE	A204022	001	Feb 28, 2017	Feb	NEWA

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb	NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb	NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb	NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb	NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb	NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb	NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May	CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May	CAHN
	@	EQ 1MG BASE	A078230	003	May 20, 2008	May	CAHN
	@	EQ 2MG BASE	A078230	004	May 20, 2008	May	CAHN
	@	EQ 3MG BASE	A078230	005	May 20, 2008	May	CAHN
	@	EQ 4MG BASE	A078230	006	May 20, 2008	May	CAHN
	@	EQ 5MG BASE	A078230	007	May 20, 2008	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May	CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May	CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May	CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May	CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May	CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun	CDFR
----	-----------	---------------------	---------	-----	--------------	-----	------

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar	CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar	CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar	CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar	CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar	NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar	NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar	NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar	NEWA
AB	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Jul	NEWA
AB		10MG	A205587	002	Jul 31, 2017	Jul	NEWA
AB		20MG	A205587	003	Jul 31, 2017	Jul	NEWA
AB		40MG	A205587	004	Jul 31, 2017	Jul	NEWA
AB	MSN LABS PVT LTD	5MG	A208898	001	Nov 22, 2017	Nov	NEWA
AB		10MG	A208898	002	Nov 22, 2017	Nov	NEWA
AB		20MG	A208898	003	Nov 22, 2017	Nov	NEWA
AB		40MG	A208898	004	Nov 22, 2017	Nov	NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr	CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr	CAHN
AB		20MG	A201619	003	Oct 31, 2016	Apr	CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr	CAHN

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May	NEWA
---	---------------------	---------------	---------	-----	--------------	-----	------

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar	NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar	NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr	CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr	CAHN

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

+	!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017	Oct	CAHN
+	!	SYMBIOMIX THERAP	2GM/PACKET	N209363	001	Sep 15, 2017	Sep	NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May	CAHN
	@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan	CAHN
	@	5MG	A074641	001	Aug 02, 1996	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

>D>	AT	WOCKHARDT	2.5%	A088228	001	Sep 01, 1983	Dec	CAHN
>A>	AT	WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Dec	CAHN

>A> SEMAGLUTIDE

>A> SOLUTION;SUBCUTANEOUS

>A> OZEMPIC

>A>	+	NOVO NORDISK INC	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Dec	NEWA
-----	---	------------------	-----------------------	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

	@ ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN
--	---------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@ ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun	CAHN
	@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun	CAHN
	@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun	CAHN
	@ ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
	@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
	@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
	@ ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007	Sep	CAHN
	@	EQ 50MG BASE	A077818	002	Feb 06, 2007	Sep	CAHN
	@	EQ 100MG BASE	A077818	003	Feb 06, 2007	Sep	CAHN
>D>	@ DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Dec	CAHN
>D>	@	EQ 50MG BASE	A076442	002	Apr 30, 2007	Dec	CAHN
>D>	@	EQ 100MG BASE	A076442	003	Apr 30, 2007	Dec	CAHN
	@ MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
	@	EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
	@	EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
>A>	@ SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Dec	CAHN
>A>	@	EQ 50MG BASE	A076442	002	Apr 30, 2007	Dec	CAHN
>A>	@	EQ 100MG BASE	A076442	003	Apr 30, 2007	Dec	CAHN
	@ SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007	Oct	DISC
	@	EQ 50MG BASE	A078108	002	Feb 06, 2007	Oct	DISC
	@	EQ 100MG BASE	A078108	003	Feb 06, 2007	Oct	DISC
	@ WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May	CAHN
	@	EQ 50MG BASE	A077663	002	Feb 06, 2007	May	CAHN
	@	EQ 100MG BASE	A077663	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May	CFTG
AB	+		2.4GM/PACKET	N022318	002	Feb 18, 2009	May	CFTG

SEVELAMER CARBONATE

AB	AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May	NEWA
AB		2.4GM/PACKET	A207624	002	Jun 13, 2017	May	NEWA

TABLET;ORAL

RENVELA

AB	+	GENZYME	800MG	N022127	001	Oct 19, 2007	Jul	CFTG
----	---	---------	-------	---------	-----	--------------	-----	------

SEVELAMER CARBONATE

AB	AMNEAL PHARMS CO	800MG	A207288	001	Nov 28, 2017	Nov	NEWA
AB	AUROBINDO PHARMA LTD	800MG	A207179	001	Jul 17, 2017	Jul	NEWA
AB	DR REDDYS LABS LTD	800MG	A206094	001	Sep 29, 2017	Sep	NEWA
AB	IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Oct	NEWA
AB	INVAGEN PHARMS	800MG	A203860	001	Oct 26, 2017	Oct	NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	TEVA	EQ 25MG BASE	A 077342	001	Mar 09, 2016	Nov	CMFD
AB		EQ 50MG BASE	A 077342	002	Mar 09, 2016	Nov	CMFD
AB		EQ 100MG BASE	A 077342	003	Mar 09, 2016	Nov	CMFD
VIAGRA							
AB	+ PFIZER INC	EQ 25MG BASE	N 020895	001	Mar 27, 1998	Nov	CTEC
	+	EQ 25MG BASE	N 020895	001	Mar 27, 1998	May	CAHN
AB	+	EQ 50MG BASE	N 020895	002	Mar 27, 1998	Nov	CTEC
	+	EQ 50MG BASE	N 020895	002	Mar 27, 1998	May	CAHN
AB	+!	EQ 100MG BASE	N 020895	003	Mar 27, 1998	Nov	CTEC
	+!	EQ 100MG BASE	N 020895	003	Mar 27, 1998	May	CAHN

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	+! ALLERGAN SALES LLC	4MG	N 022206	001	Oct 08, 2008	Mar	CFTG
AB	+	8MG	N 022206	002	Oct 08, 2008	Mar	CFTG
SILODOSIN							
AB	SANDOZ INC	4MG	A 204726	001	Mar 31, 2017	Mar	NEWA
AB		8MG	A 204726	002	Mar 31, 2017	Mar	NEWA

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	+! KING PHARMS LLC	1%	N 017381	001		Aug	CAHN
----	--------------------	----	----------	-----	--	-----	------

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+ TCG FLUENT PHARMA

+! 40MG/5ML

N 206679	001	Apr 21, 2016	Oct	CTNA
N 206679	002	Apr 21, 2016	Oct	CTNA

TABLET;ORAL

SIMVASTATIN

>A>	@ FOSUN PHARMA	5MG	A 077766	001	Dec 20, 2006	Dec	CAHN
>A>	@	10MG	A 077766	002	Dec 20, 2006	Dec	CAHN
>A>	@	20MG	A 077766	003	Dec 20, 2006	Dec	CAHN
>A>	@	40MG	A 077766	004	Dec 20, 2006	Dec	CAHN
>A>	@	80MG	A 077766	005	Dec 20, 2006	Dec	CAHN
AB	HISUN PHARM HANGZHOU	10MG	A 206557	001	Nov 13, 2017	Oct	NEWA
AB		20MG	A 206557	002	Nov 13, 2017	Oct	NEWA
AB		40MG	A 206557	003	Nov 13, 2017	Oct	NEWA
AB		80MG	A 206557	004	Nov 13, 2017	Oct	NEWA
	@ MYLAN PHARMS INC	5MG	A 090868	001	Jun 08, 2010	May	DISC
	@	10MG	A 090868	002	Jun 08, 2010	May	DISC
	@	20MG	A 090868	003	Jun 08, 2010	May	DISC
	@	40MG	A 090868	004	Jun 08, 2010	May	DISC
	@	80MG	A 090868	005	Jun 08, 2010	May	DISC
>D>	@ SANDOZ INC	5MG	A 077766	001	Dec 20, 2006	Dec	CAHN
>D>	@	10MG	A 077766	002	Dec 20, 2006	Dec	CAHN
>D>	@	20MG	A 077766	003	Dec 20, 2006	Dec	CAHN
>D>	@	40MG	A 077766	004	Dec 20, 2006	Dec	CAHN
>D>	@	80MG	A 077766	005	Dec 20, 2006	Dec	CAHN
AB	VIVA HLTHCARE	5MG	A 090383	001	Sep 16, 2011	Sep	CAHN
AB		10MG	A 090383	002	Sep 16, 2011	Sep	CAHN
AB		20MG	A 090383	003	Sep 16, 2011	Sep	CAHN
AB		40MG	A 090383	004	Sep 16, 2011	Sep	CAHN
AB		80MG	A 090383	005	Sep 16, 2011	Sep	CAHN
AB	WATSON LABS TEVA	5MG	A 076685	001	Dec 20, 2006	May	CAHN
AB		10MG	A 076685	002	Dec 20, 2006	May	CAHN
AB		20MG	A 076685	003	Dec 20, 2006	May	CAHN
AB		40MG	A 076685	004	Dec 20, 2006	May	CAHN
AB		80MG	A 076685	005	Dec 20, 2006	May	CAHN
ZOCOR							
AB	+ MSD MERCK CO	5MG	N 019766	001	Dec 23, 1991	Oct	CAHN
AB	+	10MG	N 019766	002	Dec 23, 1991	Oct	CAHN
AB	+	20MG	N 019766	003	Dec 23, 1991	Oct	CAHN
AB	+	40MG	N 019766	004	Dec 23, 1991	Oct	CAHN
AB	+!	80MG	N 019766	005	Jul 10, 1998	Oct	CAHN

SODIUM ACETATE

INJECTABLE; INJECTION
SODIUM ACETATE

	FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Oct	NEWA
+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Nov	CTNA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CAHN
----	------------------	-----------------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATE

INJECTABLE; INJECTION
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb	CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb	NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202432	001	Sep 26, 2017	Sep	NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb	NEWA
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Sep	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+!	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb	CAHN
			SODIUM CHLORIDE 0.9%					
AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jul	NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan	CAHN
			SODIUM CHLORIDE 0.9%					
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan	CAHN
			SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		FRESENIUS KABI USA	900MG/100ML	A207310	001	Sep 19, 2017	Sep	NEWA
AP	+!	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb	CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May	NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr	CAHN
			SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
	+ @	ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan	CRLD
			SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
AP		B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988	Jul	CMFD
AP	+!	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Jul	CTEC
			SODIUM CHLORIDE 5% IN PLASTIC CONTAINER					
AP		B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988	Jul	CMFD
AP	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983	Jul	CTEC
			SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD
			SOLUTION; IRRIGATION					
			SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT		ICU MEDICAL INC	900MG/100ML	N017514	001		Feb	CAHN
AT			900MG/100ML	N018314	001		Feb	CAHN

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP		JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015	Sep	CAHN
>D>	AP	UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015	Dec	DISC
>A>		@	10-200mCi/ML	A204462	001	Nov 17, 2015	Dec	DISC

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP		AKORN	25MG/ML	A208635	001	May 04, 2017	Apr	NEWA
AP		AMNEAL PHARMS CO	25MG/ML	A209493	001	Nov 07, 2017	Oct	NEWA
>A>	AP	AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017	Dec	NEWA
AP		MICRO LABS	25MG/ML	A209352	001	Dec 08, 2017	Nov	NEWA
AP		NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May	NEWA
			SOLUTION; IV (INFUSION)					
			NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
>A>	+!	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Dec	NEWA
	+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar	NEWA

SODIUM OXYBATE

SOLUTION;ORAL
SODIUM OXYBATE
AA WEST-WARD PHARMS INT 500MG/ML A202090 001 Jan 17, 2017 Jan NEWA

SODIUM PHENYL BUTYRATE

TABLET;ORAL
SODIUM PHENYL BUTYRATE
AB ALVOGEN MALTA 500MG A090910 001 Nov 18, 2011 Apr CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL
KALEXATE
AA ! KVK TECH 454GM/BOT A040905 001 Mar 30, 2009 Sep CHRS
KAYEXALATE
+ @ CONCORDIA PHARMS INC 453.6GM/BOT N011287 001 Sep DISC
SODIUM POLYSTYRENE SULFONATE
AA AILEX PHARMS LLC 454GM/BOT A206815 001 Feb 18, 2016 Sep CAHN
AA CMP PHARMA INC 454GM/BOT A089910 001 Jan 19, 1989 Apr CAHN
AA ECI PHARMS LLC 453.6GM/BOT A090313 001 Dec 21, 2011 Mar CAHN
SUSPENSION;ORAL, RECTAL
SPS
AA ! CMP PHARMA INC 15GM/60ML A087859 001 Dec 08, 1982 Apr CAHN

SOFOBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL
VOSEVI
+! GILEAD SCIENCES INC 400MG;100MG;100MG N209195 001 Jul 18, 2017 Jul NEWA

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION
SEROSTIM
EMD SERONO 4MG/VIAL N020604 003 Jul 25, 1997 Nov CTEC
VALTROPIN
BX LG CHEM LTD 5MG/VIAL N021905 001 Apr 19, 2007 Jun CAHN
ZOMACTON
+ FERRING 10MG/VIAL N019774 003 Mar 07, 2012 Nov CTEC

SONIDEGIB PHOSPHATE

CAPSULE;ORAL
ODOMZO
+! SUN PHARM INDS INC EQ 200MG BASE N205266 001 Jul 24, 2015 Mar CAHN
+! SUN PHARMA GLOBAL EQ 200MG BASE N205266 001 Jul 24, 2015 May CAHN

SOTALOL HYDROCHLORIDE

TABLET;ORAL
BETAPACE
AB1 + COVIS PHARMA BV 80MG N019865 001 Oct 30, 1992 May CAHN
AB1 + 120MG N019865 005 Apr 20, 1994 May CAHN
AB1 +! 160MG N019865 002 Oct 30, 1992 May CAHN
AB1 + 240MG N019865 003 Oct 30, 1992 May CAHN
320MG N019865 004 Oct 30, 1992 May CAHN
BETAPACE AF
@ COVIS PHARMA BV 40MG N021151 006 Apr 02, 2003 May CAHN
60MG N021151 007 Apr 02, 2003 May CAHN
AB2 + 80MG N021151 001 Feb 22, 2000 May CAHN
100MG N021151 005 Mar 14, 2003 May CAHN
AB2 + 120MG N021151 002 Feb 22, 2000 May CAHN
AB2 +! 160MG N021151 003 Feb 22, 2000 May CAHN
SORINE
AB1 UPSHER-SMITH LABS 80MG A075500 001 Apr 27, 2001 Jun CAHN
AB1 120MG A075500 004 Apr 27, 2001 Jun CAHN
AB1 160MG A075500 002 Apr 27, 2001 Jun CAHN
AB1 240MG A075500 003 Apr 27, 2001 Jun CAHN
SOTALOL HYDROCHLORIDE
@ MYLAN 80MG A075237 001 May 01, 2000 Jun DISC
80MG A075725 001 Dec 19, 2000 Jun DISC
120MG A075237 002 May 01, 2000 Jun DISC
120MG A075725 002 Dec 19, 2000 Jun DISC
160MG A075237 003 May 01, 2000 Jun DISC
160MG A075725 003 Dec 19, 2000 Jun DISC

<u>TABLET;ORAL</u>						
SOTALOL HYDROCHLORIDE						
	@	240MG	A075237	004	May 01, 2000	Jun DISC
	@	240MG	A075725	004	Dec 19, 2000	Jun DISC
AB1	UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Jun CAHN
AB1		120MG	A075366	002	May 01, 2000	Jun CAHN
AB1		160MG	A075366	003	May 01, 2000	Jun CAHN
AB1		240MG	A075366	004	May 01, 2000	Jun CAHN
<u>SOYBEAN OIL</u>						
INJECTABLE; INJECTION						
INTRALIPID 30%						
+!	FRESENIUS	30%	N019942	001	Dec 30, 1993	Sep CTEC
<u>SPIRONOLACTONE</u>						
SUSPENSION; ORAL						
CAROSPIR						
+!	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017	Sep CAHN
+!	CMP PHARMA INC	25MG/5ML	N209478	001	Aug 04, 2017	Aug NEWA
TABLET; ORAL						
SPIRONOLACTONE						
AB	ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar CAHN
AB		50MG	A203512	002	Sep 19, 2016	Mar CAHN
AB		100MG	A203512	003	Sep 19, 2016	Mar CAHN
AB	AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010	May CAHN
AB		25MG	A091426	001	Jul 02, 2010	May CMS1
AB		50MG	A091426	002	Jul 02, 2010	May CAHN
AB		50MG	A091426	002	Jul 02, 2010	May CMS1
AB		100MG	A091426	003	Jul 02, 2010	May CAHN
AB		100MG	A091426	003	Jul 02, 2010	May CMS1
AB	AUROBINDO PHARMA LTD	25MG	A202187	001	Mar 06, 2014	Nov CAHN
AB		50MG	A202187	002	Mar 06, 2014	Nov CAHN
AB		100MG	A202187	003	Mar 06, 2014	Nov CAHN
	@ UPSHER SMITH	25MG	A087554	001		Jun CAHN
<u>STAVUDINE</u>						
CAPSULE; ORAL						
STAVUDINE						
	@ MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May DISC
AB		30MG	A078775	001	Jan 05, 2009	Mar CAHN
	@	40MG	A078775	002	Jan 05, 2009	May DISC
AB		40MG	A078775	002	Jan 05, 2009	Mar CAHN
FOR SOLUTION; ORAL						
STAVUDINE						
	@ AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008	Jul DISC
<u>STERILE WATER FOR INJECTION</u>						
LIQUID; N/A						
STERILE WATER FOR INJECTION						
AP	FRESENIUS KABI USA	100%	A209689	001	Nov 24, 2017	Nov NEWA
AP	WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	100%	N018233	001		Feb CAHN
AP	+!	100%	N019869	001	Dec 26, 1989	Apr CAHN
AP	TARO	100%	A077393	001	Aug 11, 2006	Apr CAHN
<u>STERILE WATER FOR IRRIGATION</u>						
LIQUID; IRRIGATION						
STERILE WATER IN PLASTIC CONTAINER						
AT	ICU MEDICAL INC	100%	N017513	001		Feb CAHN
AT		100%	N018313	001		Feb CAHN
<u>SUCCINYLCHOLINE CHLORIDE</u>						
INJECTABLE; INJECTION						
ANECTINE						
AP	+! SANDOZ INC	20MG/ML	N008453	002		May CAHN
	@	50MG/ML	N008453	003		May CAHN
	@	500MG/VIAL	N008453	001		May CAHN
	@	1GM/VIAL	N008453	004		May CAHN

SULCONAZOLE NITRATE

CREAM; TOPICAL
EXELDERM

+! SUN PHARM INDS INC 1% N018737 001 Feb 28, 1989 Aug CAHN

SOLUTION; TOPICAL
EXELDERM

+! SUN PHARM INDS INC 1% N018738 001 Aug 30, 1985 Aug CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT SANDOZ INC 10% A089560 001 Oct 18, 1988 Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
BACTRIM

+ @ MUTUAL PHARM 80MG/ML; 16MG/ML N018374 001 Sep CRLD

+ @ SUN PHARM INDS INC 80MG/ML; 16MG/ML N018374 001 Oct CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP MYLAN LABS LTD 80MG/ML; 16MG/ML A206607 001 Aug 30, 2017 Aug NEWA

AP ! TEVA PHARMS USA 80MG/ML; 16MG/ML A073303 001 Oct 31, 1991 Aug CTEC

TABLET; ORAL

SEPTRA

AB MONARCH PHARMS 400MG; 80MG N017376 001 May CAHN

SEPTRA DS

AB MONARCH PHARMS 800MG; 160MG N017376 002 May CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB CHARTWELL MOLECULES 400MG; 80MG A078060 002 Jan 25, 2007 Mar CAHN

AB 800MG; 160MG A078060 001 Jan 25, 2007 Mar CAHN

AB CHARTWELL PHARMS LLC 400MG; 80MG A078060 002 Jan 25, 2007 Jan CAHN

AB 800MG; 160MG A078060 001 Jan 25, 2007 Jan CAHN

SUN PHARM INDUSTRIES 400MG; 80MG A071017 002 Aug 25, 1986 Oct CMS1

SULFANILAMIDE

CREAM; VAGINAL
AVC

+! MYLAN SPECIALITY LP 15% N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY; VAGINAL
AVC

@ MYLAN SPECIALITY LP 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

SULINDAC

TABLET; ORAL
SULINDAC

AB EPIC PHARMA LLC 150MG A073262 002 Sep 06, 1991 Aug CAHN

AB 200MG A073262 001 Sep 06, 1991 Aug CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP SAGENT AGILA LLC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090314 001 Jun 10, 2010 Nov CAHN

@ SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009 Mar CAHN

@ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078067 001 Feb 06, 2009 Mar CAHN

AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009 Jan CAHN

SYSTEM; IONTOPHORESIS
ZECUITY

+ @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT

+ CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Mar CTEC

+ EQ 25MG BASE N021938 002 Jan 26, 2006 Mar CTEC

+ EQ 37.5MG BASE N021938 004 Mar 31, 2009 Mar CTEC

+! EQ 50MG BASE N021938 003 Jan 26, 2006 Mar CTEC

TACROLIMUS

CAPSULE; ORAL		TACROLIMUS					
AB	BELCHER PHARMS LLC	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Nov	NEWA
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Nov	NEWA
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Nov	NEWA
INJECTABLE; INJECTION		PROGRAF					
AP	+! ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Aug	CFTG
AP	HOSPIRA INC	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Aug	NEWA

TALC

POWDER; INTRAPLEURAL		STERITALC					
+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017	Apr	NEWA
+		3GM/VIAL	N205555	002	May 01, 2017	Apr	NEWA
+	!	4GM/VIAL	N205555	003	May 01, 2017	Apr	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL		TAMOXIFEN CITRATE					
AB	!	MAYNE PHARMA	EQ 20MG BASE	A075797	002	Feb 20, 2003	Sep CMS1
AB		ZYDUS PHARMS USA INC	EQ 10MG BASE	A206694	001	Oct 27, 2017	Oct NEWA
AB			EQ 20MG BASE	A206694	002	Oct 27, 2017	Oct NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL		TAMSULOSIN HYDROCHLORIDE					
AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA
AB		ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul NEWA

TAZAROTENE

AEROSOL, FOAM; TOPICAL		FABIOR					
+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
CREAM; TOPICAL		AVAGE					
AB	+	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar CFTG
>A>	AB	G AND W LABS INC	0.1%	A208662	001	Dec 22, 2017	Dec NEWA
AB		TARO	0.1%	A208258	001	Apr 03, 2017	Mar NEWA
		TAZORAC					
AB	+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar CFTG

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION		PULMOLITE					
BS	+	JUBILANT DRAXIMAGE	N/A	N017776	001		Nov CRLD
		TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT					
BS	+	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987	Nov CRLD

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION		NEUROLITE					
+	!	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994	Nov CRLD

TECHNETIUM TC-99M EXAMETAZIME KIT

POWDER; INTRAVENOUS		DRAX EXAMETAZIME					
		JUBILANT DRAXIMAGE	N/A	N208870	001	Aug 17, 2017	Aug NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION		MDP-BRACCO					
AP		CARDINAL HEALTH 414	N/A	N018107	001		Apr CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

@ JUBILANT DRAXIMAGE N/A

N017714 001

Aug DISC

DTPA

+! DRAXIMAGE N/A

N018511 001 Dec 29, 1989

Nov CRLD

N/A

N018511 001 Dec 29, 1989

Aug CTEC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

+! MALLINKRODT NUCLEAR N/A

N019981 001 Jun 10, 1991

Nov CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP CARDINAL HEALTH 414 N/A

A078809 001 Apr 28, 2009

Sep CAHN

AP JUBILANT DRAXIMAGE N/A

A078806 001 Apr 29, 2009

Jun CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEV

+ @ GE HEALTHCARE N/A

N020372 001 Feb 09, 1996

Jul DISC

MYOVIEV 30ML

+! GE HEALTHCARE N/A

N020372 002 Jul 07, 2005

Aug CMFD

+ @ N/A

N020372 002 Jul 07, 2005

Jul DISC

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+! CARDINAL HEALTH 414 N/A

N202207 001 Mar 13, 2013

Sep CAHN

+! CARDINAL HLTH 414 N/A

N202207 001 Mar 13, 2013

Mar CAHN

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

+ @ THERAVANCE BIOPHARMA EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

Aug DISC

+ EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

May CAHN

+! EQ 750MG BASE/VIAL

N022110 002 Sep 11, 2009

May CAHN

>D> TELBIVUDINE

>D> TABLET; ORAL

>D> TYZEKA

>D> +! NOVARTIS 600MG

N022011 001 Oct 25, 2006

Dec DISC

>A> + @ 600MG

N022011 001 Oct 25, 2006

Dec DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB CADILA PHARMS LTD 20MG

A208605 001 Jul 25, 2017

Jul NEWA

AB 40MG

A208605 002 Jul 25, 2017

Jul NEWA

AB 80MG

A208605 003 Jul 25, 2017

Jul NEWA

AB GLENMARK PHARMS LTD 20MG

A090032 001 Jul 07, 2014

May CAHN

AB 40MG

A090032 002 Jul 07, 2014

May CAHN

AB 80MG

A090032 003 Jul 07, 2014

May CAHN

AB MICRO LABS 20MG

A207016 001 Oct 03, 2017

Sep NEWA

AB 40MG

A207016 002 Oct 03, 2017

Sep NEWA

AB 80MG

A207016 003 Oct 03, 2017

Sep NEWA

AB PRINSTON INC 20MG

A207882 001 May 03, 2017

Apr NEWA

AB 40MG

A207882 002 May 03, 2017

Apr NEWA

AB 80MG

A207882 003 May 03, 2017

Apr NEWA

TELOTRISTAT ETIPRATE

TABLET; ORAL

XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE

N208794 001 Feb 28, 2017

Feb NEWA

TEMAZEPACAPSULE;ORAL
RESTORIL

>D>	AB	+	MALLINCKRODT INC	7.5MG	N018163	003	Oct 25, 1991	Dec	CAHN
>D>	AB	+		15MG	N018163	001		Dec	CAHN
>D>	AB	+		22.5MG	N018163	004	Nov 02, 2004	Dec	CAHN
>D>	AB	+		30MG	N018163	002		Dec	CAHN
>A>	AB	+	SPECGX LLC	7.5MG	N018163	003	Oct 25, 1991	Dec	CAHN
>A>	AB	+		15MG	N018163	001		Dec	CAHN
>A>	AB	+		22.5MG	N018163	004	Nov 02, 2004	Dec	CAHN
>A>	AB	+		30MG	N018163	002		Dec	CAHN

TEMAZEPA

AB			ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May	CMS1
AB			PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb	CAHN
AB				15MG	A201781	002	Jun 04, 2015	Feb	CAHN
AB				22.5MG	A201781	003	Jun 04, 2015	Feb	CAHN
AB				30MG	A201781	004	Jun 04, 2015	Feb	CAHN

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB			ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb	NEWA
AB				20MG	A201528	002	Feb 27, 2017	Feb	NEWA
AB				100MG	A201528	003	Feb 27, 2017	Feb	NEWA
AB				140MG	A201528	004	Feb 27, 2017	Feb	NEWA
AB				180MG	A201528	005	Feb 27, 2017	Feb	NEWA
AB				250MG	A201528	006	Feb 27, 2017	Feb	NEWA
AB			DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr	NEWA
AB				20MG	A207658	002	Apr 26, 2017	Apr	NEWA
AB				100MG	A207658	003	Apr 26, 2017	Apr	NEWA
AB				140MG	A207658	004	Apr 26, 2017	Apr	NEWA
AB				180MG	A207658	005	Apr 26, 2017	Apr	NEWA
AB				250MG	A207658	006	Apr 26, 2017	Apr	NEWA
AB			WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr	NEWA
AB				20MG	A203959	002	Apr 18, 2017	Apr	NEWA
AB				100MG	A203959	003	Apr 18, 2017	Apr	NEWA
AB				140MG	A203959	004	Apr 18, 2017	Apr	NEWA
AB				250MG	A203959	005	Apr 18, 2017	Apr	NEWA
AB			ZYDUS PHARMS USA INC	5MG	A206750	001	Jul 31, 2017	Jul	NEWA
AB				20MG	A206750	002	Jul 31, 2017	Jul	NEWA
AB				100MG	A206750	003	Jul 31, 2017	Jul	NEWA
AB				140MG	A206750	004	Jul 31, 2017	Jul	NEWA
AB				180MG	A206750	005	Jul 31, 2017	Jul	NEWA
AB				250MG	A206750	006	Jul 31, 2017	Jul	NEWA

TENIPOSIDEINJECTABLE;INJECTION
VUMON

+	@	HQ	SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Aug	DISC
---	---	----	---------------	---------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB			MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar	CAHN
AB				EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar	CAHN
AB				EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar	CAHN
AB				EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar	CAHN

TERBINAFINE HYDROCHLORIDE

GRANULE;ORAL

LAMISIL

+	@	NOVARTIS		EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007	Aug	DISC
+	@			EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007	Aug	DISC

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@	MYLAN			EQ 250MG BASE	A077195	001	Jul 02, 2007	Aug	DISC
---	-------	--	--	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

		INJECTABLE; INJECTION							
		TERBUTALINE SULFATE							
AP	!	ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar	CAHN	
		TABLET; ORAL							
		BRETHINE							
	+	@ ANI PHARMS INC	2.5MG	N017849	001		Feb	CAHN	
	+	@	5MG	N017849	002		Feb	CAHN	
		TERBUTALINE SULFATE							
>D>		@ IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Dec	CMFD	
>A>	AB		2.5MG	A075877	001	Jun 26, 2001	Dec	CMFD	
>D>		@	5MG	A075877	002	Jun 26, 2001	Dec	CMFD	
>A>	AB		5MG	A075877	002	Jun 26, 2001	Dec	CMFD	
>D>		LANNETT	2.5MG	A077152	001	Mar 25, 2005	Dec	CTEC	
>A>	AB		2.5MG	A077152	001	Mar 25, 2005	Dec	CTEC	
>D>		!	5MG	A077152	002	Mar 25, 2005	Dec	CTEC	
>A>	AB	!	5MG	A077152	002	Mar 25, 2005	Dec	CTEC	
		!	5MG	A077152	002	Mar 25, 2005	Jan	CHRS	

TERCONAZOLE

		CREAM; VAGINAL								
		TERAZOL 3								
>D>										
>D>	AB	+	!	JANSSEN PHARMS	0.8%	N019964	001	Feb 21, 1991	Dec	DISC
>A>		+	@		0.8%	N019964	001	Feb 21, 1991	Dec	DISC
		TERCONAZOLE								
>D>	AB			TARO	0.8%	A075953	001	Apr 06, 2004	Dec	CTEC
>A>	BX			!	0.8%	A075953	001	Apr 06, 2004	Dec	CTEC

TESTOSTERONE

		GEL; TRANSDERMAL							
		ANDROGEL							
AB2	+	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun	CFTG	
AB2	+	!	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun	CFTG	
		TESTIM							
AB2	+	!	AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May	CAHN
		TESTOSTERONE							
AB2			ACTAVIS LABS UT INC	50MG/5GM PACKET	A091073	001	Sep 18, 2017	Sep	NEWA
AB2			PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun	NEWA
AB2				1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun	NEWA
		VOGELXO							
AB2			UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	CAHN
		GEL, METERED; TRANSDERMAL							
		TESTOSTERONE							
AB			ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar	CAHN
		VOGELXO							
BX			UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	CAHN
		SOLUTION, METERED; TRANSDERMAL							
		AXIRON							
	+	@	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep	DISC
AT	+	!		30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb	CFTG
		TESTOSTERONE							
AT			ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION	A205328	001	Aug 07, 2017	Jul	NEWA
AT			LUPIN LTD	30MG/1.5ML ACTUATION	A208061	001	Oct 23, 2017	Oct	NEWA
AT		!	PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Sep	CHRS
AT				30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb	NEWA
		TABLET, EXTENDED RELEASE; BUCCAL							
		STRIANT							
	+	!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May	CAHN

TESTOSTERONE CYPIONATE

		INJECTABLE; INJECTION							
		TESTOSTERONE CYPIONATE							
AO			LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun	NEWA
AO			SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar	CAHN
AO				200MG/ML	A040615	002	Aug 10, 2006	Mar	CAHN
AO			WATSON PHARMS INC	200MG/ML	A086030	001		Feb	CAHN
AO			WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan	CAHN
AO				200MG/ML	A090387	002	Jul 15, 2010	Jan	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	WATSON PHARMS INC	200MG/ML	A 085598	001			Feb	CAHN
----	-------------------	----------	----------	-----	--	--	-----	------

TETRABENAZINE

TABLET; ORAL
TETRABENAZINE

AB	ACTAVIS LABS FL INC	25MG	A 206686	001	Jul 07, 2017		Jun	NEWA	
AB	APICORE US	12.5MG	A 207682	001	Jan 31, 2017		Jan	NEWA	
AB		25MG	A 207682	002	Jan 31, 2017		Jan	NEWA	
>A>	AB	BIONPHARMA INC	12.5MG	A 208826	001	Dec 18, 2017		Dec	NEWA
>A>	AB		25MG	A 208826	002	Dec 18, 2017		Dec	NEWA
>A>	AB	DR REDDYS LABS LTD	12.5MG	A 209284	001	Jan 08, 2018		Dec	NEWA
>A>	AB		25MG	A 209284	002	Jan 08, 2018		Dec	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

AB	+ HERITAGE PHARMA	250MG	N 050278	003			Jan	CAHN
AB	+!	500MG	N 050278	001			Jan	CAHN

TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL TETRA	250MG	A 062752	001	Aug 12, 1988		Apr	CAHN
AB		500MG	A 062752	002	Aug 12, 1988		Apr	CAHN
	@ IMPAX LABS	100MG	A 060469	002			Jul	DISC
	@	250MG	A 060469	001			Jul	DISC
	@	500MG	A 060469	003			Jul	DISC

THEOPHYLLINE

ELIXIR; ORAL
THEOPHYLLINE

@	CHARTWELL RX	80MG/15ML	A 085952	001			Apr	CAHN
@	PHARM ASSOC	80MG/15ML	A 086720	001			May	CAHN

INJECTABLE; INJECTION

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+!	B BRAUN	80MG/100ML	N 019826	002	Aug 14, 1992		Nov	CTEC
----	---------	------------	----------	-----	--------------	--	-----	------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	HOSPIRA INC	4MG/ML	N 019211	007	Dec 14, 1984		Nov	CTEC
----	-------------	--------	----------	-----	--------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

>A>	NOSTRUM PHARMS LLC	100MG	A 087400	003	Feb 21, 1985		Dec	CMS1
>A>		200MG	A 087400	004	Feb 21, 1985		Dec	CMS1
	@	300MG	A 087400	002	Jan 11, 1983		May	CAHN

THEOPHYLLINE

!	ALEMBIC LTD	450MG	A 090430	002	Oct 27, 2010		Apr	CHRS
AB	ALEMBIC PHARMS LTD	300MG	A 090430	001	Oct 27, 2010		May	CAHN
!		450MG	A 090430	002	Oct 27, 2010		May	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP	SAGENT PHARMS	100MG/ML	A 206106	001	Dec 01, 2017		Nov	NEWA
	@ WEST-WARD PHARMS INT	100MG/ML	A 080575	001			Jan	CAHN

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HYDROCHLORIDE

@	ANI PHARMS INC	30MG/ML	A 089602	001	Nov 09, 1987		Jan	CAHN
@	PHARM ASSOC	30MG/ML	A 040187	001	Aug 28, 1997		May	CAHN
@		100MG/ML	A 040213	001	May 29, 1998		May	CAHN

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	WATSON LABS TEVA	15MG	A 088477	001	Nov 08, 1983		May	CAHN
@		25MG	A 088567	001	May 11, 1984		May	CAHN
@		200MG	A 088872	001	Apr 26, 1985		May	CAHN

THIOTEPAPOWDER; IV (INFUSION)
TEPADINA

+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan	NEWA
+!		100MG/VIAL	N208264	002	Jan 26, 2017	Jan	NEWA

TIAGABINE HYDROCHLORIDETABLET; ORAL
GABITRIL

AB	+	CEPHALON	12MG	N020646	002	Sep 30, 1997	Oct	CFTG
AB	+		16MG	N020646	003	Sep 30, 1997	Oct	CFTG
TIAGABINE HYDROCHLORIDE								
AB		AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Nov	NEWA
AB			4MG	A208181	002	Dec 08, 2017	Nov	NEWA
AB			12MG	A208181	003	Dec 08, 2017	Nov	NEWA
AB			16MG	A208181	004	Dec 08, 2017	Nov	NEWA
AB		WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Oct	NEWA
AB			4MG	A206857	002	Oct 13, 2017	Oct	NEWA
AB			12MG	A206857	003	Oct 13, 2017	Oct	NEWA
AB			16MG	A206857	004	Oct 13, 2017	Oct	NEWA

TICAGRELORTABLET; ORAL
BRILINTA

+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan	CAHN
+!		90MG	N022433	001	Jul 20, 2011	Jan	CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>A>	@	FOSUN PHARMA	250MG	A075318	001	Aug 20, 1999	Dec	CAHN
>A>	@		250MG	A075326	001	Aug 20, 1999	Dec	CAHN
>D>	@	SANDOZ	250MG	A075318	001	Aug 20, 1999	Dec	CAHN
>D>	@		250MG	A075326	001	Aug 20, 1999	Dec	CAHN

TIGECYCLINEPOWDER; IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb	CDFR
AP	+!	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb	CDFR

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AB		SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb	CAHN
AB			EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb	CAHN

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb	CAHN
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb	CAHN

TABLET; ORAL

TIMOLOL MALEATE

>A>	@	FOSUN PHARMA	5MG	A072550	001	Apr 13, 1989	Dec	CAHN
>A>	@		10MG	A072551	001	Apr 13, 1989	Dec	CAHN
>A>	@		20MG	A072552	001	Apr 13, 1989	Dec	CAHN
>D>	@	SANDOZ	5MG	A072550	001	Apr 13, 1989	Dec	CAHN
>D>	@		10MG	A072551	001	Apr 13, 1989	Dec	CAHN
>D>	@		20MG	A072552	001	Apr 13, 1989	Dec	CAHN

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan	CTEC
AB			500MG	A202489	002	Oct 09, 2013	Jan	CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	JUBILANT GENERICS	EQ 2MG BASE	A209605	001	Aug 04, 2017	Jul	NEWA
AB		EQ 4MG BASE	A209605	002	Aug 04, 2017	Jul	NEWA
AB		EQ 6MG BASE	A209605	003	Aug 04, 2017	Jul	NEWA
AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb	NEWA
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb	NEWA
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb	NEWA
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb	NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb	NEWA

ZANAFLEX

AB	+ COVIS PHARMA BV	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov	CAHN
AB	+	EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov	CAHN
AB	+	EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov	CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May	CAHN
AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May	CAHN
AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan	NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan	NEWA

ZANAFLEX

AB	+ @ COVIS PHARMA BV	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov	CAHN
AB	+	EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov	CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May	CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar	NEWA
AN	MYLAN PHARMS INC	300MG/5ML	A209554	001	Oct 13, 2017	Oct	NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun	NEWA
AT	TOBREX						
AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug	CAHN
----	----------------------	-----------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

>A>	@ FOSUN PHARMA	250MG	A070289	001	Mar 13, 1986	Dec	CAHN
>A>	@	500MG	A070290	001	Mar 13, 1986	Dec	CAHN
>D>	@ SANDOZ	250MG	A070289	001	Mar 13, 1986	Dec	CAHN
>D>	@	500MG	A070290	001	Mar 13, 1986	Dec	CAHN

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

!	MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CTEC
---	-------	---------------	---------	-----	--------------	-----	------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	HETERO LABS LTD III	2MG	A206419	001	Dec 12, 2017	Nov	NEWA
AB		4MG	A206419	002	Dec 12, 2017	Nov	NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

@	MYLAN	15MG	A078418	001	Oct 14, 2009	Nov	DISC
@		25MG	A078418	002	Oct 14, 2009	Nov	DISC

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun	CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

	+		100MG	N205122	003	Mar 11, 2014	Jun CAHN
	+		150MG	N205122	004	Mar 11, 2014	Jun CAHN
	+	!	200MG	N205122	005	Mar 11, 2014	Jun CAHN

TOPIRAMATE

AB		ZYDUS PHARMS USA INC	25MG	A207382	001	Nov 24, 2017	Nov NEWA
AB			50MG	A207382	002	Nov 24, 2017	Nov NEWA
AB			100MG	A207382	003	Nov 24, 2017	Nov NEWA

TROKENDI XR

AB	+	SUPERMUS PHARMS	25MG	N201635	001	Aug 16, 2013	Nov CFTG
AB	+		50MG	N201635	002	Aug 16, 2013	Nov CFTG
AB	+		100MG	N201635	003	Aug 16, 2013	Nov CFTG

TABLET;ORAL

TOPIRAMATE

	@	MYLAN	25MG	A076314	001	Mar 27, 2009	May DISC
	@		50MG	A076314	002	Mar 27, 2009	May DISC
	@		100MG	A076314	003	Mar 27, 2009	May DISC
	@		200MG	A076314	004	Mar 27, 2009	May DISC
AB		UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun CAHN
AB			50MG	A078499	002	Jan 07, 2010	Jun CAHN
AB			100MG	A078499	003	Jan 07, 2010	Jun CAHN
AB			200MG	A078499	004	Jan 07, 2010	Jun CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP		HONG KONG	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Sep CAHN
AP		NOVAST LABS LTD	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Sep CAHN
	@	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Sep DISC

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Nov CTEC
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun NEWA
AP		MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Nov NEWA

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

	+	!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
--	---	---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+	!	20MG	N020136	003	Aug 23, 1993	Mar CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar CAHN

TORSEMIDE

	@	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008	Sep DISC
	@		10MG	A078478	002	Feb 26, 2008	Sep DISC
	@		20MG	A078478	003	Feb 26, 2008	Sep DISC
	@		100MG	A078478	004	Feb 26, 2008	Sep DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

	@	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Oct DISC
AB			50MG	A202390	001	May 16, 2013	Mar CAHN
AB		AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May CAHN
>D>	AB	MALLINCKRODT	50MG	A075983	001	Jun 25, 2002	Dec CAHN
	@	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002	Nov DISC
>A>	AB	SPECGX LLC	50MG	A075983	001	Jun 25, 2002	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

	+	@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CRLD
	+	@		200MG	N021692	002	Sep 08, 2005	Mar CRLD
	+	@		300MG	N021692	003	Sep 08, 2005	Mar CRLD

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
MEKINIST

+ @ NOVARTIS PHARMS CORP EQ 1MG N204114 002 May 29, 2013 Jul DISC

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

	@ EPIC PHARMA LLC	1MG	A 077256	001	Jun 12, 2007	May	CAHN
	@	2MG	A 077256	002	Jun 12, 2007	May	CAHN
	@	4MG	A 077256	003	Jun 12, 2007	May	CAHN
	@ INVAGEN PHARMS	1MG	A 078320	001	Jun 12, 2007	Jun	DISC
BX	@	1MG	A 078320	001	Jun 12, 2007	Apr	CTEC
	@	2MG	A 078320	002	Jun 12, 2007	Jun	DISC
BX	@	2MG	A 078320	002	Jun 12, 2007	Apr	CTEC
	@	4MG	A 078320	003	Jun 12, 2007	Jun	DISC
BX	@	4MG	A 078320	003	Jun 12, 2007	Apr	CTEC
	@ MYLAN	1MG	A 078346	001	Apr 28, 2008	May	DISC
	@	2MG	A 078346	002	Apr 28, 2008	May	DISC
	@	4MG	A 078346	003	Apr 28, 2008	May	DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP	AKORN	100MG/ML	A 206594	001	Sep 28, 2017	Sep	NEWA
AP	AMNEAL PHARMS CO	100MG/ML	A 208840	001	Feb 28, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	100MG/ML	A 207239	001	Feb 13, 2017	Jan	NEWA
AP	MICRO LABS	100MG/ML	A 206713	001	Jun 27, 2017	Jun	NEWA
AP	VIRTUS PHARMS	100MG/ML	A 202755	001	Feb 25, 2016	Sep	CAHN
AP	VIVA HLTHCARE	100MG/ML	A 206713	001	Jun 27, 2017	Sep	CAHN
AP	ZYDUS PHARMS USA INC	100MG/ML	A 205228	001	Jul 17, 2017	Jul	NEWA

TABLET;ORAL

LYSTEDA

AB +! FERRING PHARMS INC 650MG N022430 001 Nov 13, 2009 Nov CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT MYLAN PHARMS INC 0.004% A 205050 001 Jul 07, 2017 Jun NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A 206923	001	Sep 08, 2017	Aug	NEWA
AB		100MG	A 206923	002	Sep 08, 2017	Aug	NEWA
AB		150MG	A 206923	003	Sep 08, 2017	Aug	NEWA
AB		300MG	A 206923	004	Sep 08, 2017	Aug	NEWA
	@ MYLAN PHARMS INC	50MG	A 090514	001	Jun 02, 2009	May	DISC
	@	100MG	A 090514	002	Jun 02, 2009	May	DISC
	@	150MG	A 090514	003	Jun 02, 2009	May	DISC
	@	300MG	A 090514	004	Jun 02, 2009	May	DISC
AB	ZYDUS PHARMS USA INC	50MG	A 205253	001	Oct 10, 2017	Sep	NEWA
AB		100MG	A 205253	002	Oct 10, 2017	Sep	NEWA
AB		150MG	A 205253	003	Oct 10, 2017	Sep	NEWA
AB		300MG	A 205253	004	Oct 10, 2017	Sep	NEWA

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	+! UNITED THERAP	1MG/ML	N 021272	001	May 21, 2002	Nov	CFTG
AP	+!	2.5MG/ML	N 021272	002	May 21, 2002	Nov	CFTG
AP	+!	5MG/ML	N 021272	003	May 21, 2002	Nov	CFTG
AP	+!	10MG/ML	N 021272	004	May 21, 2002	Nov	CFTG

TREPROSTINIL

AP	SANDOZ INC	1MG/ML	A 203649	001	Nov 30, 2017	Nov	NEWA
AP		2.5MG/ML	A 203649	002	Nov 30, 2017	Nov	NEWA
AP		5MG/ML	A 203649	003	Nov 30, 2017	Nov	NEWA
AP		10MG/ML	A 203649	004	Nov 30, 2017	Nov	NEWA

TRETINOIN

		CAPSULE;ORAL							
		TRETINOIN							
AB		GLENMARK PHARMS LTD	10MG	A208279	001	Dec 23, 2016	Jun	CAHN	
		VESANOID							
	+	@ CHEPLAPHARM	10MG	N020438	001	Nov 22, 1995	May	CAHN	
		CREAM;TOPICAL							
		TRETINOIN							
AB2		ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN	
		GEL;TOPICAL							
		RETIN-A-MICRO							
	+	! VALEANT INTL	0.06%	N020475	004	Oct 23, 2017	Oct	NEWA	
		TRETINOIN							
AB		MYLAN PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN	
AB			0.05%	A207955	001	Aug 13, 2015	Jun	CAHN	
AB			0.1%	A202026	001	Jul 17, 2013	Jun	CAHN	
		SOLUTION;TOPICAL							
		RETIN-A							
	+	@ VALEANT INTL	0.05%	N016921	001		Oct	DISC	

TRIAMCINOLONE ACETONIDE

		CREAM;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
>A>	AT	ALKEM LABS LTD	0.025%	A207651	001	Dec 26, 2017	Dec	NEWA	
>A>	AT		0.1%	A207651	002	Dec 26, 2017	Dec	NEWA	
>A>	AT		0.5%	A207651	003	Dec 26, 2017	Dec	NEWA	
AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA	
AT			0.1%	A208763	002	Feb 01, 2017	Jan	NEWA	
AT			0.5%	A208763	003	Feb 01, 2017	Jan	NEWA	
AT	+	MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN	
AT	+		0.1%	N011601	006		Jan	CAHN	
		@ TARO	0.025%	A040038	001	Oct 26, 1994	Apr	CAHN	
AT			0.1%	A040039	001	Nov 26, 1997	Apr	CAHN	
AT			0.1%	A040039	001	Nov 26, 1997	Mar	CAHN	
AT		TELIGENT PHARMA INC	0.1%	A208848	001	Sep 18, 2017	Sep	NEWA	
		FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR							
		ZILRETTA							
	+	! FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Oct	NEWA	
		INJECTABLE;INJECTION							
		KENALOG-10							
	+	APOTHECON	10MG/ML	N012041	001		Jun	CRLD	
		KENALOG-40							
AP	+	! APOTHECON	40MG/ML	N014901	001		Nov	CTEC	
		TRIAMCINOLONE ACETONIDE							
AP		AMNEAL PHARMS CO	40MG/ML	A207550	001	Dec 11, 2017	Nov	NEWA	
		@ SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr	CAHN	
		@	40MG/ML	A090164	001	Jun 01, 2009	Apr	CAHN	
		LOTION;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
>D>	AT	! WOCKHARDT	0.1%	A088451	001	Apr 03, 1985	Dec	CAHN	
>A>	AT	! WOCKHARDT BIO AG	0.025%	A088450	001	Apr 01, 1985	Dec	CAHN	
>A>	AT	!	0.1%	A088451	001	Apr 03, 1985	Dec	CAHN	
>D>	AT	! WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Dec	CAHN	
		OINTMENT;TOPICAL							
		KENALOG							
	+	@ MYLAN PHARMS INC	0.025%	N011600	003		Sep	CRLD	
		@	0.025%	N011600	003		Aug	DISC	
AT			0.025%	N011600	003		Jan	CAHN	
	+	@	0.1%	N011600	001		Sep	CRLD	
		@	0.1%	N011600	001		Aug	DISC	
AT			0.1%	N011600	001		Jan	CAHN	
		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS INC	0.5%	A208925	001	Oct 06, 2017	Sep	NEWA	
AT		GLENMARK PHARMS	0.1%	A208320	001	Aug 22, 2017	Aug	NEWA	
		@ TARO	0.025%	A040040	001	Sep 30, 1994	Apr	CAHN	
AT			0.1%	A040037	001	Sep 30, 1994	Apr	CAHN	
AT		TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb	NEWA	
		TRIAMCINOLONE ACETONIDE IN ABSORBASE							
	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr	CAHN	

	PASTE;DENTAL						
	TRIAMCINOLONE ACETONIDE						
AT	G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA
	SPRAY;TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT	RICONPHARMA LLC	0.147MG/GM	A206786	001	Sep 08, 2017	Aug	NEWA
	SPRAY, METERED;NASAL						
	TRIAMCINOLONE ACETONIDE						
	@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
	<u>TRIAMCINOLONE DIACETATE</u>						
	INJECTABLE;INJECTION						
	ARISTOCORT						
>A>	@ FOSUN PHARMA	25MG/ML	N011685	003		Dec	CAHN
>A>	+ @	40MG/ML	N012802	001		Dec	CAHN
>D>	@ SANDOZ INC	25MG/ML	N011685	003		Dec	CAHN
	@	25MG/ML	N011685	003		Jun	CAHN
>D>	+ @	40MG/ML	N012802	001		Dec	CAHN
	+ @	40MG/ML	N012802	001		Jun	CAHN
	<u>TRIAMCINOLONE HEXACETONIDE</u>						
	INJECTABLE;INJECTION						
	ARISTOSPAN						
	+! SANDOZ INC	5MG/ML	N016466	001		Jun	CAHN
	+!	20MG/ML	N016466	002		Jun	CAHN
	<u>TRIFLURIDINE</u>						
	SOLUTION/DROPS;OPHTHALMIC						
	TRIFLURIDINE						
AT	HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017	Jul	NEWA
AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN
	VIROPTIC						
AT	+! MONARCH PHARMS	1%	N018299	001		Feb	CAHN
	<u>TRIHXYPHENIDYL HYDROCHLORIDE</u>						
	ELIXIR;ORAL						
	TRIHXYPHENIDYL HYDROCHLORIDE						
AA	! PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN
	TABLET;ORAL						
	TRIHXYPHENIDYL HYDROCHLORIDE						
AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN
	<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	TIGAN						
AB	+! KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN
	<u>TRIMETHOPRIM HYDROCHLORIDE</u>						
	SOLUTION;ORAL						
	PRIMSOL						
>A>	@ ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Dec	CAHN
	+!	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN
>D>	@ AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Dec	CAHN
	<u>TRIMIPRAMINE MALEATE</u>						
	CAPSULE;ORAL						
	TRIMIPRAMINE MALEATE						
AB	ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN
	<u>TRIPTORELIN PAMOATE</u>						
	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR						
	TRIPTODUR KIT						
	+! ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	NEWA

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC
MYDRIACYL
AT ! SANDOZ INC 0.5% A 084305 001 Feb CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
TROSPIUM CHLORIDE
@ UPSHER-SMITH LABS 60MG A 091635 001 Apr 29, 2015 Jun CAHN

ULIPRISTAL ACETATE

TABLET;ORAL
ELLA
AB +! LAB HRA PHARMA 30MG N 022474 001 Aug 13, 2010 Jan CFTG
LOGILIA
AB TEVA PHARMS USA 30MG A 207952 001 Feb 13, 2017 Jan NEWA

URSODIOL

CAPSULE;ORAL
URSODIOL
@ IMPAX LABS INC 300MG A 077895 001 Jul 27, 2006 May DISC
BX 300MG A 077895 001 Jul 27, 2006 Apr CTEC
AB 300MG A 077895 001 Jul 27, 2006 Feb CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE
@ MYLAN EQ 500MG BASE A 078070 001 May 24, 2010 Jun DISC
@ EQ 1GM BASE A 078070 002 May 24, 2010 Jun DISC
>A> AB ZYDUS PHARMS USA INC EQ 500MG BASE A 079137 001 Dec 29, 2017 Dec NEWA
>A> AB EQ 1GM BASE A 079137 002 Dec 29, 2017 Dec NEWA

VALBENAZINE TOSYLATE

CAPSULE;ORAL
INGREZZA
+! NEUROCRINE 40MG N 209241 001 Apr 11, 2017 Apr NEWA
+ 80MG N 209241 002 Oct 04, 2017 Oct NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE
AB DR REDDYS LABS LTD EQ 450MG BASE A 206876 001 Dec 12, 2017 Nov NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION
VALPROATE SODIUM
AP ATHENEX INC EQ 100MG BASE/ML A 076295 001 Nov 14, 2002 Mar CAHN

VALPROIC ACID

CAPSULE;ORAL
VALPROIC ACID
@ USL PHARMA 250MG A 070631 001 Jun 11, 1987 Jun CAHN
SYRUP;ORAL
VALPROIC ACID
AA ECI PHARMS LLC 250MG/5ML A 090517 001 May 28, 2010 Mar CAHN
AA PHARM ASSOC 250MG/5ML A 075379 001 Dec 15, 2000 May CAHN
AA VISTAPHARM 250MG/5ML A 075782 001 Dec 22, 2000 Feb CAHN
>D> AA WOCKHARDT 250MG/5ML A 070868 001 Jul 01, 1986 Dec CAHN
>A> AA WOCKHARDT BIO AG 250MG/5ML A 070868 001 Jul 01, 1986 Dec CAHN

VALSARTAN

>A> SOLUTION;ORAL
>A> PREXXARTAN
>A> +! CARMEL BIOSCIENCES 20MG/5ML N 209139 001 Dec 19, 2017 Dec NEWA
>A> +! 80MG/20ML N 209139 002 Dec 19, 2017 Dec NEWA
TABLET;ORAL
VALSARTAN
AB AMNEAL PHARMS 40MG A 204011 001 Jan 11, 2016 May CAHN
AB 80MG A 204011 002 Jan 11, 2016 May CAHN
AB 160MG A 204011 003 Jan 11, 2016 May CAHN
AB 320MG A 204011 004 Jan 11, 2016 May CAHN

TABLET;ORAL

VALSARTAN

AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug CAHN
	@ TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Oct DISC
	@	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Oct DISC
	@	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Oct DISC
	@	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Oct DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Nov CTEC
+		5MG	N021400	001	Aug 19, 2003	Nov CTEC
+		10MG	N021400	002	Aug 19, 2003	Nov CTEC
+	!	20MG	N021400	004	Aug 19, 2003	Nov CTEC

VARDENAFIL HYDROCHLORIDE

@	TEVA PHARMS	2.5MG	A091347	001	May 03, 2012	Sep DISC
@		5MG	A091347	002	May 03, 2012	Sep DISC
@		10MG	A091347	003	May 03, 2012	Sep DISC
@		20MG	A091347	004	May 03, 2012	Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

+	!	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Jun CTEC
---	---	----------------	------	---------	-----	--------------	----------

VASOPRESSIN

SOLUTION;IV (INFUSION)

VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May CMFD
+	@		20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr DISC
+	!		20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr NEWA
+	!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	@	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar CAHN
AP			10MG/VIAL	A075549	001	Jun 13, 2000	Jan CAHN
AP	@		20MG/VIAL	A075218	002	Aug 23, 1999	Mar CAHN
AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001	Oct 05, 2017	Sep NEWA	
AB		EQ 75MG BASE	A204889	002	Oct 05, 2017	Sep NEWA	
AB		EQ 150MG BASE	A204889	003	Oct 05, 2017	Sep NEWA	
	@	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	Aug DISC
	@		EQ 75MG BASE	A078789	002	Jun 01, 2011	Aug DISC
	@		EQ 150MG BASE	A078789	003	Jun 01, 2011	Aug DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar NEWA	
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar NEWA	
AB	+	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

>A>	@	FOSUN PHARMA	40MG	A 073168	001	Jul 31, 1992	Dec	CAHN
>A>	@		80MG	A 071423	001	May 24, 1988	Dec	CAHN
>A>	@		120MG	A 071424	001	May 25, 1988	Dec	CAHN
>A>	AB	HERITAGE PHARMS INC	80MG	A 071881	003	Apr 05, 1988	Dec	CMS1
>D>	@	SANDOZ	40MG	A 073168	001	Jul 31, 1992	Dec	CAHN
>D>	@		80MG	A 071423	001	May 24, 1988	Dec	CAHN
>D>	@		120MG	A 071424	001	May 25, 1988	Dec	CAHN

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

	+	@	PFIZER	180MG	N 019152	002	Dec 15, 1989	Jan	CRLD
			COVERA-HS						
		@	GD SEARLE LLC	180MG	N 020552	001	Feb 26, 1996	Jan	DISC
		@		240MG	N 020552	002	Feb 26, 1996	Jan	DISC
			VERAPAMIL HYDROCHLORIDE						
AB			CADILA PHARMS LTD	180MG	A 206173	001	May 05, 2017	Apr	NEWA
AB				240MG	A 206173	002	May 05, 2017	Apr	NEWA

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+	!	LUNDBECK PHARMS LLC	500MG/PACKET	N 022006	001	Aug 21, 2009	Apr	CFTG	
		!		500MG/PACKET	N 022006	001	Aug 21, 2009	Jan	CAHN	
			VIGABATRIN							
AA			PAR PHARM INC	500MG/PACKET	A 208218	001	Apr 27, 2017	Apr	NEWA	
			TABLET;ORAL							
			SABRIL							
		+	!	LUNDBECK PHARMS LLC	500MG	N 020427	001	Aug 21, 2009	Jan	CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

	@	MYLAN LABS LTD	EQ 10MG BASE/ML	A 200148	001	Aug 31, 2012	Oct	DISC
AP		WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A 075992	001	Jun 10, 2003	Mar	CAHN
AP			EQ 10MG BASE/ML	A 076461	001	Dec 11, 2003	Jan	CAHN

VORICONAZOLE

POWDER;IV (INFUSION)

VORICONAZOLE

			XELLIA PHARMS APS	200MG/VIAL	N 208562	001	Mar 09, 2017	Mar	NEWA
--	--	--	-------------------	------------	----------	-----	--------------	-----	------

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB			USL PHARMA	1MG	A 040416	001	Oct 02, 2003	Jun	CAHN
AB				2MG	A 040416	002	Oct 02, 2003	Jun	CAHN
AB				2.5MG	A 040416	003	Oct 02, 2003	Jun	CAHN
AB				3MG	A 040416	004	Oct 02, 2003	Jun	CAHN
AB				4MG	A 040416	005	Oct 02, 2003	Jun	CAHN
AB				5MG	A 040416	006	Oct 02, 2003	Jun	CAHN
AB				6MG	A 040416	007	Oct 02, 2003	Jun	CAHN
AB				7.5MG	A 040416	008	Oct 02, 2003	Jun	CAHN
AB				10MG	A 040416	009	Oct 02, 2003	Jun	CAHN

WARFARIN SODIUM

>A>	@	FOSUN PHARMA	1MG	A 040196	001	Sep 30, 1997	Dec	CAHN
>A>	@		2MG	A 040196	002	Sep 30, 1997	Dec	CAHN
>A>	@		2.5MG	A 040196	003	Sep 30, 1997	Dec	CAHN
>A>	@		3MG	A 040196	008	Jul 26, 2000	Dec	CAHN
>A>	@		4MG	A 040196	004	Sep 30, 1997	Dec	CAHN
>A>	@		5MG	A 040196	005	Sep 30, 1997	Dec	CAHN
>A>	@		6MG	A 040196	009	Jul 26, 2000	Dec	CAHN
>A>	@		7.5MG	A 040196	006	Sep 30, 1997	Dec	CAHN
>A>	@		10MG	A 040196	007	Sep 30, 1997	Dec	CAHN
	@	MYLAN	1MG	A 040415	001	Sep 27, 2004	Apr	DISC
	@		2MG	A 040415	002	Sep 27, 2004	Apr	DISC
	@		2.5MG	A 040415	003	Sep 29, 2004	Apr	DISC
	@		3MG	A 040415	004	Sep 27, 2004	Apr	DISC
	@		4MG	A 040415	005	Sep 27, 2004	Apr	DISC
	@		5MG	A 040415	006	Sep 27, 2004	Apr	DISC

TABLET;ORAL

WARFARIN SODIUM

	@	6MG	A040415	007	Sep 27, 2004	Apr	DISC
	@	7.5MG	A040415	008	Sep 27, 2004	Apr	DISC
	@	10MG	A040415	009	Sep 27, 2004	Apr	DISC
>D>	@ SANDOZ	1MG	A040196	001	Sep 30, 1997	Dec	CAHN
>D>	@	2MG	A040196	002	Sep 30, 1997	Dec	CAHN
>D>	@	2.5MG	A040196	003	Sep 30, 1997	Dec	CAHN
>D>	@	3MG	A040196	008	Jul 26, 2000	Dec	CAHN
>D>	@	4MG	A040196	004	Sep 30, 1997	Dec	CAHN
>D>	@	5MG	A040196	005	Sep 30, 1997	Dec	CAHN
>D>	@	6MG	A040196	009	Jul 26, 2000	Dec	CAHN
>D>	@	7.5MG	A040196	006	Sep 30, 1997	Dec	CAHN
>D>	@	10MG	A040196	007	Sep 30, 1997	Dec	CAHN
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar	CAHN
AB		2MG	A040301	003	Jul 15, 1999	Mar	CAHN
AB		2.5MG	A040301	004	Jul 15, 1999	Mar	CAHN
AB		3MG	A040301	005	Jul 15, 1999	Mar	CAHN
AB		4MG	A040301	006	Jul 15, 1999	Mar	CAHN
AB		5MG	A040301	007	Jul 15, 1999	Mar	CAHN
AB		6MG	A040301	008	Jul 15, 1999	Mar	CAHN
AB		7.5MG	A040301	009	Jul 15, 1999	Mar	CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar	CAHN

ZALEPLON

CAPSULE;ORAL

ZALEPLON

	@ MYLAN	5MG	A077238	001	Jun 06, 2008	Jul	DISC
	@	10MG	A077238	002	Jun 06, 2008	Jul	DISC
	@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Jun	CAHN
	@	10MG	A078095	002	Jun 06, 2008	Jun	CAHN

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

	@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May	CAHN
--	---------------------	-------	---------	-----	--------------	-----	------

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar	NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar	CAHN
	ZYFLO CR						
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar	CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb	NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb	NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb	NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Aug	NEWA
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Aug	NEWA
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Aug	NEWA
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Aug	NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	AUROBINDO PHARMA LTD	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Nov	NEWA
>A>	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Dec	NEWA
AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep	CAHN
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep	CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep	CAHN
AP	CIPLA LTD	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Oct	NEWA
AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Oct	NEWA
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May	CAHN
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Oct	DISC

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun	NEWA
AB		5MG	A206973	002	Jun 30, 2017	Jun	NEWA
AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb	NEWA
	@ SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct	DISC
	@	5MG	A203476	002	Nov 13, 2014	Oct	DISC

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Aug	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

ZOLPIDEM TARTRATE

>A>	AB	ACME LABS	5MG	A077214	001	Apr 23, 2007	Dec	CAHN
>A>	AB		10MG	A077214	002	Apr 23, 2007	Dec	CAHN
>D>	AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Dec	CAHN
	AB		5MG	A077214	001	Apr 23, 2007	Mar	CAHN
>D>	AB		10MG	A077214	002	Apr 23, 2007	Dec	CAHN
	AB		10MG	A077214	002	Apr 23, 2007	Mar	CAHN
		@ VIVIMED GLOBAL	5MG	A076062	001	Apr 23, 2007	Aug	CAHN
		@	10MG	A076062	002	Apr 23, 2007	Aug	CAHN

TABLET;SUBLINGUAL

EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar	CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar	CAHN

ZOLPIDEM TARTRATE

AB	PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Aug	NEWA
AB		3.5MG	A204229	002	Sep 11, 2017	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May	CAHN
@		50MG	A077876	002	Feb 21, 2007	May	CAHN
@		100MG	A077876	003	Feb 21, 2007	May	CAHN
@	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun	DISC
@		50MG	A077647	002	Dec 22, 2005	Jun	DISC
@		100MG	A077647	003	Dec 22, 2005	Jun	DISC
@	UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun	CAHN
@		50MG	A077644	002	Dec 22, 2005	Jun	CAHN
@		100MG	A077644	003	Dec 22, 2005	Jun	CAHN

ACETAMINOPHENSUPPOSITORY;RECTAL
ACETAMINOPHEN

@ ACINO PRODS	120MG	A 071010	001	May 12, 1987	Oct CAHN
@	650MG	A 071011	001	May 12, 1987	Oct CAHN

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATETABLET, CHEWABLE;ORAL
FOAMCOAT

@ GUARDIAN DRUG	80MG;20MG	A 071793	001	Sep 04, 1987	Sep DISC
-----------------	-----------	----------	-----	--------------	----------

AVOBENZONE; OCTINOXATE; OXYBENZONELOTION;TOPICAL
SHADE UVAGUARD

+ @ BAYER HEALTHCARE LLC	3%;7.5%;3%	N 020045	001	Dec 07, 1992	Jun DISC
--------------------------	------------	----------	-----	--------------	----------

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
LUMIFY

>A>	+!	BAUSCH AND LOMB INC	0.025%	N 208144	001	Dec 22, 2017	Dec NEWA
-----	----	---------------------	--------	----------	-----	--------------	----------

BUTENAFINE HYDROCHLORIDECREAM;TOPICAL
BUTENAFINE HYDROCHLORIDE

TARO	1%	A 205181	001	Nov 16, 2017	Oct NEWA
------	----	----------	-----	--------------	----------

BUTOCONAZOLE NITRATECREAM;VAGINAL
FEMSTAT 3

+ @ BAYER	2%	N 020421	001	Dec 21, 1995	Aug DISC
-----------	----	----------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDECAPSULE;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
STRIDES PHARMA

10MG	A 205291	001	Jul 21, 2017	Jul NEWA
------	----------	-----	--------------	----------

SYRUP;ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
ALLIED PHARMA INC

5MG/5ML	A 091327	001	Oct 17, 2011	Apr CAHN
---------	----------	-----	--------------	----------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
ALLIED PHARMA INC

5MG/5ML	A 091327	002	Oct 17, 2011	Apr CAHN
---------	----------	-----	--------------	----------

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	GRANULES INDIA LTD	10MG	A 209274	001	Dec 22, 2017	Dec NEWA
	JUBILANT CADISTA	5MG	A 078933	001	Jun 15, 2010	Apr CAHN
		10MG	A 078933	002	Jun 15, 2010	Apr CAHN
	UNIQUE PHARM LABS	5MG	A 077829	001	Aug 26, 2009	Aug CAHN
		10MG	A 077829	004	Aug 26, 2009	Aug CAHN

CETIRIZINE HYDROCHLORIDE HIVES
JUBILANT CADISTA

5MG	A 078933	003	Jun 15, 2010	Apr CAHN
-----	----------	-----	--------------	----------

10MG

A 078933	004	Jun 15, 2010	Apr CAHN
----------	-----	--------------	----------

UNIQUE PHARM LABS

A 077829	003	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

10MG

A 077829	002	Aug 26, 2009	Aug CAHN
----------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

PERRIGO R AND D	10MG	A 205490	001	Sep 02, 2015	Aug CAHN
-----------------	------	----------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDETABLET;ORAL
ADVIL MULTI-SYMPTOM COLD & FLU

+!	PFIZER	4MG;200MG;10MG	N 022113	002	Apr 28, 2017	Apr NEWA
----	--------	----------------	----------	-----	--------------	----------

CIMETIDINETABLET;ORAL
CIMETIDINE

@ CONTRACT PHARMACAL	200MG	A 074961	001	Jun 19, 1998	Oct DISC
@	200MG	A 074963	001	Jun 19, 1998	Oct DISC
L PERRIGO CO	200MG	A 075285	001	Oct 29, 1998	Apr CAHN
@ SANDOZ INC	100MG	A 075122	001	Jun 19, 1998	Mar CAHN
@	200MG	A 075122	002	Jun 19, 1998	Mar CAHN

TABLET;ORAL								
CIMETIDINE								
@ WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999	May	CAHN		
<u>CLEMASTINE FUMARATE</u>								
TABLET;ORAL								
CLEMASTINE FUMARATE								
L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Apr	CAHN		
TAVIST-1								
+! GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992	Apr	CAHN		
<u>CLOTTRIMAZOLE</u>								
CREAM;VAGINAL								
CLOTTRIMAZOLE								
! ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993	Jun	CHRS		
TARO	1%	A072641	001	Dec 04, 1995	Apr	CAHN		
GYNE-LOTRIMIN								
+ @ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Jun	DISC		
GYNE-LOTRIMIN 3								
+ @ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Jun	DISC		
CREAM, TABLET;TOPICAL, VAGINAL								
GYNE-LOTRIMIN 3 COMBINATION PACK								
+ @ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996	Jun	DISC		
GYNE-LOTRIMIN COMBINATION PACK								
+ @ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Jun	DISC		
TABLET;VAGINAL								
GYNE-LOTRIMIN								
+ @ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Jun	DISC		
GYNE-LOTRIMIN 3								
+ @ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996	Jun	DISC		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>								
TABLET, EXTENDED RELEASE;ORAL								
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE								
ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015	Mar	CAHN		
	60MG;1.2GM	A091070	002	Aug 31, 2015	Mar	CAHN		
AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017	Mar	NEWA		
	60MG;1.2GM	A206941	002	Mar 17, 2017	Mar	NEWA		
<u>DEXTROMETHORPHAN POLISTIREX</u>								
SUSPENSION, EXTENDED RELEASE;ORAL								
DEXTROMETHORPHAN POLISTIREX								
AMNEAL PHARMS LLC	EQ 30MG HBR/5ML	A203133	001	Jul 28, 2017	Jul	NEWA		
<u>ESOMEPRAZOLE MAGNESIUM</u>								
CAPSULE, DELAYED RELEASE;ORAL								
ESOMEPRAZOLE MAGNESIUM								
AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017	Oct	NEWA		
PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017	Aug	NEWA		
<u>FAMOTIDINE</u>								
TABLET;ORAL								
FAMOTIDINE								
PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006	Apr	CAHN		
<u>FEXOFENADINE HYDROCHLORIDE</u>								
SUSPENSION;ORAL								
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY								
TARO PHARM	30MG/5ML	A208123	001	Nov 09, 2017	Oct	NEWA		
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES								
TARO PHARM	30MG/5ML	A208123	002	Nov 09, 2017	Oct	NEWA		
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
TABLET, EXTENDED RELEASE;ORAL								
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE								
AUROBINDO PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017	Oct	NEWA		

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY N022051 002 Aug 02, 2016 Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL 1.2GM A091009 002 Sep 03, 2015 Mar CAHN

GUARDIAN PHARMS 600MG A209215 001 Sep 06, 2017 Aug NEWA

1.2GM A209215 002 Sep 06, 2017 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG A091071 001 May 27, 2015 Mar CAHN

1.2GM;120MG A091071 002 May 27, 2015 Mar CAHN

>A> DR REDDYS LABS LTD 600MG;60MG A208369 001 Dec 29, 2017 Dec NEWA

>A> 1.2GM;120MG A208369 002 Dec 29, 2017 Dec NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM A202300 001 Dec 23, 2011 May CAHN

>A> ASCENT PHARMS INC EQ 200MG FREE ACID AND POTASSIUM A206999 001 Dec 21, 2017 Dec NEWA

@ CONTRACT PHARMACAL SALT 200MG A074782 001 Jul 06, 1998 Oct DISC

SUSPENSION;ORAL

IBUPROFEN

ARISE PHARMS 100MG/5ML A200457 001 Aug 18, 2011 Oct CAHN

TARO 100MG/5ML A209207 001 Jun 27, 2017 Jun NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

L PERRIGO CO 40MG/ML A075217 001 Dec 16, 1998 Apr CAHN

TABLET;ORAL

IBUPROFEN

AIPING PHARM INC 200MG A207095 001 May 05, 2017 Apr NEWA

AMNEAL PHARMS 200MG A079233 001 Mar 18, 2014 Apr CAHN

AUROBINDO PHARMA LTD 200MG A208865 001 Nov 08, 2017 Oct NEWA

@ CONTRACT PHARMACAL 200MG A071735 001 Sep 10, 1987 Oct DISC

@ 200MG A074931 001 Jul 20, 1998 Oct DISC

STRIDES PHARMA 200MG A207052 001 May 30, 2017 Jun CMS2

200MG A207052 001 May 30, 2017 May NEWA

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO 100MG A075367 001 Apr 22, 1999 Apr CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM A209235 001 Dec 01, 2017 Nov NEWA

SALT;30MG

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ CONTRACT PHARMACAL 200MG;30MG A075588 001 Apr 08, 2002 Oct DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

KREMERS URBAN PHARMS 15MG A207157 001 Sep 29, 2017 Sep NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML) N209090 001 Jan 31, 2017 Feb CAHN

+ UCB INC 2.5MG/5ML (0.5MG/ML) N209090 001 Jan 31, 2017 Jan NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG N209089 001 Jan 31, 2017 Feb CAHN

+ UCB INC 5MG N209089 001 Jan 31, 2017 Jan NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

@ FDN CONSUMER	0.75MG	A 078665	001	Aug 28, 2009	Nov	CAHN
	1.5MG	A 200670	001	Jul 12, 2012	Nov	CAHN
RECKITT BENCKISER	1.5MG	A 202246	001	Jun 05, 2015	Apr	CAHN
PLAN B						
+ @ FDN CONSUMER	0.75MG	N 021045	002	Aug 24, 2006	Nov	CAHN
PLAN B ONE-STEP						
+! FDN CONSUMER	1.5MG	N 021998	001	Jul 10, 2009	Nov	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HYDROCHLORIDE

>D>	ALLIED PHARMA INC	1MG/5ML	A 073079	001	Apr 30, 1992	Mar	CAHN
>A>	WOCKHARDT	1MG/5ML	A 074730	001	Aug 28, 1997	Dec	CAHN
	WOCKHARDT BIO AG	1MG/5ML	A 074730	001	Aug 28, 1997	Dec	CAHN

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

@ CONTRACT PHARMACAL	2MG	A 073254	001	Jul 30, 1993	Oct	DISC
L PERRIGO CO	2MG	A 075232	001	Jan 06, 2000	Apr	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO	2MG; 125MG	A 076029	001	Aug 30, 2002	Jan	CHRS
-----------	------------	----------	-----	--------------	-----	------

LORATADINE

SYRUP; ORAL

LORATADINE

>D>	TARO PHARM	1MG/ML	A 201865	001	Jul 31, 2015	Mar	CAHN
>A>	WOCKHARDT	1MG/ML	A 075815	001	Aug 20, 2004	Dec	CAHN
	WOCKHARDT BIO AG	1MG/ML	A 075815	001	Aug 20, 2004	Dec	CAHN

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

TARO	2%	A 074444	001	Jan 13, 1997	Apr	CAHN
------	----	----------	-----	--------------	-----	------

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC	2%, 200MG	A 074926	001	Apr 16, 1999	Jun	CAHN
----------------------	-----------	----------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA	100MG	A 073507	001	Nov 19, 1993	May	CAHN
----------------	-------	----------	-----	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL (FOR MEN)

WATSON LABS INC	5%	A 208092	001	Feb 17, 2017	Feb	NEWA
-----------------	----	----------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

WATSON LABS INC	5%	A 208092	002	Jul 27, 2017	Jul	NEWA
-----------------	----	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

>D>	L PERRIGO CO	2%	A 075357	001	Jul 30, 1999	Apr	CAHN
>A>	WOCKHARDT	2%	A 074767	001	Feb 28, 1997	Dec	CAHN
	WOCKHARDT BIO AG	2%	A 074767	001	Feb 28, 1997	Dec	CAHN

MINOXIDIL (FOR WOMEN)

L PERRIGO CO	2%	A 075357	002	Jul 30, 1999	Apr	CAHN
--------------	----	----------	-----	--------------	-----	------

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>D>	WOCKHARDT	5%	A 075438	001	Feb 27, 2003	Dec	CAHN
>A>	WOCKHARDT BIO AG	5%	A 075438	001	Feb 27, 2003	Dec	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ CONTRACT PHARMACAL	EQ 200MG BASE	A 074789	001	Feb 27, 1997	Oct	DISC
LNK INTL INC	EQ 200MG BASE	A 204872	001	Jan 23, 2017	Jan	NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999	Jun	CAHN
+		14MG/24HR	N020076	005	Nov 12, 1999	Jun	CAHN
+	!	21MG/24HR	N020076	006	Nov 12, 1999	Jun	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996	Nov	CHRS
	NICOTINE POLACRILEX						
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr	CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017	Jul	NEWA
---	---------------	------	---------	-----	--------------	-----	------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

@	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May	DISC
---	----------------------	--------	---------	-----	--------------	-----	------

PERMETHRIN

LOTION;TOPICAL
PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May	CAHN
--	----------------------	----	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

	AILEX PHARMS LLC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep	CAHN
--	------------------	---------------	---------	-----	--------------	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May	NEWA
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr	CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017	Oct	NEWA
		EQ 150MG BASE	A207578	001	Nov 13, 2017	Oct	NEWA
@	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999	Oct	DISC
	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
	ZANTAC 150						
+	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN
	ZANTAC 75						
+	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Nov	CRLD
		EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL
LAMISIL

+	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999	Jul	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

TIOCONAZOLE

OINTMENT;VAGINAL
VAGISTAT-1

+	COMBE	6.5%	N020676	001	Feb 11, 1997	Jul	CAHN
---	-------	------	---------	-----	--------------	-----	------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL

0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2017

NO DECEMBER 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107	001				PC	Mar 14, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551	001				D-147	Mar 23, 2018
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743	001	7803770	Mar 26, 2028	U-2009	NCE	Apr 28, 2022
		8148333	Nov 08, 2027	DP		
		8748382	Oct 03, 2027	U-2009		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	004	7855211	Dec 15, 2029	DS DP U-2132	NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	002	8822438	Aug 24, 2027	U-1579		
		8822438	Aug 24, 2027	U-1580		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	9290504	Jul 11, 2032	DS DP	NCE	Oct 31, 2022
		9758524	Jul 11, 2032	U-2145		
		9796721	Jul 01, 2036	DS DP U-2145		
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001	9610265	Nov 13, 2028	U-2000	M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916	001	9561204	May 08, 2032	U-1373		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916	002	9561204	May 08, 2032	U-1373		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	RE46417	Sep 05, 2020	DS DP U-1263		
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790	001				PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001	8445543	Dec 23, 2022	U-1078		
		9814690	Dec 23, 2022	DP U-1078		
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	001	9539258	Nov 09, 2026	U-1950		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-756 >A> ODE	Nov 06, 2020 Nov 06, 2024
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 210709 001					>A> NP >A> PED	Nov 14, 2020 May 14, 2021
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029			U-2104	
	8283369	Nov 26, 2028			U-2104	
	8357713	Nov 26, 2028	DP		U-2104	
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029			U-2104	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	9216179	Aug 01, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-2104			
	8283369	Nov 26, 2028	U-2104			
	8357713	Nov 26, 2028	DP U-2104			
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029	U-2104			
	9216179	Aug 01, 2031	U-2104			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443	Y		
	8645160	Jun 18, 2029	U-1485	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325 001	8709491	Jun 28, 2032	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP	U-2170		
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027		U-1529		
	>A> 8847766	Mar 29, 2030	DP	U-2167		
	>A> 8945005	Aug 19, 2029	DP	U-2167		
	>A> 8956288	Jul 06, 2029	DP	U-2167		
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022		U-543		
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026		U-1749		
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP	U-2168		
	>A> 9270503	Sep 19, 2034	DP	U-2169		
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP	U-543		
	>A> 9359302	Sep 25, 2022	DS DP	U-1529		
	>A> 9359302	Sep 25, 2022	DS DP	U-1749		
	>A> 9387182	Dec 25, 2023		U-1529		
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP	U-2169		
	>A> 9577864	Oct 03, 2033	DP	U-2169		
	>A> 9787511	Sep 19, 2034	DP	U-2169		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	>A> 7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP	U-2167		
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP	U-2170		
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027		U-1529		
	>A> 8847766	Mar 29, 2030	DP	U-2167		
	>A> 8945005	Aug 19, 2029	DP	U-2167		
	>A> 8956288	Jul 06, 2029	DP	U-2167		
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022		U-543		
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026		U-1749		
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP	U-2168		
	>A> 9270503	Sep 19, 2034	DP	U-2169		
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP	U-543		
	>A> 9359302	Sep 25, 2022	DS DP	U-1529		
	>A> 9359302	Sep 25, 2022	DS DP	U-1749		
	>A> 9387182	Dec 25, 2023		U-1529		
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP	U-2169		
	>A> 9577864	Oct 03, 2033	DP	U-2169		
	>A> 9787511	Sep 19, 2034	DP	U-2169		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	>A> 7053092	Jan 28, 2022		U-1529	I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	>A> 6723351	Nov 10, 2018	U-2204			
	>A> 6855339	Nov 10, 2018	U-2204			
	>A> 6861076	Nov 10, 2018	U-2204			
	>A> 6884439	Nov 10, 2018	U-2204			
	>A> 6982096	Nov 10, 2018	U-2204			
	>A> 8273379	Nov 10, 2018	U-2204			
<u>ASCORBIC ACID - ASCOR</u>						
N 209112 001					ODE	Oct 02, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 001					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 002					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 003					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 004					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					M-204	Jun 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					PC	Mar 26, 2018
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE ODE	Aug 29, 2022 Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					NCE ODE	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9655907	Aug 31, 2030	DP U-1858			
	9775851	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004 001	8962572	Nov 03, 2032	DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279 001	7959945	Dec 28, 2027	DP		NP	Sep 05, 2020
	8309126	May 15, 2026	DP		ODE	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					>A> I-759	Dec 19, 2020
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					>A> I-759	Dec 19, 2020
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	6002008	Mar 27, 2018	DS DP U-1284		>A> I-759	Dec 19, 2020
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029		U-1927	ODE	Apr 28, 2024
	9611283	Apr 10, 2034		U-1927		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029		U-1927	ODE	Apr 28, 2024
	9611283	Apr 10, 2034		U-1927		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029		U-1927	ODE	Apr 28, 2024
	9611283	Apr 10, 2034		U-1927		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001					>A> NP	Dec 22, 2020
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9770453	Apr 19, 2022	DP U-2131			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	005	6784197	Feb 21, 2021	DS DP	U-1815	
		6784197	Feb 21, 2021	DS DP	U-2130	
		6911461	Feb 21, 2021	DS DP	U-1815	
		6911461	Feb 21, 2021	DS DP	U-2130	
		8492416	Feb 21, 2021		U-1815	
		8492416	Feb 21, 2021		U-2130	
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837	001	6784197	Feb 21, 2021	DS DP	U-1815	
		6784197	Feb 21, 2021	DS DP	U-2130	
		6911461	Feb 21, 2021	DS DP	U-1815	
		6911461	Feb 21, 2021	DS DP	U-2130	
		8492416	Feb 21, 2021		U-1815	
		8492416	Feb 21, 2021		U-2130	
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838	001	6784197	Feb 21, 2021	DS DP	U-1815	
		6784197	Feb 21, 2021	DS DP	U-2130	
		6911461	Feb 21, 2021	DS DP	U-1815	
		6911461	Feb 21, 2021	DS DP	U-2130	
		8492416	Feb 21, 2021		U-1815	
		8492416	Feb 21, 2021		U-2130	
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168	001	9517220	Nov 11, 2033		U-1933	
		9561277	Jan 16, 2024		U-1933	
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866	001	9352025	Jun 07, 2030		U-2111	
		9352025	Jun 07, 2030		U-2112	
		9352025	Jun 07, 2030		U-2113	
		9352025	Jun 07, 2030		U-2114	
		9352025	Jun 07, 2030		U-2115	
		9352025	Jun 07, 2030		U-2116	
		9352025	Jun 07, 2030		U-2117	
		9352025	Jun 07, 2030		U-2118	
		9352025	Jun 07, 2030		U-2119	
		9522117	Apr 30, 2032	DP	U-976	
		9522117	Apr 30, 2032	DP	U-1939	
	>A>	9700555	Apr 30, 2032	DP	U-2183	
	>A>	9700555	Apr 30, 2032	DP	U-2184	
	>A>	9700555	Apr 30, 2032	DP	U-2185	
	>A>	9700555	Apr 30, 2032	DP	U-2186	
	>A>	9700555	Apr 30, 2032	DP	U-2187	
	>A>	9700555	Apr 30, 2032	DP	U-2188	
	>A>	9700555	Apr 30, 2032	DP	U-2189	
	>A>	9700555	Apr 30, 2032	DP	U-2190	
	>A>	9700555	Apr 30, 2032	DP	U-2191	
	>A>	9700555	Apr 30, 2032	DP	U-2192	
	>A>	9700555	Apr 30, 2032	DP	U-2193	
	>A>	9700555	Apr 30, 2032	DP	U-2194	
	>A>	9700555	Apr 30, 2032	DP	U-2195	
	>A>	9700555	Apr 30, 2032	DP	U-2196	
	>A>	9700555	Apr 30, 2032	DP	U-2197	
	>A>	9700555	Apr 30, 2032	DP	U-2198	
<u>BUDESONIDE - UCERIS</u>						
N 203634	001	9532954	Jun 09, 2020	DP	U-1325	
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	001	6123924	Sep 26, 2017	DP	M-210	Sep 11, 2020
		7367333	Nov 11, 2018	DP	>A> M-214	Dec 20, 2020
		7367333*PED	May 11, 2019		NPP	Jan 27, 2020
		7587988	Apr 10, 2026	DP	PED	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		>A> M-214	Dec 20, 2020
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646	Sep 09, 2018	U-2122			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211	Sep 09, 2018	U-2122			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	>A> 8921387	Jan 06, 2032	DP U-2173			
	>A> 8921387	Jan 06, 2032	DP U-2174			
	>A> 8975270	Sep 05, 2031	DP U-2175			
	>A> 8975270	Sep 05, 2031	DP U-2206			
	>A> 9272044	Jun 06, 2031	U-2176			
	>A> 9272044	Jun 06, 2031	U-2177			
	>A> 9272044	Jun 06, 2031	U-2178			
	>A> 9272044	Jun 06, 2031	U-2209			
	>A> 9498432	Jun 06, 2031	DP U-2179			
	>A> 9782402	Jun 06, 2031	DP U-2176			
	>A> 9782402	Jun 06, 2031	DP U-2180			
	>A> 9782402	Jun 06, 2031	DP U-2207			
	>A> 9782402	Jun 06, 2031	DP U-2208			
	>A> 9827241	Jun 06, 2031	DP U-2174			
	>A> 9827241	Jun 06, 2031	DP U-2181			
	>A> 9827241	Jun 06, 2031	DP U-2206			
	>A> 9827241	Jun 06, 2031	DP U-2210			
	>A> 9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	>A> 8921387	Jan 06, 2032	DP U-2173			
	>A> 8921387	Jan 06, 2032	DP U-2174			
	>A> 8975270	Sep 05, 2031	DP U-2175			
	>A> 8975270	Sep 05, 2031	DP U-2206			
	>A> 9272044	Jun 06, 2031	U-2176			
	>A> 9272044	Jun 06, 2031	U-2177			
	>A> 9272044	Jun 06, 2031	U-2178			
	>A> 9272044	Jun 06, 2031	U-2209			
	>A> 9498432	Jun 06, 2031	DP U-2179			
	>A> 9782402	Jun 06, 2031	DP U-2176			
	>A> 9782402	Jun 06, 2031	DP U-2180			
	>A> 9782402	Jun 06, 2031	DP U-2207			
	>A> 9782402	Jun 06, 2031	DP U-2208			
	>A> 9827241	Jun 06, 2031	DP U-2174			
	>A> 9827241	Jun 06, 2031	DP U-2181			
	>A> 9827241	Jun 06, 2031	DP U-2206			
	>A> 9827241	Jun 06, 2031	DP U-2210			
	>A> 9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030				
	8927592*PED	Apr 27, 2031		U-1630		
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9700575	Jul 10, 2035	DP		
<u>CAPSAICIN - QUTENZA</u>						
N 022395	001	6239180	Jun 04, 2021	DP		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		
		9750822	Mar 13, 2029	DP		
		9770407	Nov 10, 2028	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9533046	Dec 26, 2028	DP U-219		
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001	9522191	Jun 15, 2027	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	9493582	Feb 27, 2033	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	9493582	Feb 27, 2033	DP		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	001				M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	002				M-213	Nov 09, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003					M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004					M-213	Nov 09, 2020
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 001					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 002					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 003					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 004					PC	May 07, 2018
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIATE</u>						
N 208694 001	8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					NP	Sep 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 23, 2034	DP U-2162			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	>A> 9789057	Dec 02, 2026	DP U-137			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 9855334	Mar 11, 2035	DP		NP	Nov 28, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE NPP	Aug 27, 2017 Sep 25, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	9744181	Jan 13, 2024	DP U-257		NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	7511041	May 13, 2024	DS DP		NCE	Sep 14, 2022
	8466283	Oct 22, 2029	DS DP U-2124		ODE	Sep 14, 2024
	9636344	Mar 29, 2032	U-2124			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	9682092	Feb 16, 2027	U-1932			
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 8026284	Sep 22, 2027	U-1399		>A> M-216	Dec 22, 2020
	>A> 8026284*PED	Mar 22, 2028			>A> ODE	Apr 30, 2020
	>A> 9173851	Jun 17, 2034	DP		>A> ODE	Aug 14, 2022
	>A> 9173851*PED	Dec 17, 2034			>A> PED	Oct 30, 2020
	>A> 9192590	Jan 26, 2027	U-1399		>A> PED	Jun 22, 2021
	>A> 9192590*PED	Jul 26, 2027			>A> PED	Feb 14, 2023
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9198882*PED	Jul 26, 2027				
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9233077*PED	Dec 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 8026284	Sep 22, 2027	U-1399		>A> M-216	Dec 22, 2020
	>A> 8026284*PED	Mar 22, 2028			>A> ODE	Apr 30, 2020
	>A> 9173851	Jun 17, 2034	DP		>A> ODE	Aug 14, 2022
	>A> 9173851*PED	Dec 17, 2034			>A> PED	Oct 30, 2020
	>A> 9192590	Jan 26, 2027	U-1399		>A> PED	Jun 22, 2021
	>A> 9192590*PED	Jul 26, 2027			>A> PED	Feb 14, 2023
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9198882*PED	Jul 26, 2027				
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9233077*PED	Dec 17, 2034				
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP	Y		
	>A> 6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP	Y		
	>A> 6824822	Oct 09, 2022	DP	Y		
	>A> 6872700	Jan 14, 2020	U-654	Y		
	>A> 6956026	Jan 07, 2018	U-687	Y		
	>A> 7223440	Aug 31, 2021	DP	Y		
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7456254	Jun 30, 2025	DP U-2139			
	>A> 7563871	Apr 15, 2024	DP	Y		
	>A> 7612176	Apr 13, 2025	DP U-1223	Y		
	>A> 7741269	Jan 07, 2018	U-1224	Y		
	>A> 8216180	Jan 11, 2028	DP	Y		
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2139			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8329648	Aug 18, 2026	U-2212			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	>A> 8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8431685	Apr 13, 2025	DP U-2139			
	>A> 8439864	Mar 25, 2028	DP	Y		
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-2139			
	>A> 8690837	May 19, 2029	DP	Y		
	>A> 8721615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP	Y		
	>A> 8827963	Feb 04, 2029	DP	Y		
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9238076	Apr 15, 2024	DP U-2139			
	>A> 9320853	Mar 25, 2028	DP	Y		
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP	Y		
	>A> 6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP	Y		
	>A> 6824822	Oct 09, 2022	DP	Y		
	>A> 6872700	Jan 14, 2020	U-654	Y		
	>A> 6956026	Jan 07, 2018	U-687	Y		
	>A> 7223440	Aug 31, 2021	DP	Y		
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7456254	Jun 30, 2025	DP U-2139			
	>A> 7563871	Apr 15, 2024	DP	Y		
	>A> 7612176	Apr 13, 2025	DP U-1223	Y		
	>A> 7741269	Jan 07, 2018	U-1224	Y		
	>A> 8216180	Jan 11, 2028	DP	Y		
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2139			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8329648	Aug 18, 2026	U-2212			
	>A> 8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8431685	Apr 13, 2025	DP U-2139			
	>A> 8439864	Mar 25, 2028	DP	Y		
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-2139			
	>A> 8690837	May 19, 2029	DP	Y		
	>A> 8721615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP	Y		
	>A> 8827963	Feb 04, 2029	DP	Y		
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9238076	Apr 15, 2024	DP U-2139			
	>A> 9320853	Mar 25, 2028	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					M-211	Sep 01, 2020
					NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					M-211	Sep 01, 2020
					NPP	Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					NPP	Nov 09, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					NPP	Nov 09, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029		U-1978		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029		U-1978		
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
	>A> RE46617	Dec 28, 2029	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	>A> 7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
	7728143	Nov 20, 2027	DS		GAIN	Jun 19, 2027
	8252813	Oct 02, 2026	DP U-2028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	8273892	Aug 06, 2026	DS			
	>A> 8410077	Mar 13, 2029	DP			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	>A> 9200088	Mar 13, 2029	DP			
	>A> 9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	>A> 9750822	Mar 13, 2029	DP			
	>A> RE46617	Dec 28, 2029	DS			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 001					PC	Jan 25, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 003					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
		9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
		9814708	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846		
		9550780	Sep 18, 2033	DS DP U-1995		
		9814708	Sep 18, 2033	DP		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	9592242	Oct 20, 2020	U-1989		
		9592242	Oct 20, 2020	U-1990		
		9775849	Oct 20, 2020	U-1989		
		9775849	Oct 20, 2020	U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001	9827197	Jun 16, 2026	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001	9561200	Feb 24, 2029	U-1482		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	9539335	Oct 17, 2027	U-1614		
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001				I-758	Nov 21, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002				I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003				I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192	001	>A> 6838464	Feb 26, 2021	DS DP	NC	Nov 21, 2020
		>A> 7067522	Dec 20, 2019	DS DP	NCE	Aug 12, 2018
		>A> 7125879	Apr 21, 2025	DS DP U-257		
		>A> 8080551	Apr 11, 2023	DS DP		
		>A> 8101629	Aug 09, 2022	DP		
		>A> 8129385	Oct 05, 2027	DS DP		
		>A> 9242986	Dec 08, 2029	DS DP		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027	U-620		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027	U-620		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661	001	7560122	Jan 25, 2019	DP		
		9089489	Feb 18, 2033	DP U-1382		
		9375404	Feb 18, 2033	DP U-1382		
		9526703	Feb 18, 2033	DP U-1382		
<u>DRONABINOL - SYNDROS</u>						
N 205525	001	8222292	Aug 06, 2028	DS DP		
		9345771	Aug 06, 2028	DS DP		
<u>EDARAVONE - RADICAVA</u>						
N 209176	001	6933310	Nov 13, 2020	U-2013	NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	8598185	Apr 28, 2029	DP		
		9545414	Jun 13, 2026	DP U-750		
		9545414	Jun 13, 2026	DP U-1170		
		9744181	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9566272	Jan 03, 2028	U-1969		
		9662394	Oct 02, 2034	DP		
	>A>	9861698	Jul 08, 2030	DP		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	003	8062665	Aug 01, 2027	DP U-930		
		8062665	Aug 01, 2027	DP U-1306		
		8062665	Aug 01, 2027	DP U-1575		
		8062665	Aug 01, 2027	DP U-1714		
		8062665*PED	Feb 01, 2028			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027	001	6280959	Oct 30, 2018	DS DP U-1736	ODE PED	Aug 26, 2021 Feb 26, 2022
		6280959*PED	Apr 30, 2019			
		7160870	Nov 20, 2022	DS DP U-1736		
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021	U-1736		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021		U-1736		
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023		U-1736		
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025		U-1709		
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025		U-1709		
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027		U-1652		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027		U-1652		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001					M-206 M-207	Aug 21, 2020 Aug 21, 2020
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245	Nov 04, 2020		U-1170		
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001 >A>	9855214	Nov 06, 2032	DP			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-1892			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003 >A>	7731686	Jun 01, 2026	DP			
	>A> 7731690	Jan 15, 2025	DP			
	>A> 7749194	Oct 30, 2028	DP			
	>A> 7918823	Nov 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	>A> 7947017	Mar 12, 2028	DP			
	>A> 8016788	Mar 21, 2025	DP			
	>A> 8021344	Nov 02, 2029	DP			
	>A> 8206360	Feb 27, 2027	DP			
	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
	>A> 8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
	>A> 8608698	Nov 23, 2024	DP			
	>A> 8920377	Nov 23, 2024	DP			
	>A> 8926594	Mar 31, 2026	DP			
	>A> 9056170	Nov 23, 2024	DP			
	>A> 9149579	Jul 19, 2025	U-1758			
	>A> 9238108	Feb 20, 2027	DP			
	>A> 9259539	Feb 01, 2026	DP			
	>A> 9278182	Feb 01, 2026	DP			
	>A> 9724471	May 23, 2027	DP U-2092			
	>A> 9737669	Nov 23, 2024	DP			
	9833573	Nov 23, 2024	U-2172			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035	U-1829			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STELUJAN</u>						
N 209805 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STELUJAN</u>						
N 209805 002				>A> NCE		Dec 19, 2022
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	9730900	Jul 10, 2028	U-2086			
	>A> 9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	9730900	Jul 10, 2028	U-2086			
	>A> 9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	9730900	Jul 10, 2028	U-2086			
	>A> 9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	9730900	Jul 10, 2028	U-2086			
	>A> 9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			
	>A> 9833419	Jul 10, 2028	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025		U-1904	Y	
	9243245	Oct 27, 2028	DS	U-2097		
	9243245	Oct 27, 2028	DS	U-2098		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025		U-1904	Y	
	9243245	Oct 27, 2028	DS	U-2097		
	9243245	Oct 27, 2028	DS	U-2098		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>ETONOGESTREL - IMPLANON</u>						
N 021529 001	9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	6239124	Jul 29, 2017		U-1049		
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	6239124	Jul 29, 2017		U-1049		
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	6239124	Jul 29, 2017		U-1049		
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004					ODE	Feb 26, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6479065	Aug 10, 2020	DP		NP	Oct 20, 2020
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2154			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8895033	Oct 04, 2030	DP U-1313			
	8895033	Oct 04, 2030	DP U-2157			
	8895033	Oct 04, 2030	DP U-2158			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-493			
	6414126	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8690837	May 19, 2029	DP			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	9320853	Mar 25, 2028	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001					M-205	Aug 15, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002					M-205	Aug 15, 2020
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9731869	Jan 26, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9731121	Oct 17, 2031	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9757416	Feb 18, 2024	DS DP U-1577			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2018	DS			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	6537983	Aug 03, 2021	DP U-2125		NCE	May 10, 2018
	6759398	Aug 03, 2021	DP U-2125		NCE	Dec 18, 2018
	6878698	Aug 03, 2021	U-2134			
	7101866	Aug 03, 2021	DS DP U-2126			
	7439393	May 21, 2025	DS DP U-2127			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750762	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	7439393	May 21, 2025	DS DP U-1401		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-1691		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	7439393	May 21, 2025	DS DP U-1691		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-2099		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Mar 03, 2020	DP		NP	Sep 18, 2020
	7975690	Dec 29, 2025	U-2133			
	8327844	Oct 08, 2023	U-2133			
	8522778	May 11, 2022	DP			
	8550073	Oct 22, 2029	DP			
	8555878	Mar 20, 2020	DP			
	8978647	Aug 06, 2030	DP			
	9072857	Apr 10, 2021	DP			
	9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001					>A> M-214	Dec 20, 2020
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002					>A> M-214	Dec 20, 2020
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-749	Aug 25, 2020
	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-2163			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139*PED	Jul 09, 2021				
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	8648037	Jan 19, 2032	DS DP U-2141		NCE	Aug 03, 2022
	8937150	May 18, 2032	DS DP			
	9321807	Jun 05, 2035	DS			
	9586978	Jun 10, 2030	U-2141			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP >A> ODE	Apr 28, 2020 Apr 28, 2024
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	>A> 6962151	Oct 27, 2020	DP		>A> NP	Dec 05, 2020
	>A> 7316067	Sep 06, 2022	DP			
	>A> 7458372	Nov 18, 2024	DP			
	>A> 7931212	Nov 25, 2025	DP			
	>A> 8511581	Nov 08, 2023	DP			
	>A> 9168556	Sep 01, 2032	DP			
	>A> 9265900	Dec 07, 2028	DP			
	>A> 9604018	May 16, 2033	DP			
	>A> 9789270	Oct 30, 2030	DP			
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	9572803	Sep 13, 2027	DP			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	>A> 7381427	Jun 08, 2022	U-2205		>A> NP	Dec 14, 2020
	>A> 9675639	Jul 04, 2035	DP U-2205			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945 002					ODE	Feb 03, 2018
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					>A> NP	Dec 21, 2020
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					>A> NP	Dec 21, 2020
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1650		I-753	Aug 02, 2020
	8476284	Dec 28, 2026	U-1946		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947		ODE	Aug 02, 2024
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
	7686786	Aug 03, 2026	DP			
	8324157	Jun 25, 2030	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Jan 20, 2026	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9775954	Mar 02, 2024	DP			
	>A> 9821032	May 09, 2032	U-2182			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN LISPRO - ADMELOG</u>						
N 209196 001				>A> NP		Dec 11, 2020
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002				>A> NP		Dec 11, 2020
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6444226	Jun 29, 2020	DP	U-1534		
	6652885	Jun 29, 2020		U-1535		
	7648960	Jun 29, 2020		U-1535		
	7943178	Jun 29, 2020	DP	U-1535		
	7943572	Aug 10, 2026		U-1539		
	8119593	Aug 11, 2029		U-1537		
	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1621		
	8623817	Sep 18, 2029		U-1537		
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	9192675	Jun 12, 2029	DP	U-1788		
	9358352	Feb 15, 2031	DP	U-1861		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351 002					I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808 002					I-752	Apr 05, 2020
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	9782349	May 02, 2025	DS DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	>A> 9782425	Mar 13, 2034	U-1631			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		>A> NPP	Dec 08, 2020
	8173707*PED	Jan 30, 2024			>A> PED	Jun 08, 2021
	8586633	Jul 30, 2023	DP			
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033	DP			
	9066856*PED	Apr 23, 2034				
	9278101	Jul 30, 2023	U-1518			
	9278101*PED	Jan 30, 2024				
	9399040	Jul 30, 2023	DP			
	9399040*PED	Jan 30, 2024				
	9486406	Oct 23, 2033	DP			
	9486406*PED	Apr 23, 2034				
	>A> 9855246	Oct 23, 2033	DP			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					I-748 ODE	Jul 07, 2020 Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					>A> M-217	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7217713	Oct 21, 2022	U-1663			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-1663			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	6211233	Jun 17, 2018	DS DP			
	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETTERMOVIR - PREVMIS</u>						
N 209939 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETTERMOVIR - PREVMIS</u>						
N 209939 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETTERMOVIR - PREVMIS</u>						
N 209940 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP	U-621		
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020		DP		
	9539333	Nov 13, 2020	DS DP	U-621		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP	U-621		
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020		DP		
	9539333	Nov 13, 2020	DS DP	U-621		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP	U-621		
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020		DP		
	9539333	Nov 13, 2020	DS DP	U-621		
<u>LEVETIRACETAM - ROWEPPRA</u>						
A 090906 003					>A> PC	Sep 13, 2017
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9339489	Mar 14, 2034	DP	U-1850		
	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034		U-1850		
	9669009	Mar 14, 2034		U-2021		
	9669009	Mar 14, 2034		U-2022		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1516		
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001					I-750	Aug 25, 2020
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023		DP	M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9814751	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9707176	Nov 11, 2030	DP			
	>A> 9821032	May 09, 2032	U-2200			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9707176	Nov 11, 2030	DP			
	>A> 9821032	May 09, 2032	U-2200			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	9770455	Aug 31, 2031	U-2110			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	9770455	Aug 31, 2031	U-2110			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		PED	Jul 27, 2020
	9815827	Feb 20, 2024	U-2166			
	>A> 9827242	May 23, 2031	U-2199			
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-543			
	9815827	Feb 20, 2024	U-2166			
	>A> 9827242	May 23, 2031	U-2199			
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001					>A> NCE	Dec 20, 2022
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136	Aug 17, 2031	DS DP			
	9694025	Aug 08, 2031	U-2120			
<u>MESALAMINE - MESALAMINE</u>						
A 091640 001					PC	Jan 14, 2018
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		ODE	Apr 25, 2024
					ODE	Apr 25, 2024
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP		U-1827	
	>A> 9844544	Aug 14, 2033	DP		U-2203	
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP		U-1827	
	>A> 9844544	Aug 14, 2033	DP		U-2203	
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP		U-1827	
	>A> 9844544	Aug 14, 2033	DP		U-2204	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	9829495	Aug 15, 2036	U-1643			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001					>A> NP	Dec 08, 2020
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	9775838	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	6288082	Sep 24, 2019	DS DP U-2043		NCE	Jul 17, 2022
	7399865	Dec 29, 2025	DS DP			
	7982043	Oct 08, 2025	U-2043			
	8518446	Nov 20, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-2043			
	9139558	Oct 15, 2028	U-2043			
	9211291	Mar 24, 2030	U-2043			
	9630946	Oct 15, 2028	U-2043			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	>A> 8394826	Nov 10, 2030	DS DP U-1524		>A> NCE	Dec 18, 2022
	>A> 8450344	Jul 11, 2026	DS DP U-1524			
	>A> 9096569	Jul 11, 2026	DS DP U-1524			
	>A> 9415043	Mar 14, 2034	DS			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NITISINONE - ORFADIN</u>						
N 021232 001					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 002					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 003					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 004					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356 001					D-169	Sep 01, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9770570	May 03, 2036	U-2148		M-167	Oct 09, 2018
	9770570*PED	Nov 03, 2036				
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018	U-1942			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2102			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2103			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2102			
	8143241	Aug 12, 2027	U-2103			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNTRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>OMEPRAZOLE MAGNESIUM - OMEPRAZOLE MAGNESIUM</u>						
A 204152 001					PC	May 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001 >A>	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002 >A>	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003 >A>	9855278	Apr 13, 2027	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZENOXACIN - XEPI</u>						
N 208945 001					>A> NCE	Dec 11, 2022
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005					>A> M-215	Dec 20, 2020
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 005	>A> 8221747	Feb 20, 2028	DP			
	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	DP U-1274			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001					NPP	Sep 20, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
	9789210	Mar 16, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001					NCE	Oct 15, 2019
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 15, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 001 >A>	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 002 >A>	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 003 >A>	8829186	Jan 19, 2031	DS DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9750822	Mar 13, 2029	DP			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			NS	May 26, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029		U-1994		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7592339	Dec 11, 2020		U-1167	D-168	Oct 27, 2020
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	7592339	Dec 11, 2020		U-2142		
	9415053	Nov 13, 2024	DP	U-1167		
	9415053	Nov 13, 2024	DP	U-1200		
	9415053	Nov 13, 2024	DP	U-1301		
	9415053	Nov 13, 2024	DP	U-1302		
	9415053	Nov 13, 2024	DP	U-1303		
	9415053	Nov 13, 2024	DP	U-2142		
	9539218	Feb 17, 2034		U-1953		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7592339	Dec 11, 2020	U-1167	Y		
	7592339	Dec 11, 2020	U-1200	Y		
	7592339	Dec 11, 2020	U-1301	Y		
	7592339	Dec 11, 2020	U-1302	Y		
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					M-208	Aug 31, 2020
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
	9101615	Jul 14, 2032	U-1741			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP	U-1993	NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Sep 01, 2027		U-1993		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP	U-1993	NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS	U-1993		
	8283380	Sep 01, 2027		U-1993		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001					NCE GAIN	Sep 15, 2022 Sep 15, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 6899699	Jan 02, 2022	DP		>A> NCE	Dec 05, 2022
	>A> 7762994	May 23, 2024	DP			
	>A> 8114833	Aug 13, 2025	DP			
	>A> 8129343	Jan 29, 2029	DS DP U-2202			
	>A> 8536122	Mar 20, 2026	DS DP U-2202			
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	>A> RE46363	Aug 03, 2026	DP			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 001					>A> PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 002					>A> PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 003					>A> PC	Jun 09, 2018
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	9770406	Jul 12, 2025	DP U-172			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	9757406	Jan 30, 2034	DP		NCE NPP	Dec 06, 2018 Aug 01, 2020
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Jul 18, 2022
	7964580	Mar 26, 2029	DS DP U-2040			
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	9724297	Aug 31, 2035	DP U-2096			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	9757394	Oct 28, 2036	DP U-2109			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2018	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2019	DS DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			
	>A> 9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			
	>A> 9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003 >A>	9763920	Aug 30, 2024	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP	Y		
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP			
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP			
	7182958*PED	Oct 26, 2020				
<u>TALC - STERITALC</u>						
N 205555 001					ODE	May 01, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALC - STERITALC</u>						
N 205555 002					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2018	DS DP U-2149			
	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	RE46604	Jan 25, 2033	U-2147			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027		U-2016		
	9549938	Feb 16, 2026		U-1951		
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026		U-1970		
	9572823	Feb 16, 2026		U-1970		
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML</u>						
N 020372 002	9549999	Mar 10, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025		U-1320		
	9545434	Nov 01, 2025		U-1320		
	9545435	Nov 01, 2025		U-1320		
	9555079	Nov 01, 2025		U-1320		
	9572867	Nov 01, 2025		U-1320		
	9592273	Nov 01, 2025		U-1320		
	9592274	Nov 01, 2025		U-1320		
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		>A> I-761	Dec 14, 2020
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS		>A> I-761	Dec 14, 2020
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	8828440	Aug 04, 2031	DP		NP	Oct 06, 2020
	9555048	Aug 04, 2031		U-2151		
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP ODE	Jun 29, 2020 Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	7439393	May 21, 2025	DS DP	U-1476	NCE	May 10, 2018
	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
	9750726	Nov 29, 2030	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027	U-1995			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035		U-1857		
	9744209	Jan 30, 2035		U-1857		
	9744239	Jan 30, 2035		U-1857		
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035		U-1857		
	9687526	Jan 30, 2035		U-1857		
	9744209	Jan 30, 2035		U-1857		
	9744239	Jan 30, 2035		U-1857		
	9750785	Jan 30, 2035	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026		U-1418	I-757	Nov 06, 2020
	8470818	Aug 02, 2026		U-2164	>A> ODE	Nov 06, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	7144884	Oct 02, 2022	DS DP	U-1439		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	7144884	Oct 02, 2022	DS DP	U-1439		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	7144884	Oct 02, 2022	DS DP	U-1439		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	7144884	Oct 02, 2022	DS DP	U-1439		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	9707270	Oct 01, 2024		U-2084		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031		U-674		
	9597281	Apr 06, 2027		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031		U-674		
	9597281	Apr 06, 2027		U-674		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm